{"PMC7172811": [["Clinical definitionsBronchiolitis is a virus-induced infection with inflammation of the small bronchioles and their surrounding tissue.", [["small bronchioles", "ANATOMY", 88, 105], ["tissue", "ANATOMY", 128, 134], ["Bronchiolitis", "DISEASE", 20, 33], ["infection", "DISEASE", 53, 62], ["inflammation", "DISEASE", 68, 80], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 94, 105], ["tissue", "TISSUE", 128, 134], ["Clinical definitionsBronchiolitis", "PROBLEM", 0, 33], ["a virus", "PROBLEM", 37, 44], ["induced infection", "PROBLEM", 45, 62], ["inflammation of the small bronchioles", "PROBLEM", 68, 105], ["Bronchiolitis", "OBSERVATION", 20, 33], ["infection", "OBSERVATION", 53, 62], ["inflammation", "OBSERVATION", 68, 80], ["small", "OBSERVATION_MODIFIER", 88, 93], ["bronchioles", "ANATOMY", 94, 105], ["surrounding tissue", "OBSERVATION", 116, 134]]], ["Clinically, it is characterized as the first expiratory breathing difficulty in children less than 2 years of age.", [["expiratory breathing difficulty", "DISEASE", 45, 76], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["the first expiratory breathing difficulty", "PROBLEM", 35, 76]]], ["Other lower respiratory tract symptoms include dry cough, tachypnea, hyperinflation, chest retraction, and widespread crackles or wheezing.", [["lower respiratory tract", "ANATOMY", 6, 29], ["chest", "ANATOMY", 85, 90], ["respiratory tract symptoms", "DISEASE", 12, 38], ["dry cough", "DISEASE", 47, 56], ["tachypnea", "DISEASE", 58, 67], ["hyperinflation", "DISEASE", 69, 83], ["chest retraction", "DISEASE", 85, 101], ["wheezing", "DISEASE", 130, 138], ["lower", "ORGANISM_SUBDIVISION", 6, 11], ["respiratory tract", "ORGANISM_SUBDIVISION", 12, 29], ["Other lower respiratory tract symptoms", "PROBLEM", 0, 38], ["dry cough", "PROBLEM", 47, 56], ["tachypnea", "PROBLEM", 58, 67], ["hyperinflation", "PROBLEM", 69, 83], ["chest retraction", "PROBLEM", 85, 101], ["widespread crackles", "PROBLEM", 107, 126], ["wheezing", "PROBLEM", 130, 138], ["lower", "ANATOMY_MODIFIER", 6, 11], ["respiratory tract", "ANATOMY", 12, 29], ["dry", "OBSERVATION_MODIFIER", 47, 50], ["cough", "OBSERVATION", 51, 56], ["tachypnea", "OBSERVATION", 58, 67], ["hyperinflation", "OBSERVATION", 69, 83], ["chest", "ANATOMY", 85, 90], ["retraction", "OBSERVATION", 91, 101], ["widespread", "OBSERVATION_MODIFIER", 107, 117], ["crackles", "OBSERVATION", 118, 126], ["wheezing", "OBSERVATION", 130, 138]]], ["In many studies wheezing is not a mandatory diagnostic criterion, and the upper age limit varies from 6 months to 2 years.16", [["wheezing", "DISEASE", 16, 24], ["upper", "ORGANISM_SUBDIVISION", 74, 79], ["wheezing", "PROBLEM", 16, 24], ["wheezing", "OBSERVATION", 16, 24], ["upper", "ANATOMY_MODIFIER", 74, 79]]]], "6ee1c84f19e9c58b1a72f25b8ae2db0f709d6bdd": [["INTRODUCTIONMicrobes, including viruses, bacteria and fungi, are the causal agents of pulmonary infections.", [["pulmonary", "ANATOMY", 86, 95], ["pulmonary infections", "DISEASE", 86, 106], ["pulmonary", "ORGAN", 86, 95], ["INTRODUCTIONMicrobes", "TREATMENT", 0, 20], ["viruses", "PROBLEM", 32, 39], ["bacteria", "PROBLEM", 41, 49], ["fungi", "PROBLEM", 54, 59], ["pulmonary infections", "PROBLEM", 86, 106], ["viruses", "OBSERVATION", 32, 39], ["bacteria", "OBSERVATION_MODIFIER", 41, 49], ["pulmonary", "ANATOMY", 86, 95], ["infections", "OBSERVATION", 96, 106]]], ["[1] [2] [3] [4] Infections of nose, sinuses, and throat are included in upper tract infections.", [["nose", "ANATOMY", 30, 34], ["sinuses", "ANATOMY", 36, 43], ["throat", "ANATOMY", 49, 55], ["upper tract", "ANATOMY", 72, 83], ["upper tract infections", "DISEASE", 72, 94], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["nose", "ORGANISM_SUBDIVISION", 30, 34], ["sinuses", "MULTI-TISSUE_STRUCTURE", 36, 43], ["throat", "ORGANISM_SUBDIVISION", 49, 55], ["upper tract", "ORGANISM_SUBDIVISION", 72, 83], ["Infections of nose, sinuses, and throat", "PROBLEM", 16, 55], ["upper tract infections", "PROBLEM", 72, 94], ["nose", "ANATOMY", 30, 34], ["sinuses", "ANATOMY", 36, 43], ["throat", "ANATOMY", 49, 55], ["upper tract", "ANATOMY", 72, 83], ["infections", "OBSERVATION", 84, 94]]], ["Whereas infections of trachea, lungs and bronchial tubes are considered as lower tract infections.", [["trachea", "ANATOMY", 22, 29], ["lungs", "ANATOMY", 31, 36], ["bronchial tubes", "ANATOMY", 41, 56], ["lower tract", "ANATOMY", 75, 86], ["infections", "DISEASE", 8, 18], ["lower tract infections", "DISEASE", 75, 97], ["trachea", "MULTI-TISSUE_STRUCTURE", 22, 29], ["lungs", "ORGAN", 31, 36], ["bronchial tubes", "MULTI-TISSUE_STRUCTURE", 41, 56], ["lower tract", "ORGANISM_SUBDIVISION", 75, 86], ["infections of trachea, lungs and bronchial tubes", "PROBLEM", 8, 56], ["lower tract infections", "PROBLEM", 75, 97], ["infections", "OBSERVATION", 8, 18], ["trachea", "ANATOMY", 22, 29], ["lungs", "ANATOMY", 31, 36], ["bronchial", "ANATOMY", 41, 50], ["tubes", "OBSERVATION", 51, 56], ["lower tract", "ANATOMY", 75, 86], ["infections", "OBSERVATION", 87, 97]]], ["5 Generally, upper tract infections are mild in nature; however, severe illness and high mortality rate are reported in lower tract infections.", [["upper tract", "ANATOMY", 13, 24], ["lower tract", "ANATOMY", 120, 131], ["upper tract infections", "DISEASE", 13, 35], ["illness", "DISEASE", 72, 79], ["lower tract infections", "DISEASE", 120, 142], ["upper tract", "ORGANISM_SUBDIVISION", 13, 24], ["lower tract", "ORGANISM_SUBDIVISION", 120, 131], ["upper tract infections", "PROBLEM", 13, 35], ["severe illness", "PROBLEM", 65, 79], ["high mortality rate", "PROBLEM", 84, 103], ["lower tract infections", "PROBLEM", 120, 142], ["upper tract", "ANATOMY", 13, 24], ["infections", "OBSERVATION", 25, 35], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["lower tract", "ANATOMY", 120, 131], ["infections", "OBSERVATION", 132, 142]]], ["6 It is estimated that about 4.2 million deaths occurs globally due to lower tract infections among all the age groups and about 1.8 million deaths have been reported in children.", [["lower tract", "ANATOMY", 71, 82], ["deaths", "DISEASE", 41, 47], ["lower tract infections", "DISEASE", 71, 93], ["deaths", "DISEASE", 141, 147], ["lower tract", "ORGANISM_SUBDIVISION", 71, 82], ["children", "ORGANISM", 170, 178], ["children", "SPECIES", 170, 178], ["4.2 million deaths", "PROBLEM", 29, 47], ["lower tract infections", "PROBLEM", 71, 93], ["lower tract", "ANATOMY", 71, 82], ["infections", "OBSERVATION", 83, 93]]], ["Children are more prone to lower tract viral infections.", [["lower tract", "ANATOMY", 27, 38], ["viral infections", "DISEASE", 39, 55], ["Children", "ORGANISM", 0, 8], ["lower tract", "ORGANISM_SUBDIVISION", 27, 38], ["Children", "SPECIES", 0, 8], ["lower tract viral infections", "PROBLEM", 27, 55], ["infections", "OBSERVATION", 45, 55]]], ["3, 7 Usually the most common mode of transmission of the pulmonary infections is by contact of one person to another.", [["pulmonary", "ANATOMY", 57, 66], ["pulmonary infections", "DISEASE", 57, 77], ["pulmonary", "ORGAN", 57, 66], ["person", "SPECIES", 99, 105], ["the pulmonary infections", "PROBLEM", 53, 77], ["pulmonary", "ANATOMY", 57, 66], ["infections", "OBSERVATION", 67, 77]]], ["Such infections are transmitted by direct or indirect contact.", [["infections", "DISEASE", 5, 15], ["Such infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15]]], ["Individuals affected by cough and sneezing, transfer droplets consisting of microorganisms in a fraction of seconds through air or directly deposited into the mouth or nasal mucosa of another susceptible individual, for example, mouth droplet from people suffering from cough can be spread into another individual.", [["mouth", "ANATOMY", 159, 164], ["nasal mucosa", "ANATOMY", 168, 180], ["mouth droplet", "ANATOMY", 229, 242], ["cough", "DISEASE", 24, 29], ["sneezing", "DISEASE", 34, 42], ["cough", "DISEASE", 270, 275], ["mouth", "ORGANISM_SUBDIVISION", 159, 164], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 168, 180], ["mouth", "ORGANISM_SUBDIVISION", 229, 234], ["people", "ORGANISM", 248, 254], ["people", "SPECIES", 248, 254], ["cough", "PROBLEM", 24, 29], ["sneezing", "PROBLEM", 34, 42], ["transfer droplets", "TREATMENT", 44, 61], ["microorganisms", "PROBLEM", 76, 90], ["cough", "PROBLEM", 270, 275], ["cough", "OBSERVATION", 24, 29], ["air", "OBSERVATION", 124, 127], ["mouth", "ANATOMY", 159, 164], ["nasal mucosa", "ANATOMY", 168, 180]]], ["5 Indirect transmission involves the contact of susceptible individual with the contaminated instruments or the surface where organisms occur.", [["surface", "ANATOMY", 112, 119], ["surface", "CELLULAR_COMPONENT", 112, 119], ["the contaminated instruments", "TREATMENT", 76, 104], ["organisms", "PROBLEM", 126, 135]]], ["Microorganisms can reside on the hand of the infected person and can be transferred, for example, by the shaking of hands.", [["hand", "ANATOMY", 33, 37], ["hand", "ORGANISM_SUBDIVISION", 33, 37], ["hands", "ORGANISM_SUBDIVISION", 116, 121], ["person", "SPECIES", 54, 60], ["Microorganisms", "PROBLEM", 0, 14], ["infected", "OBSERVATION", 45, 53], ["hands", "ANATOMY", 116, 121]]], ["The needles and gloves of an infected person can also transmit infection to another person 5 .INTRODUCTIONThere are various types of pulmonary infections, such as: pneumonia, tuberculosis, pulmonary aspergillosis and nontuberculous mycobacterial infections.", [["needles", "ANATOMY", 4, 11], ["pulmonary", "ANATOMY", 133, 142], ["pulmonary", "ANATOMY", 189, 198], ["infection", "DISEASE", 63, 72], ["pulmonary infections", "DISEASE", 133, 153], ["pneumonia", "DISEASE", 164, 173], ["tuberculosis", "DISEASE", 175, 187], ["pulmonary aspergillosis", "DISEASE", 189, 212], ["mycobacterial infections", "DISEASE", 232, 256], ["person", "ORGANISM", 38, 44], ["pulmonary", "ORGAN", 133, 142], ["pulmonary", "ORGAN", 189, 198], ["person", "SPECIES", 38, 44], ["person", "SPECIES", 84, 90], ["The needles", "TREATMENT", 0, 11], ["gloves", "TREATMENT", 16, 22], ["pulmonary infections", "PROBLEM", 133, 153], ["pneumonia", "PROBLEM", 164, 173], ["tuberculosis", "PROBLEM", 175, 187], ["pulmonary aspergillosis", "PROBLEM", 189, 212], ["nontuberculous mycobacterial infections", "PROBLEM", 217, 256], ["infected", "OBSERVATION", 29, 37], ["pulmonary", "ANATOMY", 133, 142], ["infections", "OBSERVATION", 143, 153], ["pneumonia", "OBSERVATION", 164, 173], ["tuberculosis", "OBSERVATION", 175, 187], ["pulmonary", "ANATOMY", 189, 198], ["aspergillosis", "OBSERVATION", 199, 212], ["nontuberculous", "OBSERVATION_MODIFIER", 217, 231], ["mycobacterial infections", "OBSERVATION", 232, 256]]], ["Pulmonary infections are commonly reported from developing and developed countries.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary infections", "DISEASE", 0, 20], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary infections", "PROBLEM", 0, 20], ["infections", "OBSERVATION", 10, 20]]], ["4, [8] [9] [10] Although there are many microbiological testing methods available for the diagnosis of such infections and there are various antimicrobial treatment therapies for the management of pulmonary infections, sometimes the curing rate of these infections is reported to be low due to certain limitations.", [["pulmonary", "ANATOMY", 197, 206], ["infections", "DISEASE", 108, 118], ["pulmonary infections", "DISEASE", 197, 217], ["infections", "DISEASE", 254, 264], ["[8] [9] [10", "SIMPLE_CHEMICAL", 3, 14], ["pulmonary", "ORGAN", 197, 206], ["microbiological testing methods", "TEST", 40, 71], ["such infections", "PROBLEM", 103, 118], ["various antimicrobial treatment therapies", "TREATMENT", 133, 174], ["the management", "TREATMENT", 179, 193], ["pulmonary infections", "PROBLEM", 197, 217], ["these infections", "PROBLEM", 248, 264], ["infections", "OBSERVATION", 108, 118], ["antimicrobial treatment", "OBSERVATION", 141, 164], ["pulmonary", "ANATOMY", 197, 206], ["infections", "OBSERVATION", 207, 217], ["infections", "OBSERVATION", 254, 264]]], ["Microbiological testing methods are believed to be slow and insensitive, whereas, the uncontrolled and over use of antibiotics create the major problem of antibiotic resistance.", [["Microbiological testing methods", "TEST", 0, 31], ["slow and insensitive", "PROBLEM", 51, 71], ["antibiotics", "TREATMENT", 115, 126], ["antibiotic resistance", "TREATMENT", 155, 176], ["believed to be", "UNCERTAINTY", 36, 50], ["antibiotic resistance", "OBSERVATION", 155, 176]]], ["11, 12 Recently, the ability of common pathogens to acquire resistance to widely used antimicrobial therapies has been increased.", [["common pathogens", "PROBLEM", 32, 48], ["antimicrobial therapies", "TREATMENT", 86, 109], ["increased", "OBSERVATION_MODIFIER", 119, 128]]], ["13 The authors further suggested that the number of pathogens that exhibit resistance to one or multiple drugs (MDR) have been increasing gradually.INTRODUCTIONCurrently, the problem of antimicrobial resistance in both Gram-negative and Gram-positive bacteria and other pathogens causing pulmonary infections has become a major threat.", [["pulmonary", "ANATOMY", 288, 297], ["Gram-", "CHEMICAL", 219, 224], ["pulmonary infections", "DISEASE", 288, 308], ["Gram-", "GENE_OR_GENE_PRODUCT", 219, 224], ["Gram-", "GENE_OR_GENE_PRODUCT", 237, 242], ["pulmonary", "ORGAN", 288, 297], ["pathogens", "PROBLEM", 52, 61], ["multiple drugs (MDR", "TREATMENT", 96, 115], ["antimicrobial resistance", "PROBLEM", 186, 210], ["Gram-positive bacteria", "PROBLEM", 237, 259], ["other pathogens", "PROBLEM", 264, 279], ["pulmonary infections", "PROBLEM", 288, 308], ["increasing", "OBSERVATION_MODIFIER", 127, 137], ["antimicrobial resistance", "OBSERVATION", 186, 210], ["positive bacteria", "OBSERVATION", 242, 259], ["pulmonary", "ANATOMY", 288, 297], ["infections", "OBSERVATION", 298, 308]]], ["Karchmer 14 reported that antimicrobial resistance is particularly prevalent among the most common pathogens associated with community-acquired respiratory tract infections, which includes Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.", [["respiratory tract", "ANATOMY", 144, 161], ["respiratory tract infections", "DISEASE", 144, 172], ["Streptococcus pneumoniae", "DISEASE", 189, 213], ["Haemophilus influenzae", "DISEASE", 215, 237], ["Moraxella catarrhalis", "DISEASE", 239, 260], ["Streptococcus pyogenes", "DISEASE", 266, 288], ["tract", "ORGANISM_SUBDIVISION", 156, 161], ["Streptococcus pneumoniae", "ORGANISM", 189, 213], ["Haemophilus influenzae", "ORGANISM", 215, 237], ["Moraxella catarrhalis", "ORGANISM", 239, 260], ["Streptococcus pyogenes", "ORGANISM", 266, 288], ["Streptococcus pneumoniae", "SPECIES", 189, 213], ["Haemophilus influenzae", "SPECIES", 215, 237], ["Moraxella catarrhalis", "SPECIES", 239, 260], ["Streptococcus pyogenes", "SPECIES", 266, 288], ["Streptococcus pneumoniae", "SPECIES", 189, 213], ["Haemophilus influenzae", "SPECIES", 215, 237], ["Moraxella catarrhalis", "SPECIES", 239, 260], ["Streptococcus pyogenes", "SPECIES", 266, 288], ["Karchmer", "TEST", 0, 8], ["antimicrobial resistance", "PROBLEM", 26, 50], ["community-acquired respiratory tract infections", "PROBLEM", 125, 172], ["Streptococcus pneumoniae", "PROBLEM", 189, 213], ["Haemophilus influenzae", "PROBLEM", 215, 237], ["Moraxella catarrhalis", "PROBLEM", 239, 260], ["Streptococcus pyogenes", "PROBLEM", 266, 288], ["antimicrobial resistance", "OBSERVATION", 26, 50], ["most common", "OBSERVATION_MODIFIER", 87, 98], ["respiratory tract", "ANATOMY", 144, 161], ["Streptococcus pneumoniae", "OBSERVATION", 189, 213], ["Haemophilus influenzae", "OBSERVATION", 215, 237], ["Moraxella catarrhalis", "OBSERVATION", 239, 260], ["Streptococcus pyogenes", "OBSERVATION", 266, 288]]], ["15 Hence, the morbidity and mortality associated with the pulmonary infection pose a growing challenge to clinical practitioners.", [["pulmonary", "ANATOMY", 58, 67], ["pulmonary infection", "DISEASE", 58, 77], ["pulmonary", "ORGAN", 58, 67], ["the morbidity", "PROBLEM", 10, 23], ["the pulmonary infection", "PROBLEM", 54, 77], ["pulmonary", "ANATOMY", 58, 67], ["infection", "OBSERVATION", 68, 77]]], ["16 Considering the huge scope and applications of nanotechnology in biomedicine, it has been proven that nanotechnology will play a crucial role for the management of problems associated with antibiotic resistance including multiple drug resistance.", [["nanotechnology in biomedicine", "TREATMENT", 50, 79], ["the management", "TREATMENT", 149, 163], ["problems", "PROBLEM", 167, 175], ["antibiotic resistance", "TREATMENT", 192, 213], ["multiple drug resistance", "TREATMENT", 224, 248], ["drug resistance", "OBSERVATION", 233, 248]]], ["Therefore, these life-threatening challenges including pulmonary infections can now be overcome with the help of nanotechnology.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary infections", "DISEASE", 55, 75], ["pulmonary", "ORGAN", 55, 64], ["pulmonary infections", "PROBLEM", 55, 75], ["pulmonary", "ANATOMY", 55, 64], ["infections", "OBSERVATION", 65, 75]]], ["12, 17 The aim of the present chapter is to discuss the global status of various pulmonary infections and the strategies for their management.", [["pulmonary", "ANATOMY", 81, 90], ["pulmonary infections", "DISEASE", 81, 101], ["pulmonary", "ORGAN", 81, 90], ["various pulmonary infections", "PROBLEM", 73, 101], ["their management", "TREATMENT", 125, 141], ["pulmonary", "ANATOMY", 81, 90], ["infections", "OBSERVATION", 91, 101]]], ["Here, we have described treatment therapies available for pulmonary infections and their limitations.", [["pulmonary", "ANATOMY", 58, 67], ["pulmonary infections", "DISEASE", 58, 78], ["pulmonary", "ORGAN", 58, 67], ["treatment therapies", "TREATMENT", 24, 43], ["pulmonary infections", "PROBLEM", 58, 78], ["pulmonary", "ANATOMY", 58, 67], ["infections", "OBSERVATION", 68, 78]]], ["Given that multidrug resistance is a major challenge, novel and effective alternative treatment therapies need to be discovered.", [["effective alternative treatment therapies", "TREATMENT", 64, 105], ["multidrug resistance", "OBSERVATION", 11, 31]]], ["In addition, we have also discussed the role of nanotechnology for the management of pulmonary infections with a special focus on different types of nanomaterials.PNEUMONIAPneumonia is an inflammatory disease, which affects lung air sacs (known as alveoli).", [["pulmonary", "ANATOMY", 85, 94], ["lung air sacs", "ANATOMY", 224, 237], ["alveoli", "ANATOMY", 248, 255], ["pulmonary infections", "DISEASE", 85, 105], ["PNEUMONIAPneumonia", "CHEMICAL", 163, 181], ["pulmonary", "ORGAN", 85, 94], ["lung air sacs", "MULTI-TISSUE_STRUCTURE", 224, 237], ["alveoli", "MULTI-TISSUE_STRUCTURE", 248, 255], ["the management", "TREATMENT", 67, 81], ["pulmonary infections", "PROBLEM", 85, 105], ["PNEUMONIAPneumonia", "PROBLEM", 163, 181], ["an inflammatory disease", "PROBLEM", 185, 208], ["lung air sacs", "PROBLEM", 224, 237], ["pulmonary", "ANATOMY", 85, 94], ["infections", "OBSERVATION", 95, 105], ["inflammatory", "OBSERVATION_MODIFIER", 188, 200], ["disease", "OBSERVATION", 201, 208], ["lung", "ANATOMY", 224, 228], ["air sacs", "OBSERVATION", 229, 237], ["alveoli", "ANATOMY_MODIFIER", 248, 255]]], ["This disease is mostly caused by viruses, bacteria, or fungi.", [["This disease", "PROBLEM", 0, 12], ["viruses", "PROBLEM", 33, 40], ["bacteria", "PROBLEM", 42, 50], ["fungi", "PROBLEM", 55, 60], ["disease", "OBSERVATION", 5, 12], ["mostly caused", "UNCERTAINTY", 16, 29], ["viruses", "OBSERVATION", 33, 40], ["fungi", "OBSERVATION", 55, 60]]], ["Worldwide more than 450 million people suffer from pneumonia and four million people die from pneumonia annually.", [["pneumonia", "DISEASE", 51, 60], ["pneumonia", "DISEASE", 94, 103], ["people", "ORGANISM", 32, 38], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 32, 38], ["people", "SPECIES", 78, 84], ["pneumonia", "PROBLEM", 51, 60], ["pneumonia", "PROBLEM", 94, 103], ["pneumonia", "OBSERVATION", 51, 60], ["pneumonia", "OBSERVATION", 94, 103]]], ["Common symptoms of pneumonia includes-persistent cold, fever with shaking hands, chest pain, and difficulty in breathing.", [["chest", "ANATOMY", 81, 86], ["pneumonia", "DISEASE", 19, 28], ["fever", "DISEASE", 55, 60], ["chest pain", "DISEASE", 81, 91], ["chest", "ORGANISM_SUBDIVISION", 81, 86], ["Common symptoms", "PROBLEM", 0, 15], ["pneumonia", "PROBLEM", 19, 28], ["persistent cold", "PROBLEM", 38, 53], ["fever", "PROBLEM", 55, 60], ["shaking hands", "PROBLEM", 66, 79], ["chest pain", "PROBLEM", 81, 91], ["difficulty in breathing", "PROBLEM", 97, 120], ["pneumonia", "OBSERVATION", 19, 28], ["persistent", "OBSERVATION_MODIFIER", 38, 48], ["cold", "OBSERVATION", 49, 53], ["fever", "OBSERVATION", 55, 60], ["chest", "ANATOMY", 81, 86]]], ["Other severe sign and symbols of pneumonia are vomiting, unconsciousness, convulsions.", [["pneumonia", "DISEASE", 33, 42], ["vomiting", "DISEASE", 47, 55], ["unconsciousness", "DISEASE", 57, 72], ["convulsions", "DISEASE", 74, 85], ["Other severe sign", "PROBLEM", 0, 17], ["pneumonia", "PROBLEM", 33, 42], ["vomiting", "PROBLEM", 47, 55], ["unconsciousness", "PROBLEM", 57, 72], ["convulsions", "PROBLEM", 74, 85], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["pneumonia", "OBSERVATION", 33, 42]]], ["1 Bacteria are supposed to be the most common source of pneumonia.", [["pneumonia", "DISEASE", 56, 65], ["Bacteria", "PROBLEM", 2, 10], ["pneumonia", "PROBLEM", 56, 65], ["Bacteria", "OBSERVATION", 2, 10], ["supposed to be the", "UNCERTAINTY", 15, 33], ["most common", "OBSERVATION_MODIFIER", 34, 45], ["pneumonia", "OBSERVATION", 56, 65]]], ["Streptococcus pneumoniae is responsible for more than 50% of the infections, Haemophilus influenza causes 20% of the infections.", [["Streptococcus pneumoniae", "DISEASE", 0, 24], ["infections", "DISEASE", 65, 75], ["Haemophilus influenza", "DISEASE", 77, 98], ["infections", "DISEASE", 117, 127], ["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["Haemophilus influenza", "ORGANISM", 77, 98], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Haemophilus influenza", "SPECIES", 77, 98], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Haemophilus influenza", "SPECIES", 77, 98], ["Streptococcus pneumoniae", "PROBLEM", 0, 24], ["the infections", "PROBLEM", 61, 75], ["Haemophilus influenza", "PROBLEM", 77, 98], ["the infections", "PROBLEM", 113, 127], ["pneumoniae", "OBSERVATION", 14, 24], ["infections", "OBSERVATION", 65, 75], ["infections", "OBSERVATION", 117, 127]]], ["Mycoplasma pneumoniae also causes infection in 3% of the population and some other bacterium like Stenotrophomonas maltophilia also reported to cause pneumonia.", [["Mycoplasma pneumoniae", "DISEASE", 0, 21], ["infection", "DISEASE", 34, 43], ["Stenotrophomonas maltophilia", "DISEASE", 98, 126], ["pneumonia", "DISEASE", 150, 159], ["Mycoplasma pneumoniae", "ORGANISM", 0, 21], ["Stenotrophomonas maltophilia", "ORGANISM", 98, 126], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Stenotrophomonas maltophilia", "SPECIES", 98, 126], ["Mycoplasma pneumoniae", "SPECIES", 0, 21], ["Stenotrophomonas maltophilia", "SPECIES", 98, 126], ["Mycoplasma pneumoniae", "PROBLEM", 0, 21], ["infection", "PROBLEM", 34, 43], ["the population", "PROBLEM", 53, 67], ["some other bacterium", "PROBLEM", 72, 92], ["Stenotrophomonas maltophilia", "PROBLEM", 98, 126], ["pneumonia", "PROBLEM", 150, 159], ["pneumoniae", "OBSERVATION", 11, 21], ["infection", "OBSERVATION", 34, 43], ["bacterium", "OBSERVATION_MODIFIER", 83, 92], ["Stenotrophomonas maltophilia", "OBSERVATION", 98, 126], ["pneumonia", "OBSERVATION", 150, 159]]], ["18 Certain viruses like coronaviruses, influenza virus, adenovirus, and respiratory syncytial virus causes pneumonia.", [["influenza virus", "DISEASE", 39, 54], ["respiratory syncytial virus", "DISEASE", 72, 99], ["pneumonia", "DISEASE", 107, 116], ["coronaviruses", "ORGANISM", 24, 37], ["influenza virus", "ORGANISM", 39, 54], ["adenovirus", "ORGANISM", 56, 66], ["respiratory syncytial virus", "ORGANISM", 72, 99], ["coronaviruses", "SPECIES", 24, 37], ["influenza virus", "SPECIES", 39, 54], ["respiratory syncytial virus", "SPECIES", 72, 99], ["influenza virus", "SPECIES", 39, 54], ["adenovirus", "SPECIES", 56, 66], ["respiratory syncytial virus", "SPECIES", 72, 99], ["Certain viruses", "PROBLEM", 3, 18], ["coronaviruses", "PROBLEM", 24, 37], ["influenza virus", "PROBLEM", 39, 54], ["adenovirus", "TREATMENT", 56, 66], ["respiratory syncytial virus", "PROBLEM", 72, 99], ["pneumonia", "PROBLEM", 107, 116], ["pneumonia", "OBSERVATION", 107, 116]]], ["19 Fungal pneumonia is very rare.", [["Fungal pneumonia", "DISEASE", 3, 19], ["Fungal pneumonia", "PROBLEM", 3, 19], ["Fungal", "OBSERVATION_MODIFIER", 3, 9], ["pneumonia", "OBSERVATION", 10, 19]]], ["It is mostly observed in immunocompromised patients.TUBERCULOSISTuberculosis (TB) is caused by the Mycobacterium tuberculosis.", [["TUBERCULOSISTuberculosis", "CHEMICAL", 52, 76], ["TB", "DISEASE", 78, 80], ["Mycobacterium tuberculosis", "DISEASE", 99, 125], ["patients", "ORGANISM", 43, 51], ["Mycobacterium tuberculosis", "ORGANISM", 99, 125], ["patients", "SPECIES", 43, 51], ["Mycobacterium tuberculosis", "SPECIES", 99, 125], ["Mycobacterium tuberculosis", "SPECIES", 99, 125], ["TUBERCULOSISTuberculosis", "PROBLEM", 52, 76], ["TB", "PROBLEM", 78, 80], ["the Mycobacterium tuberculosis", "PROBLEM", 95, 125], ["mostly observed", "UNCERTAINTY", 6, 21], ["immunocompromised", "OBSERVATION", 25, 42], ["Mycobacterium tuberculosis", "OBSERVATION", 99, 125]]], ["These bacteria usually infect the lungs but may also affect other parts, such as liver and kidney.", [["lungs", "ANATOMY", 34, 39], ["liver", "ANATOMY", 81, 86], ["kidney", "ANATOMY", 91, 97], ["lungs", "ORGAN", 34, 39], ["liver", "ORGAN", 81, 86], ["kidney", "ORGAN", 91, 97], ["These bacteria", "PROBLEM", 0, 14], ["bacteria", "OBSERVATION", 6, 14], ["lungs", "ANATOMY", 34, 39], ["liver", "ANATOMY", 81, 86], ["kidney", "ANATOMY", 91, 97]]], ["When TB is observed outside of the lungs it is known as extra-pulmonary TB.", [["lungs", "ANATOMY", 35, 40], ["TB", "DISEASE", 5, 7], ["extra-pulmonary TB", "DISEASE", 56, 74], ["lungs", "ORGAN", 35, 40], ["TB", "PROBLEM", 5, 7], ["extra-pulmonary TB", "PROBLEM", 56, 74], ["TB", "OBSERVATION", 5, 7], ["lungs", "ANATOMY", 35, 40], ["extra-pulmonary", "ANATOMY", 56, 71], ["TB", "OBSERVATION", 72, 74]]], ["Immunocompromised patients are more susceptible to this infection.", [["infection", "DISEASE", 56, 65], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["this infection", "PROBLEM", 51, 65], ["more susceptible", "OBSERVATION_MODIFIER", 31, 47], ["infection", "OBSERVATION", 56, 65]]], ["The mode of transmission of disease is air.", [["disease", "PROBLEM", 28, 35], ["disease", "OBSERVATION", 28, 35], ["air", "OBSERVATION", 39, 42]]], ["When a TB patient speaks, coughs, or sneezes, TB bacteria may be spread and infect nearby individuals.", [["TB", "DISEASE", 7, 9], ["coughs", "DISEASE", 26, 32], ["TB", "DISEASE", 46, 48], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["coughs", "PROBLEM", 26, 32], ["sneezes", "PROBLEM", 37, 44], ["TB bacteria", "PROBLEM", 46, 57]]], ["Even if a person is infected with M. tuberculosis, it may be in inactive form and is only activated in patients with lower immunity or who is in a later stage of life.", [["M. tuberculosis", "DISEASE", 34, 49], ["M. tuberculosis", "ORGANISM", 34, 49], ["patients", "ORGANISM", 103, 111], ["person", "SPECIES", 10, 16], ["M. tuberculosis", "SPECIES", 34, 49], ["patients", "SPECIES", 103, 111], ["M. tuberculosis", "SPECIES", 34, 49], ["tuberculosis", "OBSERVATION", 37, 49]]], ["21 Common signs of TB are persistent cough with sputum for more than 3 weeks, chest pain, loss of appetite, chill, fever, sweating at night, fatigueness and weight loss.", [["sputum", "ANATOMY", 48, 54], ["chest", "ANATOMY", 78, 83], ["TB", "DISEASE", 19, 21], ["cough", "DISEASE", 37, 42], ["chest pain", "DISEASE", 78, 88], ["loss of appetite", "DISEASE", 90, 106], ["fever", "DISEASE", 115, 120], ["sweating", "DISEASE", 122, 130], ["fatigueness", "DISEASE", 141, 152], ["weight loss", "DISEASE", 157, 168], ["chest", "ORGANISM_SUBDIVISION", 78, 83], ["TB", "PROBLEM", 19, 21], ["persistent cough", "PROBLEM", 26, 42], ["sputum", "PROBLEM", 48, 54], ["chest pain", "PROBLEM", 78, 88], ["loss of appetite", "PROBLEM", 90, 106], ["chill", "PROBLEM", 108, 113], ["fever", "PROBLEM", 115, 120], ["sweating", "PROBLEM", 122, 130], ["fatigueness", "PROBLEM", 141, 152], ["weight loss", "PROBLEM", 157, 168], ["TB", "OBSERVATION", 19, 21], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["cough", "OBSERVATION", 37, 42], ["chest", "ANATOMY", 78, 83], ["fever", "OBSERVATION", 115, 120], ["weight loss", "OBSERVATION", 157, 168]]], ["Most patients do not show the 3 ExISTING TREATMENTS FOR PULMONARY INFECTIONS symptoms of TB but develop the disease at the later stage.", [["TB", "DISEASE", 89, 91], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["PULMONARY INFECTIONS symptoms", "PROBLEM", 56, 85], ["TB", "PROBLEM", 89, 91], ["the disease", "PROBLEM", 104, 115], ["PULMONARY", "ANATOMY", 56, 65], ["INFECTIONS", "OBSERVATION", 66, 76], ["disease", "OBSERVATION", 108, 115]]], ["4, 22 Not every individual become sick after this infection, they can have TB bacteria in the body but the body is able to fight against the bacteria.", [["body", "ANATOMY", 94, 98], ["body", "ANATOMY", 107, 111], ["infection", "DISEASE", 50, 59], ["TB", "DISEASE", 75, 77], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["this infection", "PROBLEM", 45, 59], ["TB bacteria in the body", "PROBLEM", 75, 98], ["the bacteria", "PROBLEM", 137, 149], ["infection", "OBSERVATION", 50, 59], ["body", "ANATOMY", 94, 98], ["bacteria", "OBSERVATION", 141, 149]]], ["People with such an infection do not spread TB infection to others.", [["infection", "DISEASE", 20, 29], ["TB", "DISEASE", 44, 46], ["infection", "DISEASE", 47, 56], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["an infection", "PROBLEM", 17, 29], ["TB infection", "PROBLEM", 44, 56], ["infection", "OBSERVATION", 20, 29]]], ["This form of infection is known as Latent TB.", [["infection", "DISEASE", 13, 22], ["TB", "DISEASE", 42, 44], ["infection", "PROBLEM", 13, 22], ["Latent TB", "PROBLEM", 35, 44], ["infection", "OBSERVATION", 13, 22], ["Latent", "OBSERVATION_MODIFIER", 35, 41], ["TB", "OBSERVATION", 42, 44]]], ["TB bacteria are active when the immunity is lower, and in this case TB bacteria can be spread.", [["TB", "DISEASE", 68, 70], ["TB bacteria", "PROBLEM", 0, 11], ["TB bacteria", "PROBLEM", 68, 79], ["bacteria", "OBSERVATION", 3, 11], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["23PULMONARY ASPERGILLOSISPulmonary aspergillosis is a fungal infection, which is mainly caused by Aspergillus species.", [["aspergillosis", "DISEASE", 35, 48], ["fungal infection", "DISEASE", 54, 70], ["Aspergillus species", "ORGANISM", 98, 117], ["PULMONARY ASPERGILLOSISPulmonary aspergillosis", "PROBLEM", 2, 48], ["a fungal infection", "PROBLEM", 52, 70], ["Aspergillus species", "PROBLEM", 98, 117], ["PULMONARY", "ANATOMY", 2, 11], ["ASPERGILLOSISPulmonary", "ANATOMY_MODIFIER", 12, 34], ["aspergillosis", "OBSERVATION", 35, 48], ["fungal", "OBSERVATION_MODIFIER", 54, 60], ["infection", "OBSERVATION", 61, 70], ["mainly caused", "UNCERTAINTY", 81, 94], ["Aspergillus species", "OBSERVATION", 98, 117]]], ["This disease is characterized by the colonization of Aspergillus spores in the lungs.", [["spores", "ANATOMY", 65, 71], ["lungs", "ANATOMY", 79, 84], ["lungs", "ORGAN", 79, 84], ["This disease", "PROBLEM", 0, 12], ["Aspergillus spores in the lungs", "PROBLEM", 53, 84], ["disease", "OBSERVATION", 5, 12], ["colonization", "OBSERVATION_MODIFIER", 37, 49], ["Aspergillus spores", "OBSERVATION", 53, 71], ["lungs", "ANATOMY", 79, 84]]], ["Aspergillosis is more commonly observed in people who are affected with TB or people with COPD.", [["Aspergillosis", "DISEASE", 0, 13], ["TB", "DISEASE", 72, 74], ["COPD", "DISEASE", 90, 94], ["people", "ORGANISM", 43, 49], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 43, 49], ["people", "SPECIES", 78, 84], ["Aspergillosis", "PROBLEM", 0, 13], ["TB", "PROBLEM", 72, 74], ["COPD", "PROBLEM", 90, 94], ["more commonly", "OBSERVATION_MODIFIER", 17, 30], ["COPD", "OBSERVATION", 90, 94]]], ["Mostly, aspergillosis is caused by A. flavus, A. niger and A. terreus.", [["aspergillosis", "DISEASE", 8, 21], ["A. flavus", "ORGANISM", 35, 44], ["A. niger", "ORGANISM", 46, 54], ["A. terreus", "ORGANISM", 59, 69], ["A. flavus", "SPECIES", 35, 44], ["A. niger", "SPECIES", 46, 54], ["A. terreus", "SPECIES", 59, 69], ["A. flavus", "SPECIES", 35, 44], ["A. niger", "SPECIES", 46, 54], ["A. terreus", "SPECIES", 59, 69], ["aspergillosis", "PROBLEM", 8, 21], ["A. flavus", "PROBLEM", 35, 44], ["aspergillosis", "OBSERVATION", 8, 21], ["flavus", "OBSERVATION", 38, 44], ["terreus", "OBSERVATION", 62, 69]]], ["A. fumigatus is commonly found in patients suffering from invasive aspergillosis.", [["invasive aspergillosis", "ANATOMY", 58, 80], ["aspergillosis", "DISEASE", 67, 80], ["A. fumigatus", "ORGANISM", 0, 12], ["patients", "ORGANISM", 34, 42], ["aspergillosis", "CANCER", 67, 80], ["A. fumigatus", "SPECIES", 0, 12], ["patients", "SPECIES", 34, 42], ["A. fumigatus", "SPECIES", 0, 12], ["A. fumigatus", "PROBLEM", 0, 12], ["invasive aspergillosis", "PROBLEM", 58, 80], ["fumigatus", "OBSERVATION", 3, 12], ["invasive", "OBSERVATION_MODIFIER", 58, 66], ["aspergillosis", "OBSERVATION", 67, 80]]], ["There are three types of pulmonary infections: allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), invasive pulmonary aspergillosis (IPA).", [["pulmonary", "ANATOMY", 25, 34], ["pulmonary", "ANATOMY", 103, 112], ["invasive pulmonary aspergillosis", "ANATOMY", 134, 166], ["pulmonary infections", "DISEASE", 25, 45], ["allergic bronchopulmonary aspergillosis", "DISEASE", 47, 86], ["ABPA", "DISEASE", 88, 92], ["chronic pulmonary aspergillosis", "DISEASE", 95, 126], ["CPA", "DISEASE", 128, 131], ["invasive pulmonary aspergillosis", "DISEASE", 134, 166], ["IPA", "DISEASE", 168, 171], ["pulmonary", "ORGAN", 25, 34], ["allergic bronchopulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 47, 86], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 103, 126], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 143, 166], ["pulmonary infections", "PROBLEM", 25, 45], ["allergic bronchopulmonary aspergillosis (ABPA)", "PROBLEM", 47, 93], ["chronic pulmonary aspergillosis (CPA)", "PROBLEM", 95, 132], ["invasive pulmonary aspergillosis", "PROBLEM", 134, 166], ["three types", "OBSERVATION_MODIFIER", 10, 21], ["pulmonary", "ANATOMY", 25, 34], ["infections", "OBSERVATION", 35, 45], ["allergic", "OBSERVATION_MODIFIER", 47, 55], ["bronchopulmonary", "ANATOMY", 56, 72], ["aspergillosis", "OBSERVATION", 73, 86], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["pulmonary", "ANATOMY", 103, 112], ["aspergillosis", "OBSERVATION", 113, 126], ["invasive", "OBSERVATION_MODIFIER", 134, 142], ["pulmonary", "ANATOMY", 143, 152], ["aspergillosis", "OBSERVATION", 153, 166]]], ["24, 25 The common symptoms of aspergillosis are fever, cough, breathlessness and chest pain.", [["chest", "ANATOMY", 81, 86], ["aspergillosis", "DISEASE", 30, 43], ["fever", "DISEASE", 48, 53], ["cough", "DISEASE", 55, 60], ["breathlessness", "DISEASE", 62, 76], ["chest pain", "DISEASE", 81, 91], ["aspergillosis", "CANCER", 30, 43], ["chest", "ORGANISM_SUBDIVISION", 81, 86], ["aspergillosis", "PROBLEM", 30, 43], ["fever", "PROBLEM", 48, 53], ["cough", "PROBLEM", 55, 60], ["breathlessness", "PROBLEM", 62, 76], ["chest pain", "PROBLEM", 81, 91], ["aspergillosis", "OBSERVATION", 30, 43], ["chest", "ANATOMY", 81, 86]]], ["ABPA infection is mainly characterized with asthmatic patients and with eosinophilia deficient patient.", [["ABPA infection", "DISEASE", 0, 14], ["asthmatic", "DISEASE", 44, 53], ["eosinophilia", "DISEASE", 72, 84], ["patients", "ORGANISM", 54, 62], ["patient", "ORGANISM", 95, 102], ["patients", "SPECIES", 54, 62], ["patient", "SPECIES", 95, 102], ["ABPA infection", "PROBLEM", 0, 14], ["asthmatic patients", "PROBLEM", 44, 62], ["eosinophilia deficient", "PROBLEM", 72, 94], ["infection", "OBSERVATION", 5, 14], ["mainly characterized with", "UNCERTAINTY", 18, 43], ["asthmatic", "OBSERVATION", 44, 53], ["eosinophilia deficient", "OBSERVATION", 72, 94]]], ["Generally, invasive aspergillosis is reported in immunocompromised patients with neutropenia and after organ transplantation.", [["invasive aspergillosis", "ANATOMY", 11, 33], ["organ", "ANATOMY", 103, 108], ["aspergillosis", "DISEASE", 20, 33], ["neutropenia", "DISEASE", 81, 92], ["aspergillosis", "CANCER", 20, 33], ["patients", "ORGANISM", 67, 75], ["organ", "ORGAN", 103, 108], ["patients", "SPECIES", 67, 75], ["invasive aspergillosis", "PROBLEM", 11, 33], ["neutropenia", "PROBLEM", 81, 92], ["organ transplantation", "TREATMENT", 103, 124], ["invasive", "OBSERVATION_MODIFIER", 11, 19], ["aspergillosis", "OBSERVATION", 20, 33], ["neutropenia", "OBSERVATION", 81, 92]]], ["26, 27 In the United States, the most predominant mycobacteria that are associated with pulmonary infections include M. avium complex, followed by M. kansasii.", [["pulmonary", "ANATOMY", 88, 97], ["pulmonary infections", "DISEASE", 88, 108], ["M. avium complex", "DISEASE", 117, 133], ["kansasii", "DISEASE", 150, 158], ["pulmonary", "ORGAN", 88, 97], ["M. avium complex", "ORGANISM", 117, 133], ["M. kansasii", "ORGANISM", 147, 158], ["M. avium", "SPECIES", 117, 125], ["M. kansasii", "SPECIES", 147, 158], ["M. avium", "SPECIES", 117, 125], ["M. kansasii", "SPECIES", 147, 158], ["the most predominant mycobacteria", "PROBLEM", 29, 62], ["pulmonary infections", "PROBLEM", 88, 108], ["M. avium complex", "PROBLEM", 117, 133], ["most predominant", "OBSERVATION_MODIFIER", 33, 49], ["mycobacteria", "OBSERVATION", 50, 62], ["associated with", "UNCERTAINTY", 72, 87], ["pulmonary", "ANATOMY", 88, 97], ["infections", "OBSERVATION", 98, 108], ["avium complex", "OBSERVATION", 120, 133], ["kansasii", "OBSERVATION", 150, 158]]], ["NTM pulmonary infections are noncontagious.", [["pulmonary", "ANATOMY", 4, 13], ["NTM pulmonary infections", "DISEASE", 0, 24], ["pulmonary", "ORGAN", 4, 13], ["NTM pulmonary infections", "PROBLEM", 0, 24], ["pulmonary", "ANATOMY", 4, 13], ["infections", "OBSERVATION", 14, 24]]], ["However, these infections are transmitted by inhalation of mycobacteria.", [["infections", "DISEASE", 15, 25], ["these infections", "PROBLEM", 9, 25], ["mycobacteria", "PROBLEM", 59, 71], ["infections", "OBSERVATION", 15, 25], ["mycobacteria", "OBSERVATION", 59, 71]]], ["Symptoms of NTM pulmonary infections are chronic cough, sputum production, high fever and weight loss.", [["pulmonary", "ANATOMY", 16, 25], ["sputum", "ANATOMY", 56, 62], ["NTM pulmonary infections", "DISEASE", 12, 36], ["cough", "DISEASE", 49, 54], ["fever", "DISEASE", 80, 85], ["weight loss", "DISEASE", 90, 101], ["pulmonary", "ORGAN", 16, 25], ["sputum", "ORGANISM_SUBSTANCE", 56, 62], ["Symptoms", "PROBLEM", 0, 8], ["NTM pulmonary infections", "PROBLEM", 12, 36], ["chronic cough", "PROBLEM", 41, 54], ["sputum production", "PROBLEM", 56, 73], ["high fever", "PROBLEM", 75, 85], ["weight loss", "PROBLEM", 90, 101], ["NTM", "OBSERVATION_MODIFIER", 12, 15], ["pulmonary", "ANATOMY", 16, 25], ["infections", "OBSERVATION", 26, 36], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["cough", "OBSERVATION", 49, 54], ["high", "OBSERVATION_MODIFIER", 75, 79], ["fever", "OBSERVATION", 80, 85], ["weight loss", "OBSERVATION", 90, 101]]], ["29 NTM pulmonary infections have been reported in immunocompromised patients, patients with lung transplantation, and those affected with cystic fibrosis (CF).", [["pulmonary", "ANATOMY", 7, 16], ["lung", "ANATOMY", 92, 96], ["cystic", "ANATOMY", 138, 144], ["NTM pulmonary infections", "DISEASE", 3, 27], ["cystic fibrosis", "DISEASE", 138, 153], ["CF", "DISEASE", 155, 157], ["pulmonary", "ORGAN", 7, 16], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 78, 86], ["lung", "ORGAN", 92, 96], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 78, 86], ["NTM pulmonary infections", "PROBLEM", 3, 27], ["lung transplantation", "TREATMENT", 92, 112], ["cystic fibrosis", "PROBLEM", 138, 153], ["pulmonary", "ANATOMY", 7, 16], ["infections", "OBSERVATION", 17, 27], ["lung", "ANATOMY", 92, 96], ["transplantation", "OBSERVATION", 97, 112], ["cystic", "OBSERVATION_MODIFIER", 138, 144], ["fibrosis", "OBSERVATION", 145, 153]]], ["30EXISTING TREATMENTS FOR PULMONARY INFECTIONSDifferent treatments are available for the management of pulmonary infections, but in case of some infections the duration of treatment may be very long, for example,TB.", [["pulmonary", "ANATOMY", 103, 112], ["pulmonary infections", "DISEASE", 103, 123], ["infections", "DISEASE", 145, 155], ["pulmonary", "ORGAN", 103, 112], ["PULMONARY INFECTIONSDifferent treatments", "TREATMENT", 26, 66], ["pulmonary infections", "PROBLEM", 103, 123], ["some infections", "PROBLEM", 140, 155], ["treatment", "TREATMENT", 172, 181], ["PULMONARY", "ANATOMY", 26, 35], ["INFECTIONSDifferent", "OBSERVATION", 36, 55], ["pulmonary", "ANATOMY", 103, 112], ["infections", "OBSERVATION", 113, 123], ["infections", "OBSERVATION", 145, 155]]], ["Macrolides drugs are commonly used in the management of various kinds of pulmonary infections and have received considerable attention because of their antiinflammatory and immunomodulatory actions, apart from the antibacterial efficacy.", [["pulmonary", "ANATOMY", 73, 82], ["Macrolides", "CHEMICAL", 0, 10], ["pulmonary infections", "DISEASE", 73, 93], ["Macrolides", "CHEMICAL", 0, 10], ["pulmonary", "ORGAN", 73, 82], ["Macrolides drugs", "TREATMENT", 0, 16], ["pulmonary infections", "PROBLEM", 73, 93], ["their antiinflammatory", "TREATMENT", 146, 168], ["immunomodulatory actions", "TREATMENT", 173, 197], ["the antibacterial efficacy", "TREATMENT", 210, 236], ["pulmonary", "ANATOMY", 73, 82], ["infections", "OBSERVATION", 83, 93], ["antibacterial efficacy", "OBSERVATION", 214, 236]]], ["Min and Jang 31 studied the in vitro and in vivo efficacy of macrolides drugs (viz. azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, and telithromycin) against respiratory viral infections caused by rhinovirus, respiratory syncytial virus and influenza virus.", [["macrolides", "CHEMICAL", 61, 71], ["azithromycin", "CHEMICAL", 84, 96], ["clarithromycin", "CHEMICAL", 98, 112], ["dirithromycin", "CHEMICAL", 114, 127], ["erythromycin", "CHEMICAL", 129, 141], ["roxithromycin", "CHEMICAL", 143, 156], ["telithromycin", "CHEMICAL", 162, 175], ["respiratory viral infections", "DISEASE", 185, 213], ["respiratory syncytial virus", "DISEASE", 236, 263], ["influenza virus", "DISEASE", 268, 283], ["macrolides", "CHEMICAL", 61, 71], ["azithromycin", "CHEMICAL", 84, 96], ["clarithromycin", "CHEMICAL", 98, 112], ["dirithromycin", "CHEMICAL", 114, 127], ["erythromycin", "CHEMICAL", 129, 141], ["roxithromycin", "CHEMICAL", 143, 156], ["telithromycin", "CHEMICAL", 162, 175], ["macrolides drugs", "SIMPLE_CHEMICAL", 61, 77], ["azithromycin", "SIMPLE_CHEMICAL", 84, 96], ["clarithromycin", "SIMPLE_CHEMICAL", 98, 112], ["dirithromycin", "SIMPLE_CHEMICAL", 114, 127], ["erythromycin", "SIMPLE_CHEMICAL", 129, 141], ["roxithromycin", "SIMPLE_CHEMICAL", 143, 156], ["telithromycin", "SIMPLE_CHEMICAL", 162, 175], ["respiratory viral", "ORGANISM", 185, 202], ["rhinovirus", "ORGANISM", 224, 234], ["respiratory syncytial virus", "ORGANISM", 236, 263], ["influenza virus", "ORGANISM", 268, 283], ["respiratory syncytial virus", "SPECIES", 236, 263], ["influenza virus", "SPECIES", 268, 283], ["respiratory syncytial virus", "SPECIES", 236, 263], ["macrolides drugs", "TREATMENT", 61, 77], ["azithromycin", "TREATMENT", 84, 96], ["clarithromycin", "TREATMENT", 98, 112], ["dirithromycin", "TREATMENT", 114, 127], ["erythromycin", "TREATMENT", 129, 141], ["roxithromycin", "TREATMENT", 143, 156], ["telithromycin", "TREATMENT", 162, 175], ["respiratory viral infections", "PROBLEM", 185, 213], ["rhinovirus", "PROBLEM", 224, 234], ["respiratory syncytial virus", "PROBLEM", 236, 263], ["influenza virus", "PROBLEM", 268, 283], ["syncytial virus", "OBSERVATION", 248, 263], ["influenza virus", "OBSERVATION", 268, 283]]], ["The results showed significant antiviral activity against all the tested pulmonary viruses.", [["pulmonary", "ANATOMY", 73, 82], ["pulmonary", "ORGAN", 73, 82], ["significant antiviral activity", "PROBLEM", 19, 49], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["antiviral activity", "OBSERVATION", 31, 49], ["pulmonary", "ANATOMY", 73, 82], ["viruses", "OBSERVATION", 83, 90]]], ["Henry et al. 32 proposed the bacteriophage therapy for the treatment of pulmonary infections caused by antibiotic-resistant bacteria.", [["pulmonary", "ANATOMY", 72, 81], ["pulmonary infections", "DISEASE", 72, 92], ["pulmonary", "ORGAN", 72, 81], ["the bacteriophage therapy", "TREATMENT", 25, 50], ["pulmonary infections", "PROBLEM", 72, 92], ["antibiotic-resistant bacteria", "PROBLEM", 103, 132], ["pulmonary", "ANATOMY", 72, 81], ["infections", "OBSERVATION", 82, 92], ["resistant bacteria", "OBSERVATION", 114, 132]]], ["They found that pulmonary infections caused by antibiotic-resistant Pseudomonas aeruginosa can be safely managed by using various bacteriophages from the Myoviridae and Podoviridae family.", [["pulmonary", "ANATOMY", 16, 25], ["pulmonary infections", "DISEASE", 16, 36], ["pulmonary", "ORGAN", 16, 25], ["Pseudomonas aeruginosa", "ORGANISM", 68, 90], ["Myoviridae", "GENE_OR_GENE_PRODUCT", 154, 164], ["Podoviridae", "GENE_OR_GENE_PRODUCT", 169, 180], ["Pseudomonas aeruginosa", "SPECIES", 68, 90], ["Pseudomonas aeruginosa", "SPECIES", 68, 90], ["pulmonary infections", "PROBLEM", 16, 36], ["antibiotic", "TREATMENT", 47, 57], ["resistant Pseudomonas aeruginosa", "PROBLEM", 58, 90], ["various bacteriophages", "TREATMENT", 122, 144], ["the Myoviridae", "TREATMENT", 150, 164], ["pulmonary", "ANATOMY", 16, 25], ["infections", "OBSERVATION", 26, 36]]], ["In another similar study, Semler et al. 33 demonstrated the use of phage therapy for respiratory infections caused by antibiotic-resistant Burkholderia cepacia.", [["respiratory", "ANATOMY", 85, 96], ["respiratory infections", "DISEASE", 85, 107], ["Burkholderia cepacia", "DISEASE", 139, 159], ["Burkholderia cepacia", "ORGANISM", 139, 159], ["Burkholderia cepacia", "SPECIES", 139, 159], ["Burkholderia cepacia", "SPECIES", 139, 159], ["phage therapy", "TREATMENT", 67, 80], ["respiratory infections", "PROBLEM", 85, 107], ["antibiotic", "TREATMENT", 118, 128], ["resistant Burkholderia cepacia", "PROBLEM", 129, 159], ["infections", "OBSERVATION", 97, 107], ["Burkholderia", "OBSERVATION_MODIFIER", 139, 151], ["cepacia", "OBSERVATION", 152, 159]]], ["The effectiveness of the therapy was studied by establishing the B. cenocepacia respiratory infections in mice using a nebulizer and a nose-only inhalation device, the mice were treated with different B. cenocepacia-specific phages delivered as either an aerosol or intraperitoneal injection.", [["respiratory", "ANATOMY", 80, 91], ["intraperitoneal", "ANATOMY", 266, 281], ["respiratory infections", "DISEASE", 80, 102], ["B. cenocepacia respiratory", "ORGANISM", 65, 91], ["mice", "ORGANISM", 106, 110], ["nose", "ORGANISM_SUBDIVISION", 135, 139], ["mice", "ORGANISM", 168, 172], ["B. cenocepacia", "ORGANISM", 201, 215], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 281], ["B. cenocepacia", "SPECIES", 65, 79], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 168, 172], ["B. cenocepacia", "SPECIES", 201, 215], ["B. cenocepacia", "SPECIES", 65, 79], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 168, 172], ["B. cenocepacia", "SPECIES", 201, 215], ["the therapy", "TREATMENT", 21, 32], ["the B. cenocepacia respiratory infections", "PROBLEM", 61, 102], ["a nebulizer", "TREATMENT", 117, 128], ["a nose-only inhalation device", "TREATMENT", 133, 162], ["different B. cenocepacia", "TREATMENT", 191, 215], ["specific phages", "TREATMENT", 216, 231], ["an aerosol or intraperitoneal injection", "TREATMENT", 252, 291], ["cenocepacia", "OBSERVATION_MODIFIER", 68, 79], ["respiratory infections", "OBSERVATION", 80, 102]]], ["The results obtained after 2 days of treatment suggested that aerosol phage therapy appears to be an effective method.", [["treatment", "TREATMENT", 37, 46], ["aerosol phage therapy", "TREATMENT", 62, 83]]], ["Whereas, the mice that received phage treatment by intraperitoneal injection did not show significant activity.EXISTING TREATMENTS FOR PULMONARY INFECTIONSAs mentioned previously, pneumonia is a pulmonary infection which affects the lungs.", [["intraperitoneal", "ANATOMY", 51, 66], ["pulmonary", "ANATOMY", 195, 204], ["lungs", "ANATOMY", 233, 238], ["pneumonia", "DISEASE", 180, 189], ["pulmonary infection", "DISEASE", 195, 214], ["mice", "ORGANISM", 13, 17], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 66], ["pulmonary", "ORGAN", 195, 204], ["lungs", "ORGAN", 233, 238], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["phage treatment", "TREATMENT", 32, 47], ["intraperitoneal injection", "TREATMENT", 51, 76], ["EXISTING TREATMENTS", "TREATMENT", 111, 130], ["PULMONARY INFECTIONSAs", "PROBLEM", 135, 157], ["pneumonia", "PROBLEM", 180, 189], ["a pulmonary infection", "PROBLEM", 193, 214], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["activity", "OBSERVATION", 102, 110], ["PULMONARY", "ANATOMY", 135, 144], ["INFECTIONSAs", "OBSERVATION", 145, 157], ["pneumonia", "OBSERVATION", 180, 189], ["pulmonary", "ANATOMY", 195, 204], ["infection", "OBSERVATION", 205, 214], ["lungs", "ANATOMY", 233, 238]]], ["It is caused by various bacteria (eg, Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae and Mycoplasma pneumoniae), viruses (eg, adenoviruses, rhinovirus, influenza virus, respiratory syncytial virus and parainfluenza virus) and fungi (eg, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Sporothrix schenckii and Cryptococcus neoformans).", [["Streptococcus pneumoniae", "DISEASE", 38, 62], ["Haemophilus influenzae", "DISEASE", 87, 109], ["Mycoplasma pneumoniae", "DISEASE", 114, 135], ["influenza virus", "DISEASE", 177, 192], ["respiratory syncytial virus and parainfluenza virus)", "DISEASE", 194, 246], ["Histoplasma capsulatum", "DISEASE", 262, 284], ["Coccidioides immitis", "DISEASE", 286, 306], ["Blastomyces dermatitidis", "DISEASE", 308, 332], ["Cryptococcus neoformans", "DISEASE", 390, 413], ["Streptococcus pneumoniae", "ORGANISM", 38, 62], ["Klebsiella pneumoniae", "ORGANISM", 64, 85], ["Haemophilus influenzae", "ORGANISM", 87, 109], ["Mycoplasma pneumoniae", "ORGANISM", 114, 135], ["adenoviruses", "ORGANISM", 151, 163], ["rhinovirus, influenza virus", "ORGANISM", 165, 192], ["respiratory syncytial virus", "ORGANISM", 194, 221], ["parainfluenza virus", "ORGANISM", 226, 245], ["Histoplasma capsulatum", "ORGANISM", 262, 284], ["Coccidioides immitis", "ORGANISM", 286, 306], ["Blastomyces dermatitidis", "ORGANISM", 308, 332], ["Paracoccidioides brasiliensis", "ORGANISM", 334, 363], ["Sporothrix schenckii", "ORGANISM", 365, 385], ["Cryptococcus neoformans", "ORGANISM", 390, 413], ["Streptococcus pneumoniae", "SPECIES", 38, 62], ["Klebsiella pneumoniae", "SPECIES", 64, 85], ["Haemophilus influenzae", "SPECIES", 87, 109], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["influenza virus", "SPECIES", 177, 192], ["respiratory syncytial virus", "SPECIES", 194, 221], ["parainfluenza virus", "SPECIES", 226, 245], ["Histoplasma capsulatum", "SPECIES", 262, 284], ["Coccidioides immitis", "SPECIES", 286, 306], ["Blastomyces dermatitidis", "SPECIES", 308, 332], ["Paracoccidioides brasiliensis", "SPECIES", 334, 363], ["Sporothrix schenckii", "SPECIES", 365, 385], ["Cryptococcus neoformans", "SPECIES", 390, 413], ["Streptococcus pneumoniae", "SPECIES", 38, 62], ["Klebsiella pneumoniae", "SPECIES", 64, 85], ["Haemophilus influenzae", "SPECIES", 87, 109], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["respiratory syncytial virus", "SPECIES", 194, 221], ["parainfluenza virus", "SPECIES", 226, 245], ["Histoplasma capsulatum", "SPECIES", 262, 284], ["Coccidioides immitis", "SPECIES", 286, 306], ["Blastomyces dermatitidis", "SPECIES", 308, 332], ["Paracoccidioides brasiliensis", "SPECIES", 334, 363], ["Sporothrix schenckii", "SPECIES", 365, 385], ["Cryptococcus neoformans", "SPECIES", 390, 413], ["various bacteria (eg", "PROBLEM", 16, 36], ["Streptococcus pneumoniae", "PROBLEM", 38, 62], ["Klebsiella pneumoniae", "PROBLEM", 64, 85], ["Haemophilus influenzae", "PROBLEM", 87, 109], ["Mycoplasma pneumoniae", "PROBLEM", 114, 135], ["viruses (eg", "PROBLEM", 138, 149], ["adenoviruses", "PROBLEM", 151, 163], ["rhinovirus", "PROBLEM", 165, 175], ["influenza virus", "PROBLEM", 177, 192], ["respiratory syncytial virus", "PROBLEM", 194, 221], ["parainfluenza virus", "PROBLEM", 226, 245], ["fungi (eg", "PROBLEM", 251, 260], ["Histoplasma capsulatum", "PROBLEM", 262, 284], ["Coccidioides immitis", "PROBLEM", 286, 306], ["Blastomyces dermatitidis", "PROBLEM", 308, 332], ["Paracoccidioides brasiliensis", "PROBLEM", 334, 363], ["Sporothrix schenckii", "TREATMENT", 365, 385], ["Cryptococcus neoformans", "TREATMENT", 390, 413], ["Mycoplasma pneumoniae", "OBSERVATION", 114, 135], ["respiratory syncytial", "ANATOMY", 194, 215], ["Blastomyces dermatitidis", "OBSERVATION", 308, 332], ["Paracoccidioides brasiliensis", "OBSERVATION", 334, 363]]], ["It is characterized primarily by inflammation of the alveoli in the lungs or by fluid filled alveoli (alveoli are microscopic sacs in the lungs that absorb oxygen).", [["alveoli", "ANATOMY", 53, 60], ["lungs", "ANATOMY", 68, 73], ["fluid", "ANATOMY", 80, 85], ["alveoli", "ANATOMY", 93, 100], ["alveoli", "ANATOMY", 102, 109], ["sacs", "ANATOMY", 126, 130], ["lungs", "ANATOMY", 138, 143], ["oxygen", "CHEMICAL", 156, 162], ["oxygen", "CHEMICAL", 156, 162], ["alveoli", "MULTI-TISSUE_STRUCTURE", 53, 60], ["lungs", "ORGAN", 68, 73], ["alveoli", "MULTI-TISSUE_STRUCTURE", 93, 100], ["alveoli", "MULTI-TISSUE_STRUCTURE", 102, 109], ["sacs", "MULTI-TISSUE_STRUCTURE", 126, 130], ["lungs", "ORGAN", 138, 143], ["oxygen", "SIMPLE_CHEMICAL", 156, 162], ["inflammation of the alveoli in the lungs", "PROBLEM", 33, 73], ["fluid filled alveoli", "PROBLEM", 80, 100], ["inflammation", "OBSERVATION", 33, 45], ["alveoli", "ANATOMY_MODIFIER", 53, 60], ["lungs", "ANATOMY", 68, 73], ["fluid filled", "OBSERVATION", 80, 92], ["alveoli", "ANATOMY_MODIFIER", 93, 100], ["alveoli", "ANATOMY_MODIFIER", 102, 109], ["lungs", "ANATOMY", 138, 143]]], ["Generally, treatment of pneumonia depends on the type and severity of infections.", [["pneumonia", "DISEASE", 24, 33], ["infections", "DISEASE", 70, 80], ["pneumonia", "PROBLEM", 24, 33], ["infections", "PROBLEM", 70, 80], ["pneumonia", "OBSERVATION", 24, 33], ["infections", "OBSERVATION", 70, 80]]], ["Bacterial pneumonia is usually treated with different antibiotics (viz. azithromycin, erythromycin, doxycycline, gemifloxacin, levofloxacin, cephalexin, amoxicillin, vancomycin, etc.).", [["pneumonia", "DISEASE", 10, 19], ["azithromycin", "CHEMICAL", 72, 84], ["erythromycin", "CHEMICAL", 86, 98], ["doxycycline", "CHEMICAL", 100, 111], ["gemifloxacin", "CHEMICAL", 113, 125], ["levofloxacin", "CHEMICAL", 127, 139], ["cephalexin", "CHEMICAL", 141, 151], ["amoxicillin", "CHEMICAL", 153, 164], ["vancomycin", "CHEMICAL", 166, 176], ["azithromycin", "CHEMICAL", 72, 84], ["erythromycin", "CHEMICAL", 86, 98], ["doxycycline", "CHEMICAL", 100, 111], ["gemifloxacin", "CHEMICAL", 113, 125], ["levofloxacin", "CHEMICAL", 127, 139], ["cephalexin", "CHEMICAL", 141, 151], ["amoxicillin", "CHEMICAL", 153, 164], ["vancomycin", "CHEMICAL", 166, 176], ["azithromycin", "SIMPLE_CHEMICAL", 72, 84], ["erythromycin", "SIMPLE_CHEMICAL", 86, 98], ["doxycycline", "SIMPLE_CHEMICAL", 100, 111], ["gemifloxacin", "SIMPLE_CHEMICAL", 113, 125], ["levofloxacin", "SIMPLE_CHEMICAL", 127, 139], ["cephalexin", "SIMPLE_CHEMICAL", 141, 151], ["amoxicillin", "SIMPLE_CHEMICAL", 153, 164], ["vancomycin", "SIMPLE_CHEMICAL", 166, 176], ["Bacterial pneumonia", "PROBLEM", 0, 19], ["different antibiotics", "TREATMENT", 44, 65], ["azithromycin", "TREATMENT", 72, 84], ["erythromycin", "TREATMENT", 86, 98], ["doxycycline", "TREATMENT", 100, 111], ["gemifloxacin", "TREATMENT", 113, 125], ["levofloxacin", "TREATMENT", 127, 139], ["cephalexin", "TREATMENT", 141, 151], ["amoxicillin", "TREATMENT", 153, 164], ["vancomycin", "TREATMENT", 166, 176], ["pneumonia", "OBSERVATION", 10, 19]]], ["34 Efficient antifungals used for the management of fungal pneumonia include first, second and third-generation triazoles and echinocandins.", [["fungal pneumonia", "DISEASE", 52, 68], ["triazoles", "CHEMICAL", 112, 121], ["echinocandins", "CHEMICAL", 126, 139], ["triazoles", "CHEMICAL", 112, 121], ["echinocandins", "CHEMICAL", 126, 139], ["third-generation triazoles", "SIMPLE_CHEMICAL", 95, 121], ["echinocandins", "SIMPLE_CHEMICAL", 126, 139], ["Efficient antifungals", "TREATMENT", 3, 24], ["the management", "TREATMENT", 34, 48], ["fungal pneumonia", "PROBLEM", 52, 68], ["third-generation triazoles", "TREATMENT", 95, 121], ["echinocandins", "TREATMENT", 126, 139], ["antifungals", "OBSERVATION", 13, 24], ["fungal", "OBSERVATION_MODIFIER", 52, 58], ["pneumonia", "OBSERVATION", 59, 68]]], ["In some cases Amphotericin B is less frequently used.", [["Amphotericin B", "CHEMICAL", 14, 28], ["Amphotericin B", "CHEMICAL", 14, 28], ["Amphotericin B", "SIMPLE_CHEMICAL", 14, 28], ["Amphotericin B", "TREATMENT", 14, 28]]], ["However, viral pneumonia is treated with rest and plenty of fluids.", [["pneumonia", "DISEASE", 15, 24], ["viral pneumonia", "PROBLEM", 9, 24], ["rest", "TREATMENT", 41, 45], ["fluids", "TREATMENT", 60, 66], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["pneumonia", "OBSERVATION", 15, 24]]], ["35 TB is also one of the most life-threatening pulmonary infections and it is a major public health problem all over the world.", [["pulmonary", "ANATOMY", 47, 56], ["TB", "DISEASE", 3, 5], ["pulmonary infections", "DISEASE", 47, 67], ["pulmonary", "ORGAN", 47, 56], ["threatening pulmonary infections", "PROBLEM", 35, 67], ["TB", "OBSERVATION", 3, 5], ["pulmonary", "ANATOMY", 47, 56], ["infections", "OBSERVATION", 57, 67]]], ["According to a survey, India contributes about 26% of the global TB burden.", [["TB", "DISEASE", 65, 67], ["the global TB burden", "PROBLEM", 54, 74], ["global", "OBSERVATION_MODIFIER", 58, 64], ["TB", "OBSERVATION", 65, 67]]], ["Since ancient times, TB has been a leading cause of morbidity and mortality.", [["TB", "DISEASE", 21, 23], ["TB", "PROBLEM", 21, 23], ["morbidity", "PROBLEM", 52, 61], ["morbidity", "OBSERVATION", 52, 61]]], ["36 Over the last decade, scientists have made significant progress in treatment for TB.", [["TB", "DISEASE", 84, 86], ["treatment", "TREATMENT", 70, 79], ["TB", "PROBLEM", 84, 86]]], ["Regimens have been optimized and directly observed therapy short-course (DOTS) initiatives have been implemented.", [["Regimens", "TREATMENT", 0, 8], ["therapy short-course (DOTS) initiatives", "TREATMENT", 51, 90]]], ["37 Currently, chemotherapy used for TB commonly includes combination of first-line drugs, isoniazid, rifampin, pyrazinamide and ethambutol for about 6 months.", [["TB", "DISEASE", 36, 38], ["isoniazid", "CHEMICAL", 90, 99], ["rifampin", "CHEMICAL", 101, 109], ["pyrazinamide", "CHEMICAL", 111, 123], ["ethambutol", "CHEMICAL", 128, 138], ["isoniazid", "CHEMICAL", 90, 99], ["rifampin", "CHEMICAL", 101, 109], ["pyrazinamide", "CHEMICAL", 111, 123], ["ethambutol", "CHEMICAL", 128, 138], ["isoniazid", "SIMPLE_CHEMICAL", 90, 99], ["rifampin", "SIMPLE_CHEMICAL", 101, 109], ["pyrazinamide", "SIMPLE_CHEMICAL", 111, 123], ["ethambutol", "SIMPLE_CHEMICAL", 128, 138], ["chemotherapy", "TREATMENT", 14, 26], ["TB", "PROBLEM", 36, 38], ["first-line drugs", "TREATMENT", 72, 88], ["isoniazid", "TREATMENT", 90, 99], ["rifampin", "TREATMENT", 101, 109], ["pyrazinamide", "TREATMENT", 111, 123], ["ethambutol", "TREATMENT", 128, 138]]], ["If treatment fails because of drug resistance, then second-line drugs, such as, paraaminosalicylate, kanamycin, fluoroquinolones, capreomycin, ethionamide and cycloserine are recommended, although these drugs may have serious side effects.", [["paraaminosalicylate", "CHEMICAL", 80, 99], ["kanamycin", "CHEMICAL", 101, 110], ["fluoroquinolones", "CHEMICAL", 112, 128], ["capreomycin", "CHEMICAL", 130, 141], ["ethionamide", "CHEMICAL", 143, 154], ["cycloserine", "CHEMICAL", 159, 170], ["paraaminosalicylate", "CHEMICAL", 80, 99], ["kanamycin", "CHEMICAL", 101, 110], ["fluoroquinolones", "CHEMICAL", 112, 128], ["capreomycin", "CHEMICAL", 130, 141], ["ethionamide", "CHEMICAL", 143, 154], ["cycloserine", "CHEMICAL", 159, 170], ["paraaminosalicylate", "SIMPLE_CHEMICAL", 80, 99], ["kanamycin", "SIMPLE_CHEMICAL", 101, 110], ["fluoroquinolones", "SIMPLE_CHEMICAL", 112, 128], ["capreomycin", "SIMPLE_CHEMICAL", 130, 141], ["ethionamide", "SIMPLE_CHEMICAL", 143, 154], ["cycloserine", "SIMPLE_CHEMICAL", 159, 170], ["drug resistance", "PROBLEM", 30, 45], ["second-line drugs", "TREATMENT", 52, 69], ["paraaminosalicylate", "TREATMENT", 80, 99], ["kanamycin", "TREATMENT", 101, 110], ["fluoroquinolones", "TREATMENT", 112, 128], ["capreomycin", "TREATMENT", 130, 141], ["ethionamide", "TREATMENT", 143, 154], ["cycloserine", "TREATMENT", 159, 170], ["these drugs", "TREATMENT", 197, 208], ["serious side effects", "PROBLEM", 218, 238]]], ["[38] [39] [40] [41] Aspergillosis in one of the most important diseases among the pulmonary infections caused by Aspergillus species.", [["pulmonary", "ANATOMY", 82, 91], ["[38] [39] [40] [41] Aspergillosis", "CHEMICAL", 0, 33], ["pulmonary infections", "DISEASE", 82, 102], ["[38] [39] [40] [41] Aspergillosis", "SIMPLE_CHEMICAL", 0, 33], ["pulmonary", "ORGAN", 82, 91], ["Aspergillus species", "ORGANISM", 113, 132], ["Aspergillosis", "PROBLEM", 20, 33], ["the pulmonary infections", "PROBLEM", 78, 102], ["Aspergillus species", "PROBLEM", 113, 132], ["Aspergillosis", "OBSERVATION", 20, 33], ["pulmonary", "ANATOMY", 82, 91], ["infections", "OBSERVATION", 92, 102], ["Aspergillus species", "OBSERVATION", 113, 132]]], ["It is reported to be an emerging cause of life-threatening infections in immunocompromised patients having infections, such as, prolonged neutropenia, advanced HIV infection, inherited immunodeficiency and in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and/or lung transplantation.", [["hematopoietic stem cell", "ANATOMY", 248, 271], ["lung", "ANATOMY", 302, 306], ["infections", "DISEASE", 59, 69], ["infections", "DISEASE", 107, 117], ["neutropenia", "DISEASE", 138, 149], ["HIV infection", "DISEASE", 160, 173], ["inherited immunodeficiency", "DISEASE", 175, 201], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 209, 217], ["hematopoietic stem cell", "CELL", 248, 271], ["lung", "ORGAN", 302, 306], ["patients", "SPECIES", 91, 99], ["HIV", "SPECIES", 160, 163], ["patients", "SPECIES", 209, 217], ["HIV", "SPECIES", 160, 163], ["life-threatening infections", "PROBLEM", 42, 69], ["infections", "PROBLEM", 107, 117], ["prolonged neutropenia", "PROBLEM", 128, 149], ["advanced HIV infection", "PROBLEM", 151, 173], ["inherited immunodeficiency", "PROBLEM", 175, 201], ["allogeneic hematopoietic stem cell transplantation", "TREATMENT", 237, 287], ["lung transplantation", "TREATMENT", 302, 322], ["threatening", "OBSERVATION_MODIFIER", 47, 58], ["infections", "OBSERVATION", 59, 69], ["infections", "OBSERVATION", 107, 117], ["prolonged", "OBSERVATION_MODIFIER", 128, 137], ["neutropenia", "OBSERVATION", 138, 149], ["HIV", "OBSERVATION_MODIFIER", 160, 163], ["infection", "OBSERVATION", 164, 173], ["allogeneic hematopoietic stem cell transplantation", "OBSERVATION", 237, 287], ["lung", "ANATOMY", 302, 306], ["transplantation", "OBSERVATION", 307, 322]]], ["Three different forms of aspergillosis have been reported so far.", [["aspergillosis", "DISEASE", 25, 38], ["aspergillosis", "CANCER", 25, 38], ["aspergillosis", "PROBLEM", 25, 38], ["aspergillosis", "OBSERVATION", 25, 38]]], ["These include invasive aspergillosis, chronic (and saprophytic) aspergillosis and allergic forms of aspergillosis.", [["invasive aspergillosis", "ANATOMY", 14, 36], ["aspergillosis", "DISEASE", 23, 36], ["chronic (and saprophytic) aspergillosis", "DISEASE", 38, 77], ["allergic forms", "DISEASE", 82, 96], ["aspergillosis", "DISEASE", 100, 113], ["aspergillosis", "CANCER", 100, 113], ["invasive aspergillosis", "PROBLEM", 14, 36], ["chronic (and saprophytic) aspergillosis", "PROBLEM", 38, 77], ["allergic", "PROBLEM", 82, 90], ["aspergillosis", "PROBLEM", 100, 113], ["invasive", "OBSERVATION_MODIFIER", 14, 22], ["aspergillosis", "OBSERVATION", 23, 36], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["saprophytic", "OBSERVATION_MODIFIER", 51, 62], ["aspergillosis", "OBSERVATION", 64, 77], ["allergic", "OBSERVATION", 82, 90], ["aspergillosis", "OBSERVATION", 100, 113]]], ["Generally, voriconazole is superior to deoxycholate amphotericin B (D-AMB) and, hence, recommended in primary treatment for invasive aspergillosis in most patients.", [["invasive aspergillosis", "ANATOMY", 124, 146], ["voriconazole", "CHEMICAL", 11, 23], ["deoxycholate", "CHEMICAL", 39, 51], ["amphotericin B", "CHEMICAL", 52, 66], ["D-AMB", "CHEMICAL", 68, 73], ["aspergillosis", "DISEASE", 133, 146], ["voriconazole", "CHEMICAL", 11, 23], ["amphotericin B", "CHEMICAL", 52, 66], ["D-AMB", "CHEMICAL", 68, 73], ["voriconazole", "SIMPLE_CHEMICAL", 11, 23], ["deoxycholate amphotericin B", "SIMPLE_CHEMICAL", 39, 66], ["D-AMB", "SIMPLE_CHEMICAL", 68, 73], ["aspergillosis", "CANCER", 133, 146], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["voriconazole", "TREATMENT", 11, 23], ["deoxycholate amphotericin B (D-AMB)", "TREATMENT", 39, 74], ["primary treatment", "TREATMENT", 102, 119], ["invasive aspergillosis", "PROBLEM", 124, 146], ["invasive", "OBSERVATION_MODIFIER", 124, 132], ["aspergillosis", "OBSERVATION", 133, 146]]], ["Apart from these, some of the FDA-approved compounds, such as, lipid formulations of amphotericin B (AMB lipid complex [ABLC], L-AMB, and AMB colloidal dispersion [ABCD]), caspofungin and antifungal triazoles (ie, itraconazole, voriconazole and posaconazole) are also recommended.", [["amphotericin B", "CHEMICAL", 85, 99], ["AMB", "CHEMICAL", 101, 104], ["ABLC", "CHEMICAL", 120, 124], ["L-AMB", "CHEMICAL", 127, 132], ["AMB", "CHEMICAL", 138, 141], ["caspofungin", "CHEMICAL", 172, 183], ["triazoles", "CHEMICAL", 199, 208], ["itraconazole", "CHEMICAL", 214, 226], ["voriconazole", "CHEMICAL", 228, 240], ["posaconazole", "CHEMICAL", 245, 257], ["amphotericin B", "CHEMICAL", 85, 99], ["AMB", "CHEMICAL", 101, 104], ["L-AMB", "CHEMICAL", 127, 132], ["AMB", "CHEMICAL", 138, 141], ["caspofungin", "CHEMICAL", 172, 183], ["triazoles", "CHEMICAL", 199, 208], ["itraconazole", "CHEMICAL", 214, 226], ["voriconazole", "CHEMICAL", 228, 240], ["posaconazole", "CHEMICAL", 245, 257], ["lipid", "SIMPLE_CHEMICAL", 63, 68], ["amphotericin B", "SIMPLE_CHEMICAL", 85, 99], ["AMB lipid complex", "SIMPLE_CHEMICAL", 101, 118], ["ABLC", "SIMPLE_CHEMICAL", 120, 124], ["L-AMB", "SIMPLE_CHEMICAL", 127, 132], ["AMB", "SIMPLE_CHEMICAL", 138, 141], ["ABCD", "SIMPLE_CHEMICAL", 164, 168], ["caspofungin", "SIMPLE_CHEMICAL", 172, 183], ["antifungal triazoles", "SIMPLE_CHEMICAL", 188, 208], ["itraconazole", "SIMPLE_CHEMICAL", 214, 226], ["voriconazole", "SIMPLE_CHEMICAL", 228, 240], ["posaconazole", "SIMPLE_CHEMICAL", 245, 257], ["lipid formulations", "TREATMENT", 63, 81], ["amphotericin B (AMB lipid complex", "TREATMENT", 85, 118], ["L-AMB", "TREATMENT", 127, 132], ["AMB colloidal dispersion", "TREATMENT", 138, 162], ["caspofungin", "TREATMENT", 172, 183], ["antifungal triazoles", "TREATMENT", 188, 208], ["itraconazole", "TREATMENT", 214, 226], ["voriconazole", "TREATMENT", 228, 240], ["posaconazole", "TREATMENT", 245, 257], ["some", "OBSERVATION_MODIFIER", 18, 22]]], ["Similarly, in chronic aspergillosis, the regular doses of itraconazole and voriconazole are usually prescribed by the physician.", [["aspergillosis", "DISEASE", 22, 35], ["itraconazole", "CHEMICAL", 58, 70], ["voriconazole", "CHEMICAL", 75, 87], ["itraconazole", "CHEMICAL", 58, 70], ["voriconazole", "CHEMICAL", 75, 87], ["itraconazole", "SIMPLE_CHEMICAL", 58, 70], ["voriconazole", "SIMPLE_CHEMICAL", 75, 87], ["chronic aspergillosis", "PROBLEM", 14, 35], ["itraconazole", "TREATMENT", 58, 70], ["voriconazole", "TREATMENT", 75, 87], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["aspergillosis", "OBSERVATION", 22, 35]]], ["Whereas, the treatment for allergic forms of aspergillosis includes combination of corticosteroids and itraconazole.", [["allergic forms", "DISEASE", 27, 41], ["aspergillosis", "DISEASE", 45, 58], ["itraconazole", "CHEMICAL", 103, 115], ["corticosteroids", "CHEMICAL", 83, 98], ["itraconazole", "CHEMICAL", 103, 115], ["itraconazole", "SIMPLE_CHEMICAL", 103, 115], ["allergic", "PROBLEM", 27, 35], ["aspergillosis", "PROBLEM", 45, 58], ["corticosteroids", "TREATMENT", 83, 98], ["itraconazole", "TREATMENT", 103, 115], ["aspergillosis", "OBSERVATION", 45, 58]]], ["42 Among the pulmonary infections, nontuberculous pulmonary infections caused by NTM are very common infections, which are increasingly recognized worldwide.", [["pulmonary", "ANATOMY", 13, 22], ["pulmonary", "ANATOMY", 50, 59], ["pulmonary infections", "DISEASE", 13, 33], ["nontuberculous pulmonary infections", "DISEASE", 35, 70], ["NTM", "DISEASE", 81, 84], ["infections", "DISEASE", 101, 111], ["pulmonary", "ORGAN", 13, 22], ["pulmonary", "ORGAN", 50, 59], ["the pulmonary infections", "PROBLEM", 9, 33], ["nontuberculous pulmonary infections", "PROBLEM", 35, 70], ["NTM", "PROBLEM", 81, 84], ["very common infections", "PROBLEM", 89, 111], ["pulmonary", "ANATOMY", 13, 22], ["infections", "OBSERVATION", 23, 33], ["nontuberculous", "OBSERVATION_MODIFIER", 35, 49], ["pulmonary", "ANATOMY", 50, 59], ["infections", "OBSERVATION", 60, 70], ["NTM", "OBSERVATION", 81, 84], ["very", "OBSERVATION_MODIFIER", 89, 93], ["common", "OBSERVATION_MODIFIER", 94, 100], ["infections", "OBSERVATION", 101, 111]]], ["About 150 different species of NTM have been described.", [["NTM", "DISEASE", 31, 34], ["NTM", "CANCER", 31, 34], ["NTM", "PROBLEM", 31, 34], ["150 different", "OBSERVATION_MODIFIER", 6, 19], ["NTM", "OBSERVATION", 31, 34]]], ["M. avium complex, M. kansasii, and M. abscessus are found to be most common NTM, which cause such infections.", [["NTM", "DISEASE", 76, 79], ["infections", "DISEASE", 98, 108], ["M. avium complex", "ORGANISM", 0, 16], ["M. kansasii", "ORGANISM", 18, 29], ["M. abscessus", "ORGANISM", 35, 47], ["M. avium", "SPECIES", 0, 8], ["M. kansasii", "SPECIES", 18, 29], ["M. abscessus", "SPECIES", 35, 47], ["M. avium", "SPECIES", 0, 8], ["M. kansasii", "SPECIES", 18, 29], ["M. abscessus", "SPECIES", 35, 47], ["M. avium complex", "PROBLEM", 0, 16], ["M. kansasii", "PROBLEM", 18, 29], ["M. abscessus", "PROBLEM", 35, 47], ["such infections", "PROBLEM", 93, 108], ["avium", "OBSERVATION_MODIFIER", 3, 8], ["complex", "OBSERVATION_MODIFIER", 9, 16], ["kansasii", "OBSERVATION", 21, 29], ["abscessus", "OBSERVATION", 38, 47], ["infections", "OBSERVATION", 98, 108]]], ["According to Davis et al. 43 existing therapy available for the treatment of nontuberculous mycobacterial pulmonary infection by M. avium showed very poor clinical response rates, drug toxicities, and side effects.", [["pulmonary", "ANATOMY", 106, 115], ["mycobacterial pulmonary infection", "DISEASE", 92, 125], ["toxicities", "DISEASE", 185, 195], ["pulmonary", "ORGAN", 106, 115], ["M. avium", "ORGANISM", 129, 137], ["M. avium", "SPECIES", 129, 137], ["M. avium", "SPECIES", 129, 137], ["existing therapy", "TREATMENT", 29, 45], ["the treatment", "TREATMENT", 60, 73], ["nontuberculous mycobacterial pulmonary infection", "PROBLEM", 77, 125], ["M. avium", "TEST", 129, 137], ["drug toxicities", "PROBLEM", 180, 195], ["side effects", "PROBLEM", 201, 213], ["nontuberculous", "OBSERVATION_MODIFIER", 77, 91], ["mycobacterial", "OBSERVATION_MODIFIER", 92, 105], ["pulmonary", "ANATOMY", 106, 115], ["infection", "OBSERVATION", 116, 125]]], ["They demonstrated that use of aerosolized amikacin as a standard oral therapy against nontuberculous mycobacterial pulmonary infection significantly improved treatment efficacy without producing systemic toxicity.", [["oral", "ANATOMY", 65, 69], ["pulmonary", "ANATOMY", 115, 124], ["amikacin", "CHEMICAL", 42, 50], ["mycobacterial pulmonary infection", "DISEASE", 101, 134], ["toxicity", "DISEASE", 204, 212], ["amikacin", "CHEMICAL", 42, 50], ["amikacin", "SIMPLE_CHEMICAL", 42, 50], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["pulmonary", "ORGAN", 115, 124], ["aerosolized amikacin", "TREATMENT", 30, 50], ["a standard oral therapy", "TREATMENT", 54, 77], ["nontuberculous mycobacterial pulmonary infection", "PROBLEM", 86, 134], ["systemic toxicity", "PROBLEM", 195, 212], ["pulmonary", "ANATOMY", 115, 124], ["infection", "OBSERVATION", 125, 134]]], ["Therefore, it was proposed that aerosolized delivery of amikacin is a promising adjunct to standard therapy for pulmonary nontuberculous mycobacterial infections.", [["amikacin", "CHEMICAL", 56, 64], ["pulmonary nontuberculous mycobacterial infections", "DISEASE", 112, 161], ["amikacin", "CHEMICAL", 56, 64], ["amikacin", "SIMPLE_CHEMICAL", 56, 64], ["amikacin", "TREATMENT", 56, 64], ["standard therapy", "TREATMENT", 91, 107], ["pulmonary nontuberculous mycobacterial infections", "PROBLEM", 112, 161], ["pulmonary", "ANATOMY", 112, 121], ["nontuberculous mycobacterial infections", "OBSERVATION", 122, 161]]], ["Moreover, extensive experimental trials are required to define its optimal role in the therapy of this disease.EXISTING TREATMENTS FOR PULMONARY INFECTIONSIn another study, Johnson and Odell 28 reviewed that the eradication of NTM infections is very difficult by the common treatment strategies.", [["NTM", "DISEASE", 227, 230], ["infections", "DISEASE", 231, 241], ["extensive experimental trials", "TREATMENT", 10, 39], ["the therapy", "TREATMENT", 83, 94], ["this disease", "PROBLEM", 98, 110], ["another study", "TEST", 158, 171], ["NTM infections", "PROBLEM", 227, 241], ["PULMONARY", "ANATOMY", 135, 144], ["NTM", "OBSERVATION", 227, 230]]], ["Moreover, it requires a prolonged course of therapy with a combination of drugs.", [["a prolonged course of therapy", "TREATMENT", 22, 51], ["drugs", "TREATMENT", 74, 79]]], ["However, there are numerous challenges regarding the treatment of NTM pulmonary infections, but few drugs which can manage these infections are available.", [["pulmonary", "ANATOMY", 70, 79], ["NTM pulmonary infections", "DISEASE", 66, 90], ["infections", "DISEASE", 129, 139], ["pulmonary", "ORGAN", 70, 79], ["NTM pulmonary infections", "PROBLEM", 66, 90], ["few drugs", "TREATMENT", 96, 105], ["these infections", "PROBLEM", 123, 139], ["numerous", "OBSERVATION_MODIFIER", 19, 27], ["NTM", "OBSERVATION_MODIFIER", 66, 69], ["pulmonary", "ANATOMY", 70, 79], ["infections", "OBSERVATION", 80, 90]]], ["Some macrolide drugs like azithromycin and clarithromycin are the efficient and important drugs in the therapy for MAC lung infections.", [["lung", "ANATOMY", 119, 123], ["macrolide", "CHEMICAL", 5, 14], ["azithromycin", "CHEMICAL", 26, 38], ["clarithromycin", "CHEMICAL", 43, 57], ["lung infections", "DISEASE", 119, 134], ["macrolide", "CHEMICAL", 5, 14], ["azithromycin", "CHEMICAL", 26, 38], ["clarithromycin", "CHEMICAL", 43, 57], ["macrolide drugs", "SIMPLE_CHEMICAL", 5, 20], ["azithromycin", "SIMPLE_CHEMICAL", 26, 38], ["clarithromycin", "SIMPLE_CHEMICAL", 43, 57], ["lung", "ORGAN", 119, 123], ["Some macrolide drugs", "TREATMENT", 0, 20], ["azithromycin", "TREATMENT", 26, 38], ["clarithromycin", "TREATMENT", 43, 57], ["important drugs", "TREATMENT", 80, 95], ["the therapy", "TREATMENT", 99, 110], ["MAC lung infections", "PROBLEM", 115, 134], ["macrolide drugs", "OBSERVATION", 5, 20], ["lung", "ANATOMY", 119, 123], ["infections", "OBSERVATION", 124, 134]]], ["In the case of a resistant strain, a combination therapy with rifampin or rifabutin, and ethambutol (triple therapy) with or without an intravenous aminoglycoside is recommended for about 18 months or more.", [["intravenous", "ANATOMY", 136, 147], ["rifampin", "CHEMICAL", 62, 70], ["rifabutin", "CHEMICAL", 74, 83], ["ethambutol", "CHEMICAL", 89, 99], ["aminoglycoside", "CHEMICAL", 148, 162], ["rifampin", "CHEMICAL", 62, 70], ["rifabutin", "CHEMICAL", 74, 83], ["ethambutol", "CHEMICAL", 89, 99], ["aminoglycoside", "CHEMICAL", 148, 162], ["rifampin", "SIMPLE_CHEMICAL", 62, 70], ["rifabutin", "SIMPLE_CHEMICAL", 74, 83], ["ethambutol", "SIMPLE_CHEMICAL", 89, 99], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 147], ["aminoglycoside", "SIMPLE_CHEMICAL", 148, 162], ["a resistant strain", "PROBLEM", 15, 33], ["a combination therapy", "TREATMENT", 35, 56], ["rifampin", "TREATMENT", 62, 70], ["rifabutin", "TREATMENT", 74, 83], ["ethambutol", "TREATMENT", 89, 99], ["triple therapy", "TREATMENT", 101, 115], ["an intravenous aminoglycoside", "TREATMENT", 133, 162], ["resistant", "OBSERVATION_MODIFIER", 17, 26], ["strain", "OBSERVATION", 27, 33]]], ["Similarly, in the case of infection by M. kansasii, combination of isoniazid, rifampin and ethanbutol is mostly recommended for about 12 months.", [["infection", "DISEASE", 26, 35], ["kansasii", "DISEASE", 42, 50], ["isoniazid", "CHEMICAL", 67, 76], ["rifampin", "CHEMICAL", 78, 86], ["ethanbutol", "CHEMICAL", 91, 101], ["isoniazid", "CHEMICAL", 67, 76], ["rifampin", "CHEMICAL", 78, 86], ["ethanbutol", "CHEMICAL", 91, 101], ["M. kansasii", "ORGANISM", 39, 50], ["isoniazid", "SIMPLE_CHEMICAL", 67, 76], ["rifampin", "SIMPLE_CHEMICAL", 78, 86], ["ethanbutol", "SIMPLE_CHEMICAL", 91, 101], ["M. kansasii", "SPECIES", 39, 50], ["M. kansasii", "SPECIES", 39, 50], ["infection", "PROBLEM", 26, 35], ["isoniazid", "TREATMENT", 67, 76], ["rifampin", "TREATMENT", 78, 86], ["ethanbutol", "TREATMENT", 91, 101], ["infection", "OBSERVATION", 26, 35], ["kansasii", "OBSERVATION", 42, 50]]], ["In addition, macrolides, such as, clarithromycin and the fourth generation fluoroquinolone moxifloxacin demonstrated very good in vitro activity against M. kansasii and may be an alternative to isoniazid.", [["macrolides", "CHEMICAL", 13, 23], ["clarithromycin", "CHEMICAL", 34, 48], ["fluoroquinolone", "CHEMICAL", 75, 90], ["moxifloxacin", "CHEMICAL", 91, 103], ["kansasii", "DISEASE", 156, 164], ["isoniazid", "CHEMICAL", 194, 203], ["macrolides", "CHEMICAL", 13, 23], ["clarithromycin", "CHEMICAL", 34, 48], ["fluoroquinolone", "CHEMICAL", 75, 90], ["moxifloxacin", "CHEMICAL", 91, 103], ["isoniazid", "CHEMICAL", 194, 203], ["macrolides", "SIMPLE_CHEMICAL", 13, 23], ["clarithromycin", "SIMPLE_CHEMICAL", 34, 48], ["moxifloxacin", "SIMPLE_CHEMICAL", 91, 103], ["M. kansasii", "ORGANISM", 153, 164], ["isoniazid", "SIMPLE_CHEMICAL", 194, 203], ["M. kansasii", "SPECIES", 153, 164], ["M. kansasii", "SPECIES", 153, 164], ["macrolides", "TREATMENT", 13, 23], ["clarithromycin", "TREATMENT", 34, 48], ["the fourth generation fluoroquinolone moxifloxacin", "TREATMENT", 53, 103], ["M. kansasii", "PROBLEM", 153, 164], ["isoniazid", "TREATMENT", 194, 203], ["macrolides", "OBSERVATION", 13, 23]]], ["Whereas, lung infections due to M. abscessus are very difficult to treat successfully with drug therapy alone.", [["lung", "ANATOMY", 9, 13], ["lung infections", "DISEASE", 9, 24], ["M. abscessus", "DISEASE", 32, 44], ["lung", "ORGAN", 9, 13], ["M. abscessus", "ORGANISM", 32, 44], ["M. abscessus", "SPECIES", 32, 44], ["M. abscessus", "SPECIES", 32, 44], ["lung infections", "PROBLEM", 9, 24], ["M. abscessus", "PROBLEM", 32, 44], ["drug therapy", "TREATMENT", 91, 103], ["lung", "ANATOMY", 9, 13], ["infections", "OBSERVATION", 14, 24], ["abscessus", "OBSERVATION", 35, 44]]], ["Chemotherapy in conjunction with surgical resection is often recommended in those who can tolerate it.", [["Chemotherapy", "TREATMENT", 0, 12], ["surgical resection", "TREATMENT", 33, 51], ["resection", "OBSERVATION", 42, 51]]], ["Overall, different kinds of medications and therapies are available for the management of pulmonary infections, but in case of some pulmonary infections existing treatments and therapies showed certain limitations, which are briefly discussed here.LIMITATIONS AND SIDE EFFECTS OF THE TREATMENT OF PULMONARY INFECTIONSThere are a number of limitations for use of conventional strategies for diagnosis and treatments of patients with pulmonary infections.", [["pulmonary", "ANATOMY", 90, 99], ["pulmonary", "ANATOMY", 132, 141], ["pulmonary", "ANATOMY", 432, 441], ["pulmonary infections", "DISEASE", 90, 110], ["pulmonary infections", "DISEASE", 132, 152], ["pulmonary infections", "DISEASE", 432, 452], ["pulmonary", "ORGAN", 90, 99], ["pulmonary", "ORGAN", 132, 141], ["patients", "ORGANISM", 418, 426], ["pulmonary", "ORGAN", 432, 441], ["patients", "SPECIES", 418, 426], ["medications", "TREATMENT", 28, 39], ["therapies", "TREATMENT", 44, 53], ["pulmonary infections", "PROBLEM", 90, 110], ["some pulmonary infections", "PROBLEM", 127, 152], ["therapies", "TREATMENT", 177, 186], ["PULMONARY INFECTIONSThere", "PROBLEM", 297, 322], ["conventional strategies", "TREATMENT", 362, 385], ["treatments", "TREATMENT", 404, 414], ["pulmonary infections", "PROBLEM", 432, 452], ["pulmonary", "ANATOMY", 90, 99], ["infections", "OBSERVATION", 100, 110], ["pulmonary", "ANATOMY", 132, 141], ["infections", "OBSERVATION", 142, 152], ["PULMONARY", "ANATOMY", 297, 306], ["INFECTIONSThere", "OBSERVATION", 307, 322], ["pulmonary", "ANATOMY", 432, 441], ["infections", "OBSERVATION", 442, 452]]], ["Consequently, unnecessary and prolonged exposure to antimicrobial agents adversely affect patient outcomes, while inappropriate and uncontrolled use of antibiotic therapy increases chance of antibiotic resistance.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["antimicrobial agents", "TREATMENT", 52, 72], ["antibiotic therapy", "TREATMENT", 152, 170], ["antibiotic resistance", "TREATMENT", 191, 212], ["antibiotic resistance", "OBSERVATION", 191, 212]]], ["According to Murdoch, 12 the role of microbiological testing methods used for the diagnosis and management of lower respiratory tract infection continues to be debated.", [["lower respiratory tract", "ANATOMY", 110, 133], ["lower respiratory tract infection", "DISEASE", 110, 143], ["lower respiratory", "ORGANISM_SUBDIVISION", 110, 127], ["tract", "ORGANISM_SUBDIVISION", 128, 133], ["microbiological testing methods", "TEST", 37, 68], ["management", "TREATMENT", 96, 106], ["lower respiratory tract infection", "PROBLEM", 110, 143], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133], ["infection", "OBSERVATION", 134, 143]]], ["There are many limitations of microbiology laboratories to perform the conventional diagnostic tests for pulmonary infections.", [["pulmonary", "ANATOMY", 105, 114], ["pulmonary infections", "DISEASE", 105, 125], ["pulmonary", "ORGAN", 105, 114], ["microbiology laboratories", "TEST", 30, 55], ["the conventional diagnostic tests", "TEST", 67, 100], ["pulmonary infections", "PROBLEM", 105, 125], ["pulmonary", "ANATOMY", 105, 114], ["infections", "OBSERVATION", 115, 125]]], ["The culture based methods that are currently used are slow, insensitive, may not distinguish colonization from infection and may be influenced by previous antimicrobial used.", [["infection", "DISEASE", 111, 120], ["The culture based methods", "TEST", 0, 25], ["infection", "PROBLEM", 111, 120], ["infection", "OBSERVATION", 111, 120]]], ["On the other hand, serological tests are also slow and poorly sensitive.", [["serological tests", "TEST", 19, 36]]], ["Therefore, many authoritative guidelines on the management of pulmonary infection, such as, community-acquired pneumonia in adults do not support routine comprehensive microbiological testing, except in certain situations or in patients with severe disease.", [["pulmonary", "ANATOMY", 62, 71], ["pulmonary infection", "DISEASE", 62, 81], ["pneumonia", "DISEASE", 111, 120], ["pulmonary", "ORGAN", 62, 71], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["the management", "TREATMENT", 44, 58], ["pulmonary infection", "PROBLEM", 62, 81], ["community-acquired pneumonia", "PROBLEM", 92, 120], ["routine comprehensive microbiological testing", "TEST", 146, 191], ["severe disease", "PROBLEM", 242, 256], ["pulmonary", "ANATOMY", 62, 71], ["infection", "OBSERVATION", 72, 81], ["pneumonia", "OBSERVATION", 111, 120], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["disease", "OBSERVATION", 249, 256]]], ["44, 45 Moreover, the uncontrolled and improper use of antibiotics as a treatment for pulmonary infections leads to the development of resistance towards those antibiotics.", [["pulmonary", "ANATOMY", 85, 94], ["pulmonary infections", "DISEASE", 85, 105], ["pulmonary", "ORGAN", 85, 94], ["antibiotics", "TREATMENT", 54, 65], ["a treatment", "TREATMENT", 69, 80], ["pulmonary infections", "PROBLEM", 85, 105], ["those antibiotics", "TREATMENT", 153, 170], ["pulmonary", "ANATOMY", 85, 94], ["infections", "OBSERVATION", 95, 105]]], ["The problem of antibiotic resistance was predominantly found in TB patients.", [["TB", "DISEASE", 64, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["antibiotic resistance", "TREATMENT", 15, 36], ["antibiotic resistance", "OBSERVATION", 15, 36]]], ["Unfortunately, some causative agents of TB and many other pulmonary infections become resistant to multiple types of antibiotics.", [["pulmonary", "ANATOMY", 58, 67], ["TB", "DISEASE", 40, 42], ["pulmonary infections", "DISEASE", 58, 78], ["pulmonary", "ORGAN", 58, 67], ["TB", "PROBLEM", 40, 42], ["many other pulmonary infections", "PROBLEM", 47, 78], ["antibiotics", "TREATMENT", 117, 128], ["pulmonary", "ANATOMY", 58, 67], ["infections", "OBSERVATION", 68, 78]]], ["The loss of efficacy of antibiotics and the decrease in their ability to fight pulmonary infections in vulnerable patients is a matter of great concern.", [["pulmonary", "ANATOMY", 79, 88], ["pulmonary infections", "DISEASE", 79, 99], ["pulmonary", "ORGAN", 79, 88], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["antibiotics", "TREATMENT", 24, 35], ["the decrease", "PROBLEM", 40, 52], ["pulmonary infections", "PROBLEM", 79, 99], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["pulmonary", "ANATOMY", 79, 88], ["infections", "OBSERVATION", 89, 99]]], ["21 Nanotechnology is a multidisciplinary field that has recently emerged, and it looks as if it will be extremely helpful in the management of pulmonary infections.", [["pulmonary", "ANATOMY", 143, 152], ["pulmonary infections", "DISEASE", 143, 163], ["pulmonary", "ORGAN", 143, 152], ["pulmonary infections", "PROBLEM", 143, 163], ["pulmonary", "ANATOMY", 143, 152], ["infections", "OBSERVATION", 153, 163]]], ["Nanotechnology based treatment methods and drug delivery strategies will help to deliver drug molecules at the specific site of infection.", [["infection", "DISEASE", 128, 137], ["Nanotechnology based treatment methods", "TREATMENT", 0, 38], ["drug delivery strategies", "TREATMENT", 43, 67], ["drug molecules", "TREATMENT", 89, 103], ["infection", "PROBLEM", 128, 137], ["infection", "OBSERVATION", 128, 137]]], ["46 The role of various nanomaterials in diagnosis and treatments of pulmonary infections is described here.NANOTECHNOLOGY IN MEDICINENanotechnology is an emerging field of science that deals with the study, synthesis and manipulation of materials at nanometer range (ie, in 1-100 nm) or the order of billionths (10 \u22129 ) of a meter.", [["pulmonary", "ANATOMY", 68, 77], ["pulmonary infections", "DISEASE", 68, 88], ["pulmonary", "ORGAN", 68, 77], ["pulmonary infections", "PROBLEM", 68, 88], ["the study", "TEST", 196, 205], ["synthesis", "TREATMENT", 207, 216], ["manipulation of materials", "TREATMENT", 221, 246], ["pulmonary", "ANATOMY", 68, 77], ["infections", "OBSERVATION", 78, 88]]], ["[47] [48] [49] [50] [51] Particles in the nanometer range have changed properties, such as, physicochemical properties, which are distinct from their bulk materials (the macroscopic or microscopic scale) and single atom or molecule (at the atomic scale).", [["[47] [48] [49] [50] [51] Particles", "SIMPLE_CHEMICAL", 0, 34], ["Particles in the nanometer range", "TEST", 25, 57], ["microscopic scale", "TEST", 185, 202], ["physicochemical properties", "OBSERVATION", 92, 118], ["distinct", "OBSERVATION_MODIFIER", 130, 138]]], ["48, 52 Nanomaterials are referred to as engineered nanometer dimensions material, which have novel properties, such as, quantum effects and large surface area to volume ratio.", [["surface area", "ANATOMY", 146, 158], ["volume ratio", "TEST", 162, 174], ["large", "OBSERVATION_MODIFIER", 140, 145], ["surface", "OBSERVATION_MODIFIER", 146, 153], ["volume ratio", "OBSERVATION", 162, 174]]], ["52 These materials are fabricated by a top-down approach, in which bulk materials or technologies are miniaturized, or a bottom-up approach, where assembly occurs atom by atom, from primary to larger, and towards more complex materials.", [["a top-down approach", "TREATMENT", 37, 56], ["larger", "OBSERVATION_MODIFIER", 193, 199]]], ["These nanoscale effects have been exploited practically in every field of technology, and include commercial applications in energy conversion, textiles, cosmetics, electronics, water purification, lubricants, computing and much more.", [["water purification", "TREATMENT", 178, 196], ["lubricants", "TREATMENT", 198, 208]]], ["54, 55 \"Nanobiotechnology\" is the study of the interaction between biological systems and nanomaterials, 56 and the related field of nanomedicine seeks to employ nanosized materials to diagnose, treat and prevent human diseases.", [["human", "ORGANISM", 213, 218], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["the study", "TEST", 30, 39], ["nanomedicine", "TREATMENT", 133, 145], ["human diseases", "PROBLEM", 213, 227]]], ["Moreover, many biological processes, such as, immune recognition and passage across biological barriers are also governed by size considerations.", [["many biological processes", "PROBLEM", 10, 35], ["immune recognition", "PROBLEM", 46, 64], ["passage across biological barriers", "PROBLEM", 69, 103]]], ["60 In this context, various applications of nanotechnology, such as, delivery of drug and nucleic acid-based therapeutics to particular disease site makes it a most promising technology of the era.", [["nucleic acid", "CHEMICAL", 90, 102], ["nucleic acid", "SIMPLE_CHEMICAL", 90, 102], ["nanotechnology", "TREATMENT", 44, 58], ["drug", "TREATMENT", 81, 85], ["nucleic acid", "TREATMENT", 90, 102], ["particular disease site", "PROBLEM", 125, 148]]], ["According to Buxton 61 delivery of therapeutics by inhalation provides an opportunity for direct transport of drug to the lung epithelium of the respiratory tract.APPLICATIONS OF DIFFERENT NANOPARTICLES FOR THE TREATMENT OF PULMONARY INFECTIONSThe multidisciplinary approach of nanotechnology plays a crucial role to find efficient solution over problems in various sectors.", [["lung epithelium", "ANATOMY", 122, 137], ["respiratory tract", "ANATOMY", 145, 162], ["lung epithelium", "TISSUE", 122, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["therapeutics", "TREATMENT", 35, 47], ["DIFFERENT NANOPARTICLES", "TREATMENT", 179, 202], ["PULMONARY INFECTIONSThe multidisciplinary approach", "TREATMENT", 224, 274], ["lung", "ANATOMY", 122, 126], ["epithelium", "ANATOMY_MODIFIER", 127, 137], ["respiratory tract", "ANATOMY", 145, 162], ["PULMONARY", "ANATOMY", 224, 233]]], ["This broad technology is capable to treat range of diseases.", [["diseases", "PROBLEM", 51, 59], ["diseases", "OBSERVATION", 51, 59]]], ["The use of nanoparticles in the field of medicine opens new possibilities and provides new methods for treatment of diseases.", [["nanoparticles", "TREATMENT", 11, 24], ["medicine", "TREATMENT", 41, 49], ["new methods", "TREATMENT", 87, 98], ["diseases", "PROBLEM", 116, 124], ["diseases", "OBSERVATION", 116, 124]]], ["Various types of nanoparticles are used in medicine to treat diseases, such as, infectious diseases, viral, bacterial, respiratory tract diseases, and so on.", [["respiratory tract", "ANATOMY", 119, 136], ["infectious diseases", "DISEASE", 80, 99], ["viral, bacterial, respiratory tract diseases", "DISEASE", 101, 145], ["nanoparticles", "TREATMENT", 17, 30], ["diseases", "PROBLEM", 61, 69], ["infectious diseases", "PROBLEM", 80, 99], ["viral, bacterial, respiratory tract diseases", "PROBLEM", 101, 145], ["nanoparticles", "OBSERVATION", 17, 30], ["bacterial", "OBSERVATION_MODIFIER", 108, 117], ["respiratory tract", "ANATOMY", 119, 136]]], ["The nanoparticles used for treatment of diseases include: metal nanoparticles, liposomes, polymeric nanoparticles, dendrimers, nanocomplexes, nanorods, quantum dots, nanoemulsions, and so on.", [["metal nanoparticles", "SIMPLE_CHEMICAL", 58, 77], ["liposomes", "SIMPLE_CHEMICAL", 79, 88], ["polymeric nanoparticles", "SIMPLE_CHEMICAL", 90, 113], ["dendrimers", "SIMPLE_CHEMICAL", 115, 125], ["nanocomplexes", "SIMPLE_CHEMICAL", 127, 140], ["nanorods", "SIMPLE_CHEMICAL", 142, 150], ["quantum dots", "SIMPLE_CHEMICAL", 152, 164], ["nanoemulsions", "SIMPLE_CHEMICAL", 166, 179], ["The nanoparticles", "TREATMENT", 0, 17], ["diseases", "PROBLEM", 40, 48], ["metal nanoparticles, liposomes", "TREATMENT", 58, 88], ["polymeric nanoparticles, dendrimers", "TREATMENT", 90, 125], ["nanocomplexes", "TREATMENT", 127, 140], ["nanorods", "TREATMENT", 142, 150], ["nanoemulsions", "TREATMENT", 166, 179]]], ["62 Currently, most recent studies in the field of nanomedicine changed the point of view of drug delivery therapy.", [["nanomedicine", "TREATMENT", 50, 62], ["drug delivery therapy", "TREATMENT", 92, 113]]], ["Scientists are using nanoparticles as a carrier for drug delivery therapy.", [["nanoparticles", "TREATMENT", 21, 34], ["a carrier", "TREATMENT", 38, 47], ["drug delivery therapy", "TREATMENT", 52, 73]]], ["63 In fact, much research has not been carried out concerning the use of nanoparticles in pulmonary diseases.", [["pulmonary", "ANATOMY", 90, 99], ["pulmonary diseases", "DISEASE", 90, 108], ["pulmonary", "ORGAN", 90, 99], ["pulmonary diseases", "PROBLEM", 90, 108], ["pulmonary", "ANATOMY", 90, 99], ["diseases", "OBSERVATION", 100, 108]]], ["However, in recent years scientists may develop promising nanocarriers for treatment of diseases that affect respiratory tract.", [["respiratory tract", "ANATOMY", 109, 126], ["respiratory tract", "ORGANISM_SUBDIVISION", 109, 126], ["promising nanocarriers", "TREATMENT", 48, 70], ["diseases", "PROBLEM", 88, 96], ["respiratory tract", "PROBLEM", 109, 126], ["diseases", "OBSERVATION", 88, 96], ["respiratory tract", "ANATOMY", 109, 126]]], ["Recent studies showed that nanoparticles in pulmonary infection treatment can influence immune system, can create oxidative stress, and can cause genotoxicity.", [["pulmonary", "ANATOMY", 44, 53], ["immune system", "ANATOMY", 88, 101], ["pulmonary infection", "DISEASE", 44, 63], ["pulmonary", "ORGAN", 44, 53], ["Recent studies", "TEST", 0, 14], ["nanoparticles", "TREATMENT", 27, 40], ["pulmonary infection treatment", "TREATMENT", 44, 73], ["oxidative stress", "PROBLEM", 114, 130], ["genotoxicity", "PROBLEM", 146, 158], ["nanoparticles", "OBSERVATION_MODIFIER", 27, 40], ["pulmonary", "ANATOMY", 44, 53], ["infection", "OBSERVATION", 54, 63]]], ["64 Studies on nanoparticles for treatment of pulmonary infectious diseases is an emerging field of interest, not only for the treatment of respiratory tract conditions but also for systemic administration of drug delivery for treatment of pulmonary disease.", [["pulmonary", "ANATOMY", 45, 54], ["respiratory tract", "ANATOMY", 139, 156], ["pulmonary", "ANATOMY", 239, 248], ["pulmonary infectious diseases", "DISEASE", 45, 74], ["respiratory tract conditions", "DISEASE", 139, 167], ["pulmonary disease", "DISEASE", 239, 256], ["pulmonary", "ORGAN", 45, 54], ["tract", "ORGANISM_SUBDIVISION", 151, 156], ["pulmonary", "ORGAN", 239, 248], ["nanoparticles", "TREATMENT", 14, 27], ["treatment", "TREATMENT", 32, 41], ["pulmonary infectious diseases", "PROBLEM", 45, 74], ["respiratory tract conditions", "PROBLEM", 139, 167], ["drug delivery", "TREATMENT", 208, 221], ["pulmonary disease", "PROBLEM", 239, 256], ["pulmonary", "ANATOMY", 45, 54], ["infectious", "OBSERVATION", 55, 65], ["respiratory tract", "ANATOMY", 139, 156], ["pulmonary", "ANATOMY", 239, 248], ["disease", "OBSERVATION", 249, 256]]], ["A variety of metal and metal oxide nanoparticles, such as, silver, gold, copper, titanium oxides, and so on have been successfully exploited for pulmonary drug delivery.", [["pulmonary", "ANATOMY", 145, 154], ["metal oxide", "CHEMICAL", 23, 34], ["silver", "CHEMICAL", 59, 65], ["copper", "CHEMICAL", 73, 79], ["titanium oxides", "CHEMICAL", 81, 96], ["metal oxide", "CHEMICAL", 23, 34], ["silver", "CHEMICAL", 59, 65], ["copper", "CHEMICAL", 73, 79], ["titanium oxides", "CHEMICAL", 81, 96], ["metal", "SIMPLE_CHEMICAL", 13, 18], ["metal oxide nanoparticles", "SIMPLE_CHEMICAL", 23, 48], ["silver", "SIMPLE_CHEMICAL", 59, 65], ["gold", "SIMPLE_CHEMICAL", 67, 71], ["copper", "SIMPLE_CHEMICAL", 73, 79], ["titanium oxides", "SIMPLE_CHEMICAL", 81, 96], ["pulmonary", "ORGAN", 145, 154], ["A variety of metal and metal oxide nanoparticles", "TREATMENT", 0, 48], ["silver, gold, copper, titanium oxides", "TREATMENT", 59, 96], ["pulmonary drug delivery", "TREATMENT", 145, 168], ["pulmonary", "ANATOMY", 145, 154], ["drug", "OBSERVATION", 155, 159]]], ["65 Globally, more than 1.5 million deaths are reported annually from respiratory infections, including at least 42% of lower respiratory infections and 24% of upper respiratory infections in developing countries like China, India, Iran, Oman, Philippines, Qatar, Republic of Korea, Saudi Arabia, Thailand, and the United Arab Emirates.", [["respiratory", "ANATOMY", 69, 80], ["respiratory", "ANATOMY", 125, 136], ["respiratory", "ANATOMY", 165, 176], ["deaths", "DISEASE", 35, 41], ["respiratory infections", "DISEASE", 69, 91], ["respiratory infections", "DISEASE", 125, 147], ["respiratory infections", "DISEASE", 165, 187], ["1.5 million deaths", "PROBLEM", 23, 41], ["respiratory infections", "PROBLEM", 69, 91], ["lower respiratory infections", "PROBLEM", 119, 147], ["upper respiratory infections", "PROBLEM", 159, 187], ["respiratory", "ANATOMY", 69, 80], ["infections", "OBSERVATION", 81, 91], ["lower", "ANATOMY_MODIFIER", 119, 124], ["respiratory", "ANATOMY", 125, 136], ["infections", "OBSERVATION", 137, 147], ["upper", "ANATOMY_MODIFIER", 159, 164], ["respiratory", "ANATOMY", 165, 176], ["infections", "OBSERVATION", 177, 187]]], ["The frequent use of antibiotics lead to antibiotic resistance, which enables antibiotic-resistant bacteria to survive despite treatment with existing antibacterial drugs.", [["antibiotics", "TREATMENT", 20, 31], ["antibiotic resistance", "TREATMENT", 40, 61], ["antibiotic", "TREATMENT", 77, 87], ["resistant bacteria", "PROBLEM", 88, 106], ["treatment", "TREATMENT", 126, 135], ["existing antibacterial drugs", "TREATMENT", 141, 169]]], ["66, 67 The growing number of multidrug resistant strains has made it imperative the development of new antibiotics and novel approaches to deliver existing agents.APPLICATIONS OF DIFFERENT NANOPARTICLES FOR THE TREATMENT OF PULMONARY INFECTIONSThe study carried out by Zhang et al. 68 revealed that polyphosphoester-based silver nanoparticles enhance in vitro antibacterial activities against pathogens associated with CF and decreases the cytotoxicity of bronchial epithelial cells in human.", [["bronchial epithelial cells", "ANATOMY", 456, 482], ["polyphosphoester", "CHEMICAL", 299, 315], ["silver", "CHEMICAL", 322, 328], ["polyphosphoester", "CHEMICAL", 299, 315], ["silver", "CHEMICAL", 322, 328], ["polyphosphoester-based silver nanoparticles", "SIMPLE_CHEMICAL", 299, 342], ["bronchial epithelial cells", "CELL", 456, 482], ["human", "ORGANISM", 486, 491], ["bronchial epithelial cells", "CELL_TYPE", 456, 482], ["human", "SPECIES", 486, 491], ["human", "SPECIES", 486, 491], ["multidrug resistant strains", "PROBLEM", 29, 56], ["new antibiotics", "TREATMENT", 99, 114], ["novel approaches", "TREATMENT", 119, 135], ["existing agents", "TREATMENT", 147, 162], ["DIFFERENT NANOPARTICLES", "TREATMENT", 179, 202], ["PULMONARY INFECTIONSThe study", "TEST", 224, 253], ["polyphosphoester-based silver nanoparticles", "TREATMENT", 299, 342], ["vitro antibacterial activities", "TREATMENT", 354, 384], ["pathogens", "PROBLEM", 393, 402], ["CF", "PROBLEM", 419, 421], ["the cytotoxicity of bronchial epithelial cells in human", "PROBLEM", 436, 491], ["growing", "OBSERVATION_MODIFIER", 11, 18], ["number", "OBSERVATION_MODIFIER", 19, 25], ["multidrug resistant strains", "OBSERVATION", 29, 56], ["new", "OBSERVATION_MODIFIER", 99, 102], ["antibiotics", "OBSERVATION", 103, 114], ["PULMONARY", "ANATOMY", 224, 233], ["bronchial epithelial cells", "OBSERVATION", 456, 482]]], ["They developed novel degradable polyphosphoester-based polymeric nanoparticles that are able to carry silver cations toward the treatment of lung infections associated with CF through formation of silver acetylides.", [["lung", "ANATOMY", 141, 145], ["polyphosphoester", "CHEMICAL", 32, 48], ["silver cations", "CHEMICAL", 102, 116], ["lung infections", "DISEASE", 141, 156], ["CF", "DISEASE", 173, 175], ["silver acetylides", "CHEMICAL", 197, 214], ["polyphosphoester", "CHEMICAL", 32, 48], ["silver", "CHEMICAL", 102, 108], ["silver acetylides", "CHEMICAL", 197, 214], ["polyphosphoester-based polymeric nanoparticles", "SIMPLE_CHEMICAL", 32, 78], ["silver cations", "SIMPLE_CHEMICAL", 102, 116], ["lung", "ORGAN", 141, 145], ["silver acetylides", "SIMPLE_CHEMICAL", 197, 214], ["novel degradable polyphosphoester-based polymeric nanoparticles", "TREATMENT", 15, 78], ["silver cations", "TREATMENT", 102, 116], ["lung infections", "PROBLEM", 141, 156], ["CF", "PROBLEM", 173, 175], ["silver acetylides", "TREATMENT", 197, 214], ["lung", "ANATOMY", 141, 145], ["infections", "OBSERVATION", 146, 156], ["silver acetylides", "OBSERVATION", 197, 214]]], ["Another study on liposomal antibacterial targeted pulmonary infection therapy revealed that after several cycles of treatment with liposome and antibacterial drug amikacin in patients showed continuous improvement in pulmonary function and significant reduction in bacterial density.", [["pulmonary", "ANATOMY", 50, 59], ["pulmonary", "ANATOMY", 217, 226], ["pulmonary infection", "DISEASE", 50, 69], ["liposome", "CHEMICAL", 131, 139], ["amikacin", "CHEMICAL", 163, 171], ["amikacin", "CHEMICAL", 163, 171], ["pulmonary", "ORGAN", 50, 59], ["liposome", "SIMPLE_CHEMICAL", 131, 139], ["amikacin", "SIMPLE_CHEMICAL", 163, 171], ["patients", "ORGANISM", 175, 183], ["pulmonary", "ORGAN", 217, 226], ["patients", "SPECIES", 175, 183], ["Another study", "TEST", 0, 13], ["liposomal antibacterial targeted pulmonary infection therapy", "TREATMENT", 17, 77], ["treatment", "TREATMENT", 116, 125], ["liposome", "TREATMENT", 131, 139], ["antibacterial drug amikacin", "TREATMENT", 144, 171], ["pulmonary function", "PROBLEM", 217, 235], ["significant reduction in bacterial density", "PROBLEM", 240, 282], ["pulmonary", "ANATOMY", 50, 59], ["infection", "OBSERVATION", 60, 69], ["pulmonary", "ANATOMY", 217, 226], ["significant", "OBSERVATION_MODIFIER", 240, 251], ["reduction", "OBSERVATION_MODIFIER", 252, 261], ["bacterial density", "OBSERVATION", 265, 282]]], ["69 These type of studies suggest that efficacy of antibacterial drugs increases when administered in combination with nanoparticles.", [["antibacterial drugs", "TREATMENT", 50, 69], ["nanoparticles", "TREATMENT", 118, 131]]], ["60 Bhardwaj and coworkers 70 used a mixture of chemotherapeutic agent-loaded vesicular system to overcome TB by developing ligand appended liposome with dry powder inhaler.", [["vesicular", "ANATOMY", 77, 86], ["TB", "DISEASE", 106, 108], ["liposome", "SIMPLE_CHEMICAL", 139, 147], ["chemotherapeutic agent", "TREATMENT", 47, 69], ["vesicular system", "TREATMENT", 77, 93], ["TB", "PROBLEM", 106, 108], ["ligand appended liposome", "TREATMENT", 123, 147], ["dry powder inhaler", "TREATMENT", 153, 171]]], ["According to Barash et al. 71 the categorization and detection of specific pattern of lung cancer can be possible using gold nanoparticles sensor with a device profiles unstable organic compounds.", [["lung cancer", "ANATOMY", 86, 97], ["lung cancer", "DISEASE", 86, 97], ["lung cancer", "CANCER", 86, 97], ["the categorization", "TEST", 30, 48], ["lung cancer", "PROBLEM", 86, 97], ["gold nanoparticles sensor", "TREATMENT", 120, 145], ["a device profiles unstable organic compounds", "PROBLEM", 151, 195], ["lung", "ANATOMY", 86, 90], ["cancer", "OBSERVATION", 91, 97], ["organic compounds", "OBSERVATION", 178, 195]]], ["Broza et al. 72 reported the use of nanomaterials-based sensors for the identification of breath-print of early-stage lung cancer.NANOTECHNOLOGY FOR PULMONARY DRUG DELIVERYPulmonary drug delivery has many advantages compared to unusual drug delivery strategies, especially rapid drug uptake, a large surface area for solute transport, and improved drug bioavailability, as well as its noninvasive nature.", [["early-stage lung cancer", "ANATOMY", 106, 129], ["surface area", "ANATOMY", 300, 312], ["lung cancer", "DISEASE", 118, 129], ["early-stage lung cancer", "CANCER", 106, 129], ["solute", "SIMPLE_CHEMICAL", 317, 323], ["nanomaterials", "TREATMENT", 36, 49], ["breath", "TEST", 90, 96], ["early-stage lung cancer", "PROBLEM", 106, 129], ["PULMONARY DRUG DELIVERYPulmonary drug delivery", "TREATMENT", 149, 195], ["unusual drug delivery strategies", "TREATMENT", 228, 260], ["rapid drug uptake", "PROBLEM", 273, 290], ["solute transport", "TREATMENT", 317, 333], ["early", "OBSERVATION_MODIFIER", 106, 111], ["stage", "OBSERVATION_MODIFIER", 112, 117], ["lung", "ANATOMY", 118, 122], ["cancer", "OBSERVATION", 123, 129], ["PULMONARY", "ANATOMY", 149, 158], ["large", "OBSERVATION_MODIFIER", 294, 299], ["surface", "OBSERVATION_MODIFIER", 300, 307]]], ["[73] [74] [75] [76] Antimicrobial agents enter into the lung by means of systemic nanoparticles administration, which is determined and potentially harmful upon systemic exposure to the drugs.", [["lung", "ANATOMY", 56, 60], ["[73] [74] [75] [76]", "CHEMICAL", 0, 19], ["[73] [74] [75] [76] Antimicrobial agents", "SIMPLE_CHEMICAL", 0, 40], ["lung", "ORGAN", 56, 60], ["Antimicrobial agents", "TREATMENT", 20, 40], ["systemic nanoparticles administration", "TREATMENT", 73, 110], ["the drugs", "TREATMENT", 182, 191], ["lung", "ANATOMY", 56, 60], ["systemic nanoparticles", "OBSERVATION", 73, 95]]], ["On the other hand, various nanoparticles exhibit privileged accumulation in the lung-other organs have also been tried.", [["lung", "ANATOMY", 80, 84], ["organs", "ANATOMY", 91, 97], ["lung", "ORGAN", 80, 84], ["organs", "ORGAN", 91, 97], ["privileged accumulation in the lung", "PROBLEM", 49, 84], ["privileged accumulation", "OBSERVATION", 49, 72], ["lung", "ANATOMY", 80, 84], ["organs", "ANATOMY", 91, 97]]], ["It was reported that intratracheally administered antibiotics loaded nanoparticles were able to enter through the alveolar-capillary barrier into the systemic circulation and collect in extra-pulmonary organ containing spleen, liver, kidney, and bone.", [["alveolar-capillary barrier", "ANATOMY", 114, 140], ["extra-pulmonary organ", "ANATOMY", 186, 207], ["spleen", "ANATOMY", 219, 225], ["liver", "ANATOMY", 227, 232], ["kidney", "ANATOMY", 234, 240], ["bone", "ANATOMY", 246, 250], ["alveolar-capillary barrier", "TISSUE", 114, 140], ["organ", "ORGAN", 202, 207], ["spleen", "ORGAN", 219, 225], ["liver", "ORGAN", 227, 232], ["kidney", "ORGAN", 234, 240], ["bone", "TISSUE", 246, 250], ["intratracheally administered antibiotics loaded nanoparticles", "TREATMENT", 21, 82], ["alveolar", "ANATOMY_MODIFIER", 114, 122], ["capillary", "ANATOMY_MODIFIER", 123, 132], ["systemic circulation", "ANATOMY", 150, 170], ["extra-pulmonary organ", "ANATOMY", 186, 207], ["spleen", "ANATOMY", 219, 225], ["liver", "ANATOMY", 227, 232], ["kidney", "ANATOMY", 234, 240], ["bone", "ANATOMY", 246, 250]]], ["77 Today, the drug dosage form and therapeutic efficiency is improved by \"micronization\" of drugs.", [["the drug dosage", "TREATMENT", 10, 25], ["therapeutic efficiency", "PROBLEM", 35, 57], ["therapeutic efficiency", "OBSERVATION", 35, 57]]], ["The drug if micronized into microspheres with appropriate particle size can be administered directly to the lungs through the mechanical prevention of capillary bed in the lungs.", [["lungs", "ANATOMY", 108, 113], ["capillary bed", "ANATOMY", 151, 164], ["lungs", "ANATOMY", 172, 177], ["lungs", "ORGAN", 108, 113], ["capillary bed", "MULTI-TISSUE_STRUCTURE", 151, 164], ["lungs", "ORGAN", 172, 177], ["The drug if micronized into microspheres", "TREATMENT", 0, 40], ["appropriate particle size", "TREATMENT", 46, 71], ["lungs", "ANATOMY", 108, 113], ["capillary bed", "ANATOMY_MODIFIER", 151, 164], ["lungs", "ANATOMY", 172, 177]]], ["78, 79 Nanosuspensions may be an ideal approach to deliver drugs that show deprived solubility in pulmonary secretions.", [["pulmonary secretions", "ANATOMY", 98, 118], ["pulmonary secretions", "MULTI-TISSUE_STRUCTURE", 98, 118], ["deliver drugs", "TREATMENT", 51, 64], ["deprived solubility in pulmonary secretions", "PROBLEM", 75, 118], ["pulmonary", "ANATOMY", 98, 107], ["secretions", "OBSERVATION", 108, 118]]], ["80 In addition, due to the nanoparticulate nature and homogeneous size distribution of nanosuspensions, it is possible that in each aerosol droplet at least one drug nanoparticle is present leading to an even distribution of drug in lungs compared to the microparticulate form of the drug.", [["lungs", "ANATOMY", 233, 238], ["lungs", "ORGAN", 233, 238], ["nanosuspensions", "TREATMENT", 87, 102], ["each aerosol droplet", "TREATMENT", 127, 147], ["drug in lungs", "PROBLEM", 225, 238], ["homogeneous", "OBSERVATION_MODIFIER", 54, 65], ["size", "OBSERVATION_MODIFIER", 66, 70], ["nanosuspensions", "OBSERVATION_MODIFIER", 87, 102], ["is possible", "UNCERTAINTY", 107, 118], ["drug nanoparticle", "OBSERVATION", 161, 178], ["drug", "OBSERVATION", 225, 229], ["lungs", "ANATOMY", 233, 238]]], ["In routine suspension aerosols, numerous droplets are free of drug and others are filled with the drug in high amounts, directing to irregular release and circulation of the drug within the lungs.", [["droplets", "ANATOMY", 41, 49], ["lungs", "ANATOMY", 190, 195], ["lungs", "ORGAN", 190, 195], ["routine suspension aerosols", "TREATMENT", 3, 30], ["numerous droplets", "TREATMENT", 32, 49], ["drug", "TREATMENT", 62, 66], ["irregular release", "PROBLEM", 133, 150], ["irregular", "OBSERVATION_MODIFIER", 133, 142], ["circulation", "OBSERVATION_MODIFIER", 155, 166], ["lungs", "ANATOMY", 190, 195]]], ["Nanosuspensions could be utilized in all available types of nebulizer.", [["Nanosuspensions", "TREATMENT", 0, 15], ["nebulizer", "TREATMENT", 60, 69]]], ["81 Aggarwal et al. 80 studied antitubercular drugs, for example, pyrazinamide, isoniazid, and rifampicin were integrated into various formulations of solid lipid ranged from 1.1 to 2.1 \u00b5m and these formulations were nebulized to guinea pigs orally for direct pulmonary delivery.", [["pulmonary", "ANATOMY", 259, 268], ["pyrazinamide", "CHEMICAL", 65, 77], ["isoniazid", "CHEMICAL", 79, 88], ["rifampicin", "CHEMICAL", 94, 104], ["pyrazinamide", "CHEMICAL", 65, 77], ["isoniazid", "CHEMICAL", 79, 88], ["rifampicin", "CHEMICAL", 94, 104], ["pyrazinamide", "SIMPLE_CHEMICAL", 65, 77], ["isoniazid", "SIMPLE_CHEMICAL", 79, 88], ["rifampicin", "SIMPLE_CHEMICAL", 94, 104], ["solid lipid", "MULTI-TISSUE_STRUCTURE", 150, 161], ["guinea", "ORGANISM", 229, 235], ["pigs", "ORGANISM", 236, 240], ["pulmonary", "ORGAN", 259, 268], ["guinea pigs", "SPECIES", 229, 240], ["guinea", "SPECIES", 229, 235], ["antitubercular drugs", "TREATMENT", 30, 50], ["pyrazinamide", "TREATMENT", 65, 77], ["isoniazid", "TREATMENT", 79, 88], ["rifampicin", "TREATMENT", 94, 104], ["solid lipid", "TREATMENT", 150, 161], ["these formulations", "TREATMENT", 192, 210], ["guinea pigs orally", "TREATMENT", 229, 247], ["direct pulmonary delivery", "TREATMENT", 252, 277], ["antitubercular drugs", "OBSERVATION", 30, 50], ["pulmonary", "ANATOMY", 259, 268]]], ["Likewise, conditions, such as, pulmonary aspergillosis can easily be targeted by applying appropriate drug candidates like amphotericin B, in the form of pulmonary nanosuspensions as a substitute of using stealth liposomes.", [["pulmonary", "ANATOMY", 31, 40], ["pulmonary", "ANATOMY", 154, 163], ["pulmonary aspergillosis", "DISEASE", 31, 54], ["amphotericin B", "CHEMICAL", 123, 137], ["amphotericin B", "CHEMICAL", 123, 137], ["pulmonary", "ORGAN", 31, 40], ["amphotericin B", "SIMPLE_CHEMICAL", 123, 137], ["pulmonary", "ORGAN", 154, 163], ["stealth liposomes", "SIMPLE_CHEMICAL", 205, 222], ["pulmonary aspergillosis", "PROBLEM", 31, 54], ["appropriate drug candidates", "TREATMENT", 90, 117], ["amphotericin B", "TREATMENT", 123, 137], ["pulmonary nanosuspensions", "TREATMENT", 154, 179], ["a substitute of using stealth liposomes", "TREATMENT", 183, 222], ["pulmonary", "ANATOMY", 31, 40], ["aspergillosis", "OBSERVATION", 41, 54], ["pulmonary", "ANATOMY", 154, 163], ["nanosuspensions", "OBSERVATION", 164, 179]]], ["82 Numerous respiratory diseases have been treated by using the nanocarrier systems, which can be easily transferred through the airways.", [["respiratory", "ANATOMY", 12, 23], ["airways", "ANATOMY", 129, 136], ["respiratory diseases", "DISEASE", 12, 32], ["airways", "MULTI-TISSUE_STRUCTURE", 129, 136], ["Numerous respiratory diseases", "PROBLEM", 3, 32], ["the nanocarrier systems", "TREATMENT", 60, 83], ["Numerous", "OBSERVATION_MODIFIER", 3, 11], ["respiratory diseases", "OBSERVATION", 12, 32], ["airways", "ANATOMY", 129, 136]]], ["83, 84 A large number of pulmonary diseases that have been searched includes-CF and some other genetic disorders, COPD, tuberculosis, pediatric diseases, and cancer.", [["pulmonary", "ANATOMY", 25, 34], ["cancer", "ANATOMY", 158, 164], ["pulmonary diseases", "DISEASE", 25, 43], ["genetic disorders", "DISEASE", 95, 112], ["COPD", "DISEASE", 114, 118], ["tuberculosis", "DISEASE", 120, 132], ["pediatric diseases", "DISEASE", 134, 152], ["cancer", "DISEASE", 158, 164], ["pulmonary", "ORGAN", 25, 34], ["cancer", "CANCER", 158, 164], ["pulmonary diseases", "PROBLEM", 25, 43], ["CF", "PROBLEM", 77, 79], ["some other genetic disorders", "PROBLEM", 84, 112], ["COPD", "PROBLEM", 114, 118], ["tuberculosis", "PROBLEM", 120, 132], ["pediatric diseases", "PROBLEM", 134, 152], ["cancer", "PROBLEM", 158, 164], ["large", "OBSERVATION_MODIFIER", 9, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["pulmonary", "ANATOMY", 25, 34], ["diseases", "OBSERVATION", 35, 43], ["genetic", "OBSERVATION_MODIFIER", 95, 102], ["disorders", "OBSERVATION", 103, 112], ["COPD", "OBSERVATION", 114, 118], ["tuberculosis", "OBSERVATION", 120, 132], ["cancer", "OBSERVATION", 158, 164]]], ["76, [85] [86] [87] [88] The pharmacodynamics and pharmacokinetics of a drug are exceedingly reliant on its physical and chemical features, which are influenced by the type of formulation used to deliver it.", [["[85] [86] [87] [88]", "SIMPLE_CHEMICAL", 4, 23], ["a drug", "PROBLEM", 69, 75]]], ["Through scaling down size of compounds, Nano-Drug Delivery System (NDDS) can transform and improve the performance of many drugs to an extent not reachable by conservative formulations.", [["Nano-Drug", "SIMPLE_CHEMICAL", 40, 49], ["Nano-Drug Delivery System", "TREATMENT", 40, 65], ["many drugs", "TREATMENT", 118, 128], ["conservative formulations", "TREATMENT", 159, 184], ["size", "OBSERVATION_MODIFIER", 21, 25], ["compounds", "OBSERVATION_MODIFIER", 29, 38]]], ["89 For example, NDDS can be capitalized to encapsulate drugs and thereby (1) protect them from degradation, (2) target the drugs to particular cells/tissues/organs, releasing them in a restricted behavior as a response to a precise stimulus, (3) increase their solubility, (4) enhance their epithelial absorption and increase their blood circulation time, and (5) enhance their uptake by cells.", [["cells", "ANATOMY", 143, 148], ["tissues", "ANATOMY", 149, 156], ["organs", "ANATOMY", 157, 163], ["epithelial", "ANATOMY", 291, 301], ["blood", "ANATOMY", 332, 337], ["cells", "ANATOMY", 388, 393], ["NDDS", "CHEMICAL", 16, 20], ["NDDS", "SIMPLE_CHEMICAL", 16, 20], ["cells", "CELL", 143, 148], ["tissues", "TISSUE", 149, 156], ["organs", "ORGAN", 157, 163], ["epithelial", "TISSUE", 291, 301], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["cells", "CELL", 388, 393], ["NDDS", "PROBLEM", 16, 20], ["drugs", "TREATMENT", 55, 60], ["the drugs", "TREATMENT", 119, 128], ["their epithelial absorption", "PROBLEM", 285, 312], ["organs", "ANATOMY", 157, 163], ["epithelial absorption", "OBSERVATION", 291, 312]]], ["[90] [91] [92] Moreover, combined NDDS can concurrently detect and treat a disease by encompassing both imaging and therapeutic compounds, which are termed as theranostics.", [["NDDS", "CHEMICAL", 34, 38], ["NDDS", "SIMPLE_CHEMICAL", 34, 38], ["combined NDDS", "PROBLEM", 25, 38], ["a disease", "PROBLEM", 73, 82], ["both imaging", "TEST", 99, 111]]], ["93 Nanomedicine could play a key role in the near future to achieve the highly desired modified medicine.", [["Nanomedicine", "CHEMICAL", 3, 15]]], ["94 Over the last few decades, the usefulness of the design and development of NDDS to overcome a variety of biopharmaceutical drawbacks in the diagnosis, prevention, vaccination, and disease treatment has been intensively explored by a large number of research groups globally, leading to an enormous number of scientific articles available in international journals.", [["NDDS", "CHEMICAL", 78, 82], ["NDDS", "SIMPLE_CHEMICAL", 78, 82], ["NDDS", "PROBLEM", 78, 82], ["biopharmaceutical drawbacks", "TREATMENT", 108, 135], ["vaccination", "TREATMENT", 166, 177], ["disease treatment", "TREATMENT", 183, 200], ["large", "OBSERVATION_MODIFIER", 236, 241], ["enormous", "OBSERVATION_MODIFIER", 292, 300]]], ["Nevertheless, and despite the fact that nanomedicine began as a discipline almost half a century ago, only a few NDDS have found their way to the market.", [["NDDS", "CANCER", 113, 117], ["nanomedicine", "TREATMENT", 40, 52], ["a few NDDS", "PROBLEM", 107, 117]]], ["94, 95 This experience could be explained by the lack of economic profitability, consumer mistrust and the lack of assurance because of poor information or education, unproductive regulation of novel and generic products, and feeble patent protection.", [["novel and generic products", "TREATMENT", 194, 220], ["feeble patent protection", "TREATMENT", 226, 250], ["patent", "OBSERVATION", 233, 239]]], ["96 The respiratory system and the skin are together directly in contact with the environment, which represents a possible entrance door for the therapeutic compounds into the body.", [["respiratory system", "ANATOMY", 7, 25], ["skin", "ANATOMY", 34, 38], ["body", "ANATOMY", 175, 179], ["skin", "ORGAN", 34, 38], ["body", "ORGANISM_SUBDIVISION", 175, 179], ["respiratory system", "ANATOMY", 7, 25], ["skin", "ANATOMY", 34, 38], ["body", "ANATOMY", 175, 179]]], ["Due to the increasing frequency of pulmonary diseases with high mortality and morbidity, the pulmonary drug delivery is emerging as a noninvasive and smart approach for the treatment of a variety of pathogenic disorders.", [["pulmonary", "ANATOMY", 35, 44], ["pulmonary", "ANATOMY", 93, 102], ["pulmonary diseases", "DISEASE", 35, 53], ["pulmonary", "ORGAN", 35, 44], ["pulmonary", "ORGAN", 93, 102], ["pulmonary diseases", "PROBLEM", 35, 53], ["high mortality", "PROBLEM", 59, 73], ["morbidity", "PROBLEM", 78, 87], ["the pulmonary drug delivery", "TREATMENT", 89, 116], ["a noninvasive and smart approach", "TREATMENT", 132, 164], ["the treatment", "TREATMENT", 169, 182], ["pathogenic disorders", "PROBLEM", 199, 219], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["pulmonary", "ANATOMY", 35, 44], ["diseases", "OBSERVATION", 45, 53], ["high", "OBSERVATION_MODIFIER", 59, 63], ["mortality", "OBSERVATION_MODIFIER", 64, 73], ["pulmonary", "ANATOMY", 93, 102]]], ["97 Therefore, intravenous and oral routes for disease management are acquiring an ever growing interest for systemic administration of therapeutic agents due to their various advantages.", [["intravenous", "ANATOMY", 14, 25], ["oral", "ANATOMY", 30, 34], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 25], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["intravenous", "TREATMENT", 14, 25], ["disease management", "TREATMENT", 46, 64], ["systemic administration", "TREATMENT", 108, 131], ["therapeutic agents", "TREATMENT", 135, 153]]], ["74 Currently, researchers have made enormous strides in the progress of pulmonary delivery technologies, both in terms of inhaler design and progresses in nanoscale carrier engineering.", [["pulmonary", "ANATOMY", 72, 81], ["pulmonary", "ORGAN", 72, 81], ["pulmonary delivery technologies", "TREATMENT", 72, 103], ["inhaler design", "TREATMENT", 122, 136], ["pulmonary", "ANATOMY", 72, 81]]], ["At present there are three main different classes of devices for pulmonary drug delivery: metered dose inhalers, nebulizers, and dry powder inhalers.", [["pulmonary", "ANATOMY", 65, 74], ["pulmonary", "ORGAN", 65, 74], ["pulmonary drug delivery", "TREATMENT", 65, 88], ["metered dose inhalers", "TREATMENT", 90, 111], ["nebulizers", "TREATMENT", 113, 123], ["dry powder inhalers", "TREATMENT", 129, 148], ["three", "OBSERVATION_MODIFIER", 21, 26], ["main", "OBSERVATION_MODIFIER", 27, 31], ["different", "OBSERVATION_MODIFIER", 32, 41], ["classes", "OBSERVATION_MODIFIER", 42, 49], ["pulmonary", "ANATOMY", 65, 74]]], ["These inhalers are based on diverse delivery mechanisms, and entail different types of drug formulations.", [["These inhalers", "TREATMENT", 0, 14], ["diverse delivery mechanisms", "TREATMENT", 28, 55], ["drug formulations", "TREATMENT", 87, 104]]], ["Furthermore, the development of novel biologically active compounds like proteins and nucleic acids require the design of innovative delivery technologies.", [["nucleic acids", "CHEMICAL", 86, 99], ["nucleic acids", "SIMPLE_CHEMICAL", 86, 99], ["novel biologically active compounds like proteins", "PROBLEM", 32, 81], ["nucleic acids", "TREATMENT", 86, 99], ["innovative delivery technologies", "TREATMENT", 122, 154]]], ["98 Bioavailability of administered drug is a major problem in pulmonary infections.", [["pulmonary", "ANATOMY", 62, 71], ["pulmonary infections", "DISEASE", 62, 82], ["pulmonary", "ORGAN", 62, 71], ["pulmonary infections", "PROBLEM", 62, 82], ["pulmonary", "ANATOMY", 62, 71], ["infections", "OBSERVATION", 72, 82]]], ["Therefore, researchers have developed considerable interest in pulmonary drug delivery and also focused on enhancement of bioavailability of therapeutic biomolecules having high molecular weight.", [["pulmonary", "ANATOMY", 63, 72], ["pulmonary", "ORGAN", 63, 72], ["pulmonary drug delivery", "TREATMENT", 63, 86], ["therapeutic biomolecules", "PROBLEM", 141, 165], ["high molecular weight", "PROBLEM", 173, 194], ["pulmonary", "ANATOMY", 63, 72], ["drug", "OBSERVATION", 73, 77]]], ["[99] [100] Among the various carriers used as drug delivery systems for pulmonary infections, nanocarriers have been found to be most promising due to their significant advantages like prolonged drug release and cellspecific targeted drug delivery.", [["pulmonary", "ANATOMY", 72, 81], ["pulmonary infections", "DISEASE", 72, 92], ["pulmonary", "ORGAN", 72, 81], ["the various carriers", "TREATMENT", 17, 37], ["drug delivery systems", "TREATMENT", 46, 67], ["pulmonary infections", "PROBLEM", 72, 92], ["nanocarriers", "TREATMENT", 94, 106], ["prolonged drug release", "TREATMENT", 185, 207], ["cellspecific targeted drug delivery", "TREATMENT", 212, 247], ["pulmonary", "ANATOMY", 72, 81], ["infections", "OBSERVATION", 82, 92]]], ["84,98CONCLUSIONSPulmonary infections caused by bacteria, fungi, and viruses are increasing and reemerging due to improper use of antibiotics and changing environmental conditions.", [["infections", "DISEASE", 26, 36], ["84,98CONCLUSIONSPulmonary infections", "PROBLEM", 0, 36], ["bacteria", "PROBLEM", 47, 55], ["fungi", "PROBLEM", 57, 62], ["viruses", "PROBLEM", 68, 75], ["antibiotics", "TREATMENT", 129, 140], ["changing environmental conditions", "TREATMENT", 145, 178], ["infections", "OBSERVATION", 26, 36], ["bacteria", "OBSERVATION", 47, 55], ["viruses", "OBSERVATION", 68, 75]]], ["The conventional methods of diagnosis and treatment of pulmonary infections have limitations.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary infections", "DISEASE", 55, 75], ["pulmonary", "ORGAN", 55, 64], ["pulmonary infections", "PROBLEM", 55, 75], ["pulmonary", "ANATOMY", 55, 64], ["infections", "OBSERVATION", 65, 75]]], ["The cultural and serological methods used for identification are slow, tedious, may not distinguish colonization from infection, and may be influenced by previous antimicrobials used for the treatment.", [["infection", "DISEASE", 118, 127], ["The cultural", "TEST", 0, 12], ["serological methods", "TEST", 17, 36], ["colonization", "PROBLEM", 100, 112], ["infection", "PROBLEM", 118, 127], ["previous antimicrobials", "TREATMENT", 154, 177], ["the treatment", "TREATMENT", 187, 200], ["infection", "OBSERVATION", 118, 127]]], ["In this context, PCR methods have been useful up to a certain extent for rapid identification of the causal organism.", [["PCR methods", "TEST", 17, 28], ["the causal organism", "PROBLEM", 97, 116]]], ["Nano-PCR and nanobiosensors may play important role in diagnosis of pulmonary infections.", [["pulmonary", "ANATOMY", 68, 77], ["pulmonary infections", "DISEASE", 68, 88], ["pulmonary", "ORGAN", 68, 77], ["Nano-PCR", "TREATMENT", 0, 8], ["nanobiosensors", "TREATMENT", 13, 27], ["pulmonary infections", "PROBLEM", 68, 88], ["pulmonary", "ANATOMY", 68, 77], ["infections", "OBSERVATION", 78, 88]]], ["The long-term treatment of pulmonary infections by antibiotics and their inappropriate use has resulted in the multidrug resistance problem.", [["pulmonary", "ANATOMY", 27, 36], ["pulmonary infections", "DISEASE", 27, 47], ["pulmonary", "ORGAN", 27, 36], ["The long-term treatment", "TREATMENT", 0, 23], ["pulmonary infections", "PROBLEM", 27, 47], ["antibiotics", "TREATMENT", 51, 62], ["the multidrug resistance problem", "PROBLEM", 107, 139], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["pulmonary", "ANATOMY", 27, 36], ["infections", "OBSERVATION", 37, 47], ["multidrug resistance", "OBSERVATION", 111, 131]]], ["This problem is mainly evidenced by tuberculosis, which has become a global problem; therefore, there is a need to develop alternative strategies for the treatment of tuberculosis.", [["tuberculosis", "DISEASE", 36, 48], ["tuberculosis", "DISEASE", 167, 179], ["tuberculosis", "PROBLEM", 36, 48], ["a global problem", "PROBLEM", 67, 83], ["alternative strategies", "TREATMENT", 123, 145], ["the treatment", "TREATMENT", 150, 163], ["tuberculosis", "PROBLEM", 167, 179], ["tuberculosis", "OBSERVATION", 36, 48], ["global", "OBSERVATION_MODIFIER", 69, 75], ["problem", "OBSERVATION", 76, 83], ["tuberculosis", "OBSERVATION", 167, 179]]], ["The use of nanotechnology in diagnosis of pulmonary infections and also for delivery of drugs would be of paramount importance.", [["pulmonary", "ANATOMY", 42, 51], ["pulmonary infections", "DISEASE", 42, 62], ["pulmonary", "ORGAN", 42, 51], ["pulmonary infections", "PROBLEM", 42, 62], ["delivery of drugs", "TREATMENT", 76, 93], ["pulmonary", "ANATOMY", 42, 51], ["infections", "OBSERVATION", 52, 62]]], ["Nanoparticles, particularly biodegradable nanoparticles, can be used for this purpose.", [["Nanoparticles", "SIMPLE_CHEMICAL", 0, 13], ["Nanoparticles", "TREATMENT", 0, 13], ["particularly biodegradable nanoparticles", "TREATMENT", 15, 55]]], ["The activity of the nanoparticles can also be enhanced by their use in combination with existing antibiotics.", [["existing antibiotics", "TREATMENT", 88, 108], ["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["Finally, nanotechnology will provide a viable alternative for the development of a long-term strategy to tackle the problems of diagnosis and drug delivery in pulmonary infections.", [["pulmonary", "ANATOMY", 159, 168], ["pulmonary infections", "DISEASE", 159, 179], ["pulmonary", "ORGAN", 159, 168], ["a long-term strategy", "TREATMENT", 81, 101], ["drug delivery", "TREATMENT", 142, 155], ["pulmonary infections", "PROBLEM", 159, 179], ["pulmonary", "ANATOMY", 159, 168], ["infections", "OBSERVATION", 169, 179]]]], "3e8b21d79404cf0d2be9bef6270ba443e636547f": [["IntroductionThe presence or absence of plasmodesmata in the wall between the guard cells and the neighbouring epidermal cells remains a controversial subject.", [["plasmodesmata", "ANATOMY", 39, 52], ["wall", "ANATOMY", 60, 64], ["guard cells", "ANATOMY", 77, 88], ["epidermal cells", "ANATOMY", 110, 125], ["plasmodesmata", "CELLULAR_COMPONENT", 39, 52], ["wall", "TISSUE", 60, 64], ["guard cells", "CELL", 77, 88], ["epidermal cells", "CELL", 110, 125], ["guard cells", "CELL_TYPE", 77, 88], ["neighbouring epidermal cells", "CELL_TYPE", 97, 125], ["plasmodesmata in the wall between the guard cells", "PROBLEM", 39, 88], ["the neighbouring epidermal cells", "PROBLEM", 93, 125], ["plasmodesmata", "OBSERVATION", 39, 52], ["wall", "ANATOMY_MODIFIER", 60, 64], ["guard cells", "OBSERVATION", 77, 88], ["neighbouring", "OBSERVATION_MODIFIER", 97, 109], ["epidermal cells", "OBSERVATION", 110, 125]]], ["The majority of light microscope studies indicate that such connections exist (KoHL 1897 , KUHLA 1900 , GARDINER and HILL 1901 , KIENITZ-GERLOFF 1902 , ESAU 1941 , SIEVERS 1959 , FRANCE 1962 a, LITZ and KIMMINS 1968 , INAMDAR 1973 ) though a few reports indicate they are absent (KIENITZ-GERLOFF 1891 , SHEFFIELD 1936 , SCHU 1942 ).", [["light microscope studies", "TEST", 16, 40]]], ["At the electron microscope level, however, where the identification of plasmodesmata is less equivocal, there is ample evidence of plasmodesmatal connections between immature guard cells and neighbouring cells (KAuvMAN et al. 1970 , SINGH and Se, IVASTAVA 1973 , PALEVITZ and HEVLER 1974 , RUTTER and WILLMER 1979 .", [["plasmodesmata", "ANATOMY", 71, 84], ["guard cells", "ANATOMY", 175, 186], ["cells", "ANATOMY", 204, 209], ["plasmodesmata", "CELLULAR_COMPONENT", 71, 84], ["guard cells", "CELL", 175, 186], ["cells", "CELL", 204, 209], ["immature guard cells", "CELL_TYPE", 166, 186], ["neighbouring cells", "CELL_TYPE", 191, 209], ["the electron microscope level", "TEST", 3, 32], ["plasmodesmatal connections between immature guard cells", "PROBLEM", 131, 186], ["plasmodesmata", "OBSERVATION", 71, 84], ["ample evidence of", "UNCERTAINTY", 113, 130], ["plasmodesmatal connections", "OBSERVATION", 131, 157], ["immature guard cells", "OBSERVATION", 166, 186]]], ["In fully developed epidermal tissue, however, virtually all studies have been unable to detect plasmodesmata between guard cells and neighbouring ceils (BROWN and JOHNSTON 1962 , MmOSLAVOV 1966 , THOMSON and De JOm~NETT 1970 , SRIVASTAVA and SINOH 1972 , SINGH and SRIVASTAVA 1973 , ZIEGLER et al. 1974 , ALLAWAY and SETT~RFIELD 1972 , GALATIS 1977 , SANCHEZ 1977 even though, in some cases, deliberate efforts were made to find them.", [["epidermal tissue", "ANATOMY", 19, 35], ["plasmodesmata", "ANATOMY", 95, 108], ["guard cells", "ANATOMY", 117, 128], ["ceils", "ANATOMY", 146, 151], ["epidermal tissue", "TISSUE", 19, 35], ["plasmodesmata", "CELLULAR_COMPONENT", 95, 108], ["guard cells", "CELL", 117, 128], ["guard cells", "CELL_TYPE", 117, 128], ["epidermal tissue", "PROBLEM", 19, 35], ["all studies", "TEST", 56, 67], ["plasmodesmata between guard cells", "PROBLEM", 95, 128], ["epidermal tissue", "OBSERVATION", 19, 35]]], ["In contrast to these negative findings, PALLAS and MOLLENHAUER (1972 a, b) have reported seeing large numbers (15-20 pores um -2) of plasmodesmata in the end walls of the guard cells of both Vicia Jaba and tobacco and FUJ\u2022NO and JINNO (1972) also report of many plasmodesmatal connections between the inner lateral subsidiary cells and guard cells of Comrnelina communis.", [["plasmodesmata", "ANATOMY", 133, 146], ["end walls", "ANATOMY", 154, 163], ["guard cells", "ANATOMY", 171, 182], ["inner lateral subsidiary cells", "ANATOMY", 301, 331], ["guard cells", "ANATOMY", 336, 347], ["NO", "CHEMICAL", 222, 224], ["NO", "CHEMICAL", 222, 224], ["guard cells", "CELL", 171, 182], ["Vicia Jaba", "ORGANISM", 191, 201], ["tobacco", "ORGANISM", 206, 213], ["FUJ\u2022NO", "CELL", 218, 224], ["inner lateral subsidiary cells", "CELL", 301, 331], ["guard cells", "CELL", 336, 347], ["Comrnelina communis", "ORGANISM", 351, 370], ["guard cells", "CELL_TYPE", 171, 182], ["inner lateral subsidiary cells", "CELL_TYPE", 301, 331], ["guard cells", "CELL_TYPE", 336, 347], ["tobacco", "SPECIES", 206, 213], ["Comrnelina communis", "SPECIES", 351, 370], ["Vicia Jaba", "SPECIES", 191, 201], ["tobacco", "SPECIES", 206, 213], ["Comrnelina communis", "SPECIES", 351, 370], ["plasmodesmata", "PROBLEM", 133, 146], ["many plasmodesmatal connections", "PROBLEM", 257, 288], ["negative", "OBSERVATION", 21, 29], ["large", "OBSERVATION_MODIFIER", 96, 101], ["numbers", "OBSERVATION_MODIFIER", 102, 109], ["walls", "ANATOMY_MODIFIER", 158, 163], ["guard cells", "OBSERVATION", 171, 182], ["both", "ANATOMY_MODIFIER", 186, 190], ["Vicia Jaba", "ANATOMY", 191, 201], ["inner", "ANATOMY_MODIFIER", 301, 306], ["lateral", "ANATOMY_MODIFIER", 307, 314], ["subsidiary cells", "OBSERVATION", 315, 331], ["guard cells", "OBSERVATION", 336, 347], ["communis", "ANATOMY_MODIFIER", 362, 370]]], ["The observations on V. faba and tobacco have been described as unconvincing in the review by CAgR (1976) and, unfortunately, the quality of the electron micrographs in the Cornmelina study does not allow critical evaluation.IntroductionIf plasmodesmata are so rare or absent in mature guard cells, as most electron microscope studies would suggest, but relatively frequent in developing guard cells, it may be presumed that these connections break-down during maturation of the guard cells.", [["plasmodesmata", "ANATOMY", 239, 252], ["guard cells", "ANATOMY", 285, 296], ["guard cells", "ANATOMY", 387, 398], ["guard cells", "ANATOMY", 478, 489], ["V. faba", "ORGANISM", 20, 27], ["tobacco", "ORGANISM", 32, 39], ["guard cells", "CELL", 285, 296], ["guard cells", "CELL", 387, 398], ["guard cells", "CELL", 478, 489], ["mature guard cells", "CELL_TYPE", 278, 296], ["guard cells", "CELL_TYPE", 387, 398], ["guard cells", "CELL_TYPE", 478, 489], ["V. faba", "SPECIES", 20, 27], ["tobacco", "SPECIES", 32, 39], ["V. faba", "SPECIES", 20, 27], ["tobacco", "SPECIES", 32, 39], ["the electron micrographs", "TEST", 140, 164], ["the Cornmelina study", "TEST", 168, 188], ["critical evaluation", "TEST", 204, 223], ["plasmodesmata", "PROBLEM", 239, 252], ["absent in mature guard cells", "PROBLEM", 268, 296], ["most electron microscope studies", "TEST", 301, 333], ["developing guard cells", "PROBLEM", 376, 398], ["guard cells", "OBSERVATION", 285, 296], ["guard cells", "OBSERVATION", 387, 398], ["may be presumed", "UNCERTAINTY", 403, 418], ["guard cells", "OBSERVATION", 478, 489]]], ["V~LA and Le~ (1975) claim to have seen su& incomplete plasmodesmata in the common guard/subsidiary cell wall in wheat.", [["plasmodesmata", "ANATOMY", 54, 67], ["cell wall", "ANATOMY", 99, 108], ["LA", "CHEMICAL", 2, 4], ["cell wall", "TISSUE", 99, 108], ["wheat", "ORGANISM_SUBDIVISION", 112, 117], ["wheat", "SPECIES", 112, 117], ["wheat", "SPECIES", 112, 117], ["LA", "ANATOMY", 2, 4], ["plasmodesmata", "OBSERVATION", 54, 67], ["common guard", "ANATOMY", 75, 87], ["subsidiary cell", "OBSERVATION", 88, 103], ["wall", "ANATOMY_MODIFIER", 104, 108]]], ["In view of the importance of knowing whether intact plasmodesmata exist or not between guard cells and neighbouring cells to our understanding of how stomata function, particularly regarding solute transport between the guard cells and neighbouring cells, we have undertaken a further search for such structures in these locations.", [["plasmodesmata", "ANATOMY", 52, 65], ["guard cells", "ANATOMY", 87, 98], ["cells", "ANATOMY", 116, 121], ["stomata", "ANATOMY", 150, 157], ["guard cells", "ANATOMY", 220, 231], ["cells", "ANATOMY", 249, 254], ["plasmodesmata", "CELLULAR_COMPONENT", 52, 65], ["guard cells", "CELL", 87, 98], ["cells", "CELL", 116, 121], ["solute", "SIMPLE_CHEMICAL", 191, 197], ["guard cells", "CELL", 220, 231], ["cells", "CELL", 249, 254], ["guard cells", "CELL_TYPE", 87, 98], ["neighbouring cells", "CELL_TYPE", 103, 121], ["guard cells", "CELL_TYPE", 220, 231], ["neighbouring cells", "CELL_TYPE", 236, 254], ["guard cells", "PROBLEM", 87, 98]]], ["We have particularly searched for aborted and incomplete plasmodesmata in the common guard/epidermal cell wall and we have serially sectioned parts of stomata in efforts to establish such facts.Materials and MethodsElectron microscope studies were made on leaf material from Phaseolus vulgare L. plants grown from seed in a John Innes potting compost No. 2.", [["plasmodesmata", "ANATOMY", 57, 70], ["epidermal cell wall", "ANATOMY", 91, 110], ["stomata", "ANATOMY", 151, 158], ["epidermal cell wall", "TISSUE", 91, 110], ["leaf material", "MULTI-TISSUE_STRUCTURE", 256, 269], ["Phaseolus vulgare", "ORGANISM", 275, 292], ["L.", "ORGANISM", 293, 295], ["plants", "ORGANISM", 296, 302], ["seed", "ORGANISM_SUBDIVISION", 314, 318], ["Phaseolus vulgare", "SPECIES", 275, 292], ["L.", "SPECIES", 293, 295], ["Phaseolus vulgare", "SPECIES", 275, 292], ["incomplete plasmodesmata", "PROBLEM", 46, 70], ["MethodsElectron microscope studies", "TEST", 208, 242], ["common guard", "ANATOMY", 78, 90], ["epidermal cell", "OBSERVATION", 91, 105], ["wall", "ANATOMY_MODIFIER", 106, 110]]], ["The plants were grown in a heated greenhouse so that temperatures never dropped below 12 ~ in the winter months and supplementary lighting was given between October and March.", [["temperatures", "TEST", 53, 65], ["supplementary lighting", "TREATMENT", 116, 138], ["grown", "OBSERVATION_MODIFIER", 16, 21]]], ["Plant material was taken from the central leaflet of the rrifoliate leaves.", [["central leaflet", "ANATOMY", 34, 49], ["leaves", "ANATOMY", 68, 74], ["central leaflet", "MULTI-TISSUE_STRUCTURE", 34, 49], ["leaves", "ORGANISM_SUBDIVISION", 68, 74], ["Plant material", "TREATMENT", 0, 14], ["central", "ANATOMY_MODIFIER", 34, 41], ["leaflet", "ANATOMY_MODIFIER", 42, 49], ["rrifoliate leaves", "OBSERVATION", 57, 74]]], ["To obtain the different stages of stomatal development leaflets of different lengths (8 mm, 15 ram, and 150ram) were cut into 1 mm squares for fixation.", [["stomatal", "ANATOMY", 34, 42], ["stomatal development leaflets", "MULTI-TISSUE_STRUCTURE", 34, 63], ["fixation", "TREATMENT", 143, 151], ["stomatal development leaflets", "OBSERVATION", 34, 63], ["different", "OBSERVATION_MODIFIER", 67, 76], ["lengths", "OBSERVATION_MODIFIER", 77, 84], ["fixation", "OBSERVATION", 143, 151]]], ["The material was fixed for 2 hours at 18 ~ in 30/0 glutaraldehyde in sodium cacodylate buffer (pH7.2).", [["glutaraldehyde", "CHEMICAL", 51, 65], ["sodium cacodylate", "CHEMICAL", 69, 86], ["glutaraldehyde", "CHEMICAL", 51, 65], ["sodium cacodylate", "CHEMICAL", 69, 86], ["glutaraldehyde", "SIMPLE_CHEMICAL", 51, 65], ["sodium cacodylate buffer", "SIMPLE_CHEMICAL", 69, 93], ["glutaraldehyde in sodium cacodylate buffer", "TREATMENT", 51, 93]]], ["After washing for 3 hours in several changes of the above buffer the tissue was placed in 20/0 osmium tetroxide and left overnight.", [["tissue", "ANATOMY", 69, 75], ["osmium tetroxide", "CHEMICAL", 95, 111], ["osmium tetroxide", "CHEMICAL", 95, 111], ["tissue", "TISSUE", 69, 75], ["osmium tetroxide", "SIMPLE_CHEMICAL", 95, 111], ["20/0 osmium tetroxide", "TREATMENT", 90, 111], ["tissue", "ANATOMY", 69, 75], ["left", "ANATOMY_MODIFIER", 116, 120]]], ["Dehydration was carried out using an ethanol-acetone-propylene oxide series and the material was then embedded in an epon/araldite mixture.", [["Dehydration", "DISEASE", 0, 11], ["ethanol-acetone-propylene oxide", "CHEMICAL", 37, 68], ["ethanol", "CHEMICAL", 37, 44], ["acetone", "CHEMICAL", 45, 52], ["propylene oxide", "CHEMICAL", 53, 68], ["ethanol", "SIMPLE_CHEMICAL", 37, 44], ["acetone-propylene oxide", "SIMPLE_CHEMICAL", 45, 68], ["Dehydration", "PROBLEM", 0, 11], ["an ethanol-acetone-propylene oxide series", "TREATMENT", 34, 75], ["an epon/araldite mixture", "TREATMENT", 114, 138]]], ["Silver sections were viewed with a JEM 100 C microscope after staining (REYNOLDS 1963) .ResultsDuring differentiation of the protodermal tissue plasmodesmata were frequently observed linking guard mother cells with neighbouring epidermal cells and also linking epidermal cell with epidermal cell (Fig. 1) .", [["Silver sections", "ANATOMY", 0, 15], ["protodermal tissue plasmodesmata", "ANATOMY", 125, 157], ["guard mother cells", "ANATOMY", 191, 209], ["epidermal cells", "ANATOMY", 228, 243], ["epidermal cell", "ANATOMY", 261, 275], ["epidermal cell", "ANATOMY", 281, 295], ["Silver", "CHEMICAL", 0, 6], ["Silver sections", "CANCER", 0, 15], ["protodermal tissue plasmodesmata", "TISSUE", 125, 157], ["guard mother cells", "CELL", 191, 209], ["epidermal cells", "CELL", 228, 243], ["epidermal cell", "CELL", 261, 275], ["epidermal cell", "CELL", 281, 295], ["guard mother cells", "CELL_TYPE", 191, 209], ["neighbouring epidermal cells", "CELL_TYPE", 215, 243], ["epidermal cell", "CELL_TYPE", 261, 275], ["epidermal cell", "CELL_TYPE", 281, 295], ["the protodermal tissue plasmodesmata", "PROBLEM", 121, 157], ["neighbouring epidermal cells", "PROBLEM", 215, 243], ["epidermal cell (Fig", "PROBLEM", 281, 300], ["protodermal tissue plasmodesmata", "OBSERVATION", 125, 157], ["epidermal cells", "OBSERVATION", 228, 243], ["epidermal cell", "OBSERVATION", 261, 275], ["epidermal cell", "OBSERVATION", 281, 295]]], ["At a later stage Fig. 1 .", [["Fig", "OBSERVATION_MODIFIER", 17, 20]]], ["A guard mother cell surrounded by vacuolated epidermal cells.", [["guard mother cell", "ANATOMY", 2, 19], ["epidermal cells", "ANATOMY", 45, 60], ["guard mother cell", "CELL", 2, 19], ["vacuolated epidermal cells", "CELL", 34, 60], ["guard mother cell", "CELL_TYPE", 2, 19], ["vacuolated epidermal cells", "CELL_TYPE", 34, 60], ["vacuolated epidermal cells", "PROBLEM", 34, 60], ["vacuolated", "OBSERVATION_MODIFIER", 34, 44], ["epidermal cells", "OBSERVATION", 45, 60]]], ["Plasmodesmata ( of development of the stomata plasmodesmata were also frequently seen connecting sister guard cells along their ventral walls, connecting neighbouring epidermal cells with guard cells, and connecting epidermal cell with epidermal cell (Fig. 2-4) .", [["stomata plasmodesmata", "ANATOMY", 38, 59], ["guard cells", "ANATOMY", 104, 115], ["ventral walls", "ANATOMY", 128, 141], ["epidermal cells", "ANATOMY", 167, 182], ["guard cells", "ANATOMY", 188, 199], ["epidermal cell", "ANATOMY", 216, 230], ["epidermal cell", "ANATOMY", 236, 250], ["stomata plasmodesmata", "MULTI-TISSUE_STRUCTURE", 38, 59], ["guard cells", "CELL", 104, 115], ["ventral walls", "TISSUE", 128, 141], ["epidermal cells", "CELL", 167, 182], ["guard cells", "CELL", 188, 199], ["epidermal cell", "CELL", 216, 230], ["epidermal cell", "CELL", 236, 250], ["sister guard cells", "CELL_TYPE", 97, 115], ["neighbouring epidermal cells", "CELL_TYPE", 154, 182], ["guard cells", "CELL_TYPE", 188, 199], ["epidermal cell", "CELL_TYPE", 216, 230], ["epidermal cell", "CELL_TYPE", 236, 250], ["the stomata plasmodesmata", "PROBLEM", 34, 59], ["guard cells", "PROBLEM", 188, 199], ["stomata plasmodesmata", "OBSERVATION", 38, 59], ["guard cells", "OBSERVATION", 104, 115], ["ventral", "ANATOMY_MODIFIER", 128, 135], ["walls", "ANATOMY_MODIFIER", 136, 141], ["epidermal cells", "OBSERVATION", 167, 182], ["guard cells", "OBSERVATION", 188, 199], ["epidermal cell", "OBSERVATION", 216, 230], ["epidermal cell", "OBSERVATION", 236, 250]]], ["A common location of the plasmodesmata at this stage of development of the guard cells appeared to be in their end walls .", [["plasmodesmata", "ANATOMY", 25, 38], ["guard cells", "ANATOMY", 75, 86], ["plasmodesmata", "CELLULAR_COMPONENT", 25, 38], ["guard cells", "CELL", 75, 86], ["guard cells", "CELL_TYPE", 75, 86], ["the guard cells", "PROBLEM", 71, 86], ["plasmodesmata", "OBSERVATION", 25, 38], ["guard cells", "OBSERVATION", 75, 86], ["walls", "ANATOMY_MODIFIER", 115, 120]]], ["However, this impression may result from a \"dilution\" effect of the plasmodesmatal numbers due to the unequal expansion of the guard cell walls, the end walls expanding much less than the dorsal or ventral walls during growth.", [["cell walls", "ANATOMY", 133, 143], ["end walls", "ANATOMY", 149, 158], ["dorsal", "ANATOMY", 188, 194], ["ventral walls", "ANATOMY", 198, 211], ["cell walls", "TISSUE", 133, 143], ["dorsal", "TISSUE", 188, 194], ["ventral walls", "MULTI-TISSUE_STRUCTURE", 198, 211], ["a \"dilution\" effect", "PROBLEM", 41, 60], ["the plasmodesmatal numbers", "TEST", 64, 90], ["the unequal expansion of the guard cell walls", "PROBLEM", 98, 143], ["unequal", "OBSERVATION_MODIFIER", 102, 109], ["expansion", "OBSERVATION", 110, 119], ["guard cell", "OBSERVATION", 127, 137], ["walls", "ANATOMY_MODIFIER", 138, 143], ["end", "OBSERVATION_MODIFIER", 149, 152], ["walls", "OBSERVATION_MODIFIER", 153, 158], ["much", "OBSERVATION_MODIFIER", 169, 173], ["less", "OBSERVATION_MODIFIER", 174, 178], ["dorsal", "ANATOMY_MODIFIER", 188, 194], ["ventral", "ANATOMY_MODIFIER", 198, 205], ["walls", "ANATOMY_MODIFIER", 206, 211], ["growth", "OBSERVATION_MODIFIER", 219, 225]]], ["At a later stage of development still, when the pore between sister guard cells had partly formed, plasmodesmata were seen between sister guard cells and between guard cells and neighbouring epidermal cells (Figs.", [["pore", "ANATOMY", 48, 52], ["guard cells", "ANATOMY", 68, 79], ["plasmodesmata", "ANATOMY", 99, 112], ["guard cells", "ANATOMY", 138, 149], ["guard cells", "ANATOMY", 162, 173], ["epidermal cells", "ANATOMY", 191, 206], ["pore", "CELLULAR_COMPONENT", 48, 52], ["guard cells", "CELL", 68, 79], ["plasmodesmata", "CELLULAR_COMPONENT", 99, 112], ["cells", "CELL", 144, 149], ["guard cells", "CELL", 162, 173], ["epidermal cells", "CELL", 191, 206], ["sister guard cells", "CELL_TYPE", 61, 79], ["sister guard cells", "CELL_TYPE", 131, 149], ["guard cells", "CELL_TYPE", 162, 173], ["neighbouring epidermal cells", "CELL_TYPE", 178, 206], ["the pore between sister guard cells", "PROBLEM", 44, 79], ["plasmodesmata", "PROBLEM", 99, 112], ["epidermal cells", "OBSERVATION", 191, 206]]], ["Usually, the plasmodesmata in all the locations occurred as single, unbranched connections but on occasions sparsely populated pit-fields were seen (Figs.", [["plasmodesmata", "ANATOMY", 13, 26], ["plasmodesmata", "CELLULAR_COMPONENT", 13, 26], ["plasmodesmata", "OBSERVATION", 13, 26], ["unbranched", "OBSERVATION_MODIFIER", 68, 78]]], ["In mature tissue complete plasmodesmatal connections between guard cells and epidermal cells were never seen although much effort was expended in trying to find them.", [["tissue", "ANATOMY", 10, 16], ["guard cells", "ANATOMY", 61, 72], ["epidermal cells", "ANATOMY", 77, 92], ["tissue", "TISSUE", 10, 16], ["guard cells", "CELL", 61, 72], ["epidermal cells", "CELL", 77, 92], ["guard cells", "CELL_TYPE", 61, 72], ["epidermal cells", "CELL_TYPE", 77, 92], ["epidermal cells", "PROBLEM", 77, 92], ["mature", "OBSERVATION_MODIFIER", 3, 9], ["tissue", "OBSERVATION_MODIFIER", 10, 16], ["complete", "OBSERVATION_MODIFIER", 17, 25], ["plasmodesmatal connections", "OBSERVATION", 26, 52], ["guard cells", "OBSERVATION", 61, 72], ["epidermal cells", "OBSERVATION", 77, 92]]], ["However, occasionally, incomplete plasmodesmata were seen, either buried in the common guard/epidermal cell wall (Fig. 11 ), or penetrating a short distance from the epidermal cell side into the common wall (Figs.", [["plasmodesmata", "ANATOMY", 34, 47], ["epidermal cell wall", "ANATOMY", 93, 112], ["epidermal cell", "ANATOMY", 166, 180], ["wall", "ANATOMY", 202, 206], ["plasmodesmata", "CELLULAR_COMPONENT", 34, 47], ["epidermal cell wall", "TISSUE", 93, 112], ["epidermal cell", "CELLULAR_COMPONENT", 166, 180], ["wall", "TISSUE", 202, 206], ["incomplete plasmodesmata", "PROBLEM", 23, 47], ["penetrating a short distance", "PROBLEM", 128, 156], ["incomplete", "OBSERVATION_MODIFIER", 23, 33], ["plasmodesmata", "OBSERVATION", 34, 47], ["common guard", "ANATOMY", 80, 92], ["epidermal cell", "OBSERVATION", 93, 107], ["wall", "ANATOMY_MODIFIER", 108, 112], ["penetrating", "OBSERVATION_MODIFIER", 128, 139], ["short", "OBSERVATION_MODIFIER", 142, 147], ["epidermal cell", "OBSERVATION", 166, 180], ["common wall", "ANATOMY", 195, 206]]], ["The view that these plasmodesmata were incomplete connections was substantiated by serially sectioning guard cells with such areas.", [["plasmodesmata", "ANATOMY", 20, 33], ["cells", "ANATOMY", 109, 114], ["plasmodesmata", "CELLULAR_COMPONENT", 20, 33], ["guard cells", "CELL", 103, 114], ["guard cells", "CELL_TYPE", 103, 114], ["incomplete connections", "PROBLEM", 39, 61], ["plasmodesmata", "OBSERVATION", 20, 33]]], ["No convincing evidence of their continuity through the wall on the guard cell side was found though, occasionally, small inconspicuous localized disruptions of the wall microfibrils were found which might conceivably represent the remains of a disrupted canal (Fig. 7) .", [["wall", "ANATOMY", 55, 59], ["guard cell", "ANATOMY", 67, 77], ["wall microfibrils", "ANATOMY", 164, 181], ["canal", "ANATOMY", 254, 259], ["wall", "TISSUE", 55, 59], ["guard cell", "CELL", 67, 77], ["wall microfibrils", "CELLULAR_COMPONENT", 164, 181], ["canal", "TISSUE", 254, 259], ["the guard cell side", "TEST", 63, 82], ["small inconspicuous localized disruptions of the wall microfibrils", "PROBLEM", 115, 181], ["a disrupted canal (Fig", "PROBLEM", 242, 264], ["convincing evidence of", "UNCERTAINTY", 3, 25], ["continuity", "OBSERVATION", 32, 42], ["wall", "ANATOMY_MODIFIER", 55, 59], ["small", "OBSERVATION_MODIFIER", 115, 120], ["inconspicuous", "OBSERVATION_MODIFIER", 121, 134], ["localized", "OBSERVATION_MODIFIER", 135, 144], ["disruptions", "OBSERVATION", 145, 156], ["wall", "ANATOMY_MODIFIER", 164, 168], ["microfibrils", "OBSERVATION", 169, 181], ["might conceivably represent", "UNCERTAINTY", 199, 226], ["disrupted", "OBSERVATION", 244, 253], ["canal", "OBSERVATION_MODIFIER", 254, 259], ["Fig", "OBSERVATION_MODIFIER", 261, 264]]], ["The incomplete plasmodesmata seen in the common guard/epidermal cell wall usually appeared to be located in a more electron-dense area of the wall and were, in several examples, connected to the epidermal ceil protoplast (Figs.", [["plasmodesmata", "ANATOMY", 15, 28], ["epidermal cell wall", "ANATOMY", 54, 73], ["wall", "ANATOMY", 142, 146], ["epidermal ceil protoplast", "ANATOMY", 195, 220], ["epidermal cell wall", "TISSUE", 54, 73], ["wall", "TISSUE", 142, 146], ["epidermal ceil protoplast", "CELL", 195, 220], ["The incomplete plasmodesmata", "PROBLEM", 0, 28], ["the epidermal ceil protoplast", "TREATMENT", 191, 220], ["incomplete", "OBSERVATION_MODIFIER", 4, 14], ["plasmodesmata", "OBSERVATION", 15, 28], ["common guard", "ANATOMY", 41, 53], ["epidermal cell", "OBSERVATION", 54, 68], ["wall", "ANATOMY_MODIFIER", 69, 73], ["more", "OBSERVATION_MODIFIER", 110, 114], ["electron", "OBSERVATION_MODIFIER", 115, 123], ["dense", "OBSERVATION_MODIFIER", 124, 129], ["area", "OBSERVATION_MODIFIER", 130, 134], ["wall", "ANATOMY_MODIFIER", 142, 146]]], ["This darker area of the wall was considered to be the remains of the initial primary wall of the developing guard and epidermal cells.", [["darker area", "ANATOMY", 5, 16], ["wall", "ANATOMY", 24, 28], ["primary wall", "ANATOMY", 77, 89], ["guard", "ANATOMY", 108, 113], ["epidermal cells", "ANATOMY", 118, 133], ["wall", "TISSUE", 24, 28], ["wall", "ORGAN", 85, 89], ["guard", "CELL", 108, 113], ["epidermal cells", "CELL", 118, 133], ["developing guard and epidermal cells", "CELL_TYPE", 97, 133], ["epidermal cells", "PROBLEM", 118, 133], ["darker", "OBSERVATION_MODIFIER", 5, 11], ["wall", "ANATOMY_MODIFIER", 24, 28], ["considered to be", "UNCERTAINTY", 33, 49], ["developing guard", "OBSERVATION", 97, 113], ["epidermal cells", "OBSERVATION", 118, 133]]], ["The layer of wall which did not contain plasmodesmata represents the thickening applied to the inside of the guard cell wall as it reaches maturity.", [["wall", "ANATOMY", 13, 17], ["plasmodesmata", "ANATOMY", 40, 53], ["guard cell wall", "ANATOMY", 109, 124], ["plasmodesmata", "CELLULAR_COMPONENT", 40, 53], ["guard cell wall", "TISSUE", 109, 124], ["the thickening", "PROBLEM", 65, 79], ["layer", "OBSERVATION_MODIFIER", 4, 9], ["wall", "ANATOMY_MODIFIER", 13, 17], ["did not contain", "UNCERTAINTY", 24, 39], ["plasmodesmata", "OBSERVATION", 40, 53], ["thickening", "OBSERVATION", 69, 79], ["guard cell", "OBSERVATION", 109, 119], ["wall", "ANATOMY_MODIFIER", 120, 124], ["maturity", "OBSERVATION_MODIFIER", 139, 147]]], ["The branched, incomplete plasmodesmata in Fig. 11 also occur in the darker region of the guard cell wall.", [["plasmodesmata", "ANATOMY", 25, 38], ["cell wall", "ANATOMY", 95, 104], ["plasmodesmata", "CELLULAR_COMPONENT", 25, 38], ["guard cell wall", "TISSUE", 89, 104], ["incomplete plasmodesmata in Fig.", "PROBLEM", 14, 46], ["branched", "OBSERVATION_MODIFIER", 4, 12], ["incomplete", "OBSERVATION_MODIFIER", 14, 24], ["plasmodesmata", "OBSERVATION", 25, 38], ["darker", "ANATOMY_MODIFIER", 68, 74], ["region", "ANATOMY_MODIFIER", 75, 81], ["guard cell", "OBSERVATION", 89, 99], ["wall", "ANATOMY_MODIFIER", 100, 104]]], ["The wall in this region has separated along the line of the middle lamella between a guard cell and an epidermal cell apparently breaking the plasmodesmata; the gap between the two walls, therefore, would be sub-stomatal cavity space.", [["wall", "ANATOMY", 4, 8], ["middle lamella", "ANATOMY", 60, 74], ["guard cell", "ANATOMY", 85, 95], ["epidermal cell", "ANATOMY", 103, 117], ["plasmodesmata", "ANATOMY", 142, 155], ["walls", "ANATOMY", 181, 186], ["wall", "TISSUE", 4, 8], ["middle lamella", "CELLULAR_COMPONENT", 60, 74], ["guard cell", "CELL", 85, 95], ["epidermal cell", "CELL", 103, 117], ["plasmodesmata", "CELLULAR_COMPONENT", 142, 155], ["guard cell", "CELL_TYPE", 85, 95], ["epidermal cell", "CELL_TYPE", 103, 117], ["a guard cell", "TREATMENT", 83, 95], ["an epidermal cell", "PROBLEM", 100, 117], ["wall", "ANATOMY_MODIFIER", 4, 8], ["region", "ANATOMY_MODIFIER", 17, 23], ["line", "OBSERVATION_MODIFIER", 48, 52], ["middle", "ANATOMY_MODIFIER", 60, 66], ["lamella", "ANATOMY_MODIFIER", 67, 74], ["guard cell", "OBSERVATION", 85, 95], ["epidermal cell", "OBSERVATION", 103, 117], ["plasmodesmata", "OBSERVATION_MODIFIER", 142, 155], ["gap", "OBSERVATION_MODIFIER", 161, 164], ["two", "OBSERVATION_MODIFIER", 177, 180], ["walls", "OBSERVATION_MODIFIER", 181, 186], ["sub", "OBSERVATION_MODIFIER", 208, 211], ["stomatal", "OBSERVATION", 212, 220], ["cavity space", "OBSERVATION", 221, 233]]], ["This process occurs during separation of young angular cells as they expand resulting in the formation of intercellular spaces.", [["angular cells", "ANATOMY", 47, 60], ["intercellular spaces", "ANATOMY", 106, 126], ["angular cells", "CELL", 47, 60], ["intercellular spaces", "CELLULAR_COMPONENT", 106, 126], ["young angular cells", "CELL_TYPE", 41, 60], ["angular cells", "OBSERVATION", 47, 60], ["intercellular spaces", "OBSERVATION", 106, 126]]], ["Plasmodesmata were also observed between neighbouring epidermal cells at all stages of the development of the epidermal tissue.DiscussionThis study supports earlier reports that complete plasmodesmatal connections occur between guard and neighbouring epidermal or subsidiary cells and between sister guard cells during the early stages of the differentiation of the epidermal tissue.", [["epidermal cells", "ANATOMY", 54, 69], ["epidermal tissue", "ANATOMY", 110, 126], ["plasmodesmatal", "ANATOMY", 187, 201], ["epidermal", "ANATOMY", 251, 260], ["cells", "ANATOMY", 275, 280], ["guard cells", "ANATOMY", 300, 311], ["epidermal tissue", "ANATOMY", 366, 382], ["epidermal cells", "CELL", 54, 69], ["epidermal tissue", "TISSUE", 110, 126], ["epidermal", "CELLULAR_COMPONENT", 251, 260], ["cells", "CELL", 275, 280], ["guard cells", "CELL", 300, 311], ["epidermal tissue", "TISSUE", 366, 382], ["neighbouring epidermal cells", "CELL_TYPE", 41, 69], ["neighbouring epidermal or subsidiary cells", "CELL_TYPE", 238, 280], ["sister guard cells", "CELL_TYPE", 293, 311], ["Plasmodesmata", "PROBLEM", 0, 13], ["neighbouring epidermal cells", "PROBLEM", 41, 69], ["the epidermal tissue", "PROBLEM", 106, 126], ["complete plasmodesmatal connections", "PROBLEM", 178, 213], ["neighbouring epidermal or subsidiary cells", "PROBLEM", 238, 280], ["sister guard cells", "PROBLEM", 293, 311], ["the epidermal tissue", "PROBLEM", 362, 382], ["epidermal cells", "OBSERVATION", 54, 69], ["epidermal tissue", "OBSERVATION", 110, 126], ["subsidiary cells", "OBSERVATION", 264, 280], ["epidermal tissue", "ANATOMY", 366, 382]]], ["However, contrary to other studies, with the exception of the unconvincing study by VELA and Lee (1975) , incomplete, non-functional plasmodesmata were occasionally seen in the common guard/epidermal cell walls.", [["plasmodesmata", "ANATOMY", 133, 146], ["epidermal cell walls", "ANATOMY", 190, 210], ["plasmodesmata", "CELLULAR_COMPONENT", 133, 146], ["epidermal cell walls", "TISSUE", 190, 210], ["other studies", "TEST", 21, 34], ["the unconvincing study", "TEST", 58, 80], ["non-functional plasmodesmata", "PROBLEM", 118, 146], ["non-functional plasmodesmata", "OBSERVATION", 118, 146], ["common guard", "ANATOMY", 177, 189], ["epidermal cell walls", "OBSERVATION", 190, 210]]], ["These incomplete plasmodesmata may have arisen due to deposition of wall material on the guard cell side occluding the plasmodesmata while, on the epidermal cell side, deposition being very much less significant, they remained open.", [["plasmodesmata", "ANATOMY", 17, 30], ["wall material", "ANATOMY", 68, 81], ["cell", "ANATOMY", 95, 99], ["plasmodesmata", "ANATOMY", 119, 132], ["epidermal cell", "ANATOMY", 147, 161], ["wall material", "CELLULAR_COMPONENT", 68, 81], ["cell side", "CELLULAR_COMPONENT", 95, 104], ["plasmodesmata", "CELLULAR_COMPONENT", 119, 132], ["epidermal cell side", "CELLULAR_COMPONENT", 147, 166], ["These incomplete plasmodesmata", "PROBLEM", 0, 30], ["deposition of wall material", "PROBLEM", 54, 81], ["the guard cell side", "TREATMENT", 85, 104], ["plasmodesmata", "OBSERVATION", 17, 30], ["may have arisen due to", "UNCERTAINTY", 31, 53], ["deposition", "OBSERVATION_MODIFIER", 54, 64], ["wall material", "OBSERVATION", 68, 81], ["guard cell", "OBSERVATION_MODIFIER", 89, 99], ["plasmodesmata", "OBSERVATION_MODIFIER", 119, 132], ["epidermal cell", "OBSERVATION_MODIFIER", 147, 161], ["open", "OBSERVATION", 227, 231]]], ["The occlusion of plasmodesmata at both ends has been reported before in cells of the pigment strand in the developing wheat seed (ZEz and O'Be, IZN 1970) but we are unaware of reports of plasmodesmata being occluded at one end only between living ceils.", [["plasmodesmata", "ANATOMY", 17, 30], ["cells", "ANATOMY", 72, 77], ["pigment strand", "ANATOMY", 85, 99], ["seed", "ANATOMY", 124, 128], ["plasmodesmata", "ANATOMY", 187, 200], ["plasmodesmata", "CELLULAR_COMPONENT", 17, 30], ["cells", "CELL", 72, 77], ["pigment strand", "CELLULAR_COMPONENT", 85, 99], ["wheat", "ORGANISM", 118, 123], ["seed", "DEVELOPING_ANATOMICAL_STRUCTURE", 124, 128], ["wheat", "SPECIES", 118, 123], ["wheat", "SPECIES", 118, 123], ["The occlusion of plasmodesmata", "PROBLEM", 0, 30], ["plasmodesmata being occluded", "PROBLEM", 187, 215], ["occlusion", "OBSERVATION", 4, 13], ["plasmodesmata", "OBSERVATION", 17, 30], ["pigment strand", "OBSERVATION", 85, 99], ["wheat seed", "OBSERVATION", 118, 128], ["occluded", "OBSERVATION", 207, 215]]], ["During stomatal opening, guard cells of some species bulge into the neighbouring cells, the dorsal cell wall strechting considerably (increases in the length of the dorsal wall of the guard cell of 10~ or greater have been recorded (MEIDNER and WILLMER 1975) , under the increasing turgor pressure.", [["stomatal", "ANATOMY", 7, 15], ["guard cells", "ANATOMY", 25, 36], ["cells", "ANATOMY", 81, 86], ["dorsal cell wall", "ANATOMY", 92, 108], ["dorsal wall", "ANATOMY", 165, 176], ["guard cell", "ANATOMY", 184, 194], ["guard cells", "CELL", 25, 36], ["cells", "CELL", 81, 86], ["dorsal cell wall", "TISSUE", 92, 108], ["dorsal wall", "MULTI-TISSUE_STRUCTURE", 165, 176], ["guard cell", "CELL", 184, 194], ["guard cells", "CELL_TYPE", 25, 36], ["neighbouring cells", "CELL_TYPE", 68, 86], ["guard cell", "CELL_TYPE", 184, 194], ["guard cells", "TREATMENT", 25, 36], ["some species bulge into the neighbouring cells", "PROBLEM", 40, 86], ["the increasing turgor pressure", "TREATMENT", 267, 297], ["stomatal opening", "OBSERVATION", 7, 23], ["guard cells", "OBSERVATION", 25, 36], ["species bulge", "OBSERVATION", 45, 58], ["neighbouring cells", "OBSERVATION", 68, 86], ["dorsal", "ANATOMY_MODIFIER", 92, 98], ["cell", "ANATOMY_MODIFIER", 99, 103], ["wall", "ANATOMY_MODIFIER", 104, 108], ["strechting", "OBSERVATION_MODIFIER", 109, 119], ["considerably", "OBSERVATION_MODIFIER", 120, 132], ["increases", "OBSERVATION_MODIFIER", 134, 143], ["length", "OBSERVATION_MODIFIER", 151, 157], ["dorsal", "ANATOMY_MODIFIER", 165, 171], ["wall", "ANATOMY_MODIFIER", 172, 176], ["guard cell", "OBSERVATION", 184, 194], ["increasing", "OBSERVATION_MODIFIER", 271, 281], ["turgor pressure", "OBSERVATION", 282, 297]]], ["Also, in some species the guard cells change their alignment in the epidermis moving slightly above or below the surface of the leaf during opening and closing movements (ScHxeENDEN~R 1881).", [["guard cells", "ANATOMY", 26, 37], ["epidermis", "ANATOMY", 68, 77], ["surface", "ANATOMY", 113, 120], ["leaf", "ANATOMY", 128, 132], ["guard cells", "CELL", 26, 37], ["epidermis", "ORGAN", 68, 77], ["leaf", "ORGAN", 128, 132], ["guard cells", "CELL_TYPE", 26, 37], ["the guard cells", "PROBLEM", 22, 37], ["guard cells", "OBSERVATION", 26, 37], ["alignment", "OBSERVATION_MODIFIER", 51, 60], ["epidermis", "ANATOMY", 68, 77], ["surface", "ANATOMY_MODIFIER", 113, 120], ["leaf", "ANATOMY", 128, 132]]], ["Such guard cell movements with accompanying wall stretching are likely to damage such delicate structures as plasmodesmata and we consider this another reason for believing that cytoplasmic connections break down between the guard cells and neighbouring cells.", [["cell", "ANATOMY", 11, 15], ["wall", "ANATOMY", 44, 48], ["plasmodesmata", "ANATOMY", 109, 122], ["cytoplasmic", "ANATOMY", 178, 189], ["guard cells", "ANATOMY", 225, 236], ["cells", "ANATOMY", 254, 259], ["guard cell", "CELL", 5, 15], ["plasmodesmata", "CELLULAR_COMPONENT", 109, 122], ["cytoplasmic", "ORGANISM_SUBSTANCE", 178, 189], ["guard cells", "CELL", 225, 236], ["cells", "CELL", 254, 259], ["guard cells", "CELL_TYPE", 225, 236], ["neighbouring cells", "CELL_TYPE", 241, 259], ["Such guard cell movements", "PROBLEM", 0, 25], ["accompanying wall stretching", "PROBLEM", 31, 59], ["cytoplasmic connections break", "PROBLEM", 178, 207], ["guard cell movements", "OBSERVATION", 5, 25], ["wall", "ANATOMY_MODIFIER", 44, 48], ["stretching", "OBSERVATION", 49, 59], ["guard cells", "OBSERVATION", 225, 236], ["neighbouring cells", "OBSERVATION", 241, 259]]], ["Curiously, we have found no intact, branched plasmodesmata at any stage in the development of the epidermal tissue although incomplete ones were found in mature guard/epidermal cell walls.", [["plasmodesmata", "ANATOMY", 45, 58], ["epidermal tissue", "ANATOMY", 98, 114], ["epidermal cell walls", "ANATOMY", 167, 187], ["plasmodesmata", "CELLULAR_COMPONENT", 45, 58], ["epidermal tissue", "TISSUE", 98, 114], ["epidermal cell walls", "TISSUE", 167, 187], ["branched plasmodesmata", "PROBLEM", 36, 58], ["the epidermal tissue", "PROBLEM", 94, 114], ["incomplete ones", "PROBLEM", 124, 139], ["no", "UNCERTAINTY", 25, 27], ["intact", "OBSERVATION", 28, 34], ["branched", "OBSERVATION_MODIFIER", 36, 44], ["plasmodesmata", "OBSERVATION", 45, 58], ["epidermal tissue", "ANATOMY", 98, 114], ["epidermal cell walls", "OBSERVATION", 167, 187]]], ["Fig. 5 (mag. \u2022 shows a developing stoma in which the central pore (large arrow) is beginning to form.", [["central pore", "ANATOMY", 53, 65], ["mag", "GENE_OR_GENE_PRODUCT", 8, 11], ["stoma", "PATHOLOGICAL_FORMATION", 34, 39], ["central pore", "MULTI-TISSUE_STRUCTURE", 53, 65], ["a developing stoma", "PROBLEM", 21, 39], ["developing", "OBSERVATION_MODIFIER", 23, 33], ["stoma", "OBSERVATION", 34, 39], ["central", "OBSERVATION_MODIFIER", 53, 60], ["pore", "OBSERVATION_MODIFIER", 61, 65], ["large", "OBSERVATION_MODIFIER", 67, 72]]], ["Plasmodesmata (\":') occur between sister guard cells in their ventral walls and between guard cells and epidermal cells.", [["guard cells", "ANATOMY", 41, 52], ["ventral walls", "ANATOMY", 62, 75], ["guard cells", "ANATOMY", 88, 99], ["epidermal cells", "ANATOMY", 104, 119], ["guard cells", "CELL", 41, 52], ["ventral walls", "TISSUE", 62, 75], ["guard cells", "CELL", 88, 99], ["epidermal cells", "CELL", 104, 119], ["sister guard cells", "CELL_TYPE", 34, 52], ["guard cells", "CELL_TYPE", 88, 99], ["epidermal cells", "CELL_TYPE", 104, 119], ["Plasmodesmata (\":')", "PROBLEM", 0, 19], ["sister guard cells", "PROBLEM", 34, 52], ["epidermal cells", "PROBLEM", 104, 119], ["guard cells", "OBSERVATION", 41, 52], ["ventral", "ANATOMY_MODIFIER", 62, 69], ["walls", "ANATOMY_MODIFIER", 70, 75], ["guard cells", "OBSERVATION", 88, 99], ["epidermal cells", "OBSERVATION", 104, 119]]], ["Dictyosomes (d) are still abundant within the guard cells at this stage of development and numerous vesicles (small arrows) are located around the periphery of the developing cell wall suggesting an active synthesis arid deposition of wall material.", [["guard cells", "ANATOMY", 46, 57], ["vesicles", "ANATOMY", 100, 108], ["cell wall", "ANATOMY", 175, 184], ["wall material", "ANATOMY", 235, 248], ["Dictyosomes", "GENE_OR_GENE_PRODUCT", 0, 11], ["guard cells", "CELL", 46, 57], ["vesicles", "CELLULAR_COMPONENT", 100, 108], ["cell wall", "CELLULAR_COMPONENT", 175, 184], ["wall material", "CELLULAR_COMPONENT", 235, 248], ["guard cells", "CELL_TYPE", 46, 57], ["numerous vesicles (small arrows)", "PROBLEM", 91, 123], ["an active synthesis arid deposition of wall material", "PROBLEM", 196, 248], ["guard cells", "OBSERVATION", 46, 57], ["numerous", "OBSERVATION_MODIFIER", 91, 99], ["vesicles", "OBSERVATION_MODIFIER", 100, 108], ["small", "OBSERVATION_MODIFIER", 110, 115], ["arrows", "OBSERVATION", 116, 122], ["periphery", "ANATOMY_MODIFIER", 147, 156], ["cell", "OBSERVATION", 175, 179], ["wall", "ANATOMY_MODIFIER", 180, 184], ["active", "OBSERVATION_MODIFIER", 199, 205], ["synthesis arid deposition", "OBSERVATION", 206, 231], ["wall material", "OBSERVATION", 235, 248]]], ["X35,500) is an enlargement of the plasmodesmata seen in Fig. 5 which connect the guard cell with an epidermal cell Figs.", [["plasmodesmata", "ANATOMY", 34, 47], ["guard cell", "ANATOMY", 81, 91], ["epidermal cell", "ANATOMY", 100, 114], ["plasmodesmata", "CELLULAR_COMPONENT", 34, 47], ["guard cell", "CELL", 81, 91], ["epidermal cell", "CELL", 100, 114], ["guard cell", "CELL_TYPE", 81, 91], ["an enlargement", "PROBLEM", 12, 26], ["the plasmodesmata", "PROBLEM", 30, 47], ["an epidermal cell Figs", "PROBLEM", 97, 119], ["enlargement", "OBSERVATION", 15, 26], ["plasmodesmata", "OBSERVATION_MODIFIER", 34, 47], ["guard cell", "OBSERVATION", 81, 91], ["epidermal cell Figs", "OBSERVATION", 100, 119]]], ["5<8,000) shows part of a fully developed stoma with an open pore (*).", [["stoma", "ANATOMY", 41, 46], ["stoma", "PATHOLOGICAL_FORMATION", 41, 46], ["a fully developed stoma", "PROBLEM", 23, 46], ["stoma", "OBSERVATION", 41, 46]]], ["The incomplete plasmodesmata in the enclosed area in Fig. 8 are enlarged and shown in Fig. 7 (mag.", [["plasmodesmata", "ANATOMY", 15, 28], ["The incomplete plasmodesmata", "PROBLEM", 0, 28], ["mag", "TEST", 94, 97], ["incomplete", "OBSERVATION_MODIFIER", 4, 14], ["plasmodesmata", "OBSERVATION", 15, 28], ["enclosed", "OBSERVATION_MODIFIER", 36, 44], ["area", "OBSERVATION_MODIFIER", 45, 49], ["Fig.", "ANATOMY", 53, 57], ["enlarged", "OBSERVATION", 64, 72]]], ["The large arrows indicate what is considered to be the border between regions of initially deposited wall material (darker area) and of wall material deposited later, on the inside of the guard cells.", [["wall material", "ANATOMY", 101, 114], ["wall material", "ANATOMY", 136, 149], ["guard cells", "ANATOMY", 188, 199], ["wall material", "TISSUE", 101, 114], ["wall material", "TISSUE", 136, 149], ["guard cells", "CELL", 188, 199], ["guard cells", "CELL_TYPE", 188, 199], ["The large arrows", "PROBLEM", 0, 16], ["initially deposited wall material", "PROBLEM", 81, 114], ["wall material", "PROBLEM", 136, 149], ["large", "OBSERVATION_MODIFIER", 4, 9], ["arrows", "OBSERVATION", 10, 16], ["is considered to be", "UNCERTAINTY", 31, 50], ["deposited", "OBSERVATION_MODIFIER", 91, 100], ["wall material", "OBSERVATION", 101, 114], ["darker", "OBSERVATION_MODIFIER", 116, 122], ["area", "OBSERVATION_MODIFIER", 123, 127], ["wall", "ANATOMY_MODIFIER", 136, 140], ["material", "OBSERVATION_MODIFIER", 141, 149], ["deposited", "OBSERVATION_MODIFIER", 150, 159], ["guard cells", "OBSERVATION", 188, 199]]], ["The small arrow shows a small disruption of the wail material whi& is thought to be the remains of an aborted plasmodesmatal canal Figs.", [["plasmodesmatal canal", "ANATOMY", 110, 130], ["a small disruption of the wail material", "PROBLEM", 22, 61], ["an aborted plasmodesmatal canal Figs", "PROBLEM", 99, 135], ["small", "OBSERVATION_MODIFIER", 4, 9], ["small", "OBSERVATION_MODIFIER", 24, 29], ["disruption", "OBSERVATION", 30, 40], ["wail material", "OBSERVATION", 48, 61], ["thought to be", "UNCERTAINTY", 70, 83], ["plasmodesmatal canal Figs", "OBSERVATION", 110, 135]]], ["X10,000) shows a fully developed stoma with incomplete plasmodesmatal connections between a guard ceil and a neighbouring epidermal cell.", [["stoma", "ANATOMY", 33, 38], ["guard ceil", "ANATOMY", 92, 102], ["epidermal cell", "ANATOMY", 122, 136], ["stoma", "PATHOLOGICAL_FORMATION", 33, 38], ["epidermal cell", "CELL", 122, 136], ["neighbouring epidermal cell", "CELL_TYPE", 109, 136], ["stoma", "PROBLEM", 33, 38], ["incomplete plasmodesmatal connections", "PROBLEM", 44, 81], ["a guard ceil", "TREATMENT", 90, 102], ["a neighbouring epidermal cell", "PROBLEM", 107, 136], ["stoma", "OBSERVATION", 33, 38], ["guard ceil", "OBSERVATION", 92, 102], ["epidermal cell", "OBSERVATION", 122, 136]]], ["The enclosed area in Fig. 9 is enlarged in Fig. 10 (mag. ?<50,000) to show the incomplete plasmodesmata (large arrow) in more detail.", [["plasmodesmata", "ANATOMY", 90, 103], ["the incomplete plasmodesmata (large arrow)", "PROBLEM", 75, 117], ["enclosed", "OBSERVATION_MODIFIER", 4, 12], ["area", "OBSERVATION_MODIFIER", 13, 17], ["Fig", "OBSERVATION_MODIFIER", 21, 24], ["enlarged", "OBSERVATION_MODIFIER", 31, 39], ["plasmodesmata", "OBSERVATION", 90, 103], ["large", "OBSERVATION_MODIFIER", 105, 110]]], ["Fig. 1I (mag. ;:<24 ,000) shows incomplete plasmodesmata embedded in the common wall between a guard celi and an epidermal cell.", [["plasmodesmata", "ANATOMY", 43, 56], ["wall", "ANATOMY", 80, 84], ["guard celi", "ANATOMY", 95, 105], ["epidermal cell", "ANATOMY", 113, 127], ["wall", "TISSUE", 80, 84], ["celi", "CANCER", 101, 105], ["epidermal cell", "CELL", 113, 127], ["epidermal cell", "CELL_TYPE", 113, 127], ["incomplete plasmodesmata embedded", "PROBLEM", 32, 65], ["a guard celi", "TREATMENT", 93, 105], ["an epidermal cell", "PROBLEM", 110, 127], ["plasmodesmata embedded", "OBSERVATION", 43, 65], ["common wall", "ANATOMY", 73, 84], ["guard celi", "OBSERVATION", 95, 105], ["epidermal cell", "OBSERVATION", 113, 127]]], ["The small arrows in Fig. 10 and 11 indicate what is considered to be the border between regions of initially deposited wall material (darker area) and of wall material deposited later Figs.", [["wall material", "ANATOMY", 119, 132], ["wall material", "ANATOMY", 154, 167], ["wall material", "TISSUE", 119, 132], ["wall material", "TISSUE", 154, 167], ["The small arrows in Fig.", "PROBLEM", 0, 24], ["initially deposited wall material", "PROBLEM", 99, 132], ["wall material", "PROBLEM", 154, 167], ["small", "OBSERVATION_MODIFIER", 4, 9], ["arrows", "OBSERVATION", 10, 16], ["wall material", "OBSERVATION", 119, 132], ["darker", "OBSERVATION_MODIFIER", 134, 140], ["wall", "ANATOMY_MODIFIER", 154, 158]]], ["9-11 PALLAS and MOLLENHAUER 1972 a, b) found branched plasmodesmata in pit fields with no restriction of wall thickening in these regions.", [["plasmodesmata", "ANATOMY", 54, 67], ["wall", "ANATOMY", 105, 109], ["wall", "TISSUE", 105, 109], ["branched plasmodesmata in pit fields", "PROBLEM", 45, 81], ["wall thickening in these regions", "PROBLEM", 105, 137], ["branched", "OBSERVATION_MODIFIER", 45, 53], ["plasmodesmata", "OBSERVATION", 54, 67], ["no", "UNCERTAINTY", 87, 89], ["restriction", "OBSERVATION_MODIFIER", 90, 101], ["wall", "ANATOMY_MODIFIER", 105, 109], ["thickening", "OBSERVATION", 110, 120], ["regions", "ANATOMY_MODIFIER", 130, 137]]], ["We wonder if their observations represent this intermediate stage of plasmodesmata developmerit.", [["plasmodesmata", "ANATOMY", 69, 82], ["plasmodesmata developmerit", "PROBLEM", 69, 95], ["plasmodesmata developmerit", "OBSERVATION", 69, 95]]], ["Light microscope studies have frequently concluded that plasmodesmata exist between mature guard and epidermal or subsidiary cells while electron microscope studies are almost unanimous in concluding that they are absent.", [["plasmodesmata", "ANATOMY", 56, 69], ["epidermal", "ANATOMY", 101, 110], ["cells", "ANATOMY", 125, 130], ["plasmodesmata", "CELLULAR_COMPONENT", 56, 69], ["epidermal", "CELLULAR_COMPONENT", 101, 110], ["cells", "CELL", 125, 130], ["mature guard and epidermal or subsidiary cells", "CELL_TYPE", 84, 130], ["Light microscope studies", "TEST", 0, 24], ["epidermal or subsidiary cells", "PROBLEM", 101, 130], ["electron microscope studies", "TEST", 137, 164]]], ["One possible explanation for this divergence of opinion is that the histochemical tests used to detect plasmodesmata at the light microscope level may give positive reactions to aborted plasmodesmata and even to weakened or structurally different areas of wall material.", [["plasmodesmata", "ANATOMY", 103, 116], ["plasmodesmata", "ANATOMY", 186, 199], ["wall material", "ANATOMY", 256, 269], ["plasmodesmata", "CELLULAR_COMPONENT", 103, 116], ["wall material", "MULTI-TISSUE_STRUCTURE", 256, 269], ["the histochemical tests", "TEST", 64, 87], ["the light microscope level", "TEST", 120, 146], ["positive reactions", "PROBLEM", 156, 174], ["aborted plasmodesmata", "PROBLEM", 178, 199], ["wall material", "PROBLEM", 256, 269], ["possible explanation for", "UNCERTAINTY", 4, 28], ["structurally", "OBSERVATION_MODIFIER", 224, 236], ["different", "OBSERVATION_MODIFIER", 237, 246], ["areas", "OBSERVATION_MODIFIER", 247, 252], ["wall material", "OBSERVATION", 256, 269]]], ["Indeed, using light microscopy and histochemical tests it was believed at one time that ectodesmata existed as fingers of cytoplasm extending through the epidermal, subsidiary and guard cell walls penetrating to the outer cuticular layer of the leaf (FRANKE 1962 b) .DiscussionMany now consider that such observations were artifacts and that the ectodesmata really consisted of regions of differently structured, or more permeable wall material.", [["fingers", "ANATOMY", 111, 118], ["cytoplasm", "ANATOMY", 122, 131], ["epidermal", "ANATOMY", 154, 163], ["cell walls", "ANATOMY", 186, 196], ["cuticular layer", "ANATOMY", 222, 237], ["leaf", "ANATOMY", 245, 249], ["wall material", "ANATOMY", 431, 444], ["cytoplasm", "ORGANISM_SUBSTANCE", 122, 131], ["epidermal", "CELLULAR_COMPONENT", 154, 163], ["cell walls", "TISSUE", 186, 196], ["outer cuticular layer", "TISSUE", 216, 237], ["leaf", "ORGAN", 245, 249], ["wall material", "TISSUE", 431, 444], ["epidermal, subsidiary and guard cell walls", "CELL_TYPE", 154, 196], ["light microscopy", "TEST", 14, 30], ["histochemical tests", "TEST", 35, 54], ["ectodesmata", "PROBLEM", 88, 99], ["cytoplasm", "PROBLEM", 122, 131], ["the ectodesmata", "PROBLEM", 342, 357], ["cytoplasm", "OBSERVATION", 122, 131], ["epidermal", "ANATOMY", 154, 163], ["guard cell", "OBSERVATION", 180, 190], ["walls", "OBSERVATION_MODIFIER", 191, 196], ["outer", "ANATOMY_MODIFIER", 216, 221], ["cuticular", "ANATOMY_MODIFIER", 222, 231], ["layer", "ANATOMY_MODIFIER", 232, 237], ["leaf", "ANATOMY_MODIFIER", 245, 249]]], ["If functional plasmodesmatal connections are absent between guard and epidermal cells important questions concerning the metabolism of guard cells and the normal functioning of stomata are raised.", [["plasmodesmatal", "ANATOMY", 14, 28], ["epidermal cells", "ANATOMY", 70, 85], ["guard cells", "ANATOMY", 135, 146], ["stomata", "ANATOMY", 177, 184], ["epidermal cells", "CELL", 70, 85], ["guard cells", "CELL", 135, 146], ["stomata", "MULTI-TISSUE_STRUCTURE", 177, 184], ["guard and epidermal cells", "CELL_TYPE", 60, 85], ["guard cells", "CELL_TYPE", 135, 146], ["functional plasmodesmatal connections", "PROBLEM", 3, 40], ["the metabolism of guard cells", "PROBLEM", 117, 146], ["plasmodesmatal connections", "OBSERVATION", 14, 40], ["guard cells", "OBSERVATION", 135, 146], ["normal", "OBSERVATION", 155, 161]]], ["It is considered that metabolites must be transported from the mesophyll to the guard cells to maintain a carbon balance since photosynthesis appears to be absent from the guard cells (RASCHKE and DITTI~ICH 1977) .", [["mesophyll", "ANATOMY", 63, 72], ["guard cells", "ANATOMY", 80, 91], ["guard cells", "ANATOMY", 172, 183], ["ICH", "DISEASE", 203, 206], ["carbon", "CHEMICAL", 106, 112], ["mesophyll", "TISSUE", 63, 72], ["guard cells", "CELL", 80, 91], ["guard cells", "CELL", 172, 183], ["guard cells", "CELL_TYPE", 80, 91], ["guard cells", "CELL_TYPE", 172, 183], ["the guard cells", "TREATMENT", 76, 91], ["a carbon balance", "TEST", 104, 120], ["photosynthesis", "TREATMENT", 127, 141], ["RASCHKE", "TEST", 185, 192], ["DITTI", "TEST", 197, 202], ["guard cells", "OBSERVATION", 172, 183]]], ["Also, it has been suggested that malic acid leaves the guard cells upon stomatal closure (BowLING 1976, DITTI~mH and RASCHKE 1977) .", [["guard cells", "ANATOMY", 55, 66], ["stomatal", "ANATOMY", 72, 80], ["malic acid", "CHEMICAL", 33, 43], ["malic acid", "CHEMICAL", 33, 43], ["malic acid", "SIMPLE_CHEMICAL", 33, 43], ["guard cells", "CELL", 55, 66], ["stomatal", "ORGAN", 72, 80], ["guard cells", "CELL_TYPE", 55, 66], ["malic acid leaves the guard cells", "PROBLEM", 33, 66], ["stomatal closure", "TREATMENT", 72, 88], ["guard cells", "OBSERVATION", 55, 66], ["stomatal closure", "OBSERVATION", 72, 88]]], ["However, in the absence of plasmodesmata between guard cells and neighbouring cells and in the absence of features such as transfer cells or extensive membrane convolutions which would increase the speed and efficiency of metabolite transport, it must be assumed that such transport to and from the guard cells is not essential for stomatal functioning.", [["plasmodesmata", "ANATOMY", 27, 40], ["guard cells", "ANATOMY", 49, 60], ["cells", "ANATOMY", 78, 83], ["cells", "ANATOMY", 132, 137], ["membrane", "ANATOMY", 151, 159], ["guard cells", "ANATOMY", 299, 310], ["stomatal", "ANATOMY", 332, 340], ["plasmodesmata", "CELLULAR_COMPONENT", 27, 40], ["guard cells", "CELL", 49, 60], ["cells", "CELL", 78, 83], ["cells", "CELL", 132, 137], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["guard cells", "CELL", 299, 310], ["guard cells", "CELL_TYPE", 49, 60], ["neighbouring cells", "CELL_TYPE", 65, 83], ["transfer cells", "CELL_TYPE", 123, 137], ["guard cells", "CELL_TYPE", 299, 310], ["plasmodesmata between guard cells", "PROBLEM", 27, 60], ["neighbouring cells", "PROBLEM", 65, 83], ["transfer cells", "PROBLEM", 123, 137], ["extensive membrane convolutions", "PROBLEM", 141, 172], ["guard cells", "OBSERVATION", 49, 60], ["neighbouring cells", "OBSERVATION", 65, 83]]], ["Possibly a carbon supply from the abundant source of guard cell starch (except in the Alliurn genus) can buffer any short-term demand for carbon by the guard cells.", [["cell", "ANATOMY", 59, 63], ["guard cells", "ANATOMY", 152, 163], ["carbon", "CHEMICAL", 138, 144], ["carbon", "CHEMICAL", 11, 17], ["carbon", "CHEMICAL", 138, 144], ["guard cell", "CELL", 53, 63], ["starch", "CELLULAR_COMPONENT", 64, 70], ["carbon", "SIMPLE_CHEMICAL", 138, 144], ["guard cells", "CELL", 152, 163], ["guard cells", "CELL_TYPE", 152, 163], ["a carbon supply", "TREATMENT", 9, 24], ["guard cell starch", "PROBLEM", 53, 70], ["carbon supply", "OBSERVATION", 11, 24], ["guard cell starch", "OBSERVATION", 53, 70], ["guard cells", "OBSERVATION", 152, 163]]], ["The absence of plasmodesmata connecting guard cells with neighbouring cells would place the guard cells in a special category; few types of mature, living cells do not possess plasmodesmatal connections and those cells which are reported not to have them (see ROBARDS 1976, p.", [["plasmodesmata", "ANATOMY", 15, 28], ["guard cells", "ANATOMY", 40, 51], ["cells", "ANATOMY", 70, 75], ["guard cells", "ANATOMY", 92, 103], ["cells", "ANATOMY", 155, 160], ["cells", "ANATOMY", 213, 218], ["plasmodesmata", "CELLULAR_COMPONENT", 15, 28], ["guard cells", "CELL", 40, 51], ["cells", "CELL", 70, 75], ["guard cells", "CELL", 92, 103], ["cells", "CELL", 155, 160], ["cells", "CELL", 213, 218], ["guard cells", "CELL_TYPE", 40, 51], ["neighbouring cells", "CELL_TYPE", 57, 75], ["guard cells", "CELL_TYPE", 92, 103], ["plasmodesmata connecting guard cells", "PROBLEM", 15, 51], ["neighbouring cells", "PROBLEM", 57, 75], ["the guard cells", "TREATMENT", 88, 103], ["plasmodesmata connecting", "OBSERVATION", 15, 39], ["guard cells", "OBSERVATION", 40, 51], ["guard cells", "OBSERVATION", 92, 103]]], ["18) appear to be related to reproductive processes in which, in many cases, a separation of genetic material is necessary.", [["reproductive processes", "PROBLEM", 28, 50], ["genetic material", "TREATMENT", 92, 108], ["appear to be related to", "UNCERTAINTY", 4, 27], ["reproductive", "OBSERVATION", 28, 40]]], ["The need for the \"isolation\" of the guard cells from the main body of the plant is more difficult to envisage particularly in view of the need for the transport of metabolites into and out of the guard cells.", [["guard cells", "ANATOMY", 36, 47], ["body", "ANATOMY", 62, 66], ["guard cells", "ANATOMY", 196, 207], ["guard cells", "CELL", 36, 47], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["guard cells", "CELL", 196, 207], ["guard cells", "CELL_TYPE", 36, 47], ["guard cells", "CELL_TYPE", 196, 207], ["the \"isolation\"", "TREATMENT", 13, 28], ["the guard cells", "TREATMENT", 32, 47], ["the transport of metabolites", "TEST", 147, 175], ["guard cells", "OBSERVATION", 36, 47], ["main body", "ANATOMY_MODIFIER", 57, 66], ["plant", "OBSERVATION", 74, 79], ["guard cells", "OBSERVATION", 196, 207]]], ["One possibility is that their \"isolation\" may be necessary for stomata to respond rapidly to changing environmental factors such as light intensity, humidity or CO 2 concentrations, though it is difficult to envisage exactly why this should be so.", [["stomata", "ANATOMY", 63, 70], ["CO 2", "CHEMICAL", 161, 165], ["CO 2", "SIMPLE_CHEMICAL", 161, 165], ["stomata", "PROBLEM", 63, 70]]], ["It is also interesting to note that guard cells are the only cells we know of which can sense changes in the concentrations of CO2 within their immediate environment and react rapidly to these changes with a resulting opening or closing of stomata.", [["guard cells", "ANATOMY", 36, 47], ["cells", "ANATOMY", 61, 66], ["stomata", "ANATOMY", 240, 247], ["CO2", "CHEMICAL", 127, 130], ["CO2", "CHEMICAL", 127, 130], ["guard cells", "CELL", 36, 47], ["cells", "CELL", 61, 66], ["CO2", "SIMPLE_CHEMICAL", 127, 130], ["guard cells", "CELL_TYPE", 36, 47], ["guard cells", "PROBLEM", 36, 47], ["closing of stomata", "PROBLEM", 229, 247]]], ["Moreover, guard cells can sense very small changes in CO2 concentrations around atmospheric levels (approximately 320 ~1 1-1 CO~).", [["guard cells", "ANATOMY", 10, 21], ["CO2", "CHEMICAL", 54, 57], ["CO2", "CHEMICAL", 54, 57], ["CO", "CHEMICAL", 125, 127], ["guard cells", "CELL", 10, 21], ["CO2", "SIMPLE_CHEMICAL", 54, 57], ["guard cells", "CELL_TYPE", 10, 21], ["guard cells", "TEST", 10, 21], ["very small changes in CO2 concentrations", "PROBLEM", 32, 72], ["atmospheric levels", "TEST", 80, 98], ["guard cells", "OBSERVATION", 10, 21], ["very", "OBSERVATION_MODIFIER", 32, 36], ["small", "OBSERVATION_MODIFIER", 37, 42], ["CO2 concentrations", "OBSERVATION_MODIFIER", 54, 72]]], ["Thus, the functional significance of the lack of plasmodesmatal connections to guard cells remains to be established.", [["guard cells", "ANATOMY", 79, 90], ["plasmodesmatal", "GENE_OR_GENE_PRODUCT", 49, 63], ["guard cells", "CELL", 79, 90], ["guard cells", "CELL_TYPE", 79, 90], ["plasmodesmatal connections to guard cells", "PROBLEM", 49, 90]]]], "17c33a231eb1b8078193a9bc694c8ae3613a5c0f": [["IntroductionThe rapid increase in the reporting of patients suffering from COVID-19 has brought about a major heath emergency worldwide.", [["COVID-19", "CHEMICAL", 75, 83], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["rapid", "OBSERVATION_MODIFIER", 16, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30]]], ["According to the WHO pandemic phases, COVID-19 is currently in Phase 5, which signifies global human-to-human spread of the virus (WHO 2009) .IntroductionThough the major symptoms are mainly respiratory in nature, ocular symptoms are generally overlooked by clinicians.", [["ocular", "ANATOMY", 214, 220], ["ocular symptoms", "DISEASE", 214, 229], ["human", "ORGANISM", 95, 100], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 104, 109], ["COVID", "TEST", 38, 43], ["global human", "PROBLEM", 88, 100], ["the major symptoms", "PROBLEM", 161, 179], ["ocular symptoms", "PROBLEM", 214, 229]]], ["The major routes of transmission are through respiratory droplets and direct contact (Lei et al. 2018; Minodier et al. 2015; Zumla et al. 2015; Otter et al. 2016) .", [["respiratory droplets", "ANATOMY", 45, 65], ["respiratory droplets", "OBSERVATION", 45, 65]]], ["Gastrointestinal tract and body fluids, including tears, can have the SARS-CoV-2 and may participate in the active spread of COVID-19, though the exact role remains uncertain (WHO 2020b).IntroductionLi Wenliang, a Chinese ophthalmologist at Wuhan Central Hospital, Hubei, the whistleblower of the disease outbreak, allegedly contracted the disease while attending a glaucoma patient and later succumbed to the illness (Wenliang 2020).", [["Gastrointestinal tract", "ANATOMY", 0, 22], ["body fluids", "ANATOMY", 27, 38], ["glaucoma", "ANATOMY", 366, 374], ["glaucoma", "DISEASE", 366, 374], ["illness", "DISEASE", 410, 417], ["Gastrointestinal tract", "PATHOLOGICAL_FORMATION", 0, 22], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["patient", "ORGANISM", 375, 382], ["patient", "SPECIES", 375, 382], ["Gastrointestinal tract and body fluids", "PROBLEM", 0, 38], ["tears", "PROBLEM", 50, 55], ["the SARS", "TEST", 66, 74], ["COVID", "TEST", 125, 130], ["the disease outbreak", "PROBLEM", 293, 313], ["the disease", "PROBLEM", 336, 347], ["tract", "OBSERVATION", 17, 22], ["body", "ANATOMY", 27, 31], ["fluids", "OBSERVATION", 32, 38], ["disease", "OBSERVATION", 297, 304]]], ["Thus, ophthalmologists, as health care professionals, are also exposed to the possible impacts of COVID-19.Spectrum of PresentationThe conjunctival sac is anatomically connected to the nasal cavity through the nasolacrimal duct.", [["conjunctival sac", "ANATOMY", 135, 151], ["nasal cavity", "ANATOMY", 185, 197], ["nasolacrimal duct", "ANATOMY", 210, 227], ["COVID-19", "CHEMICAL", 98, 106], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 135, 151], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 185, 197], ["nasolacrimal duct", "MULTI-TISSUE_STRUCTURE", 210, 227], ["COVID", "TEST", 98, 103], ["conjunctival sac", "ANATOMY", 135, 151], ["nasal cavity", "ANATOMY", 185, 197], ["nasolacrimal duct", "ANATOMY", 210, 227]]], ["Most of the upper respiratory tract infections harbor the organism in the nasal mucosa (Thomas 2020) .", [["upper respiratory tract", "ANATOMY", 12, 35], ["nasal mucosa", "ANATOMY", 74, 86], ["respiratory tract infections", "DISEASE", 18, 46], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 12, 35], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 74, 86], ["the upper respiratory tract infections", "PROBLEM", 8, 46], ["upper", "ANATOMY_MODIFIER", 12, 17], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46], ["organism", "OBSERVATION", 58, 66], ["nasal mucosa", "ANATOMY", 74, 86]]], ["Since most of the acute URTI have viral etiology, adenovirus being the commonest, the appearance of conjunctivitis in such cases is not uncommon (Epling 2010; Azari and Barney 2013) .", [["URTI", "DISEASE", 24, 28], ["conjunctivitis", "DISEASE", 100, 114], ["adenovirus", "ORGANISM", 50, 60], ["adenovirus", "SPECIES", 50, 60], ["the acute URTI", "PROBLEM", 14, 28], ["adenovirus", "PROBLEM", 50, 60], ["conjunctivitis", "PROBLEM", 100, 114], ["conjunctivitis", "OBSERVATION", 100, 114]]], ["Conjunctivitis is speculated to be an allergic immune response to the virus (Solano and Czyz 2020) .", [["Conjunctivitis", "DISEASE", 0, 14], ["allergic", "DISEASE", 38, 46], ["Conjunctivitis", "PROBLEM", 0, 14], ["an allergic immune response", "PROBLEM", 35, 62], ["the virus (Solano and Czyz", "TREATMENT", 66, 92], ["speculated to be", "UNCERTAINTY", 18, 34], ["allergic", "OBSERVATION", 38, 46]]], ["Conjunctival congestion with watery discharge is more characteristic of a viral conjunctivitis (Rietveld et al. 2003) .", [["Conjunctival", "ANATOMY", 0, 12], ["Conjunctival congestion", "DISEASE", 0, 23], ["viral conjunctivitis", "DISEASE", 74, 94], ["Conjunctival", "ORGAN", 0, 12], ["Conjunctival congestion", "PROBLEM", 0, 23], ["watery discharge", "PROBLEM", 29, 45], ["a viral conjunctivitis", "PROBLEM", 72, 94], ["congestion", "OBSERVATION", 13, 23], ["watery discharge", "OBSERVATION", 29, 45], ["more characteristic", "OBSERVATION_MODIFIER", 49, 68], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["conjunctivitis", "OBSERVATION", 80, 94]]], ["There is a wide spectrum of presentation of viral conjunctivitis ranging from pink eye to hemorrhagic conjunctivitis.Spectrum of PresentationThe disease readily spreads from person to person and has the possibility of becoming an epidemic.", [["eye", "ANATOMY", 83, 86], ["viral conjunctivitis", "DISEASE", 44, 64], ["hemorrhagic conjunctivitis", "DISEASE", 90, 116], ["eye", "ORGAN", 83, 86], ["person", "SPECIES", 174, 180], ["person", "SPECIES", 184, 190], ["viral conjunctivitis", "PROBLEM", 44, 64], ["hemorrhagic conjunctivitis", "PROBLEM", 90, 116], ["an epidemic", "PROBLEM", 227, 238], ["wide spectrum", "OBSERVATION_MODIFIER", 11, 24], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["conjunctivitis", "OBSERVATION", 50, 64], ["pink", "OBSERVATION_MODIFIER", 78, 82], ["eye", "ANATOMY", 83, 86], ["hemorrhagic", "OBSERVATION_MODIFIER", 90, 101], ["conjunctivitis", "OBSERVATION", 102, 116], ["disease", "OBSERVATION", 145, 152], ["epidemic", "OBSERVATION", 230, 238]]], ["Although viral conjunctivitis is most often mild and goes away without treatment within 1-2 weeks, it may last 2 or more weeks if complications develop.", [["viral conjunctivitis", "DISEASE", 9, 29], ["viral conjunctivitis", "PROBLEM", 9, 29], ["treatment", "TREATMENT", 71, 80], ["complications", "PROBLEM", 130, 143], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["conjunctivitis", "OBSERVATION", 15, 29]]], ["Major complications associated are punctate keratitis with subepithelial infiltrates, bacterial superinfection, conjunctival scarring and symblepharon, severe dry eye, irregular astigmatism, corneal ulceration with persistent keratoconjunctivitis, corneal scarring, and chronic infection (Bialasiewicz 2007 ).Previous Coronavirus Infections in the EyeSevere acute respiratory syndrome (SARS), a global health crisis, in 2003, was a result of infection with coronavirus strain (SARS-CoV).Previous Coronavirus Infections in the EyeMiddle East respiratory syndrome-related coronavirus (MERS-CoV), first identified in Saudi Arabia in 2012, was another coronavirus-borne disease (Centers for Disease Control and Prevention 2020a).Previous Coronavirus Infections in the EyeMost of the previously encountered coronavirus species (SARS-CoV and MERS-CoV infections) rarely cause ocular infections in humans (Li et al. 2006) .", [["subepithelial infiltrates", "ANATOMY", 59, 84], ["conjunctival", "ANATOMY", 112, 124], ["eye", "ANATOMY", 163, 166], ["corneal", "ANATOMY", 191, 198], ["corneal", "ANATOMY", 248, 255], ["ocular", "ANATOMY", 870, 876], ["keratitis", "DISEASE", 44, 53], ["superinfection", "DISEASE", 96, 110], ["conjunctival scarring", "DISEASE", 112, 133], ["symblepharon", "DISEASE", 138, 150], ["dry eye", "DISEASE", 159, 166], ["astigmatism", "DISEASE", 178, 189], ["corneal ulceration", "DISEASE", 191, 209], ["keratoconjunctivitis", "DISEASE", 226, 246], ["corneal scarring", "DISEASE", 248, 264], ["chronic infection", "DISEASE", 270, 287], ["Coronavirus Infections", "DISEASE", 318, 340], ["EyeSevere acute respiratory syndrome", "DISEASE", 348, 384], ["SARS", "DISEASE", 386, 390], ["infection", "DISEASE", 442, 451], ["SARS-CoV", "DISEASE", 477, 485], ["Infections", "DISEASE", 508, 518], ["respiratory syndrome", "DISEASE", 541, 561], ["coronavirus-borne disease", "DISEASE", 648, 673], ["Infections", "DISEASE", 746, 756], ["SARS-CoV and MERS-CoV infections", "DISEASE", 823, 855], ["ocular infections", "DISEASE", 870, 887], ["subepithelial infiltrates", "PATHOLOGICAL_FORMATION", 59, 84], ["conjunctival", "PATHOLOGICAL_FORMATION", 112, 124], ["eye", "ORGAN", 163, 166], ["corneal", "TISSUE", 248, 255], ["coronavirus strain", "ORGANISM", 457, 475], ["SARS-CoV", "ORGANISM", 477, 485], ["Coronavirus", "ORGANISM", 496, 507], ["EyeMiddle East respiratory syndrome-related coronavirus", "ORGANISM", 526, 581], ["MERS-CoV", "ORGANISM", 583, 591], ["coronavirus species", "ORGANISM", 802, 821], ["SARS-CoV", "ORGANISM", 823, 831], ["MERS-CoV infections", "ORGANISM", 836, 855], ["ocular", "ORGAN", 870, 876], ["humans", "ORGANISM", 891, 897], ["coronavirus", "SPECIES", 802, 813], ["MERS-CoV", "SPECIES", 836, 844], ["humans", "SPECIES", 891, 897], ["SARS-CoV", "SPECIES", 477, 485], ["EyeMiddle East respiratory syndrome-related coronavirus", "SPECIES", 526, 581], ["MERS-CoV", "SPECIES", 583, 591], ["SARS-CoV", "SPECIES", 823, 831], ["MERS-CoV", "SPECIES", 836, 844], ["humans", "SPECIES", 891, 897], ["Major complications", "PROBLEM", 0, 19], ["punctate keratitis", "PROBLEM", 35, 53], ["subepithelial infiltrates", "PROBLEM", 59, 84], ["bacterial superinfection", "PROBLEM", 86, 110], ["conjunctival scarring", "PROBLEM", 112, 133], ["symblepharon", "PROBLEM", 138, 150], ["severe dry eye", "PROBLEM", 152, 166], ["irregular astigmatism", "PROBLEM", 168, 189], ["corneal ulceration", "PROBLEM", 191, 209], ["persistent keratoconjunctivitis", "PROBLEM", 215, 246], ["corneal scarring", "PROBLEM", 248, 264], ["chronic infection", "PROBLEM", 270, 287], ["Previous Coronavirus Infections", "PROBLEM", 309, 340], ["the EyeSevere acute respiratory syndrome", "PROBLEM", 344, 384], ["SARS", "PROBLEM", 386, 390], ["a global health crisis", "PROBLEM", 393, 415], ["infection", "PROBLEM", 442, 451], ["coronavirus strain", "PROBLEM", 457, 475], ["Previous Coronavirus Infections", "PROBLEM", 487, 518], ["the EyeMiddle East respiratory syndrome", "PROBLEM", 522, 561], ["coronavirus", "PROBLEM", 570, 581], ["another coronavirus-borne disease", "PROBLEM", 640, 673], ["Disease Control", "TREATMENT", 687, 702], ["Previous Coronavirus Infections", "PROBLEM", 725, 756], ["the previously encountered coronavirus species", "PROBLEM", 775, 821], ["SARS", "PROBLEM", 823, 827], ["MERS", "PROBLEM", 836, 840], ["CoV infections", "PROBLEM", 841, 855], ["ocular infections in humans", "PROBLEM", 870, 897], ["complications", "OBSERVATION", 6, 19], ["punctate", "OBSERVATION_MODIFIER", 35, 43], ["keratitis", "OBSERVATION", 44, 53], ["subepithelial", "OBSERVATION_MODIFIER", 59, 72], ["infiltrates", "OBSERVATION", 73, 84], ["bacterial", "OBSERVATION_MODIFIER", 86, 95], ["superinfection", "OBSERVATION", 96, 110], ["conjunctival", "ANATOMY", 112, 124], ["scarring", "OBSERVATION", 125, 133], ["symblepharon", "OBSERVATION", 138, 150], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["dry", "OBSERVATION_MODIFIER", 159, 162], ["eye", "ANATOMY", 163, 166], ["irregular", "OBSERVATION_MODIFIER", 168, 177], ["astigmatism", "OBSERVATION", 178, 189], ["corneal", "ANATOMY", 191, 198], ["ulceration", "OBSERVATION", 199, 209], ["persistent", "OBSERVATION_MODIFIER", 215, 225], ["keratoconjunctivitis", "OBSERVATION", 226, 246], ["corneal", "ANATOMY", 248, 255], ["scarring", "OBSERVATION", 256, 264], ["chronic", "OBSERVATION_MODIFIER", 270, 277], ["infection", "OBSERVATION", 278, 287], ["Coronavirus", "OBSERVATION_MODIFIER", 318, 329], ["Infections", "OBSERVATION", 330, 340], ["acute", "OBSERVATION_MODIFIER", 358, 363], ["respiratory syndrome", "OBSERVATION", 364, 384], ["global", "OBSERVATION_MODIFIER", 395, 401], ["health crisis", "OBSERVATION", 402, 415], ["infection", "OBSERVATION", 442, 451], ["coronavirus strain", "OBSERVATION", 457, 475], ["Coronavirus", "OBSERVATION_MODIFIER", 496, 507], ["Infections", "OBSERVATION", 508, 518], ["respiratory syndrome", "OBSERVATION", 541, 561], ["coronavirus", "OBSERVATION", 570, 581], ["Coronavirus", "OBSERVATION_MODIFIER", 734, 745], ["Infections", "OBSERVATION", 746, 756], ["coronavirus species", "OBSERVATION", 802, 821], ["ocular", "ANATOMY", 870, 876], ["infections", "OBSERVATION", 877, 887]]], ["However, few reports suggest the presence of conjunctivitis of varying severity in patients suffering with coronavirus infections in different parts of the world (Finger 2003) .Previous Coronavirus Infections in the EyeThe presence of coronavirus in tear and conjunctival scrapings was also reported in few studies.Novel Coronavirus Infection (COVID-19) in the EyeFollowing the recent novel coronavirus outbreak in China, the presence of novel coronavirus in tears and conjunctival secretions of patients with COVID-19 was evaluated.", [["tear", "ANATOMY", 250, 254], ["conjunctival scrapings", "ANATOMY", 259, 281], ["tears", "ANATOMY", 459, 464], ["conjunctival secretions", "ANATOMY", 469, 492], ["conjunctivitis", "DISEASE", 45, 59], ["coronavirus infections", "DISEASE", 107, 129], ["Coronavirus Infections", "DISEASE", 186, 208], ["coronavirus", "DISEASE", 235, 246], ["Coronavirus Infection", "DISEASE", 321, 342], ["coronavirus outbreak", "DISEASE", 391, 411], ["coronavirus", "DISEASE", 444, 455], ["COVID-19", "CHEMICAL", 510, 518], ["patients", "ORGANISM", 83, 91], ["coronavirus", "ORGANISM", 235, 246], ["tear", "TISSUE", 250, 254], ["conjunctival scrapings", "TISSUE", 259, 281], ["coronavirus", "ORGANISM", 391, 402], ["coronavirus", "ORGANISM", 444, 455], ["tears", "TISSUE", 459, 464], ["conjunctival secretions", "ORGAN", 469, 492], ["patients", "ORGANISM", 496, 504], ["patients", "SPECIES", 83, 91], ["coronavirus", "SPECIES", 391, 402], ["patients", "SPECIES", 496, 504], ["conjunctivitis", "PROBLEM", 45, 59], ["varying severity", "PROBLEM", 63, 79], ["coronavirus infections", "PROBLEM", 107, 129], ["Previous Coronavirus Infections in the Eye", "PROBLEM", 177, 219], ["coronavirus in tear", "PROBLEM", 235, 254], ["conjunctival scrapings", "PROBLEM", 259, 281], ["Novel Coronavirus Infection", "PROBLEM", 315, 342], ["COVID", "TEST", 344, 349], ["novel coronavirus in tears", "PROBLEM", 438, 464], ["conjunctival secretions", "PROBLEM", 469, 492], ["COVID", "TEST", 510, 515], ["suggest the presence of", "UNCERTAINTY", 21, 44], ["conjunctivitis", "OBSERVATION", 45, 59], ["varying", "OBSERVATION_MODIFIER", 63, 70], ["severity", "OBSERVATION_MODIFIER", 71, 79], ["coronavirus infections", "OBSERVATION", 107, 129], ["Coronavirus", "OBSERVATION_MODIFIER", 186, 197], ["Infections", "OBSERVATION", 198, 208], ["Eye", "ANATOMY", 216, 219], ["coronavirus", "OBSERVATION", 235, 246], ["tear", "OBSERVATION", 250, 254], ["conjunctival scrapings", "OBSERVATION", 259, 281], ["Coronavirus", "OBSERVATION_MODIFIER", 321, 332], ["Infection", "OBSERVATION", 333, 342], ["coronavirus", "OBSERVATION", 391, 402], ["coronavirus", "OBSERVATION", 444, 455], ["conjunctival", "ANATOMY", 469, 481]]], ["Though majority of patients who had been enrolled for the study did not present with conjunctivitis, one who did had the coronavirus in tear and conjunctival swab.", [["tear", "ANATOMY", 136, 140], ["conjunctival swab", "ANATOMY", 145, 162], ["conjunctivitis", "DISEASE", 85, 99], ["coronavirus", "DISEASE", 121, 132], ["patients", "ORGANISM", 19, 27], ["coronavirus", "ORGANISM", 121, 132], ["tear", "TISSUE", 136, 140], ["conjunctival swab", "MULTI-TISSUE_STRUCTURE", 145, 162], ["patients", "SPECIES", 19, 27], ["the study", "TEST", 54, 63], ["conjunctivitis", "PROBLEM", 85, 99], ["the coronavirus in tear", "PROBLEM", 117, 140], ["conjunctival swab", "TEST", 145, 162], ["conjunctivitis", "OBSERVATION", 85, 99], ["coronavirus", "OBSERVATION", 121, 132], ["conjunctival swab", "ANATOMY", 145, 162]]], ["Conjunctivitis reported was mild, with a watery discharge.", [["Conjunctivitis", "DISEASE", 0, 14], ["watery", "DISEASE", 41, 47], ["Conjunctivitis", "PROBLEM", 0, 14], ["a watery discharge", "PROBLEM", 39, 57], ["mild", "OBSERVATION_MODIFIER", 28, 32]]], ["The results concluded that tears and conjunctival secretions had coronavirus in patients with conjunctivitis, but was absent in those without conjunctivitis.", [["tears", "ANATOMY", 27, 32], ["conjunctival secretions", "ANATOMY", 37, 60], ["coronavirus", "DISEASE", 65, 76], ["conjunctivitis", "DISEASE", 94, 108], ["conjunctivitis", "DISEASE", 142, 156], ["tears", "PATHOLOGICAL_FORMATION", 27, 32], ["conjunctival secretions", "ORGANISM_SUBSTANCE", 37, 60], ["coronavirus", "ORGANISM", 65, 76], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["tears", "PROBLEM", 27, 32], ["conjunctival secretions", "PROBLEM", 37, 60], ["coronavirus", "PROBLEM", 65, 76], ["conjunctivitis", "PROBLEM", 94, 108], ["conjunctivitis", "PROBLEM", 142, 156], ["tears", "OBSERVATION", 27, 32], ["conjunctival", "ANATOMY", 37, 49], ["conjunctivitis", "OBSERVATION", 94, 108], ["conjunctivitis", "OBSERVATION", 142, 156]]], ["This also raised an alarm among the treating ophthalmologists towards the possible spread of the virus through tears, along with other body fluids (Xia et al. 2020) .Novel Coronavirus Infection (COVID-19) in the EyeAnother study in China reported conjunctivitis in 9 patients with COVID-19, out of 1099 (0.8%).", [["body", "ANATOMY", 135, 139], ["Coronavirus Infection", "DISEASE", 172, 193], ["conjunctivitis", "DISEASE", 247, 261], ["tears", "PATHOLOGICAL_FORMATION", 111, 116], ["body", "ORGANISM_SUBDIVISION", 135, 139], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["an alarm", "PROBLEM", 17, 25], ["the virus through tears", "PROBLEM", 93, 116], ["other body fluids", "TREATMENT", 129, 146], ["Novel Coronavirus Infection", "PROBLEM", 166, 193], ["COVID", "TEST", 195, 200], ["the EyeAnother study", "TEST", 208, 228], ["conjunctivitis", "PROBLEM", 247, 261], ["COVID", "TEST", 281, 286], ["virus", "OBSERVATION", 97, 102], ["Coronavirus", "OBSERVATION_MODIFIER", 172, 183], ["Infection", "OBSERVATION", 184, 193], ["conjunctivitis", "OBSERVATION", 247, 261]]], ["Few reports also suggest that initial symptoms of COVID-19 was not conjunctivitis, but the possibility of virus spread through conjunctiva cannot be excluded (Wei-Jie et al. 2020; Wang et al. 2020; Huang et al. 2020) .", [["conjunctiva", "ANATOMY", 127, 138], ["COVID", "DISEASE", 50, 55], ["conjunctivitis", "DISEASE", 67, 81], ["conjunctiva", "ORGAN", 127, 138], ["initial symptoms", "PROBLEM", 30, 46], ["COVID", "TEST", 50, 55], ["conjunctivitis", "PROBLEM", 67, 81], ["virus spread through conjunctiva", "PROBLEM", 106, 138], ["conjunctivitis", "OBSERVATION", 67, 81], ["possibility of", "UNCERTAINTY", 91, 105], ["virus", "OBSERVATION", 106, 111], ["cannot be excluded", "UNCERTAINTY", 139, 157]]], ["The replication of virus in conjunctival epithelium is also enigmatic.Novel Coronavirus Infection (COVID-19) in the EyeIn view of the presence of coronavirus in body fluids of patients, and SARS-CoV-2 being similar to SARS-CoV, the risk of transmission through conjunctival secretion and tear cannot be neglected.Combating the Ocular Spread-Ophthalmologist's Role PlayAccording to the recent American Academy of Ophthalmology (AAO) guidelines, there are multiple reports which suggest that the novel coronavirus can cause conjunctivitis and can also be transmitted by aerosol contact with conjunctiva.Combating the Ocular Spread-Ophthalmologist's Role PlayPatients with conjunctivitis may initially report to an ophthalmologist, possibly making the eye care physician to first suspect a case of COVID-19 (Lu et al. 2020Diagnosing and Managing COVID-19 ConjunctivitisIn regions with WHO pandemic phase >2, ruling out common viral pathogens causing conjunctivitis becomes secondary.", [["conjunctival epithelium", "ANATOMY", 28, 51], ["body fluids", "ANATOMY", 161, 172], ["conjunctival", "ANATOMY", 261, 273], ["conjunctiva", "ANATOMY", 589, 600], ["eye", "ANATOMY", 749, 752], ["Coronavirus Infection", "DISEASE", 76, 97], ["coronavirus", "DISEASE", 146, 157], ["SARS", "DISEASE", 190, 194], ["SARS", "DISEASE", 218, 222], ["coronavirus", "DISEASE", 500, 511], ["conjunctivitis", "DISEASE", 522, 536], ["conjunctivitis", "DISEASE", 670, 684], ["conjunctivitis", "DISEASE", 947, 961], ["conjunctival epithelium", "TISSUE", 28, 51], ["coronavirus", "ORGANISM", 146, 157], ["body", "ORGANISM_SUBDIVISION", 161, 165], ["patients", "ORGANISM", 176, 184], ["SARS-CoV-2", "ORGANISM", 190, 200], ["SARS-CoV", "ORGANISM", 218, 226], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 261, 273], ["coronavirus", "ORGANISM", 500, 511], ["conjunctiva", "ORGAN", 589, 600], ["eye", "ORGAN", 749, 752], ["patients", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 190, 198], ["SARS-CoV", "SPECIES", 218, 226], ["The replication of virus in conjunctival epithelium", "PROBLEM", 0, 51], ["Novel Coronavirus Infection", "PROBLEM", 70, 97], ["COVID", "TEST", 99, 104], ["coronavirus", "PROBLEM", 146, 157], ["SARS", "PROBLEM", 190, 194], ["CoV", "TEST", 195, 198], ["SARS", "PROBLEM", 218, 222], ["CoV", "PROBLEM", 223, 226], ["conjunctival secretion", "PROBLEM", 261, 283], ["tear", "PROBLEM", 288, 292], ["the novel coronavirus", "PROBLEM", 490, 511], ["conjunctivitis", "PROBLEM", 522, 536], ["conjunctivitis", "PROBLEM", 670, 684], ["COVID", "TEST", 795, 800], ["Managing COVID", "TEST", 834, 848], ["WHO pandemic phase", "TEST", 882, 900], ["common viral pathogens", "PROBLEM", 916, 938], ["conjunctivitis", "PROBLEM", 947, 961], ["virus", "OBSERVATION", 19, 24], ["conjunctival epithelium", "ANATOMY", 28, 51], ["enigmatic", "OBSERVATION_MODIFIER", 60, 69], ["Coronavirus", "OBSERVATION_MODIFIER", 76, 87], ["Infection", "OBSERVATION", 88, 97], ["coronavirus", "OBSERVATION", 146, 157], ["tear", "OBSERVATION", 288, 292], ["Ocular", "ANATOMY", 327, 333], ["conjunctivitis", "OBSERVATION", 522, 536], ["Ocular", "ANATOMY", 615, 621], ["conjunctivitis", "OBSERVATION", 947, 961]]], ["Excluding the novel pathogen in such scenarios is of primary importance as it can help in the detection of subclinical cases to limit further spread of the disease.", [["the novel pathogen", "PROBLEM", 10, 28], ["subclinical cases", "PROBLEM", 107, 124], ["the disease", "PROBLEM", 152, 163], ["pathogen", "OBSERVATION", 20, 28], ["disease", "OBSERVATION", 156, 163]]], ["According to a recently published literature on COVID-19 conjunctivitis, tear sample and conjunctival swab are reported to be positive for the novel coronavirus.", [["tear sample", "ANATOMY", 73, 84], ["conjunctival swab", "ANATOMY", 89, 106], ["conjunctivitis", "DISEASE", 57, 71], ["coronavirus", "DISEASE", 149, 160], ["tear sample", "ORGANISM_SUBSTANCE", 73, 84], ["conjunctival swab", "ORGANISM_SUBSTANCE", 89, 106], ["coronavirus", "ORGANISM", 149, 160], ["COVID", "TEST", 48, 53], ["conjunctivitis", "PROBLEM", 57, 71], ["tear sample", "TEST", 73, 84], ["conjunctival swab", "TEST", 89, 106], ["the novel coronavirus", "PROBLEM", 139, 160], ["conjunctival", "ANATOMY", 89, 101], ["coronavirus", "OBSERVATION", 149, 160]]], ["So tear sample and conjunctival secretions need to be evaluated for the presence of the virus.", [["tear sample", "ANATOMY", 3, 14], ["conjunctival secretions", "ANATOMY", 19, 42], ["conjunctival secretions", "ORGAN", 19, 42], ["tear sample", "PROBLEM", 3, 14], ["conjunctival secretions", "PROBLEM", 19, 42], ["the virus", "PROBLEM", 84, 93], ["tear", "OBSERVATION", 3, 7], ["conjunctival", "ANATOMY", 19, 31], ["secretions", "OBSERVATION", 32, 42], ["virus", "OBSERVATION", 88, 93]]], ["Collection should be done using disposable sampling swab from the conjunctival fornix, preferably lower.", [["conjunctival fornix", "ANATOMY", 66, 85], ["conjunctival fornix", "MULTI-TISSUE_STRUCTURE", 66, 85], ["disposable sampling swab from the conjunctival fornix", "TEST", 32, 85], ["conjunctival fornix", "ANATOMY", 66, 85]]], ["The sample should be stored in universal transport medium at 4 C and sent for RT-PCR (real-time Polymerase Chain Reaction) assay.", [["sample", "ANATOMY", 4, 10], ["RT-PCR", "TEST", 78, 84]]], ["Two such samples should be taken within 2-3 days' interval and assay should be repeated.Diagnosing and Managing COVID-19 ConjunctivitisThe reported sensitivity and specificity of RT-PCR are 85-87% and 100%, respectively, for diagnosing previous SARS-CoV infection.", [["samples", "ANATOMY", 9, 16], ["SARS-CoV infection", "DISEASE", 245, 263], ["samples", "CANCER", 9, 16], ["SARS-CoV", "ORGANISM", 245, 253], ["SARS-CoV", "SPECIES", 245, 253], ["Two such samples", "TEST", 0, 16], ["assay", "TEST", 63, 68], ["Managing COVID", "TEST", 103, 117], ["Conjunctivitis", "PROBLEM", 121, 135], ["sensitivity", "TEST", 148, 159], ["specificity", "TEST", 164, 175], ["RT-PCR", "TEST", 179, 185], ["previous SARS", "PROBLEM", 236, 249], ["CoV infection", "PROBLEM", 250, 263], ["CoV", "OBSERVATION_MODIFIER", 250, 253], ["infection", "OBSERVATION", 254, 263]]], ["Recent data on the sensitivity and specificity of RT-PCR for novel coronavirus infection is not available.", [["coronavirus infection", "DISEASE", 67, 88], ["coronavirus", "ORGANISM", 67, 78], ["coronavirus", "SPECIES", 67, 78], ["the sensitivity", "TEST", 15, 30], ["RT-PCR", "TEST", 50, 56], ["novel coronavirus infection", "PROBLEM", 61, 88], ["coronavirus", "OBSERVATION", 67, 78]]], ["The treatment of COVID-19 conjunctivitis is an ongoing research (National Institutes of Health 2020).", [["COVID-19", "CHEMICAL", 17, 25], ["conjunctivitis", "DISEASE", 26, 40], ["COVID", "TREATMENT", 17, 22], ["conjunctivitis", "PROBLEM", 26, 40]]], ["It might have a benign course, as cases reported are mild, and may be treated as normal viral conjunctivitis treatment protocol as of now.Risk to OphthalmologistsThe transmission of COVID-19 can occur through the mucous membranes, including the conjunctiva.", [["mucous membranes", "ANATOMY", 213, 229], ["conjunctiva", "ANATOMY", 245, 256], ["conjunctivitis", "DISEASE", 94, 108], ["COVID-19", "CHEMICAL", 182, 190], ["COVID-19", "CHEMICAL", 182, 190], ["COVID-19", "GENE_OR_GENE_PRODUCT", 182, 190], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 213, 229], ["conjunctiva", "ORGAN", 245, 256], ["COVID-19", "DNA", 182, 190], ["normal viral conjunctivitis treatment protocol", "TREATMENT", 81, 127], ["COVID", "TEST", 182, 187], ["benign", "OBSERVATION_MODIFIER", 16, 22], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["viral conjunctivitis", "OBSERVATION", 88, 108], ["mucous membranes", "ANATOMY", 213, 229], ["conjunctiva", "ANATOMY", 245, 256]]], ["Also, transmission of the disease through asymptomatic contacts has also been documented (Rothe et al. 2020) .Risk to OphthalmologistsMost of the ophthalmological diagnostic procedures (slit lamp examination, direct and indirect fundus examinations, tonometry, etc.) require close proximity with patients, thereby increasing the risk of exposure (Xia et al. 2020) .", [["fundus", "ANATOMY", 229, 235], ["fundus", "MULTI-TISSUE_STRUCTURE", 229, 235], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 296, 304], ["the disease through asymptomatic contacts", "PROBLEM", 22, 63], ["the ophthalmological diagnostic procedures", "TEST", 142, 184], ["slit lamp examination", "TEST", 186, 207], ["direct and indirect fundus examinations", "TEST", 209, 248], ["tonometry", "TEST", 250, 259], ["disease", "OBSERVATION", 26, 33]]], ["Suboptimal infection control strategies at the health care level may unintentionally spread the disease and risk the entire community (Chan et al. 2006 ).Preventive Measures in Ophthalmic PracticeAccording to the WHO cases classification schemes, patients can be grouped on the basis of triage system into general, suspect, and probable categories (World Health Organization 2003; Gavidia 2020).", [["infection", "DISEASE", 11, 20], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["Suboptimal infection control strategies", "PROBLEM", 0, 39], ["the disease", "PROBLEM", 92, 103], ["Preventive Measures", "TREATMENT", 154, 173], ["infection", "OBSERVATION", 11, 20]]], ["All patients should not attend the outpatient clinic to avoid personal and community spread of the disease.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the disease", "PROBLEM", 95, 106], ["disease", "OBSERVATION", 99, 106]]], ["Triage should be performed and patients should be screened on the basis of:Preventive Measures in Ophthalmic Practice\u2022 Travel history in the last 2-3 weeks to any of the hot spots of COVID infections (China, South Korea, Italy, Iran, etc.) \u2022 History of contact with known COVID-19 patient/suspect \u2022 Symptoms of cough, cold, or fever Patients are categorized into four groups according to the triage system ( Fig. 8.1) .", [["COVID infections", "DISEASE", 183, 199], ["cough", "DISEASE", 311, 316], ["fever", "DISEASE", 327, 332], ["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 281, 288], ["Patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 281, 288], ["Patients", "SPECIES", 333, 341], ["Preventive Measures", "TREATMENT", 75, 94], ["COVID infections", "PROBLEM", 183, 199], ["Symptoms", "PROBLEM", 299, 307], ["cough", "PROBLEM", 311, 316], ["cold", "PROBLEM", 318, 322], ["fever", "PROBLEM", 327, 332], ["infections", "OBSERVATION", 189, 199], ["cough", "OBSERVATION", 311, 316]]], ["Groups 1 and 2 can be categorized as general patients and can be seen on an outpatient basis, but with personal protective equipment (PPE).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Groups 3 and 4 should be characterized as suspect/probable cases and only cases having ophthalmic urgency should be managed, in isolation ward with full protection.", [["ophthalmic urgency", "PROBLEM", 87, 105]]], ["Figure 8 .2 highlights the protocol for attending patients visiting ophthalmology clinics during COVID-19 outbreak (Huang et al. 2020 ; Rohit and Santosh 2020).Outpatient CareAs per recent AAO guidelines, as a response to the state of national emergency due to COVID-19, eye care practitioners should reduce the number of outpatient The following preventive measures should be taken by the ophthalmologist in the outpatient clinic for general patients (Group 1 and 2) during such outbreaks:Personal protectionPersonal protective equipment (PPE) ( Table 8 .1) and general precautionary measures to be taken for outpatient procedures include \u2022 Universal precaution:Personal protection-Surgical/N95 respirator mask to cover the nose and mouth.Personal protection-Gloves whenever body fluids (blood, secretions, urine, stool) are to be handled. -Water-repellant or water-resistant gowns.Personal protection-Eye protective wear or goggles (visor).\u2022 Hand sanitization:-Repeated hand washing, using hand rub (0.5-1.0% chlorhexidine in 80% ethyl alcohol).\u2022 Hand sanitization:\u2022 Gloves to be changed and hand hygiene practiced between each contact with different patients. \u2022 Avoidance of touching of face shields, mask, eye protective wear, face, head, and neck area before thorough hand wash.Examination Equipment Sterilization\u2022 Slit lamps should accompany barriers or breath shields (Fig. 8.3 ).Examination Equipment Sterilization\u2022 Applanation tonometry to be performed using Tonopen with a disposable sleeve.", [["eye", "ANATOMY", 271, 274], ["nose", "ANATOMY", 725, 729], ["mouth", "ANATOMY", 734, 739], ["body fluids", "ANATOMY", 776, 787], ["blood", "ANATOMY", 789, 794], ["secretions", "ANATOMY", 796, 806], ["urine", "ANATOMY", 808, 813], ["stool", "ANATOMY", 815, 820], ["hand", "ANATOMY", 972, 976], ["hand", "ANATOMY", 992, 996], ["hand", "ANATOMY", 1094, 1098], ["face", "ANATOMY", 1190, 1194], ["eye", "ANATOMY", 1210, 1213], ["face", "ANATOMY", 1231, 1235], ["head", "ANATOMY", 1237, 1241], ["neck area", "ANATOMY", 1247, 1256], ["hand", "ANATOMY", 1273, 1277], ["chlorhexidine", "CHEMICAL", 1011, 1024], ["ethyl alcohol", "CHEMICAL", 1032, 1045], ["chlorhexidine", "CHEMICAL", 1011, 1024], ["ethyl alcohol", "CHEMICAL", 1032, 1045], ["patients", "ORGANISM", 50, 58], ["eye", "ORGAN", 271, 274], ["patients", "ORGANISM", 443, 451], ["nose", "ORGANISM_SUBDIVISION", 725, 729], ["mouth", "ORGANISM_SUBDIVISION", 734, 739], ["body", "ORGANISM_SUBDIVISION", 776, 780], ["fluids", "ORGANISM_SUBSTANCE", 781, 787], ["blood", "ORGANISM_SUBSTANCE", 789, 794], ["secretions", "ORGANISM_SUBSTANCE", 796, 806], ["urine", "ORGANISM_SUBSTANCE", 808, 813], ["stool", "ORGANISM_SUBSTANCE", 815, 820], ["water", "SIMPLE_CHEMICAL", 861, 866], ["chlorhexidine", "SIMPLE_CHEMICAL", 1011, 1024], ["ethyl alcohol", "SIMPLE_CHEMICAL", 1032, 1045], ["hand", "ORGANISM_SUBDIVISION", 1094, 1098], ["patients", "ORGANISM", 1153, 1161], ["eye", "ORGANISM_SUBDIVISION", 1210, 1213], ["face", "ORGANISM_SUBDIVISION", 1231, 1235], ["head", "ORGANISM_SUBDIVISION", 1237, 1241], ["neck", "ORGANISM_SUBDIVISION", 1247, 1251], ["hand", "ORGANISM_SUBDIVISION", 1273, 1277], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 443, 451], ["patients", "SPECIES", 1153, 1161], ["COVID", "TEST", 261, 266], ["eye care practitioners", "TREATMENT", 271, 293], ["Personal protection", "TREATMENT", 490, 509], ["Personal protective equipment", "TREATMENT", 509, 538], ["general precautionary measures", "TREATMENT", 563, 593], ["outpatient procedures", "TREATMENT", 610, 631], ["Personal protection", "TREATMENT", 663, 682], ["Surgical/N95 respirator mask", "TREATMENT", 683, 711], ["Personal protection", "TREATMENT", 740, 759], ["Gloves", "TREATMENT", 760, 766], ["blood, secretions, urine", "TEST", 789, 813], ["Personal protection", "TREATMENT", 883, 902], ["Repeated hand washing", "TREATMENT", 963, 984], ["hand rub", "TREATMENT", 992, 1000], ["chlorhexidine", "TREATMENT", 1011, 1024], ["Gloves", "TREATMENT", 1069, 1075], ["hand hygiene", "TREATMENT", 1094, 1106], ["face shields", "TREATMENT", 1190, 1202], ["mask", "TREATMENT", 1204, 1208], ["eye protective wear", "TREATMENT", 1210, 1229], ["face, head, and neck area", "PROBLEM", 1231, 1256], ["Examination", "TEST", 1283, 1294], ["Equipment Sterilization", "TREATMENT", 1295, 1318], ["Slit lamps", "TREATMENT", 1320, 1330], ["breath shields", "TREATMENT", 1360, 1374], ["Examination", "TEST", 1387, 1398], ["Equipment Sterilization", "TREATMENT", 1399, 1422], ["Applanation tonometry", "TREATMENT", 1424, 1445], ["a disposable sleeve", "TREATMENT", 1481, 1500], ["nose", "ANATOMY", 725, 729], ["mouth", "ANATOMY", 734, 739], ["Eye", "ANATOMY", 903, 906], ["eye", "ANATOMY", 1210, 1213], ["face", "ANATOMY", 1231, 1235], ["head", "ANATOMY", 1237, 1241], ["neck", "ANATOMY", 1247, 1251], ["hand", "ANATOMY", 1273, 1277], ["wash", "OBSERVATION", 1278, 1282], ["sleeve", "OBSERVATION", 1494, 1500]]], ["For Goldmann applanation tonometry, the prism tip must be sterilized between cases with alcohol swabs or bleach solution 1:10 as recommended.", [["alcohol", "CHEMICAL", 88, 95], ["alcohol", "CHEMICAL", 88, 95], ["Goldmann applanation tonometry", "TEST", 4, 34], ["the prism tip", "TREATMENT", 36, 49], ["alcohol swabs", "TREATMENT", 88, 101], ["bleach solution", "TREATMENT", 105, 120]]], ["The prism tip should be immersed in bleach for at least 15 min. \u2022 Ultrasonography probe to be sterilized with alcohol swab after every use.Examination Equipment Sterilization\u2022 Scleral indentation for indirect ophthalmoscopy should be performed with disposable cotton swab stick. \u2022 Direct ophthalmoscopy should be avoided, instead one should use slit lamp with breath shields and a non-contact lens for fundus evaluation. \u2022 All ophthalmic instruments should be disinfected using diluted household bleach, alcohol solutions containing minimum of 70% alcohol, common EPA-registered household disinfectants including Clorox brand products, Lysol brand products, and Purell professional surface disinfectant wipes.Consultation Room Hygiene and Ventilation\u2022 Keep doors open in the clinic rooms to avoid handling of the door knobs and to maintain ventilation. \u2022 Restriction of visitors in hospital premises unless under exceptional circumstances such as disabled patients or children.Consultation Room Hygiene and VentilationFor a patient who is suspected (or probable) to have COVID-19, the following measures should be taken in treatment by the ophthalmologist:Consultation Room Hygiene and Ventilation\u2022 For known cases of COVID-19, attending the patient on an outpatient basis is contraindicated due to high risk of cross infection.", [["Scleral", "ANATOMY", 176, 183], ["fundus", "ANATOMY", 402, 408], ["surface", "ANATOMY", 682, 689], ["alcohol", "CHEMICAL", 110, 117], ["alcohol", "CHEMICAL", 504, 511], ["alcohol", "CHEMICAL", 548, 555], ["EPA", "CHEMICAL", 564, 567], ["Lysol", "CHEMICAL", 636, 641], ["infection", "DISEASE", 1318, 1327], ["alcohol", "CHEMICAL", 110, 117], ["alcohol", "CHEMICAL", 504, 511], ["alcohol", "CHEMICAL", 548, 555], ["EPA", "CHEMICAL", 564, 567], ["fundus", "MULTI-TISSUE_STRUCTURE", 402, 408], ["alcohol", "SIMPLE_CHEMICAL", 504, 511], ["alcohol", "SIMPLE_CHEMICAL", 548, 555], ["EPA", "SIMPLE_CHEMICAL", 564, 567], ["patients", "ORGANISM", 956, 964], ["children", "ORGANISM", 968, 976], ["patient", "ORGANISM", 1024, 1031], ["patient", "ORGANISM", 1242, 1249], ["patients", "SPECIES", 956, 964], ["children", "SPECIES", 968, 976], ["patient", "SPECIES", 1024, 1031], ["patient", "SPECIES", 1242, 1249], ["The prism tip", "TREATMENT", 0, 13], ["Ultrasonography", "TEST", 66, 81], ["Examination", "TEST", 139, 150], ["Equipment Sterilization", "TREATMENT", 151, 174], ["Scleral indentation", "TEST", 176, 195], ["indirect ophthalmoscopy", "TEST", 200, 223], ["disposable cotton swab stick", "TEST", 249, 277], ["Direct ophthalmoscopy", "TEST", 281, 302], ["breath shields", "TREATMENT", 360, 374], ["fundus evaluation", "TEST", 402, 419], ["All ophthalmic instruments", "TREATMENT", 423, 449], ["alcohol solutions", "TREATMENT", 504, 521], ["Clorox brand products", "TREATMENT", 613, 634], ["Lysol brand products", "TREATMENT", 636, 656], ["Purell professional surface disinfectant wipes", "TREATMENT", 662, 708], ["Ventilation", "TREATMENT", 739, 750], ["the door knobs", "TREATMENT", 809, 823], ["ventilation", "TREATMENT", 840, 851], ["Ventilation", "TREATMENT", 1007, 1018], ["COVID", "TEST", 1071, 1076], ["Ventilation", "TREATMENT", 1186, 1197], ["cross infection", "PROBLEM", 1312, 1327], ["prism", "OBSERVATION_MODIFIER", 4, 9], ["tip", "OBSERVATION_MODIFIER", 10, 13], ["Scleral", "ANATOMY", 176, 183], ["infection", "OBSERVATION", 1318, 1327]]], ["All consultations should be done inside quarantine or isolation wards. \u2022 Any ophthalmic consultation should be deferred in a case suspected to have COVID-19, till the infective status of the patient is confirmed.Inpatient Care\u2022 For attending patients in isolation ward, personal protective equipment should be used as advised for high-risk cases. \u2022 Disposable protective wear should be discarded separately, without touching any part of the skin/face.Operation Theater (OT)\u2022 Only urgent ophthalmic procedures like acute angle closure glaucoma, rhegmatogenous retinal detachment with macula on, traumatic rupture of the eye, and intraocular foreign body to be operated (South China Morning Post 2020). \u2022 All other elective surgeries to be deferred till crisis subsides.Operation Theater (OT)\u2022 Operating surgeon to be prepared with full precautions-SMS surgical gowns, shoe legging, face mask, surgeon cap, gloves, N95 mask.Operation Theater (OT)\u2022 Removal of gown-special care to be taken in order to prevent outer surface from touching any part of the skin. \u2022 Separate collection bag for waste generated and disposables used during surgery.Operation Theater (OT)\u2022 High-level disinfection practice for cleaning of operating room (Rutala et al. 1993 ; Centers for Disease Control and Prevention 2020b).Operation Theater (OT)-Laminar air flow to be maintained in the room.Operation Theater (OT)-Operating microscope-disinfection with 2% glutaraldehyde.Operation Theater (OT)-Instrument sterilization-disinfection with 2% glutaraldehyde, sterilization using ethylene oxide (ETO) for moisture and heat-sensitive instruments, hydrogen peroxide plasma sterilization for all other surgical instruments. -Operation room fumigation with 5% formaldehyde.Operation Theater (OT)\u2022 No noninfected cases to be operated in the same OT on the same day under any circumstances.Management in Case of Accidental ExposureIn case of accidental exposure to any body fluid of the infected patient, eyes should be thoroughly washed with running water and the skin area should be properly cleaned with at least 70% ethyl alcohol-based cleaning solution for at least 20 s.", [["skin", "ANATOMY", 441, 445], ["retinal", "ANATOMY", 559, 566], ["macula", "ANATOMY", 583, 589], ["eye", "ANATOMY", 619, 622], ["intraocular foreign body", "ANATOMY", 628, 652], ["face", "ANATOMY", 881, 885], ["outer surface", "ANATOMY", 1007, 1020], ["skin", "ANATOMY", 1051, 1055], ["body fluid", "ANATOMY", 1936, 1946], ["eyes", "ANATOMY", 1972, 1976], ["skin area", "ANATOMY", 2032, 2041], ["glaucoma", "DISEASE", 534, 542], ["rhegmatogenous retinal detachment", "DISEASE", 544, 577], ["rupture of the eye", "DISEASE", 604, 622], ["glutaraldehyde", "CHEMICAL", 1433, 1447], ["glutaraldehyde", "CHEMICAL", 1517, 1531], ["ethylene oxide", "CHEMICAL", 1553, 1567], ["ETO", "CHEMICAL", 1569, 1572], ["hydrogen peroxide", "CHEMICAL", 1619, 1636], ["formaldehyde", "CHEMICAL", 1729, 1741], ["ethyl alcohol", "CHEMICAL", 2087, 2100], ["glutaraldehyde", "CHEMICAL", 1433, 1447], ["glutaraldehyde", "CHEMICAL", 1517, 1531], ["ethylene oxide", "CHEMICAL", 1553, 1567], ["ETO", "CHEMICAL", 1569, 1572], ["hydrogen peroxide", "CHEMICAL", 1619, 1636], ["formaldehyde", "CHEMICAL", 1729, 1741], ["ethyl alcohol", "CHEMICAL", 2087, 2100], ["patient", "ORGANISM", 191, 198], ["patients", "ORGANISM", 242, 250], ["skin", "ORGAN", 441, 445], ["retinal", "MULTI-TISSUE_STRUCTURE", 559, 566], ["macula", "TISSUE", 583, 589], ["eye", "ORGAN", 619, 622], ["outer surface", "CELLULAR_COMPONENT", 1007, 1020], ["skin", "ORGAN", 1051, 1055], ["glutaraldehyde", "SIMPLE_CHEMICAL", 1433, 1447], ["glutaraldehyde", "SIMPLE_CHEMICAL", 1517, 1531], ["ethylene oxide", "SIMPLE_CHEMICAL", 1553, 1567], ["ETO", "SIMPLE_CHEMICAL", 1569, 1572], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 1619, 1636], ["plasma", "ORGANISM_SUBSTANCE", 1637, 1643], ["formaldehyde", "SIMPLE_CHEMICAL", 1729, 1741], ["body", "ORGANISM_SUBDIVISION", 1936, 1940], ["fluid", "ORGANISM_SUBSTANCE", 1941, 1946], ["patient", "ORGANISM", 1963, 1970], ["eyes", "ORGAN", 1972, 1976], ["skin", "ORGAN", 2032, 2036], ["ethyl", "SIMPLE_CHEMICAL", 2087, 2092], ["alcohol", "SIMPLE_CHEMICAL", 2093, 2100], ["patient", "SPECIES", 191, 198], ["patients", "SPECIES", 242, 250], ["patient", "SPECIES", 1963, 1970], ["COVID", "TEST", 148, 153], ["personal protective equipment", "TREATMENT", 270, 299], ["Disposable protective wear", "TREATMENT", 349, 375], ["urgent ophthalmic procedures", "TREATMENT", 480, 508], ["acute angle closure glaucoma", "PROBLEM", 514, 542], ["rhegmatogenous retinal detachment", "PROBLEM", 544, 577], ["macula", "PROBLEM", 583, 589], ["traumatic rupture of the eye", "PROBLEM", 594, 622], ["intraocular foreign body", "PROBLEM", 628, 652], ["All other elective surgeries", "TREATMENT", 703, 731], ["crisis", "PROBLEM", 752, 758], ["full precautions", "TREATMENT", 830, 846], ["SMS surgical gowns", "TREATMENT", 847, 865], ["face mask", "TREATMENT", 881, 890], ["N95 mask", "TREATMENT", 913, 921], ["Removal of gown", "TREATMENT", 946, 961], ["special care", "TREATMENT", 962, 974], ["Separate collection bag", "TREATMENT", 1059, 1082], ["surgery", "TREATMENT", 1131, 1138], ["High-level disinfection practice", "TREATMENT", 1163, 1195], ["Disease Control", "TREATMENT", 1261, 1276], ["Laminar air flow", "TREATMENT", 1322, 1338], ["2% glutaraldehyde", "TREATMENT", 1430, 1447], ["Instrument sterilization", "TREATMENT", 1471, 1495], ["disinfection", "TREATMENT", 1496, 1508], ["2% glutaraldehyde", "TREATMENT", 1514, 1531], ["sterilization", "TREATMENT", 1533, 1546], ["ethylene oxide (ETO)", "TREATMENT", 1553, 1573], ["moisture and heat-sensitive instruments", "TREATMENT", 1578, 1617], ["hydrogen peroxide plasma sterilization", "TREATMENT", 1619, 1657], ["all other surgical instruments", "TREATMENT", 1662, 1692], ["Operation room fumigation", "TREATMENT", 1695, 1720], ["5% formaldehyde", "TREATMENT", 1726, 1741], ["accidental exposure", "PROBLEM", 1909, 1928], ["running water", "TREATMENT", 2010, 2023], ["the skin area", "TREATMENT", 2028, 2041], ["cleaning solution", "TREATMENT", 2107, 2124], ["protective wear", "OBSERVATION", 360, 375], ["skin", "ANATOMY", 441, 445], ["face", "ANATOMY", 446, 450], ["ophthalmic", "ANATOMY", 487, 497], ["acute", "OBSERVATION_MODIFIER", 514, 519], ["angle", "OBSERVATION_MODIFIER", 520, 525], ["closure", "OBSERVATION_MODIFIER", 526, 533], ["glaucoma", "OBSERVATION", 534, 542], ["rhegmatogenous retinal detachment", "OBSERVATION", 544, 577], ["macula", "ANATOMY", 583, 589], ["traumatic", "OBSERVATION_MODIFIER", 594, 603], ["rupture", "OBSERVATION", 604, 611], ["eye", "ANATOMY", 619, 622], ["intraocular", "ANATOMY", 628, 639], ["foreign body", "OBSERVATION", 640, 652], ["surgeries", "OBSERVATION", 722, 731], ["N95 mask", "OBSERVATION", 913, 921], ["skin", "ANATOMY", 1051, 1055], ["collection bag", "OBSERVATION", 1068, 1082], ["Laminar", "OBSERVATION", 1322, 1329], ["air flow", "OBSERVATION", 1330, 1338], ["surgical instruments", "OBSERVATION", 1672, 1692], ["infected", "OBSERVATION", 1954, 1962], ["eyes", "ANATOMY", 1972, 1976], ["skin", "ANATOMY", 2032, 2036]]], ["The person should be kept under quarantine till 2 weeks (Centers for Disease Control and Prevention 2020c).", [["person", "SPECIES", 4, 10], ["Disease Control", "TREATMENT", 69, 84]]], ["Meanwhile, nasopharyngeal sampling should be done regardless of the symptoms because developing the disease is almost inevitable in such cases (Centers for Disease Control and Prevention 2020c; Lauer et al. 2020) .", [["nasopharyngeal", "ANATOMY", 11, 25], ["nasopharyngeal", "ORGAN", 11, 25], ["nasopharyngeal sampling", "TREATMENT", 11, 34], ["the symptoms", "PROBLEM", 64, 76], ["the disease", "PROBLEM", 96, 107], ["Disease Control", "TREATMENT", 156, 171], ["nasopharyngeal", "ANATOMY", 11, 25], ["disease", "OBSERVATION", 100, 107]]], ["Symptomatic and supportive treatment should be given in those developing COVID-19.", [["Symptomatic", "PROBLEM", 0, 11], ["supportive treatment", "TREATMENT", 16, 36]]], ["Postexposure prophylaxis is not yet available.Economically Weaker CountriesAforementioned precautions should be practiced in such places also.", [["Postexposure prophylaxis", "TREATMENT", 0, 24], ["Aforementioned precautions", "TREATMENT", 75, 101]]], ["In such scenarios, OPD consultation of any ophthalmological complaint should be withheld till the status of infection turns out negative.", [["infection", "DISEASE", 108, 117], ["any ophthalmological complaint", "PROBLEM", 39, 69], ["infection", "PROBLEM", 108, 117], ["infection", "OBSERVATION", 108, 117]]], ["Isolation ward, however, if urgent, should be attended with full precautions.", [["full precautions", "TREATMENT", 60, 76]]], ["Any alternative to the standard precautionary measures may not be helpful in preventing infections.", [["infections", "DISEASE", 88, 98], ["the standard precautionary measures", "TREATMENT", 19, 54], ["infections", "PROBLEM", 88, 98], ["infections", "OBSERVATION", 88, 98]]], ["Self-quarantine should be done by the suspect patient or health care provider for at least 2 weeks duration.ConclusionsOphthalmologists can play a key role in outbreak detection, surveillance, and early response to COVID-19.", [["COVID-19", "CHEMICAL", 215, 223], ["patient", "ORGANISM", 46, 53], ["COVID-19", "DNA", 215, 223], ["patient", "SPECIES", 46, 53], ["Self-quarantine", "TREATMENT", 0, 15], ["surveillance", "TEST", 179, 191], ["COVID", "TEST", 215, 220]]], ["Unawareness at the eye care level may result in mass infections among health care providers and patients.Future PerspectivesThe outbreak of COVID-19 has brought out the stark inadequacies of the health care system at various levels, specially the primary and secondary care.", [["eye", "ANATOMY", 19, 22], ["infections", "DISEASE", 53, 63], ["eye", "ORGAN", 19, 22], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Unawareness at the eye care level", "PROBLEM", 0, 33], ["mass infections", "PROBLEM", 48, 63], ["COVID", "TEST", 140, 145], ["mass", "OBSERVATION", 48, 52]]], ["It is high time the policy makers should take initiatives to strengthen primary and secondary heath care and increase investment in health, including ophthalmic care sector.Future PerspectivesPrevious studies had warned about a possible severe coronavirus pandemic, similar to SARS and MERS in near future.", [["coronavirus pandemic", "DISEASE", 244, 264], ["SARS", "DISEASE", 277, 281], ["Previous studies", "TEST", 192, 208], ["severe coronavirus pandemic", "PROBLEM", 237, 264], ["SARS", "PROBLEM", 277, 281], ["high time", "OBSERVATION_MODIFIER", 6, 15], ["possible", "UNCERTAINTY", 228, 236], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["coronavirus", "OBSERVATION", 244, 255]]], ["In order to fight forthcoming similar illnesses, proper sanitization and disinfection practices should be incorporated on a daily basis, by both doctors and people in the community.", [["people", "ORGANISM", 157, 163], ["people", "SPECIES", 157, 163], ["similar illnesses", "PROBLEM", 30, 47], ["proper sanitization", "TREATMENT", 49, 68], ["disinfection practices", "TREATMENT", 73, 95]]], ["Situational awareness and adequate training should be give to health care providers of all specialties to combat outbreak of new infectious diseases.", [["infectious diseases", "DISEASE", 129, 148], ["new infectious diseases", "PROBLEM", 125, 148], ["new", "OBSERVATION_MODIFIER", 125, 128], ["infectious", "OBSERVATION", 129, 139]]], ["Early preventive measures should be undertaken to prevent pandemics.", [["Early preventive measures", "TREATMENT", 0, 25], ["pandemics", "PROBLEM", 58, 67]]], ["Cooperation among both public and private hospital setups is crucial for management.Highlights\u2022 Early identification of COVID-19 can be done by a vigilant ophthalmologist, reducing risk of further human-to-human transmission. \u2022 Conjunctivitis can be the first symptom of COVID-19 in patients with positive travel/contact history. \u2022 SARS-CoV-2 is present in patients with COVID-19 conjunctivitis.Highlights\u2022 High risk of transmission is present through direct inoculation into conjunctiva. \u2022 Patients having no respiratory symptoms except COVID-19 conjunctivitis are also infectious.", [["conjunctiva", "ANATOMY", 476, 487], ["respiratory", "ANATOMY", 510, 521], ["Conjunctivitis", "DISEASE", 228, 242], ["conjunctivitis", "DISEASE", 380, 394], ["conjunctivitis", "DISEASE", 547, 561], ["human", "ORGANISM", 197, 202], ["human", "ORGANISM", 206, 211], ["patients", "ORGANISM", 283, 291], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 332, 342], ["patients", "ORGANISM", 357, 365], ["conjunctiva", "ORGAN", 476, 487], ["Patients", "ORGANISM", 491, 499], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 206, 211], ["patients", "SPECIES", 283, 291], ["patients", "SPECIES", 357, 365], ["Patients", "SPECIES", 491, 499], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 206, 211], ["COVID", "TEST", 120, 125], ["Conjunctivitis", "PROBLEM", 228, 242], ["COVID", "TEST", 271, 276], ["SARS", "PROBLEM", 332, 336], ["COVID", "TEST", 371, 376], ["conjunctivitis", "PROBLEM", 380, 394], ["direct inoculation into conjunctiva", "PROBLEM", 452, 487], ["respiratory symptoms", "PROBLEM", 510, 530], ["COVID", "TEST", 538, 543], ["conjunctivitis", "PROBLEM", 547, 561], ["infectious", "PROBLEM", 571, 581], ["Conjunctivitis", "OBSERVATION", 228, 242], ["conjunctivitis", "OBSERVATION", 380, 394], ["conjunctiva", "ANATOMY", 476, 487], ["no", "UNCERTAINTY", 507, 509], ["respiratory", "ANATOMY", 510, 521], ["conjunctivitis", "OBSERVATION", 547, 561], ["infectious", "OBSERVATION", 571, 581]]]], "72e37ddb3310bf50385723819244148ab9a787f2": [["BackgroundInfections with feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) are two of the most common and important infectious diseases of cats [1, 2] .", [["BackgroundInfections", "DISEASE", 0, 20], ["feline immunodeficiency virus (FIV)", "DISEASE", 26, 61], ["feline leukemia virus", "DISEASE", 66, 87], ["feline immunodeficiency virus", "ORGANISM", 26, 55], ["FIV", "ORGANISM", 57, 60], ["feline leukemia virus", "ORGANISM", 66, 87], ["FeLV", "ORGANISM", 89, 93], ["cats", "ORGANISM", 159, 163], ["feline immunodeficiency virus", "SPECIES", 26, 55], ["feline leukemia virus", "SPECIES", 66, 87], ["cats", "SPECIES", 159, 163], ["feline immunodeficiency virus", "SPECIES", 26, 55], ["FIV", "SPECIES", 57, 60], ["feline leukemia virus", "SPECIES", 66, 87], ["FeLV", "SPECIES", 89, 93], ["feline immunodeficiency virus", "PROBLEM", 26, 55], ["feline leukemia virus (FeLV)", "PROBLEM", 66, 94], ["feline immunodeficiency", "OBSERVATION", 26, 49], ["feline leukemia virus", "OBSERVATION", 66, 87], ["most common", "OBSERVATION_MODIFIER", 110, 121], ["infectious", "OBSERVATION_MODIFIER", 136, 146]]], ["The most common mode of transmission of FIV is through bites [3, 4] .", [["FIV", "DISEASE", 40, 43], ["FIV", "ORGANISM", 40, 43], ["FIV", "SPECIES", 40, 43], ["FIV", "OBSERVATION", 40, 43]]], ["FeLV infection is also commonly acquired via the oro-nasal route through mutual grooming, nursing or sharing of dishes apart from bites [3] .", [["FeLV infection", "DISEASE", 0, 14], ["FeLV", "ORGANISM", 0, 4], ["FeLV", "SPECIES", 0, 4], ["FeLV infection", "PROBLEM", 0, 14], ["the oro-nasal route", "TREATMENT", 45, 64], ["infection", "OBSERVATION", 5, 14]]], ["The known risk factors for acquiring these infections are male sex, adulthood and exposure to outdoors, whereas being neutered and indoor lifestyle are known protective factors [5] .", [["infections", "DISEASE", 43, 53], ["The known risk factors", "PROBLEM", 0, 22]]], ["However, the relative importance attributed to age, outdoor exposure and sex among infected cats is variable in the literature.", [["cats", "ORGANISM", 92, 96], ["cats", "SPECIES", 92, 96], ["infected cats", "PROBLEM", 83, 96], ["infected cats", "OBSERVATION", 83, 96]]], ["Some studies indicate that FeLV infections are age-dependent [6] and primarily acquired by \"friendly\" cats through prolonged close contact between virus shedders and susceptible cats through mutual grooming, sharing of food and water dishes, and use of common litter areas [3] .", [["FeLV infections", "DISEASE", 27, 42], ["FeLV", "ORGANISM", 27, 31], ["cats", "ORGANISM", 102, 106], ["cats", "ORGANISM", 178, 182], ["cats", "SPECIES", 102, 106], ["cats", "SPECIES", 178, 182], ["FeLV", "SPECIES", 27, 31], ["Some studies", "TEST", 0, 12], ["FeLV infections", "PROBLEM", 27, 42], ["virus shedders", "TREATMENT", 147, 161], ["FeLV infections", "OBSERVATION", 27, 42]]], ["However, other studies have indicated adulthood [1, 7] , outdoor lifestyle [1, 7] , being not neutered [8] , and fighting [8, 9] , factors commonly associated with FIV, to also be associated with FeLV infection.", [["FeLV infection", "DISEASE", 196, 210], ["FIV", "ORGANISM", 164, 167], ["FeLV", "ORGANISM", 196, 200], ["FIV", "SPECIES", 164, 167], ["FeLV", "SPECIES", 196, 200], ["other studies", "TEST", 9, 22], ["FeLV infection", "PROBLEM", 196, 210], ["infection", "OBSERVATION", 201, 210]]], ["Thus, further research is necessary to investigate the relative importance of these factors to help in management and prevention of these infections.BackgroundCase-control studies are often used in analytical epidemiology to examine the strength, magnitude and direction of associations between exposure variables and an outcome of interest [10] .", [["infections", "DISEASE", 138, 148], ["management", "TREATMENT", 103, 113], ["these infections", "PROBLEM", 132, 148], ["infections", "OBSERVATION", 138, 148]]], ["A case-case study differs from a case-control study in that the comparison group (or controls) are also selected among the cases, typically with same disease but a different strain or serotype, from the same surveillance system [11] .", [["a case-control study", "TEST", 31, 51], ["same disease", "PROBLEM", 145, 157], ["a different strain", "PROBLEM", 162, 180], ["serotype", "PROBLEM", 184, 192]]], ["The case-case study approach has been used increasingly in epidemiology e.g. to compare risk factors for two subtypes of the same disease with the goal of ascertaining relative importance of risk factors for either subtype [11] .", [["the same disease", "PROBLEM", 121, 137]]], ["The main advantage of the case-case design is its ability to limit selection and information biases: control cases have similar clinical features, are identified through the same system and are subject to the same biases as cases [11, 12] .", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The goal of this study was to assess the relative importance of known risk factors between the two common feline retroviral infections, FIV and FeLV, using the case-case study approach.Data source and study participantsA dataset consisting of diagnostic test results from 29,182 cats tested for FIV and FeLV between August and November of the year 2004 and 2007 from the United States (US) and Canada was obtained from two previous cross-sectional studies [1, 7] .", [["feline retroviral infections", "DISEASE", 106, 134], ["feline", "ORGANISM", 106, 112], ["retroviral", "ORGANISM", 113, 123], ["FIV", "ORGANISM", 136, 139], ["FeLV", "ORGANISM", 144, 148], ["cats", "ORGANISM", 279, 283], ["FIV", "ORGANISM", 295, 298], ["FeLV", "ORGANISM", 303, 307], ["feline", "SPECIES", 106, 112], ["participants", "SPECIES", 207, 219], ["cats", "SPECIES", 279, 283], ["FIV", "SPECIES", 136, 139], ["FeLV", "SPECIES", 144, 148], ["FIV", "SPECIES", 295, 298], ["FeLV", "SPECIES", 303, 307], ["this study", "TEST", 12, 22], ["known risk factors", "PROBLEM", 64, 82], ["the two common feline retroviral infections", "PROBLEM", 91, 134], ["diagnostic test", "TEST", 243, 258], ["FIV", "PROBLEM", 295, 298], ["retroviral infections", "OBSERVATION", 113, 134]]], ["The cats included in these studies were conveniently sampled from veterinary clinics and animal shelters across 40 contiguous states of the US and 9 Canadian provinces encompassing 641 US zip codes and Canadian forward sortation areas in 346 US counties and Canadian Census Divisions.", [["cats", "ORGANISM", 4, 8], ["cats", "SPECIES", 4, 8], ["these studies", "TEST", 21, 34], ["the US", "TEST", 136, 142]]], ["The first study investigated cats in the US and Canada while the second study was restricted to the Canadian cat population.", [["cats", "ORGANISM", 29, 33], ["cat", "ORGANISM", 109, 112], ["cats", "SPECIES", 29, 33], ["The first study", "TEST", 0, 15], ["the second study", "TEST", 61, 77]]], ["Data collection has been described elsewhere [1, 7] .", [["Data collection", "TEST", 0, 15]]], ["Briefly, potential veterinary clinic participants in the US were identified from the membership roster of the American Association of Feline Practitioners (AAFP) as well as from the list of all individuals who had purchased test kits for FIV and FeLV.", [["Feline", "ORGANISM", 134, 140], ["FIV", "ORGANISM", 238, 241], ["FeLV", "ORGANISM", 246, 250], ["participants", "SPECIES", 37, 49], ["FIV", "SPECIES", 238, 241], ["the US", "TEST", 53, 59]]], ["Potential animal shelter participants (including cat rescue organisations, and groups participating in Trap-Neuter-Release (TNR) programs) were derived from various Internet directories [1] .", [["participants", "SPECIES", 25, 37], ["cat rescue organisations", "TREATMENT", 49, 73]]], ["In Canada, potential veterinary clinic and animal shelter (including cat rescue programs and feral cat programs in Canada) participants were identified as all those who had purchased test kits for FIV or FeLV or submitted samples to a diagnostic laboratory [7] .", [["cat", "ORGANISM", 69, 72], ["cat", "ORGANISM_SUBDIVISION", 99, 102], ["FIV", "ORGANISM", 197, 200], ["FeLV", "ORGANISM", 204, 208], ["participants", "SPECIES", 123, 135], ["FIV", "SPECIES", 197, 200], ["FeLV", "SPECIES", 204, 208], ["cat rescue programs", "TREATMENT", 69, 88], ["feral cat programs", "TREATMENT", 93, 111], ["FIV", "PROBLEM", 197, 200], ["FeLV", "PROBLEM", 204, 208]]], ["Potential study participants were sent an invitation letter to participate in the study.", [["participants", "SPECIES", 16, 28], ["Potential study", "TEST", 0, 15], ["the study", "TEST", 78, 87]]], ["Enrolled participants submitted the diagnostic results for FIV and FeLV along with information on age, sex, neuter status, outdoor exposure, health status and test date using a standard reporting form.", [["FIV", "ORGANISM", 59, 62], ["FeLV", "ORGANISM", 67, 71], ["participants", "SPECIES", 9, 21], ["FIV", "SPECIES", 59, 62], ["FeLV", "SPECIES", 67, 71]]], ["The testing and reporting was performed from August to November 2004 for the American and Canadian participants in the first study and from August to November 2007 for the Canadian participants in the second study.Testing protocolThe testing for FIV and FeLV was carried out in-house or in-laboratory employing a commercially available ELISA (SNAP\u00ae Combo FeLV antigen/FIV antibody, PetCheck\u00ae FIV Antibody and PetCheck\u00ae FeLV Antigen; IDEXX Laboratories) using whole blood, serum or plasma.", [["whole blood", "ANATOMY", 459, 470], ["serum", "ANATOMY", 472, 477], ["plasma", "ANATOMY", 481, 487], ["SNAP", "CHEMICAL", 343, 347], ["FIV", "ORGANISM", 246, 249], ["FeLV", "ORGANISM", 254, 258], ["FeLV", "ORGANISM", 355, 359], ["FIV", "ORGANISM", 368, 371], ["FeLV", "ORGANISM", 419, 423], ["blood", "ORGANISM_SUBSTANCE", 465, 470], ["serum", "ORGANISM_SUBSTANCE", 472, 477], ["plasma", "ORGANISM_SUBSTANCE", 481, 487], ["Combo FeLV antigen", "PROTEIN", 349, 367], ["FIV antibody", "PROTEIN", 368, 380], ["PetCheck", "PROTEIN", 382, 390], ["PetCheck", "PROTEIN", 409, 417], ["FeLV Antigen", "PROTEIN", 419, 431], ["IDEXX", "PROTEIN", 433, 438], ["participants", "SPECIES", 99, 111], ["participants", "SPECIES", 181, 193], ["FIV", "SPECIES", 246, 249], ["FeLV", "SPECIES", 254, 258], ["FIV", "SPECIES", 368, 371], ["FIV", "SPECIES", 392, 395], ["The testing", "TEST", 0, 11], ["the second study", "TEST", 197, 213], ["Testing protocol", "TEST", 214, 230], ["The testing", "TEST", 230, 241], ["FIV", "PROBLEM", 246, 249], ["FeLV", "PROBLEM", 254, 258], ["Combo FeLV antigen", "TEST", 349, 367], ["FIV antibody", "TEST", 368, 380], ["PetCheck", "TEST", 382, 390], ["FIV Antibody", "TEST", 392, 404], ["PetCheck", "TEST", 409, 417], ["FeLV Antigen", "TEST", 419, 431], ["whole blood, serum or plasma", "TEST", 459, 487], ["FIV antibody", "OBSERVATION", 368, 380]]], ["The manufacturer reported sensitivity and specificity of the assay for detecting FeLV antigen of 97.6% and 99.1%, and for detecting FIV antibodies of 100% and 99.5%, respectively.", [["FeLV", "ORGANISM", 81, 85], ["FIV", "ORGANISM", 132, 135], ["FeLV antigen", "PROTEIN", 81, 93], ["FIV antibodies", "PROTEIN", 132, 146], ["FeLV", "SPECIES", 81, 85], ["FIV", "SPECIES", 132, 135], ["the assay", "TEST", 57, 66], ["FeLV antigen", "TEST", 81, 93], ["FIV antibodies", "TEST", 132, 146]]], ["Confirmatory testing was not performed.Covariate informationInformation on postal code of testing facility, type of testing facility (clinic or shelter), age of the cat (juvenile [<6 months] or adult), sex and neuter status (sexually intact female, spayed female, sexually intact male or neutered male), access to outdoors (indoors or outdoors) and general health at time of testing (healthy or sick) was also retrieved from the dataset (Table 1) .Selection of study subjects: FIV and FeLV case groupsCats testing positive for FIV antibodies in ELISA were compared to cats testing positive for FeLV antigen with all the cats having been tested for both infections.", [["infections", "DISEASE", 653, 663], ["cat", "ORGANISM", 165, 168], ["FIV", "ORGANISM", 477, 480], ["FeLV", "ORGANISM", 485, 489], ["Cats", "ORGANISM", 501, 505], ["FIV", "ORGANISM", 527, 530], ["cats", "ORGANISM", 568, 572], ["FeLV", "ORGANISM", 594, 598], ["cats", "ORGANISM", 620, 624], ["FIV antibodies", "PROTEIN", 527, 541], ["FeLV antigen", "PROTEIN", 594, 606], ["cat", "SPECIES", 165, 168], ["cats", "SPECIES", 568, 572], ["cats", "SPECIES", 620, 624], ["FIV", "SPECIES", 527, 530], ["FeLV", "SPECIES", 594, 598], ["Confirmatory testing", "TEST", 0, 20], ["Selection of study", "TEST", 448, 466], ["Cats testing", "TEST", 501, 513], ["FIV antibodies in ELISA", "PROBLEM", 527, 550], ["cats testing", "TEST", 568, 580], ["FeLV antigen", "PROBLEM", 594, 606], ["both infections", "PROBLEM", 648, 663], ["infections", "OBSERVATION", 653, 663]]], ["Cats were excluded from further analysis in this study if they tested positive for both FIV and FeLV.Logistic regressionLogistic regression models were fit to model the logit of the probability of FIV seropositivity as a function of predictor variables age, sex/neuter status, outdoor exposure, health status and testing facility in a random intercept logistic regression model framework.Univariable analysisVariables were screened for inclusion into the multivariable logistic regression model by fitting univariable logistic regression models, without random intercepts, and those predictor variables with a liberal significance level (\u03b1 = 0.2) were selected.", [["FIV", "ORGANISM", 88, 91], ["FeLV", "ORGANISM", 96, 100], ["FIV", "ORGANISM", 197, 200], ["FIV", "SPECIES", 88, 91], ["FIV", "SPECIES", 197, 200], ["further analysis", "TEST", 24, 40], ["this study", "TEST", 44, 54], ["Logistic regressionLogistic regression models", "PROBLEM", 101, 146], ["FIV seropositivity", "PROBLEM", 197, 215], ["Univariable analysisVariables", "TEST", 388, 417]]], ["Since all the predictor variables were categorical (i.e. indicator variables), the significance in the model of each group of the predictors was analyzed by applying a likelihood ratio test.", [["a likelihood ratio test", "TEST", 166, 189]]], ["Collinearity among the predictor variables with significant unconditional association with FIV seropositivity was assessed by using the Spearman rank-correlation test.", [["FIV", "ORGANISM", 91, 94], ["FIV", "SPECIES", 91, 94], ["FIV seropositivity", "PROBLEM", 91, 109], ["correlation test", "TEST", 150, 166], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["When two variables were collinear, the one with the smaller P-value was considered for further multivariable analysis while the other was removed.Multivariable analysisBackward selection was employed for multivariable model building and covariate removal from the model was based on the following criteria: (1) the highest non-significant P-value (with significance level \u03b1 = 0.05); (2) a likelihood ratio test of the model with and without the variable that was non-significant and (3) the variable was not an important confounder for other variables in the model.", [["P", "DNA", 60, 61], ["further multivariable analysis", "TEST", 87, 117], ["Multivariable analysisBackward selection", "TREATMENT", 146, 186], ["multivariable model building", "TREATMENT", 204, 232], ["covariate removal", "TREATMENT", 237, 254], ["a likelihood ratio test", "TEST", 387, 410]]], ["A confounder was a non-intervening covariate whose removal from the model resulted in greater than 20% change in coefficients on the log-odds scale for any of the remaining variables in the model.", [["a non-intervening covariate whose removal", "TREATMENT", 17, 58], ["greater", "OBSERVATION_MODIFIER", 86, 93]]], ["However, interaction terms were dropped when these led to sparse cells and unrealistic estimates.", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["sparse cells", "PROBLEM", 58, 70]]], ["Multicollinearity was tested among screened variables in the multivariable logistic regression model by estimating the variance inflation factor (VIF).", [["variance inflation factor", "PROTEIN", 119, 144], ["VIF", "PROTEIN", 146, 149]]], ["All variables with a VIF value of 10 or above were considered to indicate multicollinearity, assuming that this was not due to variable construction (e.g. interaction terms) [10] .", [["a VIF value", "TEST", 19, 30]]], ["A simpler model (without random effects) was chosen when the variance component was close to zero [13] .", [["the variance component", "PROBLEM", 57, 79]]], ["Fit of the random effect model was assessed visually by plotting the QQ-plots of the Best Linear Unbiased Predictors (BLUPs) against the normal scores [10] .Multivariable analysisThe random intercept models were fit in statistical software R (lme4 package) and Stata (xtmelogit) by seven point Gauss-Hermite adaptive quadrature method [14, 15] , using complete cases (i.e., any observations with missing values excluded from the analysis).", [["Multivariable analysis", "TEST", 157, 179], ["Stata (xtmelogit)", "TREATMENT", 261, 278], ["Hermite adaptive quadrature method", "TREATMENT", 300, 334], ["missing values", "TEST", 396, 410], ["the analysis", "TEST", 425, 437]]], ["However, the point estimates from the final model were compared to the same model fit with missing values (coded as unknown) to observe any gross deviation in direction and magnitude.Multivariable analysisThe Research Ethics Board at the University of Guelph did not require ethics approval for this study because secondary data was used without either patient or owner identifiers.", [["patient", "ORGANISM", 353, 360], ["patient", "SPECIES", 353, 360], ["missing values", "PROBLEM", 91, 105], ["any gross deviation in direction and magnitude", "PROBLEM", 136, 182], ["Multivariable analysis", "TEST", 183, 205], ["this study", "TEST", 295, 305], ["gross", "OBSERVATION_MODIFIER", 140, 145], ["deviation", "OBSERVATION", 146, 155]]], ["Table 1 presents the descriptive statistics of FIV and FeLV cases cross-tabulated by risk factors.", [["FIV", "ORGANISM", 47, 50], ["FeLV", "ORGANISM", 55, 59], ["FIV", "SPECIES", 47, 50]]], ["The total number of cases included in this study was 1289.", [["this study", "TEST", 38, 48], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Out of these retroviral cases, 696 tested positive for FIV and 593 for FeLV.Logistic regression analysisAll covariates met the inclusion criteria for multivariable modeling as explained above ( Table 2 ).", [["retroviral", "ORGANISM", 13, 23], ["FIV", "ORGANISM", 55, 58], ["FeLV", "ORGANISM", 71, 75], ["FIV", "SPECIES", 55, 58], ["FeLV", "SPECIES", 71, 75], ["FIV", "PROBLEM", 55, 58], ["FeLV", "PROBLEM", 71, 75], ["Logistic regression analysis", "TEST", 76, 104], ["multivariable modeling", "PROBLEM", 150, 172], ["retroviral", "ANATOMY", 13, 23]]], ["The final multivariable random intercept logistic regression model included the covariates/predictors age, sex/neuter status, outdoor exposure, and health status of cats ( Table 3) .", [["cats", "ORGANISM", 165, 169], ["cats", "SPECIES", 165, 169]]], ["The odds ratio (OR) associated with each variable is adjusted for the remaining variables in the model.", [["The odds ratio", "TEST", 0, 14]]], ["No significant interactions were detected between the variables that remained in the final multivariable model.Logistic regression analysisThe odds of cats being seropositive for FIV relative to FeLV was significantly greater for adult cats than juvenile cats (Table 3) .", [["cats", "ORGANISM", 151, 155], ["FIV", "ORGANISM", 179, 182], ["FeLV", "ORGANISM", 195, 199], ["cats", "ORGANISM", 236, 240], ["cats", "ORGANISM", 255, 259], ["cats", "SPECIES", 151, 155], ["cats", "SPECIES", 236, 240], ["cats", "SPECIES", 255, 259], ["FIV", "SPECIES", 179, 182], ["FeLV", "SPECIES", 195, 199], ["significant interactions", "PROBLEM", 3, 27], ["Logistic regression analysis", "TEST", 111, 139], ["FIV", "PROBLEM", 179, 182], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["interactions", "OBSERVATION", 15, 27]]], ["Similarly, the intact and neutered males were significantly more likely to be seropositive for FIV than FeLV compared to intact females.", [["FIV", "ORGANISM", 95, 98], ["FeLV", "ORGANISM", 104, 108], ["FIV", "SPECIES", 95, 98], ["FeLV", "SPECIES", 104, 108], ["FIV than FeLV", "PROBLEM", 95, 108], ["intact", "OBSERVATION_MODIFIER", 15, 21]]], ["The odds of being seropositive for FIV relative to FeLV was not significantly different between intact and spayed females based on the Wald test.", [["FIV", "ORGANISM", 35, 38], ["FeLV", "ORGANISM", 51, 55], ["FIV", "SPECIES", 35, 38], ["FeLV", "SPECIES", 51, 55], ["FIV", "PROBLEM", 35, 38], ["the Wald test", "TEST", 131, 144], ["FeLV", "OBSERVATION", 51, 55]]], ["Compared to cats kept indoors, cats with known outdoor exposure had higher odds of being seropositive for FIV relative to FeLV.", [["cats", "ORGANISM", 12, 16], ["cats", "ORGANISM", 31, 35], ["FIV", "ORGANISM", 106, 109], ["FeLV", "ORGANISM", 122, 126], ["cats", "SPECIES", 12, 16], ["cats", "SPECIES", 31, 35], ["FIV", "SPECIES", 106, 109], ["FeLV", "SPECIES", 122, 126], ["FIV", "PROBLEM", 106, 109]]], ["For clinically ill cats, the odds of being seropositive for FIV relative to FeLV were smaller compared to cats without clinical illness.Logistic regression analysisThe variance components obtained from the multilevel logistic regression model for the individual level and clinic/shelter level were 3.29 and 1.16, respectively.Logistic regression analysisA random effects logistic regression model was deemed appropriate due to clustering expected for cats tested within the same facility and because the variance of the random effect was 3.29, which given the associated small standard error was interpreted as the variance being different from zero (Table 3 ).", [["cats", "ORGANISM", 19, 23], ["FIV", "ORGANISM", 60, 63], ["FeLV", "ORGANISM", 76, 80], ["cats", "ORGANISM", 106, 110], ["cats", "ORGANISM", 451, 455], ["cats", "SPECIES", 19, 23], ["cats", "SPECIES", 106, 110], ["FIV", "SPECIES", 60, 63], ["FeLV", "SPECIES", 76, 80], ["clinically ill cats", "PROBLEM", 4, 23], ["FIV", "PROBLEM", 60, 63], ["FeLV", "PROBLEM", 76, 80], ["clinical illness", "PROBLEM", 119, 135], ["Logistic regression analysis", "TEST", 136, 164], ["The variance components", "TEST", 164, 187], ["Logistic regression analysisA", "TREATMENT", 326, 355], ["cats", "TEST", 451, 455], ["the associated small standard error", "PROBLEM", 556, 591], ["smaller", "OBSERVATION_MODIFIER", 86, 93], ["small", "OBSERVATION_MODIFIER", 571, 576], ["standard error", "OBSERVATION", 577, 591]]], ["Normal quantile plot of the BLUPs indicated no gross deviation from normality.DiscussionThis case-case study is based on cross-sectional or prevalence data and thus generally not suited to identify risk factors.", [["gross deviation from normality", "PROBLEM", 47, 77], ["quantile plot", "OBSERVATION", 7, 20], ["no", "UNCERTAINTY", 44, 46], ["gross", "OBSERVATION_MODIFIER", 47, 52], ["deviation", "OBSERVATION", 53, 62]]], ["However, only known risk factors [3] were evaluated in this study with respect to their importance as risk factors for infection with FIV compared to FeLV.", [["infection", "DISEASE", 119, 128], ["FIV", "DISEASE", 134, 137], ["FIV", "ORGANISM", 134, 137], ["FeLV", "ORGANISM", 150, 154], ["FIV", "SPECIES", 134, 137], ["this study", "TEST", 55, 65], ["infection", "PROBLEM", 119, 128], ["FIV", "TREATMENT", 134, 137]]], ["The results from this study imply that risk factors commonly associated with FIV and FeLV differ in their relative effects for these two diseases.", [["FIV", "ORGANISM", 77, 80], ["FeLV", "ORGANISM", 85, 89], ["FIV", "SPECIES", 77, 80], ["this study", "TEST", 17, 27], ["risk factors", "PROBLEM", 39, 51], ["FIV", "PROBLEM", 77, 80], ["FeLV", "PROBLEM", 85, 89], ["these two diseases", "PROBLEM", 127, 145]]], ["For example adult, male, or outdoor cats are more likely to be seropositive for FIV than FeLV when compared to juvenile, female or cats kept exclusively indoors.", [["cats", "ORGANISM", 36, 40], ["FIV", "ORGANISM", 80, 83], ["FeLV", "ORGANISM", 89, 93], ["cats", "ORGANISM", 131, 135], ["cats", "SPECIES", 36, 40], ["cats", "SPECIES", 131, 135], ["FIV", "SPECIES", 80, 83], ["FeLV", "SPECIES", 89, 93], ["FIV", "PROBLEM", 80, 83]]], ["In contrast, neuter status was not significantly different for either infection.", [["infection", "DISEASE", 70, 79], ["infection", "PROBLEM", 70, 79], ["significantly different", "OBSERVATION_MODIFIER", 35, 58], ["infection", "OBSERVATION", 70, 79]]], ["Further, whether cats were tested at clinics or shelters was not different for these infections.DiscussionMost FIV infections are acquired as a consequence of bite wounds inflicted by an infected cat, presumably through inoculation of virus or virus infected cells [16, 17] .", [["wounds", "ANATOMY", 164, 170], ["cells", "ANATOMY", 259, 264], ["infections", "DISEASE", 85, 95], ["FIV infections", "DISEASE", 111, 125], ["bite wounds", "DISEASE", 159, 170], ["cats", "ORGANISM", 17, 21], ["FIV", "ORGANISM", 111, 114], ["wounds", "PATHOLOGICAL_FORMATION", 164, 170], ["cat", "ORGANISM", 196, 199], ["cells", "CELL", 259, 264], ["virus infected cells", "CELL_TYPE", 244, 264], ["cats", "SPECIES", 17, 21], ["FIV", "SPECIES", 111, 114], ["these infections", "PROBLEM", 79, 95], ["FIV infections", "PROBLEM", 111, 125], ["bite wounds", "PROBLEM", 159, 170], ["an infected cat", "PROBLEM", 184, 199], ["inoculation of virus", "PROBLEM", 220, 240], ["virus infected cells", "PROBLEM", 244, 264], ["infections", "OBSERVATION", 85, 95], ["infected", "OBSERVATION", 187, 195]]], ["Although, vertical transmission of infection from queen to kitten may occur, it is considered rare [18] .", [["infection", "DISEASE", 35, 44], ["infection", "PROBLEM", 35, 44], ["vertical", "OBSERVATION_MODIFIER", 10, 18], ["infection", "OBSERVATION", 35, 44]]], ["Adult, male, outdoor exposed cats would be expected to have a higher likelihood of getting infected with FIV due to higher likelihood of encountering infected cats, and being prone to aggression and territorial fights.", [["FIV", "DISEASE", 105, 108], ["aggression", "DISEASE", 184, 194], ["cats", "ORGANISM", 29, 33], ["FIV", "ORGANISM", 105, 108], ["cats", "ORGANISM", 159, 163], ["cats", "SPECIES", 29, 33], ["cats", "SPECIES", 159, 163], ["FIV", "SPECIES", 105, 108], ["FIV", "TREATMENT", 105, 108], ["infected", "OBSERVATION", 150, 158], ["territorial fights", "OBSERVATION", 199, 217]]], ["On the contrary, most FeLV infections occur after oro-nasal spread of the virus from the viremic cats [17, [19] [20] [21] [22] .", [["oro-nasal", "ANATOMY", 50, 59], ["FeLV infections", "DISEASE", 22, 37], ["FeLV", "ORGANISM", 22, 26], ["cats", "ORGANISM", 97, 101], ["FeLV", "SPECIES", 22, 26], ["most FeLV infections", "PROBLEM", 17, 37], ["oro-nasal spread", "PROBLEM", 50, 66], ["the virus", "PROBLEM", 70, 79], ["the viremic cats", "TEST", 85, 101], ["infections", "OBSERVATION", 27, 37]]], ["FeLV infection, thus, is a concern in cats that are \"friendly\" and in close contact with infected cats through nursing, mutual grooming or sharing dishes, but also through bites [3] .DiscussionThis study found a higher likelihood of FIV (compared to FeLV) seropositivity in adults.", [["FeLV infection", "DISEASE", 0, 14], ["FeLV", "ORGANISM", 0, 4], ["cats", "ORGANISM", 38, 42], ["cats", "ORGANISM", 98, 102], ["FIV", "ORGANISM", 233, 236], ["FeLV", "ORGANISM", 250, 254], ["cats", "SPECIES", 38, 42], ["cats", "SPECIES", 98, 102], ["FeLV", "SPECIES", 0, 4], ["FIV", "SPECIES", 233, 236], ["FeLV", "SPECIES", 250, 254], ["FeLV infection", "PROBLEM", 0, 14], ["This study", "TEST", 193, 203], ["FIV", "PROBLEM", 233, 236], ["infection", "OBSERVATION", 5, 14], ["FIV", "OBSERVATION", 233, 236]]], ["In contrast to FIV, FeLV is reported to be age dependent with older cats becoming increasingly resistant to infection [23, 24] .", [["infection", "DISEASE", 108, 117], ["FIV", "ORGANISM", 15, 18], ["FeLV", "ORGANISM", 20, 24], ["cats", "ORGANISM", 68, 72], ["cats", "SPECIES", 68, 72], ["FIV", "SPECIES", 15, 18], ["FeLV", "SPECIES", 20, 24], ["older cats", "PROBLEM", 62, 72], ["infection", "PROBLEM", 108, 117], ["FeLV", "OBSERVATION", 20, 24], ["resistant", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 108, 117]]], ["Of note, however, is the fact that while age at acquisition is similar for both infections, FeLV can cause serious, often fatal, disease.", [["infections", "DISEASE", 80, 90], ["FeLV", "DISEASE", 92, 96], ["FeLV", "ORGANISM", 92, 96], ["FeLV", "SPECIES", 92, 96], ["both infections", "PROBLEM", 75, 90], ["disease", "PROBLEM", 129, 136], ["infections", "OBSERVATION", 80, 90]]], ["As a result, FeLV-infected cats have shorter survival rates [25, 26] and not many live to adulthood, while most FIV infected cats do.", [["FIV infected", "DISEASE", 112, 124], ["FeLV", "ORGANISM", 13, 17], ["cats", "ORGANISM", 27, 31], ["FIV", "ORGANISM", 112, 115], ["cats", "ORGANISM", 125, 129], ["cats", "SPECIES", 27, 31], ["cats", "SPECIES", 125, 129], ["FIV", "SPECIES", 112, 115], ["FeLV", "PROBLEM", 13, 17], ["infected cats", "PROBLEM", 18, 31], ["survival rates", "TEST", 45, 59], ["infected", "OBSERVATION", 116, 124]]], ["Higher probability of infection can be expected in males compared to females for FIV [9, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .", [["infection", "DISEASE", 22, 31], ["FIV [9, [27] [28] [29] [30] [31] [32] [33]", "CHEMICAL", 81, 123], ["FIV", "ORGANISM", 81, 84], ["[27] [28] [29] [30] [31] [32] [33] [34] [35", "SIMPLE_CHEMICAL", 89, 132], ["FIV", "SPECIES", 81, 84], ["infection", "PROBLEM", 22, 31], ["FIV", "TEST", 81, 84], ["infection", "OBSERVATION", 22, 31]]], ["But for FeLV, most studies did not find an association between sex and seropositivity [28, 38] except for a single report [9] .", [["FeLV", "ORGANISM", 8, 12], ["FeLV", "PROBLEM", 8, 12], ["seropositivity", "TEST", 71, 85]]], ["The association between male sex and FIV infection has been primarily related to increased risk of infection transmission due to greater predisposition of males to exhibit territorial behaviour involving fighting.", [["FIV infection", "DISEASE", 37, 50], ["infection", "DISEASE", 99, 108], ["FIV", "ORGANISM", 37, 40], ["FIV", "SPECIES", 37, 40], ["FIV infection", "PROBLEM", 37, 50], ["infection transmission", "PROBLEM", 99, 121], ["FIV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["infection", "OBSERVATION", 99, 108], ["territorial behaviour", "OBSERVATION", 172, 193]]], ["In this study, regression models included contrasts to compare the likelihood of seropositivity of FIV between intact and neutered male cats as well as between intact and spayed female cats.", [["FIV", "ORGANISM", 99, 102], ["cats", "ORGANISM", 136, 140], ["cats", "ORGANISM", 185, 189], ["cats", "SPECIES", 136, 140], ["cats", "SPECIES", 185, 189], ["FIV", "SPECIES", 99, 102], ["this study", "TEST", 3, 13], ["seropositivity of FIV", "PROBLEM", 81, 102], ["FIV", "OBSERVATION", 99, 102]]], ["Although, compared to females, males were found to be more likely to test seropositive for FIV compared to FeLV, no significant differences were evident between intact and neutered cats for the same sex (Table 3 and 4 ).", [["FIV", "ORGANISM", 91, 94], ["FeLV", "ORGANISM", 107, 111], ["cats", "ORGANISM", 181, 185], ["cats", "SPECIES", 181, 185], ["FIV", "SPECIES", 91, 94], ["FeLV", "SPECIES", 107, 111], ["FIV", "PROBLEM", 91, 94], ["significant differences", "PROBLEM", 116, 139]]], ["Various studies have reported an association between neutering and lower risk of infection of FIV and FeLV among domestic cats [8] .", [["infection of FIV and FeLV", "DISEASE", 81, 106], ["FIV", "ORGANISM", 94, 97], ["FeLV", "ORGANISM", 102, 106], ["cats", "SPECIES", 122, 126], ["FIV", "SPECIES", 94, 97], ["FeLV", "SPECIES", 102, 106], ["Various studies", "TEST", 0, 15], ["infection of FIV", "PROBLEM", 81, 97], ["infection", "OBSERVATION", 81, 90]]], ["However, there are reports suggesting that neutering and spaying have no significant effect on the prevalence of FIV [27, 39, 40] and that such cats still retain territorial aggressiveness [39, 40] .", [["FIV", "DISEASE", 113, 116], ["aggressiveness", "DISEASE", 174, 188], ["FIV", "ORGANISM", 113, 116], ["cats", "ORGANISM", 144, 148], ["cats", "SPECIES", 144, 148], ["FIV", "SPECIES", 113, 116]]], ["It should be noted that when a predictor is common to both FIV and FeLV, due to its inherent design, a case-case study might not detect a difference between the two case groups.", [["FeLV", "DISEASE", 67, 71], ["FIV", "ORGANISM", 59, 62], ["FeLV", "ORGANISM", 67, 71], ["FIV", "SPECIES", 59, 62], ["a case-case study", "TEST", 101, 118]]], ["In other words, if neutering were significantly associated with both FIV and FeLV seropositivity, this study design would not detect it.", [["FIV", "ORGANISM", 69, 72], ["FeLV", "ORGANISM", 77, 81], ["FIV", "SPECIES", 69, 72], ["FeLV", "SPECIES", 77, 81], ["both FIV and FeLV seropositivity", "PROBLEM", 64, 96], ["this study", "TEST", 98, 108]]], ["Since a higher likelihood of seropositivity was found in intact compared to neutered cats when non-infected cats were included [1, 7] , it is possible that sterilization characteristics are not different between FIV and FeLV infected cats.DiscussionCats were more likely seropositive for FIV than FeLV when exposed to outdoors than being indoors.", [["FIV and FeLV infected", "DISEASE", 212, 233], ["cats", "ORGANISM", 85, 89], ["cats", "ORGANISM", 108, 112], ["FIV", "ORGANISM", 212, 215], ["FeLV", "ORGANISM", 220, 224], ["cats", "ORGANISM", 234, 238], ["FIV", "ORGANISM", 288, 291], ["FeLV", "ORGANISM", 297, 301], ["cats", "SPECIES", 85, 89], ["cats", "SPECIES", 108, 112], ["cats", "SPECIES", 234, 238], ["FIV", "SPECIES", 212, 215], ["FeLV", "SPECIES", 220, 224], ["FIV", "SPECIES", 288, 291], ["FeLV", "SPECIES", 297, 301], ["seropositivity", "PROBLEM", 29, 43], ["non-infected cats", "TEST", 95, 112], ["sterilization characteristics", "PROBLEM", 156, 185], ["FIV and FeLV infected cats", "TREATMENT", 212, 238], ["seropositivity", "OBSERVATION", 29, 43], ["FeLV", "OBSERVATION_MODIFIER", 220, 224], ["infected cats", "OBSERVATION", 225, 238]]], ["This finding suggests that outdoor exposure is more important to acquire FIV infection than FeLV.", [["FIV infection", "DISEASE", 73, 86], ["FIV", "ORGANISM", 73, 76], ["FeLV", "ORGANISM", 92, 96], ["FIV", "SPECIES", 73, 76], ["FeLV", "SPECIES", 92, 96], ["FIV infection", "PROBLEM", 73, 86], ["infection", "OBSERVATION", 77, 86]]], ["Considering prevalence studies where non-infected cats were included, there seems to be consensus that the probability of FIV infection is higher for cats that roam outdoors [9, 41] due increased opportunity for transmission via fights.", [["FIV infection", "DISEASE", 122, 135], ["cats", "ORGANISM", 50, 54], ["FIV", "ORGANISM", 122, 125], ["cats", "ORGANISM", 150, 154], ["cats", "SPECIES", 50, 54], ["cats", "SPECIES", 150, 154], ["FIV", "SPECIES", 122, 125], ["prevalence studies", "TEST", 12, 30], ["non-infected cats", "TEST", 37, 54], ["FIV infection", "PROBLEM", 122, 135], ["infection", "OBSERVATION", 126, 135]]], ["In contrast, the relationship between outdoor exposure and FeLV infection is not very clear.DiscussionHealthy cats were more likely to test positive for FIV than FeLV compared to cats presenting as ill at the time of testing.", [["FeLV infection", "DISEASE", 59, 73], ["FeLV", "ORGANISM", 59, 63], ["cats", "ORGANISM", 110, 114], ["FIV", "ORGANISM", 153, 156], ["FeLV", "ORGANISM", 162, 166], ["cats", "ORGANISM", 179, 183], ["cats", "SPECIES", 110, 114], ["cats", "SPECIES", 179, 183], ["FeLV", "SPECIES", 59, 63], ["FIV", "SPECIES", 153, 156], ["FeLV", "SPECIES", 162, 166], ["FeLV infection", "PROBLEM", 59, 73], ["FIV than FeLV", "PROBLEM", 153, 166], ["testing", "TEST", 217, 224], ["FeLV infection", "OBSERVATION", 59, 73], ["not very", "UNCERTAINTY", 77, 85], ["clear", "OBSERVATION", 86, 91]]], ["Both viruses induce immunodeficiency, but FeLV is more rapidly pathogenic and its effects manifest sooner and include other disease conditions [26] .", [["immunodeficiency", "DISEASE", 20, 36], ["FeLV", "ORGANISM", 42, 46], ["FeLV", "SPECIES", 42, 46], ["immunodeficiency", "PROBLEM", 20, 36], ["FeLV", "PROBLEM", 42, 46], ["other disease conditions", "PROBLEM", 118, 142], ["viruses", "OBSERVATION", 5, 12], ["immunodeficiency", "OBSERVATION", 20, 36]]], ["FIV infection causes gradually developing immunodeficiency and has only a minor impact on lifespan.", [["FIV infection", "DISEASE", 0, 13], ["immunodeficiency", "DISEASE", 42, 58], ["FIV", "ORGANISM", 0, 3], ["FIV", "SPECIES", 0, 3], ["FIV infection", "PROBLEM", 0, 13], ["gradually developing immunodeficiency", "PROBLEM", 21, 58], ["infection", "OBSERVATION", 4, 13], ["immunodeficiency", "OBSERVATION", 42, 58], ["minor", "OBSERVATION_MODIFIER", 74, 79], ["impact", "OBSERVATION_MODIFIER", 80, 86]]], ["Therefore, cats with FeLV are more likely to be presented with illness.", [["illness", "DISEASE", 63, 70], ["cats", "ORGANISM", 11, 15], ["FeLV", "ORGANISM", 21, 25], ["cats", "SPECIES", 11, 15], ["FeLV", "PROBLEM", 21, 25], ["illness", "PROBLEM", 63, 70]]], ["This contributes to more sick cats testing FeLV positive rather than FIV positive.DiscussionThe variance components of the random effects model indicate that some degree of clustering was evident at testing facility (ICC = 0.26) suggesting that FIV seropositive status compared to FeLV was not independent of shelter or clinic.DiscussionA few important limitations of the case-case study design in the context of this study merits attention.", [["cats", "ORGANISM", 30, 34], ["FeLV", "ORGANISM", 43, 47], ["FIV", "ORGANISM", 69, 72], ["FIV", "ORGANISM", 245, 248], ["FeLV", "ORGANISM", 281, 285], ["FIV", "SPECIES", 69, 72], ["FIV", "SPECIES", 245, 248], ["FeLV", "SPECIES", 281, 285], ["sick cats testing FeLV", "TEST", 25, 47], ["FIV positive", "PROBLEM", 69, 81], ["ICC", "TEST", 217, 220], ["FIV seropositive status", "PROBLEM", 245, 268], ["case study", "TEST", 377, 387], ["this study", "TEST", 413, 423]]], ["This study entailed comparison of FIV seropositive cats to FeLV seropositive cats with regard to known risk factors and explored the strength of their effects between the two infections.", [["infections", "DISEASE", 175, 185], ["FIV", "ORGANISM", 34, 37], ["cats", "ORGANISM", 51, 55], ["FeLV", "ORGANISM", 59, 63], ["cats", "ORGANISM", 77, 81], ["cats", "SPECIES", 51, 55], ["cats", "SPECIES", 77, 81], ["FIV", "SPECIES", 34, 37], ["This study", "TEST", 0, 10], ["FIV seropositive cats", "TREATMENT", 34, 55], ["FeLV seropositive cats", "TREATMENT", 59, 81], ["known risk factors", "PROBLEM", 97, 115], ["the two infections", "PROBLEM", 167, 185], ["infections", "OBSERVATION", 175, 185]]], ["Therefore, care should be taken before extrapolating results of this study to the general population with non-infected cats.", [["cats", "ORGANISM", 119, 123], ["cats", "SPECIES", 119, 123], ["this study", "TEST", 64, 74], ["non-infected cats", "TREATMENT", 106, 123]]], ["The risk factors that are common to both comparison groups tend to be underestimated or unidentified in a case-case study [11, 12] .", [["The risk factors", "PROBLEM", 0, 16]]], ["Since the study does not include a disease-free population, the odds ratios can only be interpreted as the odds of exposure to one disease group (FIV) in reference to the other (FeLV), and do not provide the estimate of the association between a risk factor and disease in the general population [42, 43] .ConclusionIn conclusion, while similar risk factors have been reported for both FIV and FeLV infection, this study demonstrated, through comparison of one infection with the other, that adulthood, being male (neutered or not) and having access to outdoors are of greater importance to FIV seropositivity compared to FeLV.", [["FIV and FeLV infection", "DISEASE", 386, 408], ["infection", "DISEASE", 461, 470], ["FeLV", "ORGANISM", 178, 182], ["FIV", "ORGANISM", 386, 389], ["FeLV", "ORGANISM", 394, 398], ["FIV", "ORGANISM", 591, 594], ["FeLV", "ORGANISM", 622, 626], ["FIV", "SPECIES", 146, 149], ["FIV", "SPECIES", 386, 389], ["FeLV", "SPECIES", 394, 398], ["FIV", "SPECIES", 591, 594], ["FeLV", "SPECIES", 622, 626], ["the study", "TEST", 6, 15], ["a disease-free population", "PROBLEM", 33, 58], ["a risk factor", "PROBLEM", 244, 257], ["disease", "PROBLEM", 262, 269], ["FIV", "PROBLEM", 386, 389], ["FeLV infection", "PROBLEM", 394, 408], ["this study", "TEST", 410, 420], ["one infection", "PROBLEM", 457, 470], ["FIV seropositivity", "PROBLEM", 591, 609], ["FeLV infection", "OBSERVATION", 394, 408], ["infection", "OBSERVATION", 461, 470]]], ["Clinical illness was a stronger predictor for FeLV seropositivity.", [["illness", "DISEASE", 9, 16], ["FeLV", "ORGANISM", 46, 50], ["FeLV", "SPECIES", 46, 50], ["Clinical illness", "PROBLEM", 0, 16], ["FeLV seropositivity", "PROBLEM", 46, 65]]], ["Further studies are warranted to assess the implications of these findings in regard to the management and control of these infections.Competing interestsThe authors declare that they have no competing interests.", [["infections", "DISEASE", 124, 134], ["Further studies", "TEST", 0, 15], ["the management", "TREATMENT", 88, 102], ["these infections", "PROBLEM", 118, 134], ["infections", "OBSERVATION", 124, 134]]]], "PMC7402059": [["The impact of COVID-19 on global public health and economy has been severe.", [["COVID-19", "CHEMICAL", 14, 22], ["COVID", "TREATMENT", 14, 19], ["severe", "OBSERVATION_MODIFIER", 68, 74]]], ["The etiological agent of COVID-19 is SARS-CoV-2, which shares ~78% genetic similarity with SARS-CoV, the virus that led to the SARS outbreak in 2003.", [["SARS-CoV", "DISEASE", 91, 99], ["SARS", "DISEASE", 127, 131], ["COVID-19", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 37, 47], ["SARS-CoV", "ORGANISM", 91, 99], ["SARS-CoV", "SPECIES", 91, 99], ["COVID", "TEST", 25, 30], ["SARS-CoV", "TEST", 37, 45], ["SARS", "PROBLEM", 91, 95], ["CoV", "PROBLEM", 96, 99], ["the virus", "PROBLEM", 101, 110], ["the SARS outbreak", "PROBLEM", 123, 140]]], ["Although coronavirus outbreaks such as COVID-19 are not unpredicted, the high mortality rate and the ease of transmission of SARS-CoV-2 is unprecedented.INTRODUCTIONCurrently there are few antivirals and no vaccines available for SARS-CoV-2.", [["coronavirus outbreaks", "DISEASE", 9, 30], ["SARS", "DISEASE", 125, 129], ["SARS", "DISEASE", 230, 234], ["coronavirus", "ORGANISM", 9, 20], ["SARS-CoV-2", "ORGANISM", 125, 135], ["SARS-CoV-2", "ORGANISM", 230, 240], ["coronavirus", "SPECIES", 9, 20], ["SARS-CoV", "SPECIES", 125, 133], ["SARS-CoV", "SPECIES", 230, 238], ["coronavirus outbreaks", "PROBLEM", 9, 30], ["COVID", "TEST", 39, 44], ["the high mortality rate", "PROBLEM", 69, 92], ["SARS", "PROBLEM", 125, 129], ["CoV", "TEST", 130, 133], ["few antivirals", "TREATMENT", 185, 199], ["vaccines", "TREATMENT", 207, 215], ["SARS", "TEST", 230, 234], ["CoV", "TEST", 235, 238]]], ["As such, it is imperative to identify drug targets that could lead to effective antivirals.", [["drug targets", "PROBLEM", 38, 50], ["effective antivirals", "TREATMENT", 70, 90]]], ["Guided by research of the similar coronaviruses, SARS-CoV and MERS-CoV, several viral proteins have been prioritized as SARS-CoV-2 antiviral drug targets: the spike protein, the RNA-dependent RNA polymerase (RdRp), the main protease (Mpro), and the papain-like protease (PLpro).1,2 The SARS-CoV-2 RdRp inhibitor remdesivir was granted emergency use authorization from FDA on May 1st 2020.", [["SARS", "DISEASE", 49, 53], ["remdesivir", "CHEMICAL", 312, 322], ["remdesivir", "CHEMICAL", 312, 322], ["coronaviruses", "ORGANISM", 34, 47], ["SARS-CoV", "ORGANISM", 49, 57], ["MERS-CoV", "ORGANISM", 62, 70], ["SARS-CoV-2", "ORGANISM", 120, 130], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 178, 206], ["RdRp", "GENE_OR_GENE_PRODUCT", 208, 212], ["Mpro", "GENE_OR_GENE_PRODUCT", 234, 238], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 249, 269], ["PLpro", "GENE_OR_GENE_PRODUCT", 271, 276], ["CoV-2", "ORGANISM", 291, 296], ["remdesivir", "SIMPLE_CHEMICAL", 312, 322], ["viral proteins", "PROTEIN", 80, 94], ["SARS-CoV-2 antiviral drug targets", "DNA", 120, 153], ["spike protein", "PROTEIN", 159, 172], ["RNA-dependent RNA polymerase", "PROTEIN", 178, 206], ["RdRp", "PROTEIN", 208, 212], ["protease", "PROTEIN", 224, 232], ["Mpro", "PROTEIN", 234, 238], ["papain-like protease", "PROTEIN", 249, 269], ["PLpro", "PROTEIN", 271, 276], ["SARS-CoV", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 62, 70], ["the similar coronaviruses", "PROBLEM", 22, 47], ["SARS", "PROBLEM", 49, 53], ["several viral proteins", "PROBLEM", 72, 94], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["the spike protein", "TEST", 155, 172], ["the RNA", "TEST", 174, 181], ["dependent RNA polymerase", "PROBLEM", 182, 206], ["the main protease (Mpro)", "TREATMENT", 215, 239], ["the papain", "TREATMENT", 245, 255], ["protease (PLpro)", "TREATMENT", 261, 277], ["The SARS", "TEST", 282, 290], ["CoV", "TEST", 291, 294], ["RdRp inhibitor remdesivir", "TREATMENT", 297, 322], ["coronaviruses", "OBSERVATION", 34, 47]]], ["Remdesivir has broad-spectrum antiviral activity against SARS-CoV, SARS-CoV-2, and MERS-CoV in cell culture.3\u20135 The antiviral efficacy was further confirmed in MERS-CoV infection mouse and rhesus macaque models.6,7 Additional RdRp inhibitors under investigation for SARS-CoV-2 include EIDD-2801, favipiravir (T-705), ribavirin, and galidesivir.8,9 The fusion inhibitor EK1C4, which was designed based on the H2 peptide in the S2 domain of the HCoV-OC43 spike protein, showed promising broad-spectrum antiviral activity against SARS-CoV-2, SARS-CoV, MERS-CoV, as well as human coronaviruses HCoV-229E, HCoV-NL63, and HCoV-OC43.10,11 Meanwhile, the Mpro has been extensively explored as a drug target for not only SARS-CoV-2, but also SARS-CoV, MERS-CoV, as well as enteroviruses, rhinoviruses, and noroviruses.12 Mpro is a viral encoded cysteine protease that has a unique preference for a glutamine residue at the P1 site in the substrate, which was recently confirmed for SARS-CoV-2 by substrate profiling.13 Consequently, the majority of designed Mpro inhibitors contain either 2-pyrrolidone or 2-piperidinone at the P1 site as a mimetic of the glutamine residue in the substrate.14 Examples include compounds N3, 13b, 11a, 11b, and our recently identified GC-376,15\u201318 all of which have potent enzymatic inhibition in biochemical assay and antiviral activity in cell culture.", [["cell culture", "ANATOMY", 95, 107], ["cell culture", "ANATOMY", 1365, 1377], ["Remdesivir", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 57, 61], ["3\u20135", "CHEMICAL", 108, 111], ["infection", "DISEASE", 169, 178], ["SARS", "DISEASE", 266, 270], ["EIDD-2801", "CHEMICAL", 285, 294], ["favipiravir", "CHEMICAL", 296, 307], ["T-705", "CHEMICAL", 309, 314], ["ribavirin", "CHEMICAL", 317, 326], ["galidesivir", "CHEMICAL", 332, 343], ["EK1C4", "CHEMICAL", 369, 374], ["Mpro", "CHEMICAL", 647, 651], ["enteroviruses", "DISEASE", 764, 777], ["rhinoviruses", "DISEASE", 779, 791], ["noroviruses", "DISEASE", 797, 808], ["glutamine", "CHEMICAL", 889, 898], ["2-pyrrolidone", "CHEMICAL", 1080, 1093], ["2-piperidinone", "CHEMICAL", 1097, 1111], ["glutamine", "CHEMICAL", 1147, 1156], ["Remdesivir", "CHEMICAL", 0, 10], ["EIDD-2801", "CHEMICAL", 285, 294], ["favipiravir", "CHEMICAL", 296, 307], ["T-705", "CHEMICAL", 309, 314], ["ribavirin", "CHEMICAL", 317, 326], ["galidesivir", "CHEMICAL", 332, 343], ["H2 peptide", "CHEMICAL", 408, 418], ["cysteine", "CHEMICAL", 836, 844], ["glutamine", "CHEMICAL", 889, 898], ["2-pyrrolidone", "CHEMICAL", 1080, 1093], ["2-piperidinone", "CHEMICAL", 1097, 1111], ["glutamine", "CHEMICAL", 1147, 1156], ["GC-376,15\u201318", "CHEMICAL", 1259, 1271], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV", "ORGANISM", 57, 65], ["SARS-CoV-2", "ORGANISM", 67, 77], ["MERS-CoV", "ORGANISM", 83, 91], ["cell culture", "CELL", 95, 107], ["MERS-CoV", "ORGANISM", 160, 168], ["mouse", "ORGANISM", 179, 184], ["rhesus", "ORGANISM", 189, 195], ["macaque", "ORGANISM", 196, 203], ["EIDD-2801", "SIMPLE_CHEMICAL", 285, 294], ["favipiravir", "SIMPLE_CHEMICAL", 296, 307], ["T-705", "SIMPLE_CHEMICAL", 309, 314], ["ribavirin", "SIMPLE_CHEMICAL", 317, 326], ["galidesivir", "SIMPLE_CHEMICAL", 332, 343], ["EK1C4", "SIMPLE_CHEMICAL", 369, 374], ["HCoV", "GENE_OR_GENE_PRODUCT", 443, 447], ["SARS-CoV-2", "ORGANISM", 527, 537], ["SARS-CoV", "ORGANISM", 539, 547], ["MERS-CoV", "ORGANISM", 549, 557], ["human", "ORGANISM", 570, 575], ["coronaviruses", "ORGANISM", 576, 589], ["HCoV-229E", "ORGANISM", 590, 599], ["HCoV-NL63", "CELL", 601, 610], ["HCoV-OC43", "CELL", 616, 625], ["Mpro", "GENE_OR_GENE_PRODUCT", 647, 651], ["SARS-CoV-2", "ORGANISM", 712, 722], ["SARS-CoV", "ORGANISM", 733, 741], ["MERS-CoV", "ORGANISM", 743, 751], ["enteroviruses", "ORGANISM", 764, 777], ["rhinoviruses", "ORGANISM", 779, 791], ["Mpro", "GENE_OR_GENE_PRODUCT", 812, 816], ["cysteine", "AMINO_ACID", 836, 844], ["glutamine", "AMINO_ACID", 889, 898], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 973, 983], ["Mpro", "GENE_OR_GENE_PRODUCT", 1049, 1053], ["2-pyrrolidone", "SIMPLE_CHEMICAL", 1080, 1093], ["2-piperidinone", "SIMPLE_CHEMICAL", 1097, 1111], ["glutamine", "AMINO_ACID", 1147, 1156], ["13b", "SIMPLE_CHEMICAL", 1216, 1219], ["11a, 11b", "SIMPLE_CHEMICAL", 1221, 1229], ["GC-376,15\u201318", "SIMPLE_CHEMICAL", 1259, 1271], ["cell culture", "CELL", 1365, 1377], ["S2 domain", "PROTEIN", 426, 435], ["HCoV", "PROTEIN", 443, 447], ["OC43 spike protein", "PROTEIN", 448, 466], ["Mpro", "DNA", 647, 651], ["Mpro", "PROTEIN", 812, 816], ["viral encoded cysteine protease", "PROTEIN", 822, 853], ["P1 site", "DNA", 914, 921], ["P1 site", "DNA", 1119, 1126], ["mouse", "SPECIES", 179, 184], ["rhesus macaque", "SPECIES", 189, 203], ["human", "SPECIES", 570, 575], ["SARS-CoV", "SPECIES", 57, 65], ["SARS-CoV", "SPECIES", 67, 75], ["MERS-CoV", "SPECIES", 83, 91], ["MERS-CoV", "SPECIES", 160, 168], ["mouse", "SPECIES", 179, 184], ["rhesus macaque", "SPECIES", 189, 203], ["SARS-CoV", "SPECIES", 266, 274], ["SARS-CoV", "SPECIES", 527, 535], ["SARS-CoV", "SPECIES", 539, 547], ["MERS-CoV", "SPECIES", 549, 557], ["human coronaviruses HCoV-229E", "SPECIES", 570, 599], ["HCoV", "SPECIES", 601, 605], ["HCoV-OC43", "SPECIES", 616, 625], ["SARS-CoV", "SPECIES", 712, 720], ["SARS-CoV", "SPECIES", 733, 741], ["MERS-CoV", "SPECIES", 743, 751], ["Remdesivir", "TREATMENT", 0, 10], ["broad-spectrum antiviral activity", "TREATMENT", 15, 48], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["MERS", "PROBLEM", 83, 87], ["CoV in cell culture", "TEST", 88, 107], ["The antiviral efficacy", "TREATMENT", 112, 134], ["CoV infection mouse", "PROBLEM", 165, 184], ["Additional RdRp inhibitors", "TREATMENT", 215, 241], ["SARS", "PROBLEM", 266, 270], ["CoV", "TEST", 271, 274], ["EIDD", "TREATMENT", 285, 289], ["favipiravir", "TREATMENT", 296, 307], ["ribavirin", "TREATMENT", 317, 326], ["galidesivir", "TREATMENT", 332, 343], ["The fusion inhibitor EK1C4", "TEST", 348, 374], ["the H2 peptide", "TEST", 404, 418], ["the HCoV", "TEST", 439, 447], ["OC43 spike protein", "TEST", 448, 466], ["SARS", "TEST", 527, 531], ["CoV", "TEST", 532, 535], ["SARS", "PROBLEM", 539, 543], ["CoV", "TEST", 544, 547], ["MERS", "TEST", 549, 553], ["CoV", "TEST", 554, 557], ["human coronaviruses HCoV", "TEST", 570, 594], ["HCoV", "TEST", 601, 605], ["HCoV", "TEST", 616, 620], ["SARS", "PROBLEM", 712, 716], ["CoV", "TEST", 717, 720], ["SARS", "PROBLEM", 733, 737], ["CoV", "PROBLEM", 738, 741], ["MERS", "PROBLEM", 743, 747], ["CoV", "PROBLEM", 748, 751], ["enteroviruses", "PROBLEM", 764, 777], ["rhinoviruses", "PROBLEM", 779, 791], ["noroviruses", "PROBLEM", 797, 808], ["a viral encoded cysteine protease", "PROBLEM", 820, 853], ["a glutamine residue at the P1 site", "PROBLEM", 887, 921], ["SARS", "PROBLEM", 973, 977], ["CoV", "TEST", 978, 981], ["designed Mpro inhibitors", "TREATMENT", 1040, 1064], ["pyrrolidone", "TREATMENT", 1082, 1093], ["piperidinone", "TREATMENT", 1099, 1111], ["the glutamine residue in the substrate", "PROBLEM", 1143, 1181], ["GC", "TEST", 1259, 1261], ["potent enzymatic inhibition", "PROBLEM", 1290, 1317], ["biochemical assay", "TEST", 1321, 1338], ["cell culture", "TEST", 1365, 1377], ["antiviral activity", "OBSERVATION", 30, 48], ["antiviral efficacy", "OBSERVATION", 116, 134], ["antiviral activity", "OBSERVATION", 500, 518], ["enteroviruses", "OBSERVATION", 764, 777], ["rhinoviruses", "OBSERVATION", 779, 791], ["noroviruses", "OBSERVATION", 797, 808], ["glutamine residue", "OBSERVATION", 889, 906], ["glutamine residue", "OBSERVATION", 1147, 1164], ["antiviral activity", "OBSERVATION", 1343, 1361]]], ["Their mechanism of action and mode of inhibition were revealed by the drug-bound X-ray crystal structures.15\u201318INTRODUCTIONInterestingly, our previous study discovered two un-conventional SARS-CoV-2 Mpro inhibitors, calpain inhibitors II and XII, that are structurally dissimilar to the traditional Mpro inhibitors, such as GC-376.15 Specifically, calpain inhibitors II and XII incorporate the hydrophobic methionine and norvaline side chains in the P1 position.", [["methionine", "CHEMICAL", 406, 416], ["norvaline", "CHEMICAL", 421, 430], ["methionine", "CHEMICAL", 406, 416], ["norvaline", "CHEMICAL", 421, 430], ["Mpro", "GENE_OR_GENE_PRODUCT", 199, 203], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 216, 237], ["XII", "GENE_OR_GENE_PRODUCT", 242, 245], ["Mpro", "SIMPLE_CHEMICAL", 299, 303], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 348, 369], ["XII", "GENE_OR_GENE_PRODUCT", 374, 377], ["methionine", "SIMPLE_CHEMICAL", 406, 416], ["norvaline side chains", "SIMPLE_CHEMICAL", 421, 442], ["calpain inhibitors II and XII", "PROTEIN", 216, 245], ["calpain inhibitors II and XII", "PROTEIN", 348, 377], ["hydrophobic methionine and norvaline side chains", "PROTEIN", 394, 442], ["our previous study", "TEST", 138, 156], ["CoV-2 Mpro inhibitors", "TREATMENT", 193, 214], ["calpain inhibitors", "TREATMENT", 216, 234], ["the traditional Mpro inhibitors", "TREATMENT", 283, 314], ["GC", "TEST", 324, 326], ["calpain inhibitors II", "TREATMENT", 348, 369], ["the hydrophobic methionine and norvaline side chains", "TREATMENT", 390, 442]]], ["This discovery challenges the idea that a hydrophilic glutamine mimetic is required at the P1 position.", [["glutamine", "CHEMICAL", 54, 63], ["glutamine", "CHEMICAL", 54, 63], ["glutamine", "AMINO_ACID", 54, 63], ["a hydrophilic glutamine mimetic", "TREATMENT", 40, 71]]], ["Furthermore, calpain inhibitor II is a potent inhibitor of human protease cathepsin L, with a Ki of 50 nM.19 Cathepsin L plays an important role in SARS-CoV-2 viral entry by activating the viral spike protein,20,2122 and has a relatively broad substrate preference at the P1 position on the substrate.23,24 Studies have indicated that cathepsin L inhibitors can block or significantly decrease virus entry.20,25 To dissect the mechanism of action of these two promising drug candidates, we solved the high-resolution X-ray crystal structures of Mpro with calpain inhibitors II and XII (Fig. 1).", [["inhibitor II", "CHEMICAL", 21, 33], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 13, 33], ["human", "ORGANISM", 59, 64], ["protease cathepsin L", "GENE_OR_GENE_PRODUCT", 65, 85], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 109, 120], ["SARS-CoV-2 viral", "ORGANISM", 148, 164], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 335, 346], ["Mpro", "SIMPLE_CHEMICAL", 545, 549], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 555, 576], ["XII", "GENE_OR_GENE_PRODUCT", 581, 584], ["calpain", "PROTEIN", 13, 20], ["human protease cathepsin L", "PROTEIN", 59, 85], ["Cathepsin L", "PROTEIN", 109, 120], ["viral spike protein", "PROTEIN", 189, 208], ["20,2122", "PROTEIN", 209, 216], ["P1 position", "PROTEIN", 272, 283], ["calpain inhibitors II and XII", "PROTEIN", 555, 584], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["calpain inhibitor II", "TREATMENT", 13, 33], ["human protease cathepsin L", "TREATMENT", 59, 85], ["a Ki", "TEST", 92, 96], ["SARS", "TEST", 148, 152], ["CoV", "TEST", 153, 156], ["the viral spike protein", "TEST", 185, 208], ["Studies", "TEST", 307, 314], ["cathepsin L inhibitors", "TREATMENT", 335, 357], ["significantly decrease virus entry", "PROBLEM", 371, 405], ["the high-resolution X-ray crystal structures", "TREATMENT", 497, 541], ["calpain inhibitors", "TREATMENT", 555, 573]]], ["We found that calpain inhibitor II is bound to Mpro in the canonical, extended conformation, but calpain inhibitor XII adopted an unexpected binding mode, where it assumes an inverted, semi-helical conformation in which the P1\u2019 pyridine ring is placed in the S1 pocket instead of the P1 norvaline sidechain, as one would expect.", [["pyridine", "CHEMICAL", 228, 236], ["pyridine", "CHEMICAL", 228, 236], ["norvaline", "CHEMICAL", 287, 296], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 14, 34], ["Mpro", "GENE_OR_GENE_PRODUCT", 47, 51], ["calpain", "GENE_OR_GENE_PRODUCT", 97, 104], ["XII", "GENE_OR_GENE_PRODUCT", 115, 118], ["calpain inhibitor II", "PROTEIN", 14, 34], ["Mpro", "PROTEIN", 47, 51], ["calpain", "PROTEIN", 97, 104], ["XII", "PROTEIN", 115, 118], ["S1 pocket", "PROTEIN", 259, 268], ["calpain inhibitor II", "TREATMENT", 14, 34], ["calpain inhibitor XII", "TREATMENT", 97, 118], ["an inverted, semi-helical conformation", "PROBLEM", 172, 210], ["the P1\u2019 pyridine ring", "TREATMENT", 220, 241], ["the P1 norvaline sidechain", "TREATMENT", 280, 306], ["S1", "ANATOMY", 259, 261], ["pocket", "ANATOMY_MODIFIER", 262, 268]]], ["The complex structures of calpain inhibitors II and XII, together with the structure-activity relationship studies of calpain inhibitors II/XII, revealed the S1 pocket of Mpro can accommodate both hydrophilic and hydrophobic substitutions, paving the way for the design of dual inhibitors that target both the viral Mpro and host cathepsin L. Finally, guided by the X-ray crystal structure of SARSA-CoV-2 Mpro with GC-376 (PDB: 6WTT),15 three analogs UAWJ246, UAWJ247, and UAWJ248 were designed to profile the sidechain preferences of the S1\u2019, S2, S3 and S4 pockets.", [["Mpro", "CHEMICAL", 171, 175], ["GC-376", "CHEMICAL", 415, 421], ["UAWJ246", "CHEMICAL", 451, 458], ["UAWJ247", "CHEMICAL", 460, 467], ["UAWJ248", "CHEMICAL", 473, 480], ["UAWJ246", "CHEMICAL", 451, 458], ["UAWJ247", "CHEMICAL", 460, 467], ["UAWJ248", "CHEMICAL", 473, 480], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 26, 47], ["XII", "GENE_OR_GENE_PRODUCT", 52, 55], ["calpain", "GENE_OR_GENE_PRODUCT", 118, 125], ["XII", "GENE_OR_GENE_PRODUCT", 140, 143], ["Mpro", "SIMPLE_CHEMICAL", 171, 175], ["Mpro", "GENE_OR_GENE_PRODUCT", 316, 320], ["cathepsin L.", "GENE_OR_GENE_PRODUCT", 330, 342], ["GC-376", "SIMPLE_CHEMICAL", 415, 421], ["UAWJ246", "SIMPLE_CHEMICAL", 451, 458], ["UAWJ247", "SIMPLE_CHEMICAL", 460, 467], ["UAWJ248", "SIMPLE_CHEMICAL", 473, 480], ["calpain inhibitors II and XII", "PROTEIN", 26, 55], ["calpain inhibitors II/XII", "PROTEIN", 118, 143], ["Mpro", "PROTEIN", 171, 175], ["viral Mpro", "PROTEIN", 310, 320], ["SARSA", "PROTEIN", 393, 398], ["CoV", "PROTEIN", 399, 402], ["Mpro", "PROTEIN", 405, 409], ["S1\u2019, S2, S3 and S4 pockets", "PROTEIN", 539, 565], ["calpain inhibitors", "TREATMENT", 26, 44], ["calpain inhibitors", "TREATMENT", 118, 136], ["the S1 pocket of Mpro", "PROBLEM", 154, 175], ["both hydrophilic and hydrophobic substitutions", "PROBLEM", 192, 238], ["dual inhibitors", "TREATMENT", 273, 288], ["host cathepsin L.", "TREATMENT", 325, 342], ["the X-ray crystal structure", "TEST", 362, 389], ["SARSA", "TEST", 393, 398], ["CoV", "TEST", 399, 402], ["GC", "TEST", 415, 417], ["PDB", "TEST", 423, 426], ["UAWJ247", "TEST", 460, 467], ["S3 and S4 pockets", "PROBLEM", 548, 565], ["hydrophilic", "OBSERVATION_MODIFIER", 197, 208], ["hydrophobic substitutions", "OBSERVATION", 213, 238], ["S1\u2019", "ANATOMY", 539, 542], ["S2", "ANATOMY", 544, 546], ["S3", "ANATOMY_MODIFIER", 548, 550], ["S4 pockets", "OBSERVATION", 555, 565]]], ["The X-ray crystal structures and activity profile presented herein offer valuable insights into the substrate promiscuity of Mpro, as well as the design of new SARS-CoV-2 Mpro inhibitors.SARS-CoV-2 Mpro constructs used in this study ::: RESULTS AND DISCUSSIONThree Mpro constructs were used in this study: the tag-free native Mpro (Mpro), Mpro with two extra residues: histidine and methionine at the N-terminus (HM-Mpro), the Mpro with a native Nterminus, and a C-terminal his-tag (Mpro-His).", [["Mpro", "CHEMICAL", 125, 129], ["SARS", "DISEASE", 187, 191], ["histidine", "CHEMICAL", 369, 378], ["methionine", "CHEMICAL", 383, 393], ["histidine", "CHEMICAL", 369, 378], ["methionine", "CHEMICAL", 383, 393], ["N", "CHEMICAL", 401, 402], ["C", "CHEMICAL", 463, 464], ["His", "CHEMICAL", 488, 491], ["Mpro", "SIMPLE_CHEMICAL", 125, 129], ["Mpro", "GENE_OR_GENE_PRODUCT", 171, 175], ["Mpro", "GENE_OR_GENE_PRODUCT", 326, 330], ["Mpro", "GENE_OR_GENE_PRODUCT", 332, 336], ["Mpro", "GENE_OR_GENE_PRODUCT", 339, 343], ["histidine", "AMINO_ACID", 369, 378], ["methionine", "AMINO_ACID", 383, 393], ["Mpro-His", "GENE_OR_GENE_PRODUCT", 483, 491], ["Mpro", "PROTEIN", 125, 129], ["SARS-CoV-2 Mpro constructs", "DNA", 187, 213], ["Mpro constructs", "DNA", 265, 280], ["tag", "PROTEIN", 310, 313], ["native Mpro", "PROTEIN", 319, 330], ["Mpro", "PROTEIN", 332, 336], ["Mpro", "PROTEIN", 339, 343], ["N-terminus", "PROTEIN", 401, 411], ["HM", "PROTEIN", 413, 415], ["Mpro", "PROTEIN", 416, 420], ["Mpro", "PROTEIN", 427, 431], ["Nterminus", "PROTEIN", 446, 455], ["C-terminal his-tag", "PROTEIN", 463, 481], ["Mpro", "PROTEIN", 483, 487], ["His", "PROTEIN", 488, 491], ["The X-ray crystal structures", "TEST", 0, 28], ["new SARS", "TEST", 156, 164], ["CoV", "TEST", 165, 168], ["2 Mpro inhibitors", "TREATMENT", 169, 186], ["SARS", "TEST", 187, 191], ["this study", "TEST", 294, 304], ["the tag", "TEST", 306, 313], ["histidine", "TREATMENT", 369, 378], ["methionine", "TREATMENT", 383, 393]]], ["The tag-free Mpro was used for all functional assays, while the other two constructs were used for structure determination due to ease of crystallization.", [["Mpro", "SIMPLE_CHEMICAL", 13, 17], ["tag-free Mpro", "PROTEIN", 4, 17], ["all functional assays", "TEST", 31, 52], ["structure determination", "TEST", 99, 122], ["crystallization", "PROBLEM", 138, 153]]], ["The HM-Mpro construct was used for the complex structures of all five compounds including calpain inhibitors II and XII, UAWJ246, UAWJ247, and UAWJ248.", [["UAWJ248", "CHEMICAL", 143, 150], ["UAWJ246", "CHEMICAL", 121, 128], ["UAWJ247", "CHEMICAL", 130, 137], ["UAWJ248", "CHEMICAL", 143, 150], ["calpain", "GENE_OR_GENE_PRODUCT", 90, 97], ["XII", "GENE_OR_GENE_PRODUCT", 116, 119], ["UAWJ246", "SIMPLE_CHEMICAL", 121, 128], ["UAWJ247", "SIMPLE_CHEMICAL", 130, 137], ["UAWJ248", "SIMPLE_CHEMICAL", 143, 150], ["HM-Mpro construct", "DNA", 4, 21], ["Mpro construct", "TREATMENT", 7, 21], ["the complex structures", "PROBLEM", 35, 57], ["XII", "TEST", 116, 119], ["UAWJ246", "TEST", 121, 128], ["UAWJ247", "TEST", 130, 137]]], ["In addition, the Mpro-His construct was also co-crystallized with UAWJ246 as a control for the potential influence of extra HM residues of the N-terminus.SARS-CoV-2 Mpro constructs used in this study ::: RESULTS AND DISCUSSIONThe Mpro-His and the native Mpro have similar enzymatic activity with kcat/Km values of 6,689 s\u22121M\u22121, 5,748 s\u22121M\u22121, respectively (Supplementary Fig. S1a).", [["UAWJ246", "CHEMICAL", 66, 73], ["SARS", "DISEASE", 154, 158], ["His", "CHEMICAL", 22, 25], ["UAWJ246", "CHEMICAL", 66, 73], ["Mpro", "GENE_OR_GENE_PRODUCT", 17, 21], ["UAWJ246", "SIMPLE_CHEMICAL", 66, 73], ["Mpro-His", "GENE_OR_GENE_PRODUCT", 230, 238], ["Mpro", "GENE_OR_GENE_PRODUCT", 254, 258], ["Mpro-His construct", "DNA", 17, 35], ["N-terminus", "PROTEIN", 143, 153], ["SARS-CoV-2 Mpro constructs", "DNA", 154, 180], ["native Mpro", "PROTEIN", 247, 258], ["UAWJ246", "TREATMENT", 66, 73], ["extra HM residues of the N-terminus", "PROBLEM", 118, 153], ["SARS", "TEST", 154, 158], ["Mpro", "TEST", 230, 234], ["kcat", "TEST", 296, 300], ["Km values", "TEST", 301, 310], ["extra HM residues", "OBSERVATION", 118, 135], ["enzymatic activity", "OBSERVATION", 272, 290]]], ["The HM-Mpro construct has significantly reduced enzymatic activity with a kcat/Km value of 214 s\u22121M\u22121, which is about 3.7% of the Mpro (kcat/Km = 5,748 s\u22121M\u22121) (Supplementary Fig. S1a).", [["HM-Mpro", "GENE_OR_GENE_PRODUCT", 4, 11], ["HM-Mpro construct", "DNA", 4, 21], ["significantly reduced enzymatic activity", "PROBLEM", 26, 66], ["a kcat/Km value", "TEST", 72, 87], ["the Mpro", "TEST", 126, 134], ["kcat", "TEST", 136, 140], ["Km", "TEST", 141, 143], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["reduced", "OBSERVATION_MODIFIER", 40, 47], ["enzymatic activity", "OBSERVATION", 48, 66]]], ["This was expected as it has been shown that Mpro requires dimerization to be catalytically active and the N-terminal finger plays an essential role in dimerization.26 Specifically, the first residue serine (Ser1) from one protomer interacts with the Glu166 of the adjacent protomer, a feature that is important for catalytic activity (Supplementary Fig. S1b).", [["Mpro", "CHEMICAL", 44, 48], ["N", "CHEMICAL", 106, 107], ["serine", "CHEMICAL", 199, 205], ["Mpro", "GENE_OR_GENE_PRODUCT", 44, 48], ["serine", "AMINO_ACID", 199, 205], ["Ser1", "AMINO_ACID", 207, 211], ["Glu166", "GENE_OR_GENE_PRODUCT", 250, 256], ["Mpro", "PROTEIN", 44, 48], ["N-terminal finger", "PROTEIN", 106, 123], ["Glu166", "PROTEIN", 250, 256], ["adjacent protomer", "PROTEIN", 264, 281], ["catalytically active", "PROBLEM", 77, 97]]], ["Nevertheless, the HM-Mpro turned out to be an excellent construct for crystallization, and we were able to determine several high-resolution drug-bound X-ray crystal structures.", [["X", "PROTEIN", 152, 153], ["the HM", "TEST", 14, 20]]], ["In contrast, efforts to obtain high-quality crystals with the Mpro-His construct was challenging, because of the localization of the disordered His-tag at the crystal packing interface.15 To validate the relevance of the use of the enzymatic inactive HM-Mpro construct for the crystallization, we crystalized UAWJ246 with both the HM-Mpro and Mpro-His constructs, and the binding pose of UAWJ246 in these two constructs was nearly superimposable (Supplementary information, S3).", [["UAWJ246", "CHEMICAL", 309, 316], ["UAWJ246", "CHEMICAL", 388, 395], ["Mpro-His", "CHEMICAL", 62, 70], ["His", "CHEMICAL", 144, 147], ["UAWJ246", "CHEMICAL", 309, 316], ["His", "CHEMICAL", 348, 351], ["UAWJ246", "CHEMICAL", 388, 395], ["UAWJ246", "SIMPLE_CHEMICAL", 309, 316], ["UAWJ246", "SIMPLE_CHEMICAL", 388, 395], ["Mpro-His construct", "DNA", 62, 80], ["disordered His-tag", "PROTEIN", 133, 151], ["enzymatic inactive HM-Mpro construct", "DNA", 232, 268], ["HM-Mpro and Mpro-His constructs", "DNA", 331, 362], ["UAWJ246", "PROTEIN", 388, 395], ["the enzymatic inactive HM", "TREATMENT", 228, 253], ["packing interface", "OBSERVATION", 167, 184]]], ["Several previous studies similarly used the enzymatically inactive Mpro with extra residues at the N-terminus for the structural studies, and the ligand binding poses were identical to those with tag-free Mpro (e.g., PDB 7BRP vs 6WNP, 6WTJ vs 6L70).27 Therefore, the use of enzymatic inactive HM-Mpro construct for crystallographic study of inhibitor binding is justified.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONPrevious studies have shown SARS-CoV and SARS-CoV-2 Mpro cleave polyproteins at P2-P1 \u2193 P1\u2019 where P1\u2019 is a residue with a small side chain (Ala, Ser, or Gly), P1 is glutamine and P2 is a large, hydrophobic residue, such as leucine or phenylalanine.13,28,29 This consensus sequence has operated as the foundation for extensive inhibitor designs where a reactive warhead, usually an aldehyde, \u03b1,\u03b2-unsaturated ester, or \u03b1-ketoamide, is linked to a glutamine surrogate pyrrolidone that is connected to a hydrophobic residue via an amide bond.12,30\u201332 This strategy has been largely successful, with the development of inhibitors such as GC-376 and 13b that have IC50 values in the low nM range for SARS-CoV-2 Mpro.15,17X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONWe recently reported calpain inhibitors II and XII and boceprevir have low \u03bcM IC50 values against SARS-CoV-2 Mpro.15 Importantly, these compounds have a hydrophobic side chain at the P1 position, challenging the notion that a hydrophilic moiety is required at this position (Table 1).", [["glutamine", "CHEMICAL", 654, 663], ["leucine", "CHEMICAL", 712, 719], ["phenylalanine", "CHEMICAL", 723, 736], ["13,28,29", "CHEMICAL", 737, 745], ["aldehyde", "CHEMICAL", 870, 878], ["\u03b1,\u03b2-unsaturated ester", "CHEMICAL", 880, 901], ["\u03b1-ketoamide", "CHEMICAL", 906, 917], ["glutamine", "CHEMICAL", 934, 943], ["pyrrolidone", "CHEMICAL", 954, 965], ["12,30\u201332", "CHEMICAL", 1027, 1035], ["boceprevir", "CHEMICAL", 1376, 1386], ["N", "CHEMICAL", 99, 100], ["Ala", "CHEMICAL", 629, 632], ["Ser", "CHEMICAL", 634, 637], ["Gly", "CHEMICAL", 642, 645], ["glutamine", "CHEMICAL", 654, 663], ["leucine", "CHEMICAL", 712, 719], ["phenylalanine", "CHEMICAL", 723, 736], ["aldehyde", "CHEMICAL", 870, 878], ["\u03b1,\u03b2-unsaturated ester", "CHEMICAL", 880, 901], ["\u03b1-ketoamide", "CHEMICAL", 906, 917], ["glutamine", "CHEMICAL", 934, 943], ["pyrrolidone", "CHEMICAL", 954, 965], ["amide", "CHEMICAL", 1016, 1021], ["boceprevir", "CHEMICAL", 1376, 1386], ["Mpro", "SIMPLE_CHEMICAL", 67, 71], ["Mpro", "SIMPLE_CHEMICAL", 205, 209], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 400, 415], ["calpain", "GENE_OR_GENE_PRODUCT", 432, 439], ["SARS-CoV", "ORGANISM", 517, 525], ["SARS-CoV-2", "ORGANISM", 530, 540], ["Mpro", "GENE_OR_GENE_PRODUCT", 541, 545], ["Ala", "AMINO_ACID", 629, 632], ["Ser", "AMINO_ACID", 634, 637], ["Gly", "AMINO_ACID", 642, 645], ["glutamine", "AMINO_ACID", 654, 663], ["P2", "AMINO_ACID", 668, 670], ["leucine", "AMINO_ACID", 712, 719], ["phenylalanine", "AMINO_ACID", 723, 736], ["aldehyde", "SIMPLE_CHEMICAL", 870, 878], ["\u03b1,\u03b2-unsaturated ester", "SIMPLE_CHEMICAL", 880, 901], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 906, 917], ["glutamine surrogate pyrrolidone", "SIMPLE_CHEMICAL", 934, 965], ["GC-376", "SIMPLE_CHEMICAL", 1122, 1128], ["13b", "SIMPLE_CHEMICAL", 1133, 1136], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 1264, 1285], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 1342, 1363], ["XII", "GENE_OR_GENE_PRODUCT", 1368, 1371], ["boceprevir", "SIMPLE_CHEMICAL", 1376, 1386], ["enzymatically inactive Mpro", "PROTEIN", 44, 71], ["N-terminus", "PROTEIN", 99, 109], ["tag", "PROTEIN", 196, 199], ["Mpro", "PROTEIN", 205, 209], ["7BRP", "PROTEIN", 221, 225], ["6WNP", "PROTEIN", 229, 233], ["6WTJ", "PROTEIN", 235, 239], ["6L70", "PROTEIN", 243, 247], ["enzymatic inactive HM-Mpro construct", "DNA", 274, 310], ["Mpro", "PROTEIN", 411, 415], ["calpain inhibitors II and XII", "PROTEIN", 432, 461], ["SARS-CoV and SARS-CoV-2 Mpro cleave polyproteins", "PROTEIN", 517, 565], ["P2", "DNA", 569, 571], ["P1", "DNA", 572, 574], ["P1", "DNA", 577, 579], ["P1", "DNA", 587, 589], ["consensus sequence", "DNA", 751, 769], ["Mpro", "PROTEIN", 1243, 1247], ["calpain inhibitors II and XII", "PROTEIN", 1264, 1293], ["XII", "PROTEIN", 1368, 1371], ["SARS-CoV", "SPECIES", 517, 525], ["SARS-CoV", "SPECIES", 1419, 1427], ["Several previous studies", "TEST", 0, 24], ["extra residues", "PROBLEM", 77, 91], ["the structural studies", "TEST", 114, 136], ["tag", "TEST", 196, 199], ["PDB", "TEST", 217, 220], ["enzymatic inactive HM", "TREATMENT", 274, 295], ["Mpro construct", "TREATMENT", 296, 310], ["crystallographic study", "TEST", 315, 337], ["inhibitor binding", "PROBLEM", 341, 358], ["X-ray crystal structures", "TEST", 372, 396], ["SARS", "PROBLEM", 400, 404], ["CoV", "TEST", 405, 408], ["calpain inhibitors", "TREATMENT", 432, 450], ["DISCUSSIONPrevious studies", "TEST", 479, 505], ["SARS", "PROBLEM", 517, 521], ["CoV", "TEST", 522, 525], ["SARS", "TEST", 530, 534], ["CoV", "TEST", 535, 538], ["Mpro cleave polyproteins", "TREATMENT", 541, 565], ["a residue", "PROBLEM", 594, 603], ["a small side chain", "PROBLEM", 609, 627], ["Ala, Ser, or Gly)", "TEST", 629, 646], ["glutamine", "TEST", 654, 663], ["a large, hydrophobic residue", "PROBLEM", 674, 702], ["leucine or phenylalanine", "TREATMENT", 712, 736], ["This consensus sequence", "TEST", 746, 769], ["extensive inhibitor designs", "TREATMENT", 805, 832], ["a reactive warhead", "PROBLEM", 839, 857], ["\u03b1-ketoamide", "TREATMENT", 906, 917], ["a glutamine surrogate pyrrolidone", "TREATMENT", 932, 965], ["a hydrophobic residue", "PROBLEM", 987, 1008], ["an amide bond", "TREATMENT", 1013, 1026], ["inhibitors", "TREATMENT", 1103, 1113], ["GC", "TEST", 1122, 1124], ["IC50 values", "TEST", 1147, 1158], ["SARS", "TEST", 1183, 1187], ["CoV", "TEST", 1188, 1191], ["Mpro", "TEST", 1194, 1198], ["SARS", "PROBLEM", 1232, 1236], ["CoV", "TEST", 1237, 1240], ["calpain inhibitors", "TREATMENT", 1264, 1282], ["calpain inhibitors", "TREATMENT", 1342, 1360], ["boceprevir", "TREATMENT", 1376, 1386], ["IC50 values", "TEST", 1399, 1410], ["SARS", "PROBLEM", 1419, 1423], ["CoV", "TEST", 1424, 1427], ["a hydrophobic side chain", "TREATMENT", 1472, 1496], ["a hydrophilic moiety", "TREATMENT", 1545, 1565], ["SARS", "OBSERVATION", 400, 404], ["small", "OBSERVATION_MODIFIER", 611, 616], ["large", "OBSERVATION_MODIFIER", 676, 681], ["hydrophobic residue", "OBSERVATION", 683, 702], ["reactive", "OBSERVATION_MODIFIER", 841, 849], ["largely", "OBSERVATION_MODIFIER", 1059, 1066], ["successful", "OBSERVATION", 1067, 1077], ["low nM", "OBSERVATION_MODIFIER", 1166, 1172], ["hydrophilic moiety", "OBSERVATION", 1547, 1565]]], ["This has previously been demonstrated with SARS-CoV Mpro, where the aldehyde inhibitor Cm-FF-H binds with a Ki of 2.24 \u00b1 0.58 \u03bcM despite having a phenylalanine at the P1 position.33 The observed substrate plasticity is in part attributed to the reactivity of the electrophilic warhead aldehyde with the catalytic cysteine, which offsets the requirement for favorable interactions with the hydrophilic S1 subsite.", [["aldehyde", "CHEMICAL", 68, 76], ["Cm-FF-H", "CHEMICAL", 87, 94], ["phenylalanine", "CHEMICAL", 146, 159], ["aldehyde", "CHEMICAL", 285, 293], ["cysteine", "CHEMICAL", 313, 321], ["aldehyde", "CHEMICAL", 68, 76], ["Cm-FF-H", "CHEMICAL", 87, 94], ["phenylalanine", "CHEMICAL", 146, 159], ["aldehyde", "CHEMICAL", 285, 293], ["cysteine", "CHEMICAL", 313, 321], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 43, 56], ["aldehyde", "SIMPLE_CHEMICAL", 68, 76], ["Cm-FF-H", "SIMPLE_CHEMICAL", 87, 94], ["phenylalanine", "AMINO_ACID", 146, 159], ["aldehyde", "SIMPLE_CHEMICAL", 285, 293], ["cysteine", "AMINO_ACID", 313, 321], ["hydrophilic S1 subsite", "PROTEIN", 389, 411], ["SARS-CoV", "SPECIES", 43, 51], ["the aldehyde inhibitor Cm", "TEST", 64, 89], ["a Ki", "TEST", 106, 110], ["a phenylalanine at the P1 position", "TREATMENT", 144, 178], ["the catalytic cysteine", "TREATMENT", 299, 321], ["the hydrophilic S1 subsite", "PROBLEM", 385, 411], ["substrate plasticity", "OBSERVATION", 195, 215], ["electrophilic warhead", "OBSERVATION", 263, 284], ["catalytic cysteine", "OBSERVATION", 303, 321]]], ["Furthermore, it introduces the prospect of modifying the P1 residue so that it interacts with multiple host or viral protease enzymes that are essential for promoting SARS-CoV-2 viral entry or replication, which would increase antiviral spectrum and genetic barrier to resistance.", [["SARS-CoV-2", "ORGANISM", 167, 177], ["viral protease enzymes", "PROTEIN", 111, 133], ["modifying the P1 residue", "TREATMENT", 43, 67], ["viral protease enzymes", "TEST", 111, 133], ["promoting SARS", "PROBLEM", 157, 171], ["CoV", "TEST", 172, 175], ["antiviral spectrum", "TREATMENT", 227, 245], ["genetic barrier", "TREATMENT", 250, 265]]], ["To visualize the interactions between the P1 site and the hydrophobic S1 residue, we solved the complex structures of SARS-CoV-2 Mpro with calpain inhibitor II and calpain inhibitor XII.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONThe crystal structures of the SARS-CoV-2 HM-Mpro in complex with calpain inhibitors II (PDB: 6XA4) and XII (PDB: 6XFN) were solved in the C2 space group at 1.65 and 1.70 \u00c5 resolution respectively, with one protomer per asymmetric unit (Fig. 1, Supplementary Table 1).", [["SARS", "DISEASE", 118, 122], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 139, 159], ["calpain inhibitor XII", "GENE_OR_GENE_PRODUCT", 164, 185], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 214, 229], ["calpain", "GENE_OR_GENE_PRODUCT", 246, 253], ["calpain inhibitors II", "SIMPLE_CHEMICAL", 368, 389], ["PDB: 6XA4", "SIMPLE_CHEMICAL", 391, 400], ["XII (PDB: 6XFN", "SIMPLE_CHEMICAL", 406, 420], ["P1 site", "DNA", 42, 49], ["hydrophobic S1 residue", "PROTEIN", 58, 80], ["SARS-CoV-2 Mpro", "PROTEIN", 118, 133], ["calpain inhibitor II", "PROTEIN", 139, 159], ["calpain inhibitor XII", "PROTEIN", 164, 185], ["Mpro", "PROTEIN", 225, 229], ["calpain inhibitors II and XII", "PROTEIN", 246, 275], ["HM", "PROTEIN", 344, 346], ["Mpro", "PROTEIN", 347, 351], ["calpain inhibitors II", "PROTEIN", 368, 389], ["XII", "PROTEIN", 406, 409], ["PDB: 6XFN", "PROTEIN", 411, 420], ["C2 space group", "PROTEIN", 441, 455], ["the interactions between the P1 site", "PROBLEM", 13, 49], ["the hydrophobic S1 residue", "PROBLEM", 54, 80], ["SARS", "PROBLEM", 118, 122], ["CoV", "TEST", 123, 126], ["calpain inhibitor II", "TREATMENT", 139, 159], ["calpain inhibitor XII", "TREATMENT", 164, 185], ["X-ray crystal structures", "TEST", 186, 210], ["SARS", "PROBLEM", 214, 218], ["CoV", "TEST", 219, 222], ["calpain inhibitors", "TREATMENT", 246, 264], ["the SARS", "TEST", 329, 337], ["CoV", "TEST", 338, 341], ["Mpro", "TREATMENT", 347, 351], ["calpain inhibitors", "TREATMENT", 368, 386], ["hydrophobic S1 residue", "OBSERVATION", 58, 80], ["SARS", "OBSERVATION", 214, 218], ["crystal", "OBSERVATION_MODIFIER", 307, 314], ["SARS", "OBSERVATION", 333, 337], ["C2", "ANATOMY", 441, 443]]], ["Like other peptidomimetic aldehyde inhibitors, the thiohemiacetal of calpain inhibitor II occupies the oxyanion hole formed by the backbone amide groups of Gly143, Ser144, and Cys145 (Fig. 1a).", [["aldehyde", "CHEMICAL", 26, 34], ["thiohemiacetal", "CHEMICAL", 51, 65], ["inhibitor II", "CHEMICAL", 77, 89], ["aldehyde", "CHEMICAL", 26, 34], ["thiohemiacetal", "CHEMICAL", 51, 65], ["amide", "CHEMICAL", 140, 145], ["Gly143", "CHEMICAL", 156, 162], ["Ser144", "CHEMICAL", 164, 170], ["Cys145", "CHEMICAL", 176, 182], ["aldehyde", "SIMPLE_CHEMICAL", 26, 34], ["thiohemiacetal", "SIMPLE_CHEMICAL", 51, 65], ["calpain inhibitor II", "SIMPLE_CHEMICAL", 69, 89], ["Gly143", "SIMPLE_CHEMICAL", 156, 162], ["Ser144", "AMINO_ACID", 164, 170], ["Cys145", "AMINO_ACID", 176, 182], ["Fig. 1a", "GENE_OR_GENE_PRODUCT", 184, 191], ["calpain inhibitor II", "PROTEIN", 69, 89], ["other peptidomimetic aldehyde inhibitors", "TREATMENT", 5, 45], ["the thiohemiacetal of calpain inhibitor II", "TREATMENT", 47, 89], ["the oxyanion hole", "TREATMENT", 99, 116], ["peptidomimetic", "OBSERVATION", 11, 25], ["aldehyde inhibitors", "OBSERVATION", 26, 45], ["oxyanion hole", "OBSERVATION", 103, 116]]], ["Here it adopts the (S) configuration, which is typical for most Mpro aldehyde inhibitors, although the (R) configuration has also been observed.15,34 Like previous Mpro and cathepsin L complex structures, the body of the inhibitor extends the length of the substrate-binding channel, with the side chains placed in their respective recognition pockets.", [["body", "ANATOMY", 209, 213], ["Mpro aldehyde", "CHEMICAL", 64, 77], ["Mpro aldehyde", "CHEMICAL", 64, 77], ["Mpro aldehyde", "SIMPLE_CHEMICAL", 64, 77], ["Mpro", "GENE_OR_GENE_PRODUCT", 164, 168], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 173, 184], ["body", "ORGANISM_SUBDIVISION", 209, 213], ["Mpro", "PROTEIN", 164, 168], ["cathepsin L complex", "PROTEIN", 173, 192], ["substrate-binding channel", "PROTEIN", 257, 282], ["side chains", "PROTEIN", 293, 304], ["most Mpro aldehyde inhibitors", "TREATMENT", 59, 88], ["cathepsin L complex structures", "TREATMENT", 173, 203], ["the inhibitor", "TREATMENT", 217, 230], ["the side chains", "TREATMENT", 289, 304], ["aldehyde inhibitors", "OBSERVATION", 69, 88], ["cathepsin L", "OBSERVATION_MODIFIER", 173, 184], ["complex", "OBSERVATION_MODIFIER", 185, 192], ["body", "ANATOMY_MODIFIER", 209, 213], ["length", "OBSERVATION_MODIFIER", 243, 249], ["binding channel", "OBSERVATION", 267, 282], ["recognition pockets", "OBSERVATION", 332, 351]]], ["The P1 methionine side chain projects into the S1 subsite where the sulfur forms a hydrogen bond (HB) with His163.", [["methionine", "CHEMICAL", 7, 17], ["sulfur", "CHEMICAL", 68, 74], ["His163", "CHEMICAL", 107, 113], ["methionine", "CHEMICAL", 7, 17], ["sulfur", "CHEMICAL", 68, 74], ["hydrogen", "CHEMICAL", 83, 91], ["His", "CHEMICAL", 107, 110], ["sulfur", "SIMPLE_CHEMICAL", 68, 74], ["P1 methionine side chain", "PROTEIN", 4, 28], ["S1 subsite", "PROTEIN", 47, 57], ["The P1 methionine side chain", "TREATMENT", 0, 28], ["S1", "ANATOMY", 47, 49], ["hydrogen bond", "OBSERVATION", 83, 96]]], ["The P2 valine side chain forms hydrophobic interactions in the S2 pocket, while the P3 valine occupies the solvent-accessible S3 position.", [["P2 valine", "CHEMICAL", 4, 13], ["valine", "CHEMICAL", 7, 13], ["valine", "CHEMICAL", 87, 93], ["valine", "AMINO_ACID", 87, 93], ["P2 valine side chain", "PROTEIN", 4, 24], ["S2 pocket", "PROTEIN", 63, 72], ["P3 valine", "PROTEIN", 84, 93], ["solvent-accessible S3 position", "PROTEIN", 107, 137], ["The P2 valine side chain", "TREATMENT", 0, 24], ["hydrophobic interactions in the S2 pocket", "PROBLEM", 31, 72], ["the P3 valine", "TEST", 80, 93], ["hydrophobic interactions", "OBSERVATION", 31, 55], ["S2", "ANATOMY", 63, 65], ["pocket", "ANATOMY_MODIFIER", 66, 72], ["accessible S3", "OBSERVATION", 115, 128], ["position", "OBSERVATION_MODIFIER", 129, 137]]], ["Multiple hydrogen bonds form between the amide backbone and the main chains of His164, Met165, and Glu166.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONIn contrast to the pose of calpain inhibitor II, calpain inhibitor XII demonstrates an atypical binding mode where it adopts an inverted, semi-helical conformation that wraps around the catalytic core (PDB: 6XFN) (Fig. 1b).", [["Glu166", "CHEMICAL", 99, 105], ["hydrogen", "CHEMICAL", 9, 17], ["amide", "CHEMICAL", 41, 46], ["His", "CHEMICAL", 79, 82], ["Met", "CHEMICAL", 87, 90], ["Glu", "CHEMICAL", 99, 102], ["His164", "AMINO_ACID", 79, 85], ["Met165", "AMINO_ACID", 87, 93], ["Glu166", "AMINO_ACID", 99, 105], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 134, 149], ["calpain", "GENE_OR_GENE_PRODUCT", 166, 173], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 250, 270], ["calpain", "GENE_OR_GENE_PRODUCT", 272, 279], ["XII", "GENE_OR_GENE_PRODUCT", 290, 293], ["Mpro", "PROTEIN", 145, 149], ["calpain inhibitors II and XII", "PROTEIN", 166, 195], ["calpain inhibitor II", "PROTEIN", 250, 270], ["calpain inhibitor XII", "PROTEIN", 272, 293], ["catalytic core", "PROTEIN", 409, 423], ["6XFN", "PROTEIN", 430, 434], ["Multiple hydrogen bonds", "TEST", 0, 23], ["the amide backbone", "TEST", 37, 55], ["Met", "TEST", 87, 90], ["Glu", "TEST", 99, 102], ["X-ray crystal structures", "TEST", 106, 130], ["SARS", "PROBLEM", 134, 138], ["CoV", "TEST", 139, 142], ["calpain inhibitors", "TREATMENT", 166, 184], ["calpain inhibitor II", "TREATMENT", 250, 270], ["calpain inhibitor XII", "TREATMENT", 272, 293], ["an atypical binding mode", "PROBLEM", 307, 331], ["an inverted, semi-helical conformation", "TREATMENT", 348, 386], ["hydrogen bonds", "OBSERVATION", 9, 23], ["main", "ANATOMY_MODIFIER", 64, 68], ["chains", "ANATOMY_MODIFIER", 69, 75], ["SARS", "OBSERVATION", 134, 138]]], ["This is dissimilar to the extended configuration of previously published peptidomimetic inhibitors, including other \u03b1-ketoamide compounds such as 13b (Fig. 1c, d).18 For calpain inhibitor XII, the P1\u2019 pyridine is placed in the S1 site while the P1 norvaline occupies the S1\u2019 site, the P2 valine projects outwards towards the solvent near the TSEDMLN loop (residues 45\u201351) and the terminal carboxybenzyl group curls back towards the S1 site, forcing Asn142 upwards while forming a water-mediated hydrogen bond with Glu166.", [["\u03b1-ketoamide", "CHEMICAL", 116, 127], ["pyridine", "CHEMICAL", 201, 209], ["P2 valine", "CHEMICAL", 285, 294], ["carboxybenzyl", "CHEMICAL", 389, 402], ["Asn142", "CHEMICAL", 449, 455], ["Glu166", "CHEMICAL", 514, 520], ["\u03b1-ketoamide", "CHEMICAL", 116, 127], ["pyridine", "CHEMICAL", 201, 209], ["norvaline", "CHEMICAL", 248, 257], ["valine", "CHEMICAL", 288, 294], ["carboxybenzyl", "CHEMICAL", 389, 402], ["Asn142", "CHEMICAL", 449, 455], ["hydrogen", "CHEMICAL", 495, 503], ["Glu", "CHEMICAL", 514, 517], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 116, 127], ["calpain", "GENE_OR_GENE_PRODUCT", 170, 177], ["XII", "GENE_OR_GENE_PRODUCT", 188, 191], ["P1\u2019 pyridine", "SIMPLE_CHEMICAL", 197, 209], ["valine", "AMINO_ACID", 288, 294], ["Asn142", "SIMPLE_CHEMICAL", 449, 455], ["Glu166", "SIMPLE_CHEMICAL", 514, 520], ["calpain inhibitor XII", "PROTEIN", 170, 191], ["S1 site", "DNA", 227, 234], ["P1 norvaline", "DNA", 245, 257], ["S1\u2019 site", "DNA", 271, 279], ["TSEDMLN loop", "PROTEIN", 342, 354], ["terminal carboxybenzyl group", "PROTEIN", 380, 408], ["S1 site", "PROTEIN", 432, 439], ["Asn142", "PROTEIN", 449, 455], ["previously published peptidomimetic inhibitors", "TREATMENT", 52, 98], ["other \u03b1-ketoamide compounds", "PROBLEM", 110, 137], ["calpain inhibitor XII", "TREATMENT", 170, 191], ["the P1\u2019 pyridine", "TREATMENT", 193, 209], ["the P2 valine", "TREATMENT", 281, 294], ["the terminal carboxybenzyl group curls", "TREATMENT", 376, 414], ["Glu", "TEST", 514, 517], ["S1", "ANATOMY", 227, 229], ["S1", "ANATOMY", 271, 273], ["P2 valine", "OBSERVATION", 285, 294], ["terminal", "OBSERVATION_MODIFIER", 380, 388], ["S1", "ANATOMY", 432, 434]]], ["Corresponding to this unique binding pose, we observed the (R) configuration of the thiohemiketal-Cys145 adduct for the first time among the known \u03b1-ketoamide inhibitors (Fig. 1d, e).", [["thiohemiketal-Cys", "CHEMICAL", 84, 101], ["thiohemiketal-Cys145", "CHEMICAL", 84, 104], ["\u03b1-ketoamide", "CHEMICAL", 147, 158], ["thiohemiketal-Cys145 adduct", "SIMPLE_CHEMICAL", 84, 111], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 147, 158], ["the known \u03b1-ketoamide inhibitors", "TREATMENT", 137, 169]]], ["From our recent X-ray crystal structure of the SARS-CoV-2 Mpro in complex with GC-376 (PDB: 6WTT),15 it is known that the thiohemiacetal center of aldehyde-based inhibitors can assume either an (R) or (S) configuration, depending on which face of the aldehyde group undergoes nucleophilic attack from the thiolate of Cys145 during covalent bond formation.15 In contrast, the thiohemiketal group of all crystallographic solved \u03b1-ketoamide Mpro inhibitors such as N3 and 13b adopt the (S) configuration (Fig. 1f).16,17 The new calpain inhibitor XII structure demonstrates that, like aldehyde-based inhibitors, the covalent adduct formed between \u03b1-ketoamide compounds and the catalytic cysteine can assume two different configurations as well.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONIn both the (R) and (S) configurations of the thiohemiketal adducts, the hydroxyl group is placed near His41, while the amide oxygen is positioned in the oxyanion hole.", [["SARS", "DISEASE", 47, 51], ["GC-376", "CHEMICAL", 79, 85], ["aldehyde", "CHEMICAL", 147, 155], ["aldehyde", "CHEMICAL", 251, 259], ["Cys145", "CHEMICAL", 317, 323], ["\u03b1-ketoamide", "CHEMICAL", 426, 437], ["aldehyde", "CHEMICAL", 581, 589], ["\u03b1-ketoamide", "CHEMICAL", 643, 654], ["thiohemiketal", "CHEMICAL", 903, 916], ["hydroxyl", "CHEMICAL", 930, 938], ["His41", "CHEMICAL", 960, 965], ["oxygen", "CHEMICAL", 983, 989], ["GC-376", "CHEMICAL", 79, 85], ["thiohemiacetal", "CHEMICAL", 122, 136], ["aldehyde", "CHEMICAL", 147, 155], ["aldehyde", "CHEMICAL", 251, 259], ["thiolate", "CHEMICAL", 305, 313], ["Cys145", "CHEMICAL", 317, 323], ["thiohemiketal", "CHEMICAL", 375, 388], ["\u03b1-ketoamide", "CHEMICAL", 426, 437], ["N3", "CHEMICAL", 462, 464], ["aldehyde", "CHEMICAL", 581, 589], ["\u03b1-ketoamide", "CHEMICAL", 643, 654], ["cysteine", "CHEMICAL", 683, 691], ["thiohemiketal", "CHEMICAL", 903, 916], ["hydroxyl", "CHEMICAL", 930, 938], ["His41", "CHEMICAL", 960, 965], ["amide", "CHEMICAL", 977, 982], ["oxygen", "CHEMICAL", 983, 989], ["GC-376", "SIMPLE_CHEMICAL", 79, 85], ["thiohemiacetal", "SIMPLE_CHEMICAL", 122, 136], ["aldehyde", "SIMPLE_CHEMICAL", 147, 155], ["aldehyde", "SIMPLE_CHEMICAL", 251, 259], ["Cys145", "SIMPLE_CHEMICAL", 317, 323], ["covalent bond", "SIMPLE_CHEMICAL", 331, 344], ["thiohemiketal", "SIMPLE_CHEMICAL", 375, 388], ["\u03b1-ketoamide Mpro inhibitors", "SIMPLE_CHEMICAL", 426, 453], ["N3", "SIMPLE_CHEMICAL", 462, 464], ["13b", "SIMPLE_CHEMICAL", 469, 472], ["calpain", "GENE_OR_GENE_PRODUCT", 525, 532], ["XII", "GENE_OR_GENE_PRODUCT", 543, 546], ["aldehyde", "SIMPLE_CHEMICAL", 581, 589], ["\u03b1-ketoamide compounds", "SIMPLE_CHEMICAL", 643, 664], ["cysteine", "AMINO_ACID", 683, 691], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 768, 783], ["calpain", "GENE_OR_GENE_PRODUCT", 800, 807], ["thiohemiketal adducts", "SIMPLE_CHEMICAL", 903, 924], ["hydroxyl", "SIMPLE_CHEMICAL", 930, 938], ["His41", "SIMPLE_CHEMICAL", 960, 965], ["amide oxygen", "SIMPLE_CHEMICAL", 977, 989], ["SARS-CoV-2 Mpro", "PROTEIN", 47, 62], ["calpain", "PROTEIN", 525, 532], ["XII structure", "PROTEIN", 543, 556], ["Mpro", "PROTEIN", 779, 783], ["calpain inhibitors II and XII", "PROTEIN", 800, 829], ["the SARS", "TEST", 43, 51], ["CoV", "TEST", 52, 55], ["GC", "TEST", 79, 81], ["PDB", "TEST", 87, 90], ["aldehyde-based inhibitors", "TREATMENT", 147, 172], ["an (R) or (S) configuration", "PROBLEM", 191, 218], ["nucleophilic attack", "PROBLEM", 276, 295], ["the thiolate of Cys145 during covalent bond formation", "TREATMENT", 301, 354], ["all crystallographic solved \u03b1-ketoamide Mpro inhibitors", "TREATMENT", 398, 453], ["N3", "TREATMENT", 462, 464], ["The new calpain inhibitor XII structure", "TREATMENT", 517, 556], ["aldehyde-based inhibitors", "TREATMENT", 581, 606], ["the covalent adduct", "PROBLEM", 608, 627], ["\u03b1-ketoamide compounds", "TREATMENT", 643, 664], ["the catalytic cysteine", "TREATMENT", 669, 691], ["X-ray crystal structures", "TEST", 740, 764], ["SARS", "PROBLEM", 768, 772], ["CoV", "TEST", 773, 776], ["calpain inhibitors", "TREATMENT", 800, 818], ["the thiohemiketal adducts", "TREATMENT", 899, 924], ["the hydroxyl group", "TREATMENT", 926, 944], ["the amide oxygen", "TREATMENT", 973, 989], ["the oxyanion hole", "TREATMENT", 1007, 1024], ["SARS", "OBSERVATION", 47, 51], ["nucleophilic attack", "OBSERVATION", 276, 295], ["covalent bond formation", "OBSERVATION", 331, 354], ["new", "OBSERVATION_MODIFIER", 521, 524], ["calpain", "OBSERVATION", 525, 532], ["covalent adduct", "OBSERVATION", 612, 627], ["two", "OBSERVATION_MODIFIER", 703, 706], ["different", "OBSERVATION_MODIFIER", 707, 716], ["configurations", "OBSERVATION_MODIFIER", 717, 731], ["SARS", "OBSERVATION", 768, 772], ["adducts", "OBSERVATION", 917, 924], ["hydroxyl group", "OBSERVATION", 930, 944], ["oxyanion hole", "OBSERVATION", 1011, 1024]]], ["However, the exact locations of these two functional groups result in different HB patterns.", [["different HB patterns", "PROBLEM", 70, 91], ["different", "OBSERVATION_MODIFIER", 70, 79], ["HB patterns", "OBSERVATION", 80, 91]]], ["Compared to other \u03b1-ketoamide inhibitors, the unique binding mode of calpain inhibitor XII alters the hydrogen-bonding network of the catalytic core (Fig. 1e, f).", [["\u03b1-ketoamide", "CHEMICAL", 18, 29], ["\u03b1-ketoamide", "CHEMICAL", 18, 29], ["hydrogen", "CHEMICAL", 102, 110], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 18, 29], ["calpain", "GENE_OR_GENE_PRODUCT", 69, 76], ["XII", "GENE_OR_GENE_PRODUCT", 87, 90], ["calpain inhibitor XII", "PROTEIN", 69, 90], ["catalytic core", "PROTEIN", 134, 148], ["other \u03b1-ketoamide inhibitors", "TREATMENT", 12, 40], ["calpain inhibitor", "TREATMENT", 69, 86]]], ["The hydroxyl group forms a short HB (2.5 \u00c5 in length) with the catalytic His41, and two weak HBs (3.3 \u00c5) with the main chain carbonyl of His164 and a water molecule in the central channel between the S1 and S2 pockets.", [["hydroxyl", "CHEMICAL", 4, 12], ["His164", "CHEMICAL", 137, 143], ["hydroxyl", "CHEMICAL", 4, 12], ["His41", "CHEMICAL", 73, 78], ["carbonyl", "CHEMICAL", 125, 133], ["His", "CHEMICAL", 137, 140], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["His164", "SIMPLE_CHEMICAL", 137, 143], ["HB", "PROTEIN", 33, 35], ["catalytic His41", "PROTEIN", 63, 78], ["HBs", "PROTEIN", 93, 96], ["S1 and S2 pockets", "PROTEIN", 200, 217], ["a short HB", "PROBLEM", 25, 35], ["the catalytic His41", "TEST", 59, 78], ["two weak HBs", "PROBLEM", 84, 96], ["water molecule", "OBSERVATION", 150, 164], ["central channel", "ANATOMY_MODIFIER", 172, 187], ["S1", "ANATOMY", 200, 202], ["S2", "ANATOMY", 207, 209], ["pockets", "ANATOMY_MODIFIER", 210, 217]]], ["The ketoamide amide oxygen establishes three HBs in the oxyanion hole (2.9, 3.2 and 3.1 \u00c5 to the backbone \u2212NH of Gly143, Ser144 and Cys145 respectively), and its nitrogen forms a HB (3.1 \u00c5) with the mainchain carbonyl of His164.", [["ketoamide amide", "CHEMICAL", 4, 19], ["oxygen", "CHEMICAL", 20, 26], ["HBs", "CHEMICAL", 45, 48], ["nitrogen", "CHEMICAL", 162, 170], ["His164", "CHEMICAL", 221, 227], ["ketoamide amide oxygen", "CHEMICAL", 4, 26], ["NH", "CHEMICAL", 107, 109], ["Gly", "CHEMICAL", 113, 116], ["Ser144", "CHEMICAL", 121, 127], ["Cys145", "CHEMICAL", 132, 138], ["nitrogen", "CHEMICAL", 162, 170], ["carbonyl", "CHEMICAL", 209, 217], ["His", "CHEMICAL", 221, 224], ["ketoamide amide oxygen", "SIMPLE_CHEMICAL", 4, 26], ["Gly143", "AMINO_ACID", 113, 119], ["Ser144", "AMINO_ACID", 121, 127], ["Cys145", "AMINO_ACID", 132, 138], ["nitrogen", "SIMPLE_CHEMICAL", 162, 170], ["His164", "SIMPLE_CHEMICAL", 221, 227], ["HBs", "PROTEIN", 45, 48], ["The ketoamide amide oxygen", "TREATMENT", 0, 26], ["the oxyanion hole", "TREATMENT", 52, 69], ["a HB", "TEST", 177, 181]]], ["In the canonical binding conformation for \u03b1-ketoamide inhibitors, such as 13b and those described herein, the hydroxyl group establishes one standard HB (2.8 \u00c5) with His41 and another HB (3.3 \u00c5) with a bulk water molecule.", [["\u03b1-ketoamide", "CHEMICAL", 42, 53], ["hydroxyl", "CHEMICAL", 110, 118], ["His41", "CHEMICAL", 166, 171], ["\u03b1-ketoamide", "CHEMICAL", 42, 53], ["hydroxyl", "CHEMICAL", 110, 118], ["His41", "CHEMICAL", 166, 171], ["\u03b1-ketoamide inhibitors", "SIMPLE_CHEMICAL", 42, 64], ["13b", "SIMPLE_CHEMICAL", 74, 77], ["hydroxyl", "SIMPLE_CHEMICAL", 110, 118], ["His41", "SIMPLE_CHEMICAL", 166, 171], ["His41", "PROTEIN", 166, 171], ["HB", "PROTEIN", 184, 186], ["\u03b1-ketoamide inhibitors", "TREATMENT", 42, 64], ["His41", "TEST", 166, 171], ["another HB", "TEST", 176, 186], ["a bulk water molecule", "TREATMENT", 200, 221]]], ["Meanwhile, the HBs between the amide oxygen and the oxyanion hole now have distances of 3.3, 3.0 and 2.5 \u00c5 respectively, while the amide nitrogen forms no HBs with the protein.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONThe S1 pocket recognizes the most conserved residue in the Mpro substrate, the P1 glutamine.", [["HBs", "CHEMICAL", 15, 18], ["oxygen", "CHEMICAL", 37, 43], ["amide nitrogen", "CHEMICAL", 131, 145], ["glutamine", "CHEMICAL", 375, 384], ["amide", "CHEMICAL", 31, 36], ["oxygen", "CHEMICAL", 37, 43], ["amide", "CHEMICAL", 131, 136], ["nitrogen", "CHEMICAL", 137, 145], ["glutamine", "CHEMICAL", 375, 384], ["HBs", "GENE_OR_GENE_PRODUCT", 15, 18], ["amide oxygen", "SIMPLE_CHEMICAL", 31, 43], ["amide nitrogen", "SIMPLE_CHEMICAL", 131, 145], ["HBs", "GENE_OR_GENE_PRODUCT", 155, 158], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 204, 219], ["calpain", "GENE_OR_GENE_PRODUCT", 236, 243], ["glutamine", "AMINO_ACID", 375, 384], ["HBs", "PROTEIN", 15, 18], ["HBs", "PROTEIN", 155, 158], ["Mpro", "PROTEIN", 215, 219], ["calpain inhibitors II and XII", "PROTEIN", 236, 265], ["S1 pocket", "PROTEIN", 297, 306], ["Mpro substrate", "PROTEIN", 352, 366], ["the HBs", "TEST", 11, 18], ["the amide oxygen", "TREATMENT", 27, 43], ["the oxyanion hole", "TREATMENT", 48, 65], ["the amide nitrogen", "TREATMENT", 127, 145], ["X-ray crystal structures", "TEST", 176, 200], ["SARS", "PROBLEM", 204, 208], ["CoV", "TEST", 209, 212], ["calpain inhibitors", "TREATMENT", 236, 254], ["The S1 pocket", "PROBLEM", 293, 306], ["the Mpro substrate", "TREATMENT", 348, 366], ["the P1 glutamine", "TREATMENT", 368, 384], ["SARS", "OBSERVATION", 204, 208], ["S1", "ANATOMY", 297, 299], ["pocket", "OBSERVATION", 300, 306], ["residue", "OBSERVATION_MODIFIER", 337, 344]]], ["Underscoring its importance for ligand binding, most specific Mpro inhibitors have a glutamine surrogate such as the pyrrolidone ring that occupies the S1 pocket.", [["glutamine", "CHEMICAL", 85, 94], ["pyrrolidone", "CHEMICAL", 117, 128], ["glutamine", "CHEMICAL", 85, 94], ["pyrrolidone", "CHEMICAL", 117, 128], ["Mpro", "GENE_OR_GENE_PRODUCT", 62, 66], ["glutamine", "AMINO_ACID", 85, 94], ["pyrrolidone ring", "SIMPLE_CHEMICAL", 117, 133], ["S1 pocket", "PROTEIN", 152, 161], ["ligand binding", "PROBLEM", 32, 46], ["specific Mpro inhibitors", "TREATMENT", 53, 77], ["a glutamine surrogate", "TREATMENT", 83, 104], ["the pyrrolidone ring", "TREATMENT", 113, 133], ["pyrrolidone ring", "OBSERVATION", 117, 133], ["S1 pocket", "OBSERVATION", 152, 161]]], ["Compounds like calpain inhibitor II, calpain inhibitor XII, and Boceprivir prove that a hydrophobic side chain can also be accommodated in the S1 pocket.", [["Boceprivir", "CHEMICAL", 64, 74], ["Boceprivir", "CHEMICAL", 64, 74], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 15, 35], ["calpain", "GENE_OR_GENE_PRODUCT", 37, 44], ["XII", "GENE_OR_GENE_PRODUCT", 55, 58], ["Boceprivir", "SIMPLE_CHEMICAL", 64, 74], ["calpain inhibitor II", "PROTEIN", 15, 35], ["calpain inhibitor XII", "PROTEIN", 37, 58], ["S1 pocket", "PROTEIN", 143, 152], ["calpain inhibitor II", "TREATMENT", 15, 35], ["calpain inhibitor XII", "TREATMENT", 37, 58], ["Boceprivir", "TREATMENT", 64, 74], ["a hydrophobic side chain", "TREATMENT", 86, 110], ["S1", "ANATOMY", 143, 145], ["pocket", "ANATOMY_MODIFIER", 146, 152]]], ["Like previous inhibitors, hydrophobic interactions are observed between the newly identified inhibitors and the backbone atoms of Leu141/Asn142/Met165.", [["Leu141", "CHEMICAL", 130, 136], ["As", "CHEMICAL", 137, 139], ["previous inhibitors", "TREATMENT", 5, 24], ["hydrophobic interactions", "PROBLEM", 26, 50]]], ["However, these interactions are further enhanced in calpain inhibitor XII, where its aromatic pyridine ring is stacked and sandwiched between the two planar peptide bonds involving Asn142 and Met165 respectively.", [["aromatic pyridine", "CHEMICAL", 85, 102], ["pyridine", "CHEMICAL", 94, 102], ["Asn142", "CHEMICAL", 181, 187], ["Met165", "CHEMICAL", 192, 198], ["calpain", "GENE_OR_GENE_PRODUCT", 52, 59], ["XII", "GENE_OR_GENE_PRODUCT", 70, 73], ["Asn142", "SIMPLE_CHEMICAL", 181, 187], ["Met165", "GENE_OR_GENE_PRODUCT", 192, 198], ["calpain inhibitor XII", "PROTEIN", 52, 73], ["Met165", "PROTEIN", 192, 198], ["calpain inhibitor XII", "TREATMENT", 52, 73], ["its aromatic pyridine ring", "TREATMENT", 81, 107]]], ["Furthermore, a hydrogen bond is observed between His163 and the methionine sulfur and pyridine nitrogen for calpain inhibitors II and XII, respectively.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONTo dissect the importance of the hydrogen bond between His163 and the pyridine nitrogen from calpain inhibitor XII, we designed the benzene counterpart of calpain inhibitor XII, compound UAWJ257.", [["His163", "CHEMICAL", 49, 55], ["methionine sulfur", "CHEMICAL", 64, 81], ["pyridine nitrogen", "CHEMICAL", 86, 103], ["His163", "CHEMICAL", 324, 330], ["pyridine nitrogen", "CHEMICAL", 339, 356], ["benzene", "CHEMICAL", 401, 408], ["UAWJ257", "CHEMICAL", 456, 463], ["hydrogen", "CHEMICAL", 15, 23], ["His", "CHEMICAL", 49, 52], ["methionine sulfur", "CHEMICAL", 64, 81], ["pyridine", "CHEMICAL", 86, 94], ["nitrogen", "CHEMICAL", 95, 103], ["hydrogen", "CHEMICAL", 302, 310], ["His", "CHEMICAL", 324, 327], ["pyridine", "CHEMICAL", 339, 347], ["nitrogen", "CHEMICAL", 348, 356], ["benzene", "CHEMICAL", 401, 408], ["UAWJ257", "CHEMICAL", 456, 463], ["His163", "SIMPLE_CHEMICAL", 49, 55], ["methionine sulfur", "SIMPLE_CHEMICAL", 64, 81], ["pyridine nitrogen", "SIMPLE_CHEMICAL", 86, 103], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 108, 129], ["XII", "GENE_OR_GENE_PRODUCT", 134, 137], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 180, 195], ["calpain", "GENE_OR_GENE_PRODUCT", 212, 219], ["His163", "SIMPLE_CHEMICAL", 324, 330], ["pyridine", "SIMPLE_CHEMICAL", 339, 347], ["calpain inhibitor XII", "GENE_OR_GENE_PRODUCT", 362, 383], ["benzene", "SIMPLE_CHEMICAL", 401, 408], ["calpain", "GENE_OR_GENE_PRODUCT", 424, 431], ["XII", "GENE_OR_GENE_PRODUCT", 442, 445], ["UAWJ257", "SIMPLE_CHEMICAL", 456, 463], ["calpain", "PROTEIN", 108, 115], ["XII", "PROTEIN", 134, 137], ["Mpro", "PROTEIN", 191, 195], ["calpain inhibitors II and XII", "PROTEIN", 212, 241], ["calpain inhibitor XII", "PROTEIN", 362, 383], ["calpain", "PROTEIN", 424, 431], ["a hydrogen bond", "TEST", 13, 28], ["the methionine sulfur", "TREATMENT", 60, 81], ["pyridine nitrogen", "TREATMENT", 86, 103], ["calpain inhibitors II", "TREATMENT", 108, 129], ["X-ray crystal structures", "TEST", 152, 176], ["SARS", "PROBLEM", 180, 184], ["CoV", "TEST", 185, 188], ["calpain inhibitors", "TREATMENT", 212, 230], ["the pyridine nitrogen", "TREATMENT", 335, 356], ["calpain inhibitor XII", "TREATMENT", 362, 383], ["calpain inhibitor XII", "TREATMENT", 424, 445], ["hydrogen bond", "OBSERVATION", 15, 28], ["SARS", "OBSERVATION", 180, 184]]], ["It was found that UAWJ257 demonstrated no detectable inhibition against SARS-CoV-2 Mpro (IC50 > 20 \u03bcM) (Table 1).", [["UAWJ257", "CHEMICAL", 18, 25], ["UAWJ257", "CHEMICAL", 18, 25], ["UAWJ257", "SIMPLE_CHEMICAL", 18, 25], ["SARS-CoV", "SPECIES", 72, 80], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["IC50", "TEST", 89, 93], ["no detectable", "UNCERTAINTY", 39, 52]]], ["Likewise, no binding was detected in the thermal shift assay (\u0394Tm = \u22120.07 \u00b0C).", [["binding", "PROBLEM", 13, 20], ["the thermal shift assay", "TEST", 37, 60], ["\u0394Tm", "TEST", 62, 65], ["no", "UNCERTAINTY", 10, 12]]], ["In addition to abolishing the hydrogen bond, the dramatic loss of inhibition might be attributed to a clash between His163 and the benzene hydrogen that replaces the lone pair on the pyridine nitrogen, which lies only 3.1 \u00c5 away from His163.", [["His163", "CHEMICAL", 116, 122], ["benzene", "CHEMICAL", 131, 138], ["pyridine nitrogen", "CHEMICAL", 183, 200], ["His163", "CHEMICAL", 234, 240], ["hydrogen", "CHEMICAL", 30, 38], ["His", "CHEMICAL", 116, 119], ["benzene", "CHEMICAL", 131, 138], ["hydrogen", "CHEMICAL", 139, 147], ["pyridine", "CHEMICAL", 183, 191], ["nitrogen", "CHEMICAL", 192, 200], ["His", "CHEMICAL", 234, 237], ["His163", "SIMPLE_CHEMICAL", 116, 122], ["benzene hydrogen", "SIMPLE_CHEMICAL", 131, 147], ["pyridine nitrogen", "SIMPLE_CHEMICAL", 183, 200], ["the hydrogen bond", "PROBLEM", 26, 43], ["the dramatic loss of inhibition", "PROBLEM", 45, 76], ["the benzene hydrogen", "TREATMENT", 127, 147], ["the pyridine nitrogen", "TREATMENT", 179, 200], ["hydrogen bond", "OBSERVATION", 30, 43], ["dramatic", "OBSERVATION_MODIFIER", 49, 57], ["clash", "OBSERVATION", 102, 107]]], ["Similarly, this hydrogen bond is important for calpain inhibitor II binding, since its butyl analogue, calpain inhibitor I, has an IC50 that is ~ 10-fold weaker (Table 1).", [["hydrogen", "CHEMICAL", 16, 24], ["butyl", "CHEMICAL", 87, 92], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 47, 67], ["butyl analogue", "SIMPLE_CHEMICAL", 87, 101], ["calpain inhibitor I", "GENE_OR_GENE_PRODUCT", 103, 122], ["calpain inhibitor II", "PROTEIN", 47, 67], ["calpain inhibitor I", "PROTEIN", 103, 122], ["this hydrogen bond", "PROBLEM", 11, 29], ["calpain inhibitor II binding", "PROBLEM", 47, 75], ["its butyl analogue", "TREATMENT", 83, 101], ["calpain inhibitor", "TREATMENT", 103, 120], ["an IC50", "TEST", 128, 135]]], ["Overall, the structure-activity relationship results of calpain inhibitors II and XII are consistent with the binding poses shown in the X-ray crystal structures.X-ray crystal structures of SARS-CoV-2 Mpro in complex with calpain inhibitors II and XII. ::: RESULTS AND DISCUSSIONWhile calpain inhibitor II was previously reported to inhibit cathepsin L with an inhibition constant Ki of 0.6 nM,19 which was confirmed by our data as well (IC50 = 0.41 nM), the inhibition of cathepsin L by calpain inhibitor XII was unknown.", [["inhibitor II", "CHEMICAL", 293, 305], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 56, 77], ["XII", "GENE_OR_GENE_PRODUCT", 82, 85], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 190, 205], ["calpain", "GENE_OR_GENE_PRODUCT", 222, 229], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 285, 305], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 341, 352], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 473, 484], ["calpain", "GENE_OR_GENE_PRODUCT", 488, 495], ["XII", "GENE_OR_GENE_PRODUCT", 506, 509], ["calpain inhibitors II and XII", "PROTEIN", 56, 85], ["Mpro", "PROTEIN", 201, 205], ["calpain inhibitors II and XII", "PROTEIN", 222, 251], ["calpain inhibitor II", "PROTEIN", 285, 305], ["cathepsin L", "PROTEIN", 341, 352], ["cathepsin L", "PROTEIN", 473, 484], ["calpain inhibitor XII", "PROTEIN", 488, 509], ["calpain inhibitors II and XII", "PROBLEM", 56, 85], ["X-ray crystal structures", "TEST", 162, 186], ["SARS", "PROBLEM", 190, 194], ["CoV", "TEST", 195, 198], ["calpain inhibitors", "TREATMENT", 222, 240], ["calpain inhibitor II", "TREATMENT", 285, 305], ["cathepsin L", "TREATMENT", 341, 352], ["an inhibition constant Ki", "TEST", 358, 383], ["IC50", "TEST", 438, 442], ["cathepsin L", "TREATMENT", 473, 484], ["calpain inhibitor XII", "TREATMENT", 488, 509], ["consistent with", "UNCERTAINTY", 90, 105], ["SARS", "OBSERVATION", 190, 194]]], ["We determined that calpain inhibitor XII is also a potent inhibitor of cathepsin L, with an IC50 value of 1.62 \u00b1 0.33 nM.", [["calpain", "GENE_OR_GENE_PRODUCT", 19, 26], ["XII", "GENE_OR_GENE_PRODUCT", 37, 40], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 71, 82], ["calpain inhibitor XII", "PROTEIN", 19, 40], ["cathepsin L", "PROTEIN", 71, 82], ["calpain inhibitor XII", "TREATMENT", 19, 40], ["a potent inhibitor of cathepsin L", "TREATMENT", 49, 82], ["an IC50 value", "TEST", 89, 102]]], ["Because cathepsin L has been shown to activate the SARS-CoV-2 spike protein, cathepsin L inhibitors decrease viral entry.20 Importantly, this may provide an explanation for the superior antiviral activity of calpain inhibitor II and XII despite having inferior affinity for Mpro compared to the specific inhibitors GC-376, N3, UAWJ246, UAWJ247, and UAWJ248 (Table 1, 2 and references15,18).", [["Mpro", "CHEMICAL", 274, 278], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 8, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 77, 88], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 208, 228], ["XII", "GENE_OR_GENE_PRODUCT", 233, 236], ["Mpro", "SIMPLE_CHEMICAL", 274, 278], ["GC-376", "SIMPLE_CHEMICAL", 315, 321], ["cathepsin L", "PROTEIN", 8, 19], ["SARS-CoV-2 spike protein", "PROTEIN", 51, 75], ["cathepsin L", "PROTEIN", 77, 88], ["calpain inhibitor II and XII", "PROTEIN", 208, 236], ["cathepsin L", "TREATMENT", 8, 19], ["the SARS", "TEST", 47, 55], ["CoV", "TEST", 56, 59], ["2 spike protein", "PROBLEM", 60, 75], ["cathepsin L inhibitors", "TREATMENT", 77, 99], ["calpain inhibitor II", "TREATMENT", 208, 228], ["inferior affinity", "PROBLEM", 252, 269], ["the specific inhibitors GC", "TEST", 291, 317], ["UAWJ246", "TEST", 327, 334], ["UAWJ247", "TEST", 336, 343], ["Table", "TEST", 358, 363], ["viral entry", "OBSERVATION", 109, 120]]], ["Both calpain inhibitors II and XII had no detectable inhibition against the SARS-CoV-2 papain-like protease (PLpro) (IC50 > 20 \u03bcM) (Table 1), suggesting they are not non-specific cysteine protease inhibitors.", [["cysteine", "CHEMICAL", 179, 187], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 5, 26], ["XII", "GENE_OR_GENE_PRODUCT", 31, 34], ["PLpro", "SIMPLE_CHEMICAL", 109, 114], ["calpain inhibitors II and XII", "PROTEIN", 5, 34], ["SARS-CoV-2 papain-like protease", "PROTEIN", 76, 107], ["PLpro", "PROTEIN", 109, 114], ["SARS-CoV", "SPECIES", 76, 84], ["Both calpain inhibitors", "TREATMENT", 0, 23], ["the SARS", "TEST", 72, 80], ["CoV", "TEST", 81, 84], ["papain", "TREATMENT", 87, 93], ["protease (PLpro) (IC50", "TREATMENT", 99, 121], ["non-specific cysteine protease inhibitors", "TREATMENT", 166, 207]]], ["Collectively, the X-ray crystal structures of SARS-CoV-2 HM-Mpro in complex with calpain inhibitors II and XII, along with the enzymatic assay results, suggest that it is feasible to develop dual inhibitors that simultaneously targeting the SARS-CoV-2 Mpro and the host cathepsin L, both of which are validated antiviral drug targets for SARS-CoV-2.20,21Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONWe recently demonstrated the inhibition of SARs-CoV-2 Mpro by GC-376, and solved the X-ray crystal structure of Mpro-His with GC-376 (PDB: 6WTT).15 To profile the substrate spectrum of SARS-CoV-2 Mpro in the S1\u2019, S2, S3, and S4 sites, several GC-376 analogues were designed.", [["GC-376", "CHEMICAL", 373, 379], ["GC-376", "CHEMICAL", 577, 583], ["Mpro-His", "CHEMICAL", 627, 635], ["GC-376", "CHEMICAL", 641, 647], ["SARS", "DISEASE", 700, 704], ["GC-376", "CHEMICAL", 758, 764], ["UAWJ246", "CHEMICAL", 458, 465], ["UAWJ247", "CHEMICAL", 467, 474], ["Mpro-His", "CHEMICAL", 627, 635], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 81, 102], ["XII", "GENE_OR_GENE_PRODUCT", 107, 110], ["CoV-2", "ORGANISM", 246, 251], ["Mpro", "GENE_OR_GENE_PRODUCT", 252, 256], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 270, 281], ["GC-376 analogues", "SIMPLE_CHEMICAL", 373, 389], ["UAWJ246", "SIMPLE_CHEMICAL", 458, 465], ["GC-376", "SIMPLE_CHEMICAL", 577, 583], ["Mpro-His", "SIMPLE_CHEMICAL", 627, 635], ["GC-376", "SIMPLE_CHEMICAL", 641, 647], ["S3", "GENE_OR_GENE_PRODUCT", 732, 734], ["GC-376 analogues", "SIMPLE_CHEMICAL", 758, 774], ["HM", "PROTEIN", 57, 59], ["Mpro", "PROTEIN", 60, 64], ["calpain inhibitors II and XII", "PROTEIN", 81, 110], ["SARS-CoV-2 Mpro", "PROTEIN", 241, 256], ["cathepsin L", "PROTEIN", 270, 281], ["Mpro", "PROTEIN", 627, 631], ["SARS-CoV-2 Mpro", "DNA", 700, 715], ["S1\u2019, S2, S3, and S4 sites", "DNA", 723, 748], ["the X-ray crystal structures", "TEST", 14, 42], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["Mpro", "TREATMENT", 60, 64], ["calpain inhibitors", "TREATMENT", 81, 99], ["the enzymatic assay", "TEST", 123, 142], ["dual inhibitors", "TREATMENT", 191, 206], ["the SARS", "TEST", 237, 245], ["CoV", "TEST", 246, 249], ["the host cathepsin L", "TREATMENT", 261, 281], ["antiviral drug targets", "TREATMENT", 311, 333], ["SARS", "PROBLEM", 338, 342], ["CoV", "TEST", 343, 346], ["GC", "TEST", 373, 375], ["the X-ray crystal structures", "TEST", 394, 422], ["SARS", "TEST", 426, 430], ["CoV", "TEST", 431, 434], ["UAWJ247", "TEST", 467, 474], ["SARs", "TEST", 558, 562], ["CoV", "TEST", 563, 566], ["GC", "TEST", 577, 579], ["the X-ray", "TEST", 596, 605], ["Mpro", "TEST", 627, 631], ["GC", "TEST", 641, 643], ["SARS", "TEST", 700, 704], ["CoV", "TEST", 705, 708], ["several GC", "TEST", 750, 760], ["S1", "ANATOMY", 723, 725], ["S2", "ANATOMY", 728, 730], ["S3", "ANATOMY", 732, 734], ["S4", "ANATOMY", 740, 742]]], ["Specifically, compound UAWJ246 was designed to occupy the S1\u2019 pocket according to the overlay structures of SARS-CoV-2 Mpro+GC-376 (PDB: 6WTT) and SARS-CoV Mpro (H41A)+substrate (PDB: 2Q6G) (Supplementary Fig. S2).", [["UAWJ246", "CHEMICAL", 23, 30], ["SARS-CoV-2 Mpro+GC-376", "CHEMICAL", 108, 130], ["UAWJ246", "CHEMICAL", 23, 30], ["UAWJ246", "SIMPLE_CHEMICAL", 23, 30], ["Mpro+GC-376", "SIMPLE_CHEMICAL", 119, 130], ["PDB: 6WTT", "SIMPLE_CHEMICAL", 132, 141], ["SARS-CoV Mpro", "SIMPLE_CHEMICAL", 147, 160], ["H41A)+substrate", "SIMPLE_CHEMICAL", 162, 177], ["S1\u2019 pocket", "PROTEIN", 58, 68], ["6WTT", "PROTEIN", 137, 141], ["SARS-CoV Mpro (H41A)+substrate", "PROTEIN", 147, 177], ["S2", "PROTEIN", 210, 212], ["SARS-CoV", "SPECIES", 147, 155], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["Mpro+GC", "TEST", 119, 126], ["PDB", "TEST", 132, 135], ["6WTT", "TEST", 137, 141], ["SARS", "TEST", 147, 151], ["CoV Mpro", "TEST", 152, 160], ["S1", "ANATOMY", 58, 60]]], ["We found that UAWJ246 inhibited SARS-CoV-2 Mpro with an IC50 value of 0.045 \u00b1 0.012 \u03bcM, which is similar to that of GC-376 (IC50 = 0.033 \u00b1 0.005 \u03bcM) (Table 2).", [["UAWJ246", "CHEMICAL", 14, 21], ["GC-376", "CHEMICAL", 116, 122], ["UAWJ246", "CHEMICAL", 14, 21], ["GC-376", "CHEMICAL", 116, 122], ["UAWJ246", "SIMPLE_CHEMICAL", 14, 21], ["GC-376", "SIMPLE_CHEMICAL", 116, 122], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["an IC50 value", "TEST", 53, 66], ["GC", "TEST", 116, 118], ["IC50", "TEST", 124, 128]]], ["UAWJ246 contains a pharmacological compliant \u03b1-ketoamide reactive warhead with a cyclopropyl substitution.", [["UAWJ246", "CHEMICAL", 0, 7], ["\u03b1-ketoamide", "CHEMICAL", 45, 56], ["cyclopropyl", "CHEMICAL", 81, 92], ["UAWJ246", "CHEMICAL", 0, 7], ["\u03b1-ketoamide", "CHEMICAL", 45, 56], ["cyclopropyl", "CHEMICAL", 81, 92], ["UAWJ246", "SIMPLE_CHEMICAL", 0, 7], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 45, 56], ["cyclopropyl", "SIMPLE_CHEMICAL", 81, 92], ["a cyclopropyl substitution", "TREATMENT", 79, 105]]], ["UAWJ247 was designed to probe the substrate promiscuity in the S2 pocket.", [["UAWJ247", "CHEMICAL", 0, 7], ["UAWJ247", "CHEMICAL", 0, 7], ["UAWJ247", "SIMPLE_CHEMICAL", 0, 7], ["S2 pocket", "PROTEIN", 63, 72], ["S2", "ANATOMY", 63, 65], ["pocket", "ANATOMY_MODIFIER", 66, 72]]], ["In the X-ray crystal structure of Mpro-His with GC-376, the TSEDMLN loop constituting the S2 pocket exhibits significant flexibility among the three protomers in the asymmetric unit, indicating a variety of substitutions can be accommodated at this position.", [["Mpro-His", "CHEMICAL", 34, 42], ["GC-376", "CHEMICAL", 48, 54], ["Mpro-His", "CHEMICAL", 34, 42], ["Mpro-His", "SIMPLE_CHEMICAL", 34, 42], ["GC-376", "SIMPLE_CHEMICAL", 48, 54], ["TSEDMLN loop", "PROTEIN", 60, 72], ["S2 pocket", "PROTEIN", 90, 99], ["Mpro", "TEST", 34, 38], ["GC", "TEST", 48, 50], ["the TSEDMLN loop constituting the S2 pocket", "PROBLEM", 56, 99], ["a variety of substitutions", "PROBLEM", 194, 220], ["S2 pocket", "OBSERVATION", 90, 99], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["flexibility", "OBSERVATION_MODIFIER", 121, 132], ["asymmetric unit", "OBSERVATION_MODIFIER", 166, 181], ["variety", "OBSERVATION_MODIFIER", 196, 203], ["substitutions", "OBSERVATION", 207, 220]]], ["To test this hypothesis, UAWJ247 was designed with a benzyl substitution at the P2 position instead of the isopropyl of GC-376.", [["UAWJ247", "CHEMICAL", 25, 32], ["benzyl", "CHEMICAL", 53, 59], ["isopropyl", "CHEMICAL", 107, 116], ["GC-376", "CHEMICAL", 120, 126], ["UAWJ247", "CHEMICAL", 25, 32], ["benzyl", "CHEMICAL", 53, 59], ["isopropyl", "CHEMICAL", 107, 116], ["UAWJ247", "SIMPLE_CHEMICAL", 25, 32], ["benzyl", "SIMPLE_CHEMICAL", 53, 59], ["isopropyl", "SIMPLE_CHEMICAL", 107, 116], ["GC-376", "SIMPLE_CHEMICAL", 120, 126], ["a benzyl substitution", "TREATMENT", 51, 72], ["GC", "TEST", 120, 122]]], ["We found that UAWJ247 has a similar inhibition constant of SARS-CoV-2 Mpro as GC-376 (IC50 = 0.042 \u03bcM, Table 2).", [["UAWJ247", "CHEMICAL", 14, 21], ["GC-376", "CHEMICAL", 78, 84], ["UAWJ247", "CHEMICAL", 14, 21], ["UAWJ247", "SIMPLE_CHEMICAL", 14, 21], ["GC-376", "SIMPLE_CHEMICAL", 78, 84], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["GC", "TEST", 78, 80], ["IC50", "TEST", 86, 90]]], ["UAWJ248 is a tripeptide and was designed to incorporate the P3 substitution.", [["UAWJ248", "CHEMICAL", 0, 7], ["UAWJ248", "CHEMICAL", 0, 7], ["tripeptide", "CHEMICAL", 13, 23], ["UAWJ248", "SIMPLE_CHEMICAL", 0, 7], ["a tripeptide", "TREATMENT", 11, 23], ["the P3 substitution", "TREATMENT", 56, 75], ["P3 substitution", "OBSERVATION", 60, 75]]], ["This slightly improved the IC50 to 0.012 \u03bcM, a ~3 -fold improvement compared to GC-376 (Table 2).", [["GC-376", "CHEMICAL", 80, 86], ["the IC50", "TEST", 23, 31], ["GC", "TEST", 80, 82], ["slightly", "OBSERVATION_MODIFIER", 5, 13], ["improved", "OBSERVATION_MODIFIER", 14, 22]]], ["None of these compounds showed inhibition against the SARS-CoV-2 PLpro (IC50 > 20 \u03bcM) (Table 2).Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONNext, we determined the mechanism of action with thermal shift binding assay, native mass spectrometry, and enzyme kinetic studies.", [["GC-376", "CHEMICAL", 115, 121], ["GC-376", "CHEMICAL", 115, 121], ["UAWJ246", "CHEMICAL", 200, 207], ["UAWJ247", "CHEMICAL", 209, 216], ["GC-376 analogues", "SIMPLE_CHEMICAL", 115, 131], ["these compounds", "TEST", 8, 23], ["the SARS", "TEST", 50, 58], ["CoV", "TEST", 59, 62], ["PLpro (IC50", "TREATMENT", 65, 76], ["GC", "TEST", 115, 117], ["analogues", "TEST", 122, 131], ["the X-ray crystal structures", "TEST", 136, 164], ["SARS", "TEST", 168, 172], ["CoV", "TEST", 173, 176], ["UAWJ246", "TEST", 200, 207], ["UAWJ247", "TEST", 209, 216], ["thermal shift binding assay", "TEST", 306, 333], ["native mass spectrometry", "TEST", 335, 359], ["enzyme kinetic studies", "TEST", 365, 387]]], ["As expected, binding of UAWJ246, UAWJ247, and UAWJ248 all stabilized SARS-CoV-2 Mpro, as shown by the \u0394Tm shift of 11.08, 8.28, and 18.10 \u00b0C, respectively (Fig. 2a).", [["UAWJ247", "CHEMICAL", 33, 40], ["UAWJ248", "CHEMICAL", 46, 53], ["UAWJ246", "GENE_OR_GENE_PRODUCT", 24, 31], ["UAWJ247", "GENE_OR_GENE_PRODUCT", 33, 40], ["Mpro", "GENE_OR_GENE_PRODUCT", 80, 84], ["UAWJ246", "TEST", 24, 31], ["UAWJ247", "TEST", 33, 40], ["CoV", "TEST", 74, 77]]], ["All three compounds also stabilized the Mpro-His construct to the same degree as the tag free Mpro, suggesting these two constructs are functional equivalent (Fig. 2a).", [["His", "CHEMICAL", 45, 48], ["Mpro", "GENE_OR_GENE_PRODUCT", 94, 98], ["Mpro-His construct", "DNA", 40, 58], ["Mpro", "PROTEIN", 94, 98]]], ["In contrast, compounds UAWJ246 and UAWJ247 did not show stabilization for the HM-Mpro construct, while the more potent GC-376 and UAWJ248 stabilized this construct with \u0394Tm shift of 2.45, and 10.01 \u00b0C, respectively (Fig. 2a).Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONThe binding of all three compounds UAWJ246, 247, and 248 to Mpro was further confirmed by native mass spectrometry (Fig. 2b\u2013e).", [["UAWJ246", "CHEMICAL", 23, 30], ["UAWJ247", "CHEMICAL", 35, 42], ["UAWJ248", "CHEMICAL", 130, 137], ["GC-376", "CHEMICAL", 244, 250], ["UAWJ246, 247, and 248", "CHEMICAL", 421, 442], ["UAWJ246", "CHEMICAL", 23, 30], ["UAWJ247", "CHEMICAL", 35, 42], ["UAWJ248", "CHEMICAL", 130, 137], ["GC-376", "CHEMICAL", 244, 250], ["UAWJ246", "CHEMICAL", 329, 336], ["UAWJ247", "CHEMICAL", 338, 345], ["UAWJ246", "CHEMICAL", 421, 428], ["UAWJ246", "SIMPLE_CHEMICAL", 23, 30], ["UAWJ247", "SIMPLE_CHEMICAL", 35, 42], ["GC-376", "SIMPLE_CHEMICAL", 119, 125], ["UAWJ248", "SIMPLE_CHEMICAL", 130, 137], ["GC-376 analogues", "SIMPLE_CHEMICAL", 244, 260], ["UAWJ246", "SIMPLE_CHEMICAL", 421, 428], ["Mpro", "GENE_OR_GENE_PRODUCT", 446, 450], ["HM-Mpro construct", "DNA", 78, 95], ["the HM", "TEST", 74, 80], ["\u0394Tm shift", "TEST", 169, 178], ["GC", "TEST", 244, 246], ["analogues", "TEST", 251, 260], ["the X-ray crystal structures", "TEST", 265, 293], ["SARS", "TEST", 297, 301], ["CoV", "TEST", 302, 305], ["UAWJ246", "TEST", 329, 336], ["UAWJ247", "TEST", 338, 345], ["Mpro", "TEST", 446, 450], ["stabilization", "OBSERVATION", 56, 69], ["mass", "OBSERVATION", 483, 487]]], ["Like GC-376, addition of the ligands resulted in two new sets of peaks corresponding to one ligand per dimer and two ligands per dimer.Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONEnzyme kinetic studies showed that compounds UAWJ246 and UAWJ247 bound to Mpro reversibly with inhibition constant KI values of 0.036 \u00b1 0.007 and 0.035 \u00b1 0.008 \u03bcM, respectively (Fig. 2g, h).", [["GC-376", "CHEMICAL", 5, 11], ["GC-376", "CHEMICAL", 154, 160], ["UAWJ246", "CHEMICAL", 341, 348], ["UAWJ247", "CHEMICAL", 353, 360], ["Mpro", "CHEMICAL", 370, 374], ["GC-376", "CHEMICAL", 154, 160], ["UAWJ246", "CHEMICAL", 239, 246], ["UAWJ247", "CHEMICAL", 248, 255], ["UAWJ246", "CHEMICAL", 341, 348], ["UAWJ247", "CHEMICAL", 353, 360], ["GC-376", "SIMPLE_CHEMICAL", 5, 11], ["GC-376 analogues", "SIMPLE_CHEMICAL", 154, 170], ["UAWJ246", "SIMPLE_CHEMICAL", 341, 348], ["UAWJ247", "SIMPLE_CHEMICAL", 353, 360], ["Mpro", "SIMPLE_CHEMICAL", 370, 374], ["GC", "TEST", 5, 7], ["GC", "TEST", 154, 156], ["analogues", "TEST", 161, 170], ["the X-ray crystal structures", "TEST", 175, 203], ["SARS", "TEST", 207, 211], ["CoV", "TEST", 212, 215], ["UAWJ246", "TEST", 239, 246], ["UAWJ247", "TEST", 248, 255], ["DISCUSSIONEnzyme kinetic studies", "TEST", 286, 318], ["inhibition constant KI values", "TEST", 391, 420]]], ["In contrast, the enzyme kinetic curves for compound UAWJ248 (Fig. 2i) was similar to that of GC-376 (Fig. 2f), which showed a biphasic progression character, suggesting UAWJ248 inhibits Mpro through a two-step process with an initial reversible binding followed by an irreversible inactivation.", [["UAWJ248", "CHEMICAL", 52, 59], ["GC-376", "CHEMICAL", 93, 99], ["UAWJ248", "CHEMICAL", 169, 176], ["Mpro", "CHEMICAL", 186, 190], ["UAWJ248", "CHEMICAL", 52, 59], ["UAWJ248", "CHEMICAL", 169, 176], ["UAWJ248", "SIMPLE_CHEMICAL", 52, 59], ["GC-376", "SIMPLE_CHEMICAL", 93, 99], ["UAWJ248", "SIMPLE_CHEMICAL", 169, 176], ["Mpro", "GENE_OR_GENE_PRODUCT", 186, 190], ["Mpro", "PROTEIN", 186, 190], ["the enzyme kinetic curves", "TEST", 13, 38], ["GC", "TEST", 93, 95], ["a biphasic progression character", "PROBLEM", 124, 156], ["an initial reversible binding", "PROBLEM", 223, 252], ["an irreversible inactivation", "PROBLEM", 265, 293], ["biphasic", "OBSERVATION_MODIFIER", 126, 134], ["progression", "OBSERVATION_MODIFIER", 135, 146], ["reversible binding", "OBSERVATION", 234, 252], ["irreversible", "OBSERVATION_MODIFIER", 268, 280], ["inactivation", "OBSERVATION", 281, 293]]], ["Fitting the progression curves with the two-step Morrison equation revealed the first step equilibrium dissociation constant KI and the second step reaction constant k2 as 13.20 nM and 0.001195 s\u22121, respectively, which corresponds to an overall k2/KI value of 9.05 \u00d7 104 M\u22121s\u22121.", [["the progression curves", "PROBLEM", 8, 30], ["the two-step Morrison equation", "TEST", 36, 66], ["KI value", "TEST", 248, 256], ["M\u22121s", "TEST", 271, 275]]], ["In comparison, the k2/KI value for GC-376 is 2.84 \u00d7 104 M\u22121s\u22121, suggesting UAWJ248 is 3.2-fold more potent than GC-376.Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONMost Mpro inhibitors with antiviral activity against SARS-CoV-2 use an \u03b1-ketoamide or aldehyde/bisulfite warhead to form a covalent adduct with the catalytic Cys145.15,17 We previously reported GC-376 as one of the most potent inhibitors of SARS-CoV-2 Mpro in vitro with an IC50 of 0.033 \u03bcM and EC50 of 3.37 \u03bcM in the enzymatic assay and antiviral CPE assay.15 Here we show the \u03b1-ketoamide analogue of GC-376, UAWJ246 has a comparable IC50 of 0.045 \u03bcM, suggesting the \u03b1-ketoamide and the aldehyde are nearly equivalent in terms of inhibitory activity.", [["GC-376", "CHEMICAL", 35, 41], ["UAWJ248", "CHEMICAL", 75, 82], ["GC-376", "CHEMICAL", 112, 118], ["GC-376", "CHEMICAL", 138, 144], ["\u03b1-ketoamide", "CHEMICAL", 351, 362], ["aldehyde", "CHEMICAL", 366, 374], ["bisulfite", "CHEMICAL", 375, 384], ["Cys145.15,17", "CHEMICAL", 438, 450], ["GC-376", "CHEMICAL", 474, 480], ["\u03b1-ketoamide", "CHEMICAL", 658, 669], ["GC-376", "CHEMICAL", 682, 688], ["UAWJ246", "CHEMICAL", 690, 697], ["\u03b1-ketoamide", "CHEMICAL", 748, 759], ["aldehyde", "CHEMICAL", 768, 776], ["UAWJ248", "CHEMICAL", 75, 82], ["GC-376", "CHEMICAL", 112, 118], ["GC-376", "CHEMICAL", 138, 144], ["UAWJ246", "CHEMICAL", 223, 230], ["UAWJ247", "CHEMICAL", 232, 239], ["\u03b1-ketoamide", "CHEMICAL", 351, 362], ["aldehyde", "CHEMICAL", 366, 374], ["bisulfite", "CHEMICAL", 375, 384], ["Cys", "CHEMICAL", 438, 441], ["GC-376", "CHEMICAL", 474, 480], ["\u03b1-ketoamide", "CHEMICAL", 658, 669], ["GC-376", "CHEMICAL", 682, 688], ["UAWJ246", "CHEMICAL", 690, 697], ["\u03b1-ketoamide", "CHEMICAL", 748, 759], ["aldehyde", "CHEMICAL", 768, 776], ["GC-376", "SIMPLE_CHEMICAL", 35, 41], ["UAWJ248", "SIMPLE_CHEMICAL", 75, 82], ["GC-376", "SIMPLE_CHEMICAL", 112, 118], ["GC-376 analogues", "SIMPLE_CHEMICAL", 138, 154], ["Mpro", "GENE_OR_GENE_PRODUCT", 285, 289], ["SARS-CoV-2", "ORGANISM", 333, 343], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 351, 362], ["aldehyde", "SIMPLE_CHEMICAL", 366, 374], ["bisulfite", "SIMPLE_CHEMICAL", 375, 384], ["GC-376", "CELL", 474, 480], ["SARS-CoV-2 Mpro", "ORGANISM", 521, 536], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 658, 669], ["GC-376", "SIMPLE_CHEMICAL", 682, 688], ["UAWJ246", "SIMPLE_CHEMICAL", 690, 697], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 748, 759], ["aldehyde", "SIMPLE_CHEMICAL", 768, 776], ["catalytic Cys145.15,17", "PROTEIN", 428, 450], ["SARS-CoV", "SPECIES", 333, 341], ["the k2/KI value", "TEST", 15, 30], ["GC", "TEST", 35, 37], ["M\u22121s", "TEST", 56, 60], ["UAWJ248", "TEST", 75, 82], ["GC", "TEST", 112, 114], ["GC", "TEST", 138, 140], ["analogues", "TEST", 145, 154], ["the X-ray crystal structures", "TEST", 159, 187], ["SARS", "TEST", 191, 195], ["CoV", "TEST", 196, 199], ["UAWJ246", "TEST", 223, 230], ["UAWJ247", "TEST", 232, 239], ["Mpro inhibitors", "TREATMENT", 285, 300], ["antiviral activity", "TREATMENT", 306, 324], ["SARS", "PROBLEM", 333, 337], ["an \u03b1-ketoamide", "TREATMENT", 348, 362], ["aldehyde/bisulfite warhead", "TREATMENT", 366, 392], ["the catalytic Cys", "TEST", 424, 441], ["GC", "TEST", 474, 476], ["SARS", "TEST", 521, 525], ["CoV", "TEST", 526, 529], ["an IC50", "TEST", 551, 558], ["EC50", "TEST", 575, 579], ["the enzymatic assay", "TEST", 594, 613], ["antiviral CPE assay", "TEST", 618, 637], ["GC", "TEST", 682, 684], ["the \u03b1-ketoamide and the aldehyde", "PROBLEM", 744, 776], ["antiviral CPE", "OBSERVATION", 618, 631]]], ["We solved the complex structure of UAWJ246 with both SARS-CoV-2 HM-Mpro at 1.45 \u00c5 resolution as a dimer (PDB: 6XBG) and Mpro-His at 2.35 \u00c5 as a trimer in the asymmetric unit (Fig. 3a, b; Supplementary information, Fig. S3).", [["UAWJ246", "CHEMICAL", 35, 42], ["UAWJ246", "CHEMICAL", 35, 42], ["Mpro-His", "CHEMICAL", 120, 128], ["UAWJ246", "SIMPLE_CHEMICAL", 35, 42], ["Mpro-His", "SIMPLE_CHEMICAL", 120, 128], ["dimer", "PROTEIN", 98, 103], ["Mpro", "PROTEIN", 120, 124], ["CoV", "TEST", 58, 61], ["Mpro", "TREATMENT", 67, 71], ["Mpro", "TEST", 120, 124]]], ["The binding pose of UAWJ246 in these two constructs was nearly superimposable (Supplementary information, Fig. S3), suggesting the use of enzymatic inactive HM-Mpro construct for crystallographic study of inhibitor binding is justified.", [["UAWJ246", "CHEMICAL", 20, 27], ["UAWJ246", "CHEMICAL", 20, 27], ["UAWJ246", "SIMPLE_CHEMICAL", 20, 27], ["UAWJ246", "DNA", 20, 27], ["enzymatic inactive HM-Mpro construct", "DNA", 138, 174], ["enzymatic inactive HM", "TREATMENT", 138, 159], ["crystallographic study", "TEST", 179, 201], ["inhibitor binding", "PROBLEM", 205, 222]]], ["In the dimer structure of HM-Mpro with UAWJ246, the amide oxygen of the \u03b1-ketoamide occupies the oxyanion hole, while the thiohemiketal hydroxide forms a hydrogen bond with the catalytic histidine, His41.", [["UAWJ246", "CHEMICAL", 39, 46], ["oxygen", "CHEMICAL", 58, 64], ["\u03b1-ketoamide", "CHEMICAL", 72, 83], ["thiohemiketal hydroxide", "CHEMICAL", 122, 145], ["histidine", "CHEMICAL", 187, 196], ["HM-Mpro", "CHEMICAL", 26, 33], ["UAWJ246", "CHEMICAL", 39, 46], ["amide", "CHEMICAL", 52, 57], ["oxygen", "CHEMICAL", 58, 64], ["\u03b1-ketoamide", "CHEMICAL", 72, 83], ["thiohemiketal hydroxide", "CHEMICAL", 122, 145], ["hydrogen", "CHEMICAL", 154, 162], ["histidine", "CHEMICAL", 187, 196], ["His41", "CHEMICAL", 198, 203], ["HM-Mpro", "SIMPLE_CHEMICAL", 26, 33], ["UAWJ246", "SIMPLE_CHEMICAL", 39, 46], ["amide oxygen", "SIMPLE_CHEMICAL", 52, 64], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 72, 83], ["thiohemiketal hydroxide", "SIMPLE_CHEMICAL", 122, 145], ["histidine", "AMINO_ACID", 187, 196], ["His41", "SIMPLE_CHEMICAL", 198, 203], ["His41", "PROTEIN", 198, 203], ["the amide oxygen", "TREATMENT", 48, 64], ["the \u03b1-ketoamide", "TREATMENT", 68, 83], ["the oxyanion hole", "TREATMENT", 93, 110], ["the thiohemiketal hydroxide", "TREATMENT", 118, 145], ["a hydrogen bond", "TREATMENT", 152, 167], ["the catalytic histidine", "TREATMENT", 173, 196], ["His41", "TREATMENT", 198, 203], ["oxyanion hole", "OBSERVATION", 97, 110]]], ["The cyclopropyl group extends partly into the S1\u2019 subpocket.", [["cyclopropyl", "CHEMICAL", 4, 15], ["cyclopropyl", "CHEMICAL", 4, 15], ["cyclopropyl", "SIMPLE_CHEMICAL", 4, 15], ["S1", "PROTEIN", 46, 48], ["The cyclopropyl group", "TREATMENT", 0, 21], ["S1", "ANATOMY", 46, 48]]], ["Interestingly, the carboxybenzyl of UAWJ246 adopts a different conformation in each protomer (Fig. 3a, b).", [["carboxybenzyl", "CHEMICAL", 19, 32], ["UAWJ246", "CHEMICAL", 36, 43], ["carboxybenzyl", "CHEMICAL", 19, 32], ["UAWJ246", "CHEMICAL", 36, 43], ["UAWJ246", "SIMPLE_CHEMICAL", 36, 43], ["UAWJ246", "PROTEIN", 36, 43]]], ["In the A protomer of the 1.45 \u00c5 resolution structure crystallized in P21 space group, the carboxybenzyl moiety extends the length of the S3 and S4 subsites, forcing residues 189\u2013191 to flip outwards (Fig. 3a).", [["carboxybenzyl", "CHEMICAL", 90, 103], ["carboxybenzyl", "CHEMICAL", 90, 103], ["carboxybenzyl moiety", "SIMPLE_CHEMICAL", 90, 110], ["P21 space group", "PROTEIN", 69, 84], ["S3 and S4 subsites", "PROTEIN", 137, 155], ["P21 space group", "TREATMENT", 69, 84], ["the carboxybenzyl moiety", "TREATMENT", 86, 110], ["P21 space", "OBSERVATION", 69, 78], ["length", "OBSERVATION_MODIFIER", 123, 129], ["S3", "ANATOMY", 137, 139], ["S4 subsites", "OBSERVATION", 144, 155]]], ["In the B protomer, the carboxybenzyl moiety projects upwards, where the S3 sidechain is normally positioned (Fig. 3b).", [["carboxybenzyl", "CHEMICAL", 23, 36], ["carboxybenzyl", "CHEMICAL", 23, 36], ["carboxybenzyl moiety", "SIMPLE_CHEMICAL", 23, 43], ["B protomer", "PROTEIN", 7, 17], ["the carboxybenzyl moiety", "TREATMENT", 19, 43], ["S3", "ANATOMY", 72, 74], ["sidechain", "ANATOMY_MODIFIER", 75, 84], ["normally", "OBSERVATION_MODIFIER", 88, 96], ["positioned", "OBSERVATION_MODIFIER", 97, 107]]], ["The A-conformation resembles that of GC-376 in our previously solved structure (PDB: 6WTT) (Supplementary information, Fig. S4a), whereas the B-conformation resembles GC-376 from PDB ID 7BRR (Supplementary information, Fig. S4b)37.", [["GC-376", "CHEMICAL", 37, 43], ["GC-376", "CHEMICAL", 167, 173], ["6WTT", "PROTEIN", 85, 89], ["S4a", "PROTEIN", 124, 127], ["B", "PROTEIN", 142, 143], ["GC", "TEST", 37, 39], ["GC", "TEST", 167, 169]]], ["The downward conformation establishes extensive interactions with the S4 pocket, and may be one of the main reasons for the superior in vitro activity of GC-376 and its analogues.", [["GC-376", "CHEMICAL", 154, 160], ["GC-376", "CHEMICAL", 154, 160], ["GC-376", "SIMPLE_CHEMICAL", 154, 160], ["the S4 pocket", "PROBLEM", 66, 79], ["GC", "TEST", 154, 156], ["downward", "OBSERVATION_MODIFIER", 4, 12], ["extensive", "OBSERVATION_MODIFIER", 38, 47]]], ["The upward conformation also forms favorable interactions with protein residues constituting the S3 site, including Glu166 and Gln189.", [["Glu166", "CHEMICAL", 116, 122], ["Gln189", "CHEMICAL", 127, 133], ["Glu166", "GENE_OR_GENE_PRODUCT", 116, 122], ["Gln189", "AMINO_ACID", 127, 133], ["S3 site", "DNA", 97, 104], ["Glu166", "PROTEIN", 116, 122], ["Gln189", "PROTEIN", 127, 133], ["protein residues", "PROBLEM", 63, 79], ["Glu166", "TEST", 116, 122]]], ["Additionally, it enables the formation of intramolecular interactions between the benzyl ring and the P1 sidechain, similar to the hydrophobic intramolecular interactions formed between the P1 and P3 moieties in calpain inhibitor II and boceprevir, as well as, to some degree, the \u03c0-\u03c0 stacking between the pyridine and the carboxybenzyl of calpain inhibitor XII (Fig. 2\u20133; Supplementary information, Fig. S5).38 It is likely that GC-376, UAWJ246, and other analogues exist in a dynamic equilibrium between these conformations and the captured crystallographic poses are, in part, determined by the crystal-packing interface between protomers and/or differences in the pH or ionic strength of the crystallization solution.Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONThe chemical structure of UAWJ247 is nearly identical to GC-376, except for the replacement of its S2 isobutyl moiety for a benzyl group, analogous to a Leu \u2192 Phe exchange.", [["benzyl", "CHEMICAL", 82, 88], ["inhibitor II", "CHEMICAL", 220, 232], ["boceprevir", "CHEMICAL", 237, 247], ["pyridine", "CHEMICAL", 306, 314], ["GC-376", "CHEMICAL", 430, 436], ["UAWJ246", "CHEMICAL", 438, 445], ["GC-376", "CHEMICAL", 740, 746], ["UAWJ247", "CHEMICAL", 908, 915], ["GC-376", "CHEMICAL", 939, 945], ["isobutyl", "CHEMICAL", 984, 992], ["benzyl", "CHEMICAL", 1006, 1012], ["Leu", "CHEMICAL", 1035, 1038], ["Phe", "CHEMICAL", 1041, 1044], ["benzyl", "CHEMICAL", 82, 88], ["boceprevir", "CHEMICAL", 237, 247], ["pyridine", "CHEMICAL", 306, 314], ["carboxybenzyl", "CHEMICAL", 323, 336], ["UAWJ246", "CHEMICAL", 438, 445], ["GC-376", "CHEMICAL", 740, 746], ["UAWJ246", "CHEMICAL", 825, 832], ["UAWJ247", "CHEMICAL", 834, 841], ["UAWJ247", "CHEMICAL", 908, 915], ["isobutyl", "CHEMICAL", 984, 992], ["benzyl", "CHEMICAL", 1006, 1012], ["Leu", "CHEMICAL", 1035, 1038], ["Phe", "CHEMICAL", 1041, 1044], ["benzyl ring", "SIMPLE_CHEMICAL", 82, 93], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 212, 232], ["boceprevir", "SIMPLE_CHEMICAL", 237, 247], ["pyridine", "SIMPLE_CHEMICAL", 306, 314], ["calpain", "GENE_OR_GENE_PRODUCT", 340, 347], ["XII", "GENE_OR_GENE_PRODUCT", 358, 361], ["S5", "GENE_OR_GENE_PRODUCT", 405, 407], ["GC-376", "SIMPLE_CHEMICAL", 430, 436], ["UAWJ246", "SIMPLE_CHEMICAL", 438, 445], ["GC-376 analogues", "SIMPLE_CHEMICAL", 740, 756], ["UAWJ247", "SIMPLE_CHEMICAL", 908, 915], ["GC-376", "SIMPLE_CHEMICAL", 939, 945], ["S2 isobutyl moiety", "SIMPLE_CHEMICAL", 981, 999], ["benzyl", "SIMPLE_CHEMICAL", 1006, 1012], ["Phe", "AMINO_ACID", 1041, 1044], ["P1 and P3 moieties", "PROTEIN", 190, 208], ["calpain", "PROTEIN", 212, 219], ["calpain", "PROTEIN", 340, 347], ["XII", "PROTEIN", 358, 361], ["S5", "PROTEIN", 405, 407], ["intramolecular interactions", "PROBLEM", 42, 69], ["the benzyl ring and the P1 sidechain", "TREATMENT", 78, 114], ["the hydrophobic intramolecular interactions", "PROBLEM", 127, 170], ["the P1 and P3 moieties", "TREATMENT", 186, 208], ["calpain inhibitor II", "TREATMENT", 212, 232], ["boceprevir", "TREATMENT", 237, 247], ["the pyridine", "TREATMENT", 302, 314], ["the carboxybenzyl of calpain inhibitor XII", "TREATMENT", 319, 361], ["GC", "TEST", 430, 432], ["UAWJ246", "TEST", 438, 445], ["other analogues", "PROBLEM", 451, 466], ["the crystal-packing interface between protomers", "TREATMENT", 594, 641], ["the crystallization solution", "TREATMENT", 692, 720], ["GC", "TEST", 740, 742], ["analogues", "TEST", 747, 756], ["the X-ray crystal structures", "TEST", 761, 789], ["SARS", "TEST", 793, 797], ["CoV", "TEST", 798, 801], ["UAWJ246", "TEST", 825, 832], ["UAWJ247", "TEST", 834, 841], ["GC", "TEST", 939, 941], ["the replacement of its S2 isobutyl moiety", "TREATMENT", 958, 999], ["a benzyl group", "TREATMENT", 1004, 1018], ["Phe exchange", "TREATMENT", 1041, 1053], ["intramolecular interactions", "OBSERVATION", 42, 69], ["benzyl ring", "OBSERVATION", 82, 93], ["likely", "UNCERTAINTY", 418, 424], ["packing interface", "OBSERVATION", 606, 623], ["chemical structure", "OBSERVATION", 886, 904], ["replacement", "OBSERVATION", 962, 973]]], ["To visualize the binding mode of UAWJ247, we solved the complex structure with SARS-CoV-2 Mpro at 1.60 \u00c5 in the C2 space group with one protomer per asymmetric unit (PDB: 6XBH) (Fig. 3c, d).", [["UAWJ247", "CHEMICAL", 33, 40], ["UAWJ247", "SIMPLE_CHEMICAL", 33, 40], ["UAWJ247", "PROTEIN", 33, 40], ["C2 space group", "PROTEIN", 112, 126], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["C2", "ANATOMY", 112, 114]]], ["Like their chemical structures, the binding poses between UAWJ247 and GC-376 are very similar (Fig. 3d), with minor differences observed for Gln189 and the catalytic histidine, His41, which swivels towards the S2 benzyl group to form face-to-face \u03c0-stacking interactions.", [["UAWJ247", "CHEMICAL", 58, 65], ["GC-376", "CHEMICAL", 70, 76], ["histidine", "CHEMICAL", 166, 175], ["His41", "CHEMICAL", 177, 182], ["benzyl", "CHEMICAL", 213, 219], ["GC-376", "CHEMICAL", 70, 76], ["Gln189", "CHEMICAL", 141, 147], ["histidine", "CHEMICAL", 166, 175], ["His41", "CHEMICAL", 177, 182], ["benzyl", "CHEMICAL", 213, 219], ["UAWJ247", "SIMPLE_CHEMICAL", 58, 65], ["GC-376", "GENE_OR_GENE_PRODUCT", 70, 76], ["Gln189", "SIMPLE_CHEMICAL", 141, 147], ["histidine", "AMINO_ACID", 166, 175], ["His41", "SIMPLE_CHEMICAL", 177, 182], ["Gln189", "PROTEIN", 141, 147], ["UAWJ247", "TEST", 58, 65], ["GC", "TEST", 70, 72], ["the catalytic histidine", "TREATMENT", 152, 175], ["His41", "TEST", 177, 182], ["chemical structures", "OBSERVATION", 11, 30]]], ["As expected, the IC50 of 0.045 \u03bcM for UAWJ247 is very close to that of GC-376 and consistent with the preference for a hydrophobic residue at the S2 site.", [["UAWJ247", "CHEMICAL", 38, 45], ["GC-376", "CHEMICAL", 71, 77], ["UAWJ247", "CHEMICAL", 38, 45], ["UAWJ247", "SIMPLE_CHEMICAL", 38, 45], ["S2 site", "DNA", 146, 153], ["the IC50", "TEST", 13, 21], ["GC", "TEST", 71, 73], ["a hydrophobic residue at the S2 site", "PROBLEM", 117, 153], ["consistent with", "UNCERTAINTY", 82, 97], ["hydrophobic residue", "OBSERVATION", 119, 138], ["S2", "ANATOMY", 146, 148]]], ["This data also suggests replacing Leu for a larger Phe is tolerated, and that aromaticity can be incorporated into the S2 site for the purpose of improving pharmacokinetic properties or broadening the spectrum of activity, with limited effect on Mpro inhibition.Rational design of GC-376 analogues and the X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248. ::: RESULTS AND DISCUSSIONUAWJ248 was designed to occupy the additional S4 pocket compared to UAWJ246.", [["Leu", "CHEMICAL", 34, 37], ["Phe", "CHEMICAL", 51, 54], ["GC-376", "CHEMICAL", 281, 287], ["UAWJ246", "CHEMICAL", 491, 498], ["Leu", "CHEMICAL", 34, 37], ["Phe", "CHEMICAL", 51, 54], ["GC-376", "CHEMICAL", 281, 287], ["UAWJ246", "CHEMICAL", 366, 373], ["UAWJ247", "CHEMICAL", 375, 382], ["UAWJ246", "CHEMICAL", 491, 498], ["Phe", "AMINO_ACID", 51, 54], ["Mpro", "SIMPLE_CHEMICAL", 246, 250], ["GC-376 analogues", "SIMPLE_CHEMICAL", 281, 297], ["S2 site", "DNA", 119, 126], ["UAWJ246", "PROTEIN", 491, 498], ["Mpro inhibition", "TREATMENT", 246, 261], ["GC", "TEST", 281, 283], ["analogues", "TEST", 288, 297], ["the X-ray crystal structures", "TEST", 302, 330], ["SARS", "TEST", 334, 338], ["CoV", "TEST", 339, 342], ["UAWJ246", "TEST", 366, 373], ["UAWJ247", "TEST", 375, 382], ["the additional S4 pocket", "PROBLEM", 454, 478], ["larger", "OBSERVATION_MODIFIER", 44, 50], ["S4 pocket", "OBSERVATION", 469, 478]]], ["We solved the complex structure of UAWJ248 with SARS-CoV-2 HM-Mpro at 1.70 \u00c5 as a dimer in the P1 monoclinic space group (PDB: 6XBI) (Fig. 3e, f).", [["UAWJ248", "CHEMICAL", 35, 42], ["UAWJ248", "CHEMICAL", 35, 42], ["UAWJ248", "SIMPLE_CHEMICAL", 35, 42], ["P1 monoclinic space group", "PROTEIN", 95, 120], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["Mpro", "TEST", 62, 66]]], ["The conformation is consistent in both protomers The \u03b1-ketoamide warhead forms an adduct with Cys145 in the (S) conformation, like other cyclopropane \u03b1-ketoamide analogues described herein including UAWJ246 and previously published 13b.17 Similarly, the P1 \u03b3-lactam and P2 isobutyl moieties occupy their respective S1 and S2 subsites.", [["\u03b1-ketoamide", "CHEMICAL", 53, 64], ["Cys145", "CHEMICAL", 94, 100], ["cyclopropane \u03b1-ketoamide", "CHEMICAL", 137, 161], ["\u03b3-lactam", "CHEMICAL", 257, 265], ["P2 isobutyl", "CHEMICAL", 270, 281], ["\u03b1-ketoamide", "CHEMICAL", 53, 64], ["Cys", "CHEMICAL", 94, 97], ["cyclopropane \u03b1-ketoamide", "CHEMICAL", 137, 161], ["UAWJ246", "CHEMICAL", 199, 206], ["\u03b3-lactam", "CHEMICAL", 257, 265], ["isobutyl", "CHEMICAL", 273, 281], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 53, 64], ["Cys145", "SIMPLE_CHEMICAL", 94, 100], ["cyclopropane \u03b1-ketoamide analogues", "SIMPLE_CHEMICAL", 137, 171], ["UAWJ246", "SIMPLE_CHEMICAL", 199, 206], ["P2 isobutyl moieties", "SIMPLE_CHEMICAL", 270, 290], ["S1 and S2 subsites", "PROTEIN", 315, 333], ["Cys", "TEST", 94, 97], ["other cyclopropane \u03b1-ketoamide analogues", "TREATMENT", 131, 171], ["the P1 \u03b3-lactam", "TEST", 250, 265], ["S1", "ANATOMY", 315, 317], ["S2 subsites", "OBSERVATION", 322, 333]]], ["The P3 isobutyl orients upwards into the S3 site where it forms no meaningful interactions.", [["P3 isobutyl", "CHEMICAL", 4, 15], ["isobutyl", "CHEMICAL", 7, 15], ["P3 isobutyl", "SIMPLE_CHEMICAL", 4, 15], ["S3 site", "DNA", 41, 48], ["S3", "ANATOMY", 41, 43]]], ["However, the insertion of an additional leucine into the UAWJ246 core ensures the formation of a hydrogen bond with the main chain amide oxygen of Glu166.", [["leucine", "CHEMICAL", 40, 47], ["oxygen", "CHEMICAL", 137, 143], ["Glu166", "CHEMICAL", 147, 153], ["leucine", "CHEMICAL", 40, 47], ["hydrogen", "CHEMICAL", 97, 105], ["amide", "CHEMICAL", 131, 136], ["oxygen", "CHEMICAL", 137, 143], ["Glu", "CHEMICAL", 147, 150], ["leucine", "AMINO_ACID", 40, 47], ["oxygen", "SIMPLE_CHEMICAL", 137, 143], ["Glu166", "AMINO_ACID", 147, 153], ["UAWJ246 core", "DNA", 57, 69], ["an additional leucine", "TREATMENT", 26, 47], ["a hydrogen bond", "TREATMENT", 95, 110], ["Glu", "TEST", 147, 150], ["hydrogen bond", "OBSERVATION", 97, 110], ["main", "OBSERVATION_MODIFIER", 120, 124]]], ["The terminal carboxybenzyl is placed in the S4-S5 site, where nonspecific interactions occur between the benzene and side chain of Pro168 and Ala191 and \u03c0 stacking with the main chain amides of Gln189, Thr190, and Ala191.Molecular dynamics simulations of SARS-CoV-2 Mpro with inhibitors. ::: RESULTS AND DISCUSSIONThe binding interactions between the covalently bound calpain inhibitor II, calpain inhibitor XII, UAWJ246, UAWJ247, and UAWJ248, with SARS-CoV-2 Mpro were further explored using 100 ns-MD simulations with starting structures the X-ray structures with PBD IDs 6XA4, 6XFN, 6XBG (dimer), 6XBH (monomer), 6XBI (dimer).", [["carboxybenzyl", "CHEMICAL", 13, 26], ["benzene", "CHEMICAL", 105, 112], ["Ala191", "CHEMICAL", 214, 220], ["carboxybenzyl", "CHEMICAL", 13, 26], ["benzene", "CHEMICAL", 105, 112], ["Pro168", "CHEMICAL", 131, 137], ["Ala191", "CHEMICAL", 142, 148], ["\u03c0", "CHEMICAL", 153, 154], ["amides", "CHEMICAL", 184, 190], ["Gln189", "CHEMICAL", 194, 200], ["Thr", "CHEMICAL", 202, 205], ["Ala", "CHEMICAL", 214, 217], ["6XBH", "CHEMICAL", 600, 604], ["benzene", "SIMPLE_CHEMICAL", 105, 112], ["Pro168", "SIMPLE_CHEMICAL", 131, 137], ["Ala191", "SIMPLE_CHEMICAL", 142, 148], ["Gln189", "SIMPLE_CHEMICAL", 194, 200], ["Thr190", "AMINO_ACID", 202, 208], ["Ala191", "AMINO_ACID", 214, 220], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 368, 388], ["calpain", "GENE_OR_GENE_PRODUCT", 390, 397], ["XII", "GENE_OR_GENE_PRODUCT", 408, 411], ["UAWJ246", "GENE_OR_GENE_PRODUCT", 413, 420], ["UAWJ247", "GENE_OR_GENE_PRODUCT", 422, 429], ["UAWJ248", "SIMPLE_CHEMICAL", 435, 442], ["6XFN", "SIMPLE_CHEMICAL", 580, 584], ["6XBG", "SIMPLE_CHEMICAL", 586, 590], ["6XBH", "SIMPLE_CHEMICAL", 600, 604], ["6XBI", "SIMPLE_CHEMICAL", 616, 620], ["S4-S5 site", "DNA", 44, 54], ["calpain inhibitor II", "PROTEIN", 368, 388], ["calpain", "PROTEIN", 390, 397], ["XII", "PROTEIN", 408, 411], ["6XFN", "PROTEIN", 580, 584], ["6XBG", "PROTEIN", 586, 590], ["dimer", "PROTEIN", 592, 597], ["6XBH", "PROTEIN", 600, 604], ["6XBI", "PROTEIN", 616, 620], ["dimer", "PROTEIN", 622, 627], ["The terminal carboxybenzyl", "TREATMENT", 0, 26], ["nonspecific interactions", "PROBLEM", 62, 86], ["Ala191", "TEST", 142, 148], ["Thr", "TEST", 202, 205], ["Ala", "TEST", 214, 217], ["SARS", "TEST", 255, 259], ["CoV", "TEST", 260, 263], ["inhibitors", "TREATMENT", 276, 286], ["the covalently bound calpain inhibitor II", "TREATMENT", 347, 388], ["calpain inhibitor XII", "TEST", 390, 411], ["UAWJ246", "TEST", 413, 420], ["UAWJ247", "TEST", 422, 429], ["UAWJ248", "TEST", 435, 442], ["SARS", "TEST", 449, 453], ["CoV", "TEST", 454, 457], ["the X-ray structures", "TEST", 540, 560], ["PBD IDs", "TEST", 566, 573], ["6XFN", "TEST", 580, 584], ["terminal", "OBSERVATION_MODIFIER", 4, 12], ["carboxybenzyl", "OBSERVATION", 13, 26], ["S4", "ANATOMY", 44, 46], ["nonspecific", "OBSERVATION_MODIFIER", 62, 73]]], ["The simulations demonstrate that the complexes formed are stable, and the ligand positions do not deviate significantly from the crystallographic ones, with C\u03b1 RMSD values less than 2.4 \u00c5 and an overall ligand RMSD less than 3.5 \u00c5 (Fig. 4).", [["C\u03b1 RMSD values", "TEST", 157, 171], ["an overall ligand RMSD", "TEST", 192, 214], ["stable", "OBSERVATION_MODIFIER", 58, 64], ["ligand RMSD", "OBSERVATION", 203, 214]]], ["The MD simulations further verified the stability of the interactions inside the binding cavity of SARS-CoV-2 Mpro observed in the X-ray structures, as inspected from the trajectories and shown in frequency interaction plots (Fig. 4a, d, g, j, m, p, s).Molecular dynamics simulations of SARS-CoV-2 Mpro with inhibitors. ::: RESULTS AND DISCUSSIONCompared to calpain inhibitor II (Fig. 4a, b), in UAWJ247, which also has an aldehyde warhead, the methionine P1 substituent was changed to 3-(2-pyrrolidinone) and additional hydrogen bonding interactions are formed.", [["inhibitor II", "CHEMICAL", 366, 378], ["UAWJ247", "CHEMICAL", 396, 403], ["aldehyde", "CHEMICAL", 423, 431], ["methionine", "CHEMICAL", 445, 455], ["3-(2-pyrrolidinone", "CHEMICAL", 486, 504], ["UAWJ247", "CHEMICAL", 396, 403], ["aldehyde", "CHEMICAL", 423, 431], ["methionine", "CHEMICAL", 445, 455], ["3-(2-pyrrolidinone)", "CHEMICAL", 486, 505], ["hydrogen", "CHEMICAL", 521, 529], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 358, 378], ["Fig. 4a, b)", "SIMPLE_CHEMICAL", 380, 391], ["UAWJ247", "SIMPLE_CHEMICAL", 396, 403], ["aldehyde", "SIMPLE_CHEMICAL", 423, 431], ["methionine P1 substituent", "SIMPLE_CHEMICAL", 445, 470], ["3-(2-pyrrolidinone", "SIMPLE_CHEMICAL", 486, 504], ["calpain", "PROTEIN", 358, 365], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107], ["SARS", "TEST", 287, 291], ["CoV", "TEST", 292, 295], ["inhibitors", "TREATMENT", 308, 318], ["calpain inhibitor II", "TREATMENT", 358, 378], ["the methionine P1 substituent", "TREATMENT", 441, 470], ["pyrrolidinone", "TREATMENT", 491, 504], ["additional hydrogen bonding interactions", "TREATMENT", 510, 550], ["aldehyde warhead", "OBSERVATION", 423, 439]]], ["UAWJ247 forms important hydrogen bonding interactions between the P1 2-pyrrolidinone NH group and E166 side chain, and peptidic carbonyl of F140 (Fig. 4m, n), in addition to the hydrogen bonds with G143, S144, C145, H164, Q189.", [["UAWJ247", "CHEMICAL", 0, 7], ["P1 2-pyrrolidinone", "CHEMICAL", 66, 84], ["E166", "CHEMICAL", 98, 102], ["UAWJ247", "CHEMICAL", 0, 7], ["hydrogen", "CHEMICAL", 24, 32], ["2-pyrrolidinone", "CHEMICAL", 69, 84], ["NH", "CHEMICAL", 85, 87], ["E166", "CHEMICAL", 98, 102], ["carbonyl", "CHEMICAL", 128, 136], ["F140", "CHEMICAL", 140, 144], ["hydrogen", "CHEMICAL", 178, 186], ["G143", "CHEMICAL", 198, 202], ["S144", "CHEMICAL", 204, 208], ["C145", "CHEMICAL", 210, 214], ["H164", "CHEMICAL", 216, 220], ["Q189", "CHEMICAL", 222, 226], ["UAWJ247", "SIMPLE_CHEMICAL", 0, 7], ["P1 2-pyrrolidinone NH", "SIMPLE_CHEMICAL", 66, 87], ["E166 side chain", "SIMPLE_CHEMICAL", 98, 113], ["peptidic carbonyl", "SIMPLE_CHEMICAL", 119, 136], ["F140", "SIMPLE_CHEMICAL", 140, 144], ["G143", "SIMPLE_CHEMICAL", 198, 202], ["S144", "SIMPLE_CHEMICAL", 204, 208], ["C145", "SIMPLE_CHEMICAL", 210, 214], ["P1 2-pyrrolidinone NH group", "PROTEIN", 66, 93], ["pyrrolidinone NH group and E166 side chain", "TREATMENT", 71, 113], ["peptidic carbonyl of F140", "TREATMENT", 119, 144], ["hydrogen bonding", "OBSERVATION", 24, 40]]], ["Furthermore, the P2 benzyl group in UAWJ247 fits better in the S2 subsite than the isopropyl from calpain inhibitor II, resulting in new van der Waals interactions with M49, H41, M165 (Fig. 4m, n).", [["benzyl", "CHEMICAL", 20, 26], ["UAWJ247", "CHEMICAL", 36, 43], ["isopropyl", "CHEMICAL", 83, 92], ["benzyl", "CHEMICAL", 20, 26], ["UAWJ247", "CHEMICAL", 36, 43], ["isopropyl", "CHEMICAL", 83, 92], ["M49", "CHEMICAL", 169, 172], ["H41", "CHEMICAL", 174, 177], ["M165", "CHEMICAL", 179, 183], ["P2 benzyl", "SIMPLE_CHEMICAL", 17, 26], ["UAWJ247", "SIMPLE_CHEMICAL", 36, 43], ["isopropyl", "SIMPLE_CHEMICAL", 83, 92], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 98, 118], ["M49", "SIMPLE_CHEMICAL", 169, 172], ["calpain inhibitor II", "PROTEIN", 98, 118], ["the P2 benzyl group", "TREATMENT", 13, 32], ["the isopropyl", "TREATMENT", 79, 92], ["calpain inhibitor II", "TREATMENT", 98, 118], ["new van der Waals interactions", "PROBLEM", 133, 163], ["M49", "TEST", 169, 172]]], ["These additional stabilizing interactions reduce the IC50 against SARS-CoV-2 Mpro by 23-fold, i.e., from 0.97 \u03bcM in calpain inhibitor II to 0.042 \u03bcM in UAWJ247.Molecular dynamics simulations of SARS-CoV-2 Mpro with inhibitors. ::: RESULTS AND DISCUSSIONCalpain inhibitor XII, UAWJ246 and UAWJ248 are ketoamides having a ketone carbonyl compared to the aldehyde group in calpain inhibitor II and UAWJ247.", [["UAWJ247", "CHEMICAL", 152, 159], ["UAWJ246", "CHEMICAL", 276, 283], ["UAWJ248", "CHEMICAL", 288, 295], ["ketoamides", "CHEMICAL", 300, 310], ["ketone carbonyl", "CHEMICAL", 320, 335], ["aldehyde", "CHEMICAL", 352, 360], ["UAWJ247", "CHEMICAL", 395, 402], ["UAWJ246", "CHEMICAL", 276, 283], ["UAWJ248", "CHEMICAL", 288, 295], ["ketoamides", "CHEMICAL", 300, 310], ["ketone carbonyl", "CHEMICAL", 320, 335], ["aldehyde", "CHEMICAL", 352, 360], ["UAWJ247", "CHEMICAL", 395, 402], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 116, 136], ["XII", "GENE_OR_GENE_PRODUCT", 271, 274], ["UAWJ246", "SIMPLE_CHEMICAL", 276, 283], ["UAWJ248", "SIMPLE_CHEMICAL", 288, 295], ["ketoamides", "SIMPLE_CHEMICAL", 300, 310], ["ketone carbonyl", "SIMPLE_CHEMICAL", 320, 335], ["aldehyde", "SIMPLE_CHEMICAL", 352, 360], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 370, 390], ["UAWJ247", "SIMPLE_CHEMICAL", 395, 402], ["calpain inhibitor II", "PROTEIN", 116, 136], ["calpain", "PROTEIN", 370, 377], ["SARS-CoV", "SPECIES", 66, 74], ["the IC50", "TEST", 49, 57], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["calpain inhibitor II", "TREATMENT", 116, 136], ["SARS", "TEST", 194, 198], ["CoV", "TEST", 199, 202], ["inhibitors", "TREATMENT", 215, 225], ["UAWJ246", "TEST", 276, 283], ["ketoamides", "TREATMENT", 300, 310], ["a ketone carbonyl", "TREATMENT", 318, 335], ["the aldehyde group in calpain inhibitor II", "TREATMENT", 348, 390]]], ["Calpain inhibitor XII forms hydrogen bond interactions with residues H41, G143, S144, C145, H164 and E166 (Fig. 4d, e).", [["hydrogen", "CHEMICAL", 28, 36], ["H41", "CHEMICAL", 69, 72], ["G143", "CHEMICAL", 74, 78], ["S144", "CHEMICAL", 80, 84], ["C145", "CHEMICAL", 86, 90], ["H164", "CHEMICAL", 92, 96], ["E166", "CHEMICAL", 101, 105], ["Calpain", "GENE_OR_GENE_PRODUCT", 0, 7], ["XII", "GENE_OR_GENE_PRODUCT", 18, 21], ["Calpain inhibitor XII", "PROTEIN", 0, 21], ["Calpain inhibitor XII", "TREATMENT", 0, 21]]], ["The P1 pyridinyl group is positioned in the S1 region and forms hydrogen bond with His163.", [["pyridinyl", "CHEMICAL", 7, 16], ["His163", "CHEMICAL", 83, 89], ["pyridinyl", "CHEMICAL", 7, 16], ["hydrogen", "CHEMICAL", 64, 72], ["His", "CHEMICAL", 83, 86], ["His163", "SIMPLE_CHEMICAL", 83, 89], ["P1 pyridinyl group", "PROTEIN", 4, 22], ["S1 region", "PROTEIN", 44, 53], ["The P1 pyridinyl group", "TREATMENT", 0, 22], ["S1", "ANATOMY", 44, 46], ["region", "ANATOMY_MODIFIER", 47, 53], ["hydrogen bond", "OBSERVATION", 64, 77]]], ["Compared to calpain inhibitor XII, in UAWJ246 the 3-(pyrrolidin-2-one)methyl substitution occupies the S1 subsite instead of (2-pyridinyl)methyl in calpain inhibitor XII, leading to additional stabilizing hydrogen bonds as described previously.", [["UAWJ246", "CHEMICAL", 38, 45], ["3-(pyrrolidin-2-one)methyl", "CHEMICAL", 50, 76], ["(2-pyridinyl)methyl", "CHEMICAL", 125, 144], ["UAWJ246", "CHEMICAL", 38, 45], ["3-(pyrrolidin-2-one)methyl", "CHEMICAL", 50, 76], ["(2-pyridinyl)methyl", "CHEMICAL", 125, 144], ["hydrogen", "CHEMICAL", 205, 213], ["calpain inhibitor XII", "GENE_OR_GENE_PRODUCT", 12, 33], ["UAWJ246", "SIMPLE_CHEMICAL", 38, 45], ["3-(pyrrolidin-2-one)methyl", "SIMPLE_CHEMICAL", 50, 76], ["(2-pyridinyl)methyl", "SIMPLE_CHEMICAL", 125, 144], ["calpain", "GENE_OR_GENE_PRODUCT", 148, 155], ["XII", "GENE_OR_GENE_PRODUCT", 166, 169], ["calpain inhibitor XII", "PROTEIN", 12, 33], ["calpain inhibitor XII", "PROTEIN", 148, 169], ["calpain inhibitor XII", "TEST", 12, 33], ["pyrrolidin", "TREATMENT", 53, 63], ["methyl substitution", "TREATMENT", 70, 89], ["methyl in calpain inhibitor XII", "TREATMENT", 138, 169], ["additional stabilizing hydrogen bonds", "TREATMENT", 182, 219], ["hydrogen bonds", "OBSERVATION", 205, 219]]], ["In addition, the small cyclopropyl group fits in S1\u2019 subsite, avoiding steric repulsions with S1\u2019 subsite amino acids as seen in the MD simulation trajectory with calpain inhibitor XII.", [["cyclopropyl", "CHEMICAL", 23, 34], ["fits", "DISEASE", 41, 45], ["amino acids", "CHEMICAL", 106, 117], ["cyclopropyl", "CHEMICAL", 23, 34], ["amino acids", "CHEMICAL", 106, 117], ["amino acids", "AMINO_ACID", 106, 117], ["calpain inhibitor XII", "GENE_OR_GENE_PRODUCT", 163, 184], ["S1", "PROTEIN", 49, 51], ["S1", "PROTEIN", 94, 96], ["calpain", "PROTEIN", 163, 170], ["XII", "PROTEIN", 181, 184], ["the small cyclopropyl group fits", "TREATMENT", 13, 45], ["S1\u2019 subsite", "TREATMENT", 49, 60], ["steric repulsions", "PROBLEM", 71, 88], ["S1\u2019 subsite amino acids", "TREATMENT", 94, 117], ["calpain inhibitor XII", "TREATMENT", 163, 184], ["small", "OBSERVATION_MODIFIER", 17, 22], ["cyclopropyl group", "OBSERVATION", 23, 40], ["steric repulsions", "OBSERVATION", 71, 88]]], ["These changes resulted in a potency enhancement by 100-fold, i.e., from 0.45 \u03bcM for calpain inhibitor XII to 0.045 \u03bcM for UAWJ246.", [["UAWJ246", "CHEMICAL", 122, 129], ["UAWJ246", "CHEMICAL", 122, 129], ["calpain inhibitor XII", "GENE_OR_GENE_PRODUCT", 84, 105], ["calpain", "PROTEIN", 84, 91], ["XII", "PROTEIN", 102, 105], ["a potency enhancement", "PROBLEM", 26, 47], ["calpain inhibitor XII", "TREATMENT", 84, 105], ["potency", "OBSERVATION_MODIFIER", 28, 35], ["enhancement", "OBSERVATION_MODIFIER", 36, 47]]], ["In UAWJ248 the length of the peptide was increased by adding a leucine between P2 Leu and Cbz group and additional lipophilic contacts with P168 are observed (Fig. 4p, q, s, t) but the activity remained unchanged.", [["leucine", "CHEMICAL", 63, 70], ["P2 Leu", "CHEMICAL", 79, 85], ["Cbz", "CHEMICAL", 90, 93], ["leucine", "CHEMICAL", 63, 70], ["Leu", "CHEMICAL", 82, 85], ["Cbz", "CHEMICAL", 90, 93], ["P168", "CHEMICAL", 140, 144], ["UAWJ248", "SIMPLE_CHEMICAL", 3, 10], ["leucine", "AMINO_ACID", 63, 70], ["P2 Leu", "SIMPLE_CHEMICAL", 79, 85], ["Cbz", "SIMPLE_CHEMICAL", 90, 93], ["P168", "SIMPLE_CHEMICAL", 140, 144], ["a leucine between P2 Leu and Cbz group", "TREATMENT", 61, 99], ["lipophilic contacts", "OBSERVATION", 115, 134], ["unchanged", "OBSERVATION_MODIFIER", 203, 212]]], ["Two drug-bound complexes are shown for UAWJ246 (pose 1 and pose 2) (Fig. 4g\u2013i, 4j\u2013l) and for UAWJ248 (pose 1 and pose 2) (Fig. 4p\u2013r, 4s\u2013u), which correspond to different protomers.", [["UAWJ246", "CHEMICAL", 39, 46], ["UAWJ246", "CHEMICAL", 39, 46], ["UAWJ248", "CHEMICAL", 93, 100], ["UAWJ246", "SIMPLE_CHEMICAL", 39, 46], ["UAWJ246", "TEST", 39, 46], ["UAWJ248", "TEST", 93, 100]]], ["Minor differences are observed in the hydrogen bonding interactions between the two binding cavities in each protomer, reflecting the dynamic nature of the complexes.", [["hydrogen", "CHEMICAL", 38, 46], ["hydrogen", "CHEMICAL", 38, 46], ["hydrogen", "SIMPLE_CHEMICAL", 38, 46], ["hydrogen bonding", "OBSERVATION", 38, 54], ["binding cavities", "OBSERVATION", 84, 100], ["dynamic nature", "OBSERVATION", 134, 148]]], ["For example, a hydrogen bond with His41 was observed in UAWJ246 pose 1 (Fig. 4g, h), while in UAWJ246 pose 2 a hydrogen bond with Asn142 was observed (Fig. 4j, k).", [["His41", "CHEMICAL", 34, 39], ["hydrogen", "CHEMICAL", 15, 23], ["His41", "CHEMICAL", 34, 39], ["hydrogen", "CHEMICAL", 111, 119], ["Asn142", "CHEMICAL", 130, 136], ["His41", "SIMPLE_CHEMICAL", 34, 39], ["Asn142", "SIMPLE_CHEMICAL", 130, 136], ["His41", "PROTEIN", 34, 39], ["a hydrogen bond", "TEST", 13, 28], ["His41", "TEST", 34, 39], ["a hydrogen bond", "TEST", 109, 124], ["hydrogen bond", "OBSERVATION", 15, 28]]], ["Similarly, hydrogen bonds with His41 and Thr190 were observed in UAWJ248 pose 1 (Fig. 4p, q), and a hydrogen bond with Ser144 was observed in UAWJ248 in pose 2 (Fig. 4s, t).Cellular antiviral activity and cytotoxicity of GC-376 analogues ::: RESULTS AND DISCUSSIONTo profile the antiviral activity of the GC-376 analogues UAWJ246, 247, and 248, we first tested their cellular cytotoxicity against multiple cell lines.", [["cellular", "ANATOMY", 367, 375], ["cell lines", "ANATOMY", 406, 416], ["hydrogen", "CHEMICAL", 11, 19], ["His41", "CHEMICAL", 31, 36], ["Thr", "CHEMICAL", 41, 44], ["GC-376", "CHEMICAL", 221, 227], ["GC-376", "CHEMICAL", 305, 311], ["UAWJ246", "CHEMICAL", 322, 329], ["hydrogen", "CHEMICAL", 11, 19], ["His41", "CHEMICAL", 31, 36], ["Thr", "CHEMICAL", 41, 44], ["hydrogen", "CHEMICAL", 100, 108], ["Ser144", "CHEMICAL", 119, 125], ["UAWJ248", "CHEMICAL", 142, 149], ["GC-376", "CHEMICAL", 305, 311], ["UAWJ246, 247, and 248", "CHEMICAL", 322, 343], ["His41", "SIMPLE_CHEMICAL", 31, 36], ["Thr190", "AMINO_ACID", 41, 47], ["Ser144", "SIMPLE_CHEMICAL", 119, 125], ["Cellular", "CELL", 173, 181], ["GC-376", "SIMPLE_CHEMICAL", 221, 227], ["GC-376", "SIMPLE_CHEMICAL", 305, 311], ["UAWJ246", "SIMPLE_CHEMICAL", 322, 329], ["cellular", "CELL", 367, 375], ["cell lines", "CELL", 406, 416], ["multiple cell lines", "CELL_LINE", 397, 416], ["hydrogen bonds", "TEST", 11, 25], ["His41", "TEST", 31, 36], ["Thr", "TEST", 41, 44], ["a hydrogen bond", "TEST", 98, 113], ["Cellular antiviral activity", "TEST", 173, 200], ["cytotoxicity", "TEST", 205, 217], ["GC", "TEST", 221, 223], ["the GC", "TEST", 301, 307], ["analogues UAWJ246", "TEST", 312, 329], ["multiple cell lines", "TREATMENT", 397, 416], ["hydrogen bonds", "OBSERVATION", 11, 25], ["antiviral activity", "OBSERVATION", 182, 200], ["multiple cell lines", "OBSERVATION", 397, 416]]], ["All three compounds were not toxic to these cell lines with CC50 values greater than 100 \u03bcM in most cases (Supplementary information Table S2).", [["cell lines", "ANATOMY", 44, 54], ["cell lines", "CELL", 44, 54], ["CC50", "SIMPLE_CHEMICAL", 60, 64], ["cell lines", "CELL_LINE", 44, 54], ["CC50 values", "TEST", 60, 71]]], ["The antiviral activity of GC-376 analogues was tested in both the immunofluorescence assay and plaque assay using the wild-type SARS-CoV-2 virus.", [["plaque", "ANATOMY", 95, 101], ["GC-376", "CHEMICAL", 26, 32], ["GC-376", "CHEMICAL", 26, 32], ["GC-376 analogues", "SIMPLE_CHEMICAL", 26, 42], ["wild-type SARS-CoV-2 virus", "ORGANISM", 118, 144], ["CoV-2 virus", "SPECIES", 133, 144], ["SARS-CoV-2 virus", "SPECIES", 128, 144], ["GC", "TEST", 26, 28], ["the immunofluorescence assay", "TEST", 62, 90], ["plaque assay", "TEST", 95, 107], ["the wild", "TEST", 114, 122], ["type SARS", "PROBLEM", 123, 132], ["CoV", "TEST", 133, 136], ["antiviral activity", "OBSERVATION", 4, 22]]], ["GC-376 was included as a positive control.", [["GC-376", "CHEMICAL", 0, 6], ["GC-376", "CHEMICAL", 0, 6], ["GC-376", "SIMPLE_CHEMICAL", 0, 6], ["GC", "TEST", 0, 2]]], ["In the immunofluorescence assay with the SARS-CoV-2 GFP reporter virus, GC-376, UAWJ246, UAWJ247, and UAWJ248 inhibited the viral replication in a dose-response manner with EC50 values of 1.50 \u00b1 0.42 \u03bcM, 15.13 \u00b1 6.44 \u03bcM, 6.81 \u00b1 0.65 \u03bcM, and 20.49 \u00b1 3.71 \u03bcM, respectively (Fig. 5a\u2013d, 5i).", [["GC-376", "CHEMICAL", 72, 78], ["UAWJ246", "CHEMICAL", 80, 87], ["UAWJ247", "CHEMICAL", 89, 96], ["UAWJ248", "CHEMICAL", 102, 109], ["UAWJ246", "CHEMICAL", 80, 87], ["UAWJ248", "CHEMICAL", 102, 109], ["SARS-CoV-2", "ORGANISM", 41, 51], ["GFP", "GENE_OR_GENE_PRODUCT", 52, 55], ["GC-376", "CELL", 72, 78], ["UAWJ246", "SIMPLE_CHEMICAL", 80, 87], ["UAWJ247", "SIMPLE_CHEMICAL", 89, 96], ["UAWJ248", "SIMPLE_CHEMICAL", 102, 109], ["SARS-CoV", "SPECIES", 41, 49], ["the immunofluorescence assay", "TEST", 3, 31], ["the SARS", "TEST", 37, 45], ["CoV", "TEST", 46, 49], ["GC", "TEST", 72, 74], ["UAWJ246", "TEST", 80, 87], ["UAWJ247", "TEST", 89, 96], ["the viral replication", "TREATMENT", 120, 141], ["EC50 values", "TEST", 173, 184], ["\u03bcM", "TEST", 200, 202], ["\u03bcM", "TEST", 217, 219], ["\u03bcM", "TEST", 233, 235], ["M", "TEST", 255, 256], ["Fig.", "TEST", 272, 276], ["viral replication", "OBSERVATION", 124, 141]]], ["In the plaque assay, GC-376, UAWJ246, UAWJ247, and UAWJ248 inhibited the viral replication with EC50 values of 0.48 \u00b1 0.29 \u03bcM, 4.61 \u00b1 3.60 \u03bcM, 2.06 \u00b1 0.93 \u03bcM, and 11.1 \u00b1 4.2 \u03bcM, respectively (Fig. 5e\u2013h, 5j).", [["plaque", "ANATOMY", 7, 13], ["GC-376", "CHEMICAL", 21, 27], ["UAWJ246", "CHEMICAL", 29, 36], ["UAWJ247", "CHEMICAL", 38, 45], ["UAWJ248", "CHEMICAL", 51, 58], ["UAWJ246", "CHEMICAL", 29, 36], ["UAWJ247", "CHEMICAL", 38, 45], ["UAWJ248", "CHEMICAL", 51, 58], ["GC-376", "SIMPLE_CHEMICAL", 21, 27], ["UAWJ246", "SIMPLE_CHEMICAL", 29, 36], ["UAWJ247", "SIMPLE_CHEMICAL", 38, 45], ["UAWJ248", "SIMPLE_CHEMICAL", 51, 58], ["the plaque assay", "TEST", 3, 19], ["GC", "TEST", 21, 23], ["UAWJ246", "TEST", 29, 36], ["UAWJ247", "TEST", 38, 45], ["UAWJ248", "TEST", 51, 58], ["the viral replication", "TEST", 69, 90], ["EC50 values", "TEST", 96, 107], ["\u03bcM", "TEST", 123, 125], ["\u03bcM", "TEST", 139, 141], ["M", "TEST", 156, 157], ["\u00b1", "TEST", 168, 169], ["M", "TEST", 175, 176], ["Fig.", "TEST", 192, 196], ["plaque", "ANATOMY", 7, 13], ["viral replication", "OBSERVATION", 73, 90]]], ["Overall, all three GC-376 analogues UAWJ246, UAWJ247, and UAWJ248 had confirmed antiviral activity in cell culture.", [["cell culture", "ANATOMY", 102, 114], ["UAWJ246", "CHEMICAL", 36, 43], ["UAWJ247", "CHEMICAL", 45, 52], ["UAWJ248", "CHEMICAL", 58, 65], ["UAWJ246", "CHEMICAL", 36, 43], ["UAWJ247", "CHEMICAL", 45, 52], ["UAWJ248", "CHEMICAL", 58, 65], ["GC-376", "SIMPLE_CHEMICAL", 19, 25], ["UAWJ246", "SIMPLE_CHEMICAL", 36, 43], ["UAWJ247", "SIMPLE_CHEMICAL", 45, 52], ["UAWJ248", "SIMPLE_CHEMICAL", 58, 65], ["cell culture", "CELL", 102, 114], ["analogues UAWJ246", "TEST", 26, 43], ["UAWJ247", "TEST", 45, 52], ["UAWJ248", "TEST", 58, 65], ["antiviral activity in cell culture", "PROBLEM", 80, 114], ["antiviral activity", "OBSERVATION", 80, 98]]], ["Comparing Mpro binding and anti-viral potency among the GC-376 analogues, it appears that the aldehyde warhead may be more suitable for cell-based activities than the \u03b1-ketoamide.", [["cell", "ANATOMY", 136, 140], ["Mpro", "CHEMICAL", 10, 14], ["GC-376", "CHEMICAL", 56, 62], ["aldehyde", "CHEMICAL", 94, 102], ["\u03b1-ketoamide", "CHEMICAL", 167, 178], ["aldehyde", "CHEMICAL", 94, 102], ["\u03b1-ketoamide", "CHEMICAL", 167, 178], ["Mpro", "SIMPLE_CHEMICAL", 10, 14], ["GC-376 analogues", "SIMPLE_CHEMICAL", 56, 72], ["aldehyde", "SIMPLE_CHEMICAL", 94, 102], ["cell", "CELL", 136, 140], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 167, 178], ["Mpro binding", "PROBLEM", 10, 22], ["anti-viral potency", "TREATMENT", 27, 45], ["the GC", "TEST", 52, 58], ["the aldehyde warhead", "PROBLEM", 90, 110], ["the \u03b1-ketoamide", "TREATMENT", 163, 178], ["anti-viral potency", "OBSERVATION_MODIFIER", 27, 45]]], ["While the terminal groups of UAWJ248 may enhance the enzymatic inhibition potency of GC-376 by simultaneously occupying both S3 and S4 subpockets, the weaker cellular antiviral activity of UAWJ248 might be due to decreased cellular permeability or increased metabolic degradation.", [["cellular", "ANATOMY", 158, 166], ["cellular", "ANATOMY", 223, 231], ["UAWJ248", "CHEMICAL", 29, 36], ["GC-376", "CHEMICAL", 85, 91], ["UAWJ248", "CHEMICAL", 189, 196], ["UAWJ248", "CHEMICAL", 29, 36], ["UAWJ248", "CHEMICAL", 189, 196], ["UAWJ248", "SIMPLE_CHEMICAL", 29, 36], ["GC-376", "SIMPLE_CHEMICAL", 85, 91], ["S4", "GENE_OR_GENE_PRODUCT", 132, 134], ["cellular", "CELL", 158, 166], ["UAWJ248", "SIMPLE_CHEMICAL", 189, 196], ["cellular", "CELL", 223, 231], ["GC", "TEST", 85, 87], ["the weaker cellular antiviral activity of UAWJ248", "PROBLEM", 147, 196], ["decreased cellular permeability", "PROBLEM", 213, 244], ["increased metabolic degradation", "PROBLEM", 248, 279], ["both", "ANATOMY_MODIFIER", 120, 124], ["S3", "ANATOMY_MODIFIER", 125, 127], ["S4 subpockets", "OBSERVATION", 132, 145], ["weaker", "OBSERVATION_MODIFIER", 151, 157], ["cellular", "OBSERVATION_MODIFIER", 158, 166], ["antiviral activity", "OBSERVATION", 167, 185], ["might be due to", "UNCERTAINTY", 197, 212], ["decreased", "OBSERVATION_MODIFIER", 213, 222], ["cellular permeability", "OBSERVATION", 223, 244], ["increased", "OBSERVATION_MODIFIER", 248, 257], ["metabolic degradation", "OBSERVATION", 258, 279]]], ["In addition, as shown by our previous study, the calpain inhibitors demonstrated better antiviral activity than GC-376 despite showing weaker binding affinity against Mpro in vitro,15 consistent with our hypothesis of synergistic inhibition of cathepsin L.CONCLUSIONThe ongoing COVID-19 pandemic needs an immediate intervention.", [["GC-376", "CHEMICAL", 112, 118], ["GC-376", "CHEMICAL", 112, 118], ["calpain", "GENE_OR_GENE_PRODUCT", 49, 56], ["GC-376", "SIMPLE_CHEMICAL", 112, 118], ["Mpro", "SIMPLE_CHEMICAL", 167, 171], ["cathepsin", "GENE_OR_GENE_PRODUCT", 244, 253], ["calpain", "PROTEIN", 49, 56], ["Mpro", "PROTEIN", 167, 171], ["cathepsin", "PROTEIN", 244, 253], ["our previous study", "TEST", 25, 43], ["the calpain inhibitors", "TREATMENT", 45, 67], ["GC", "TEST", 112, 114], ["weaker binding affinity", "PROBLEM", 135, 158], ["cathepsin", "TREATMENT", 244, 253], ["ongoing COVID", "TREATMENT", 270, 283], ["an immediate intervention", "TREATMENT", 302, 327]]], ["If the previous SARS-CoV and MERS-CoV outbreaks are not severe enough to attract the attention from the scientific community, the current COVID-19 outbreak is a timely reminder of the threat of coronavirus.", [["SARS", "DISEASE", 16, 20], ["coronavirus", "DISEASE", 194, 205], ["SARS-CoV", "ORGANISM", 16, 24], ["MERS-CoV", "ORGANISM", 29, 37], ["coronavirus", "ORGANISM", 194, 205], ["SARS-CoV", "SPECIES", 16, 24], ["MERS-CoV", "SPECIES", 29, 37], ["the previous SARS", "PROBLEM", 3, 20], ["CoV outbreaks", "PROBLEM", 34, 47], ["coronavirus", "PROBLEM", 194, 205], ["coronavirus", "OBSERVATION", 194, 205]]], ["Encouraging progress has been made in developing antivirals and vaccines against SARS-CoV-2, such as remdesivir.", [["SARS", "DISEASE", 81, 85], ["remdesivir", "CHEMICAL", 101, 111], ["remdesivir", "CHEMICAL", 101, 111], ["SARS-CoV-2", "ORGANISM", 81, 91], ["remdesivir", "SIMPLE_CHEMICAL", 101, 111], ["SARS-CoV", "SPECIES", 81, 89], ["antivirals", "TREATMENT", 49, 59], ["vaccines", "TREATMENT", 64, 72], ["SARS", "PROBLEM", 81, 85], ["remdesivir", "TREATMENT", 101, 111]]], ["However, despite the proof-reading function of the SARS-CoV-2 RdRp, SARS-CoV-2 continues to mutate, which will inevitably lead to drug resistance.", [["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "ORGANISM", 51, 61], ["RdRp", "ORGANISM", 62, 66], ["SARS-CoV-2", "ORGANISM", 68, 78], ["SARS-CoV-2 RdRp", "PROTEIN", 51, 66], ["SARS-CoV-2 RdRp", "SPECIES", 51, 66], ["the SARS", "PROBLEM", 47, 55], ["CoV", "TEST", 56, 59], ["RdRp", "PROBLEM", 62, 66], ["SARS", "PROBLEM", 68, 72], ["drug resistance", "PROBLEM", 130, 145]]], ["Drug resistance has been evolved in cell culture against remdesivir using a model coronavirus, the murine hepatitis virus (MHV),39 raising concerns for the monotherapy of remdesivir.", [["cell culture", "ANATOMY", 36, 48], ["remdesivir", "CHEMICAL", 57, 67], ["murine hepatitis virus", "DISEASE", 99, 121], ["remdesivir", "CHEMICAL", 171, 181], ["remdesivir", "CHEMICAL", 171, 181], ["cell", "CELL", 36, 40], ["remdesivir", "SIMPLE_CHEMICAL", 57, 67], ["coronavirus", "ORGANISM", 82, 93], ["murine hepatitis virus", "ORGANISM", 99, 121], ["MHV", "ORGANISM", 123, 126], ["remdesivir", "SIMPLE_CHEMICAL", 171, 181], ["coronavirus", "SPECIES", 82, 93], ["murine", "SPECIES", 99, 105], ["hepatitis virus", "SPECIES", 106, 121], ["murine hepatitis virus", "SPECIES", 99, 121], ["MHV", "SPECIES", 123, 126], ["Drug resistance", "PROBLEM", 0, 15], ["cell culture", "TEST", 36, 48], ["remdesivir", "TREATMENT", 57, 67], ["a model coronavirus", "PROBLEM", 74, 93], ["the murine hepatitis virus", "PROBLEM", 95, 121], ["the monotherapy of remdesivir", "TREATMENT", 152, 181], ["cell", "OBSERVATION", 36, 40], ["hepatitis virus", "OBSERVATION", 106, 121]]], ["As such, new drugs with distinct mechanisms of action are needed.CONCLUSIONThe coronavirus Mpro (3CLpro) has long been pursued as a promising antiviral drug target.12 The unique feature of Mpro is its stringent preference for the glutamine residue at the P1 position, while no known host protease has such preference.", [["Mpro", "CHEMICAL", 189, 193], ["glutamine", "CHEMICAL", 230, 239], ["glutamine", "CHEMICAL", 230, 239], ["coronavirus", "ORGANISM", 79, 90], ["Mpro", "GENE_OR_GENE_PRODUCT", 91, 95], ["3CLpro", "GENE_OR_GENE_PRODUCT", 97, 103], ["Mpro", "GENE_OR_GENE_PRODUCT", 189, 193], ["glutamine", "AMINO_ACID", 230, 239], ["coronavirus Mpro", "PROTEIN", 79, 95], ["Mpro", "PROTEIN", 189, 193], ["P1 position", "PROTEIN", 255, 266], ["protease", "PROTEIN", 288, 296], ["coronavirus", "SPECIES", 79, 90], ["new drugs", "TREATMENT", 9, 18], ["coronavirus Mpro (3CLpro)", "TREATMENT", 79, 104], ["a promising antiviral drug target", "TREATMENT", 130, 163], ["the glutamine residue", "PROBLEM", 226, 247], ["known host protease", "PROBLEM", 277, 296], ["Mpro", "OBSERVATION", 189, 193], ["glutamine residue", "OBSERVATION", 230, 247], ["no known", "UNCERTAINTY", 274, 282], ["host protease", "OBSERVATION", 283, 296]]], ["Accordingly, the majority of Mpro inhibitors are designed to contain a glutamine mimetic at the P1 position such as pyrrolidone or 2-piperidinone.", [["glutamine", "CHEMICAL", 71, 80], ["pyrrolidone", "CHEMICAL", 116, 127], ["2-piperidinone", "CHEMICAL", 131, 145], ["glutamine", "CHEMICAL", 71, 80], ["pyrrolidone", "CHEMICAL", 116, 127], ["2-piperidinone", "CHEMICAL", 131, 145], ["Mpro", "GENE_OR_GENE_PRODUCT", 29, 33], ["glutamine", "AMINO_ACID", 71, 80], ["pyrrolidone", "SIMPLE_CHEMICAL", 116, 127], ["2-piperidinone", "SIMPLE_CHEMICAL", 131, 145], ["Mpro inhibitors", "TREATMENT", 29, 44], ["a glutamine mimetic", "TREATMENT", 69, 88], ["pyrrolidone", "TREATMENT", 116, 127], ["piperidinone", "TREATMENT", 133, 145]]], ["One of the most advanced lead compounds in this class is GC-376, an investigational veterinary drug that is currently being developed to treat feline infectious peritonitis.", [["GC-376", "CHEMICAL", 57, 63], ["feline infectious peritonitis", "DISEASE", 143, 172], ["GC-376", "CHEMICAL", 57, 63], ["GC-376", "SIMPLE_CHEMICAL", 57, 63], ["feline", "ORGANISM", 143, 149], ["feline", "SPECIES", 143, 149], ["GC", "TEST", 57, 59], ["an investigational veterinary drug", "TREATMENT", 65, 99], ["feline infectious peritonitis", "PROBLEM", 143, 172], ["infectious", "OBSERVATION_MODIFIER", 150, 160], ["peritonitis", "OBSERVATION", 161, 172]]], ["GC-376 has optimal in vivo pharmacokinetic properties and in vivo antiviral efficacy in FIPD infection cat model.40,41 Our earlier study, coupled with an independent study from Vuong et al, showed that GC-376 can similarly inhibit the enzymatic activity of SARS-CoV-2 Mpro and the viral replication of SARS-CoV-2 in cell culture.37 While this result is expected, our study also identified three additional non-conventional hits, Boceprevir, calpain inhibitors II and XII.15 These three compounds differ from known Mpro inhibitors in that they contain hydrophobic substitutions at the P1 site, challenging the notion that hydrophilic glutamine mimetics are required for potent inhibition.", [["cell culture", "ANATOMY", 316, 328], ["GC-376", "CHEMICAL", 0, 6], ["infection", "DISEASE", 93, 102], ["GC-376", "CHEMICAL", 202, 208], ["Boceprevir", "CHEMICAL", 429, 439], ["glutamine", "CHEMICAL", 633, 642], ["GC-376", "CHEMICAL", 0, 6], ["GC-376", "CHEMICAL", 202, 208], ["glutamine", "CHEMICAL", 633, 642], ["GC-376", "SIMPLE_CHEMICAL", 0, 6], ["cat", "ORGANISM", 103, 106], ["GC-376", "SIMPLE_CHEMICAL", 202, 208], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 257, 272], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 302, 312], ["cell culture", "CELL", 316, 328], ["Boceprevir", "SIMPLE_CHEMICAL", 429, 439], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 441, 462], ["XII", "GENE_OR_GENE_PRODUCT", 467, 470], ["Mpro", "GENE_OR_GENE_PRODUCT", 514, 518], ["glutamine", "AMINO_ACID", 633, 642], ["calpain inhibitors II and XII", "PROTEIN", 441, 470], ["P1 site", "DNA", 584, 591], ["SARS-CoV", "SPECIES", 257, 265], ["SARS-CoV", "SPECIES", 302, 310], ["GC", "TEST", 0, 2], ["vivo pharmacokinetic properties", "TREATMENT", 22, 53], ["vivo antiviral efficacy", "TREATMENT", 61, 84], ["FIPD infection cat model", "TREATMENT", 88, 112], ["Our earlier study", "TEST", 119, 136], ["an independent study", "TEST", 151, 171], ["GC", "TEST", 202, 204], ["SARS", "TEST", 257, 261], ["CoV", "TEST", 262, 265], ["Mpro", "TREATMENT", 268, 272], ["the viral replication", "TEST", 277, 298], ["SARS", "PROBLEM", 302, 306], ["CoV", "TEST", 307, 310], ["cell culture", "TEST", 316, 328], ["our study", "TEST", 363, 372], ["Boceprevir", "TREATMENT", 429, 439], ["calpain inhibitors", "TREATMENT", 441, 459], ["known Mpro inhibitors", "TREATMENT", 508, 529], ["hydrophobic substitutions at the P1 site", "PROBLEM", 551, 591], ["hydrophilic glutamine mimetics", "TREATMENT", 621, 651], ["potent inhibition", "TREATMENT", 669, 686], ["antiviral efficacy", "OBSERVATION", 66, 84], ["infection", "OBSERVATION", 93, 102], ["viral replication", "OBSERVATION", 281, 298], ["hydrophobic substitutions", "OBSERVATION", 551, 576]]], ["Intrigued by this finding, we pursued to solve the X-ray crystal structures of SARS-CoV-2 Mpro with Boceprevir and calpain inhibitors II and XII.", [["SARS", "DISEASE", 79, 83], ["Boceprevir", "CHEMICAL", 100, 110], ["Boceprevir", "CHEMICAL", 100, 110], ["Boceprevir", "SIMPLE_CHEMICAL", 100, 110], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 115, 136], ["XII", "GENE_OR_GENE_PRODUCT", 141, 144], ["calpain inhibitors II and XII", "PROTEIN", 115, 144], ["SARS", "PROBLEM", 79, 83], ["CoV", "TEST", 84, 87], ["Mpro", "TREATMENT", 90, 94], ["Boceprevir", "TREATMENT", 100, 110], ["calpain inhibitors", "TREATMENT", 115, 133]]], ["During this process, the X-ray crystal structures of SARS-CoV-2 Mpro in complex with Boceprevir were released in PDB (PDB ID: 7BRP and 6WNP), and we therefore shifted our focus to calpain inhibitors II and XII.", [["Boceprevir", "CHEMICAL", 85, 95], ["Boceprevir", "CHEMICAL", 85, 95], ["Boceprevir", "SIMPLE_CHEMICAL", 85, 95], ["calpain inhibitors II", "GENE_OR_GENE_PRODUCT", 180, 201], ["XII", "GENE_OR_GENE_PRODUCT", 206, 209], ["Mpro", "PROTEIN", 64, 68], ["calpain inhibitors II and XII", "PROTEIN", 180, 209], ["the X-ray crystal structures", "TEST", 21, 49], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61], ["Boceprevir", "TREATMENT", 85, 95], ["calpain inhibitors", "TREATMENT", 180, 198], ["PDB", "ANATOMY", 113, 116]]], ["The binding pose of calpain inhibitor II in the active site of Mpro is consistent with other peptidomimetic inhibitors, where the methionine and leucine side chains occupy the S1 and S2 pockets, respectively.", [["inhibitor II", "CHEMICAL", 28, 40], ["Mpro", "CHEMICAL", 63, 67], ["methionine", "CHEMICAL", 130, 140], ["leucine", "CHEMICAL", 145, 152], ["methionine", "CHEMICAL", 130, 140], ["leucine", "CHEMICAL", 145, 152], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 20, 40], ["Mpro", "GENE_OR_GENE_PRODUCT", 63, 67], ["methionine", "SIMPLE_CHEMICAL", 130, 140], ["leucine side chains", "SIMPLE_CHEMICAL", 145, 164], ["calpain inhibitor II", "PROTEIN", 20, 40], ["Mpro", "PROTEIN", 63, 67], ["S1 and S2 pockets", "PROTEIN", 176, 193], ["calpain inhibitor II", "TREATMENT", 20, 40], ["other peptidomimetic inhibitors", "TREATMENT", 87, 118], ["the methionine and leucine side chains", "TREATMENT", 126, 164], ["consistent with", "UNCERTAINTY", 71, 86], ["S1", "ANATOMY", 176, 178], ["S2", "ANATOMY", 183, 185], ["pockets", "ANATOMY_MODIFIER", 186, 193]]], ["The methionine sulfur atom forms a hydrogen bond with the side chain imidazole of His163.", [["methionine sulfur", "CHEMICAL", 4, 21], ["imidazole", "CHEMICAL", 69, 78], ["His163", "CHEMICAL", 82, 88], ["methionine sulfur", "CHEMICAL", 4, 21], ["hydrogen", "CHEMICAL", 35, 43], ["imidazole", "CHEMICAL", 69, 78], ["His", "CHEMICAL", 82, 85], ["methionine sulfur atom", "SIMPLE_CHEMICAL", 4, 26], ["His163", "SIMPLE_CHEMICAL", 82, 88], ["The methionine sulfur atom", "TREATMENT", 0, 26], ["a hydrogen bond", "TREATMENT", 33, 48], ["the side chain imidazole", "TREATMENT", 54, 78]]], ["In contrast, calpain inhibitor XII binds to the Mpro active site in an inverted conformation, projecting the pyridine instead of the norvaline residue in the S1 pocket.", [["pyridine", "CHEMICAL", 109, 117], ["norvaline", "CHEMICAL", 133, 142], ["pyridine", "CHEMICAL", 109, 117], ["norvaline", "CHEMICAL", 133, 142], ["calpain", "GENE_OR_GENE_PRODUCT", 13, 20], ["XII", "GENE_OR_GENE_PRODUCT", 31, 34], ["pyridine", "SIMPLE_CHEMICAL", 109, 117], ["calpain", "PROTEIN", 13, 20], ["XII", "PROTEIN", 31, 34], ["Mpro active site", "DNA", 48, 64], ["S1 pocket", "PROTEIN", 158, 167], ["calpain inhibitor XII binds", "TREATMENT", 13, 40], ["projecting the pyridine", "TREATMENT", 94, 117], ["the norvaline residue in the S1 pocket", "PROBLEM", 129, 167], ["S1", "ANATOMY", 158, 160], ["pocket", "ANATOMY_MODIFIER", 161, 167]]], ["Again, the nitrogen from the pyridine forms a hydrogen bond with the side chain imidazole of His163.", [["nitrogen", "CHEMICAL", 11, 19], ["pyridine", "CHEMICAL", 29, 37], ["imidazole", "CHEMICAL", 80, 89], ["His163", "CHEMICAL", 93, 99], ["nitrogen", "CHEMICAL", 11, 19], ["pyridine", "CHEMICAL", 29, 37], ["hydrogen", "CHEMICAL", 46, 54], ["imidazole", "CHEMICAL", 80, 89], ["His", "CHEMICAL", 93, 96], ["nitrogen", "SIMPLE_CHEMICAL", 11, 19], ["pyridine", "SIMPLE_CHEMICAL", 29, 37], ["His163", "SIMPLE_CHEMICAL", 93, 99], ["the nitrogen", "TREATMENT", 7, 19], ["the pyridine", "TREATMENT", 25, 37], ["a hydrogen bond", "TREATMENT", 44, 59], ["the side chain imidazole", "TREATMENT", 65, 89]]], ["Collectively, these two structures suggest that His163 residue at the S1 pocket represents a binding hot spot for Mpro inhibitors, and that the pyridine ring is a suitable side chain to engineer potent interactions with the S1 subsite.", [["His163", "CHEMICAL", 48, 54], ["pyridine", "CHEMICAL", 144, 152], ["His", "CHEMICAL", 48, 51], ["pyridine", "CHEMICAL", 144, 152], ["Mpro", "GENE_OR_GENE_PRODUCT", 114, 118], ["pyridine", "SIMPLE_CHEMICAL", 144, 152], ["S1 pocket", "PROTEIN", 70, 79], ["S1 subsite", "PROTEIN", 224, 234], ["His163 residue at the S1 pocket", "PROBLEM", 48, 79], ["a binding hot spot", "PROBLEM", 91, 109], ["Mpro inhibitors", "TREATMENT", 114, 129], ["the pyridine ring", "TREATMENT", 140, 157], ["a suitable side chain", "TREATMENT", 161, 182], ["163 residue", "OBSERVATION", 51, 62], ["S1", "ANATOMY", 70, 72], ["pocket", "ANATOMY_MODIFIER", 73, 79], ["binding hot", "OBSERVATION", 93, 104]]], ["The substrate plasticity of the P1 site suggests that it is feasible to design dual inhibitors targeting both the viral Mpro and other important proteases, such as cathepsin L. Cathepsin L has been identified as a critical host-protease for the SARS-CoV-2 cell entry.", [["cell", "ANATOMY", 256, 260], ["Mpro", "GENE_OR_GENE_PRODUCT", 120, 124], ["cathepsin L. Cathepsin L", "GENE_OR_GENE_PRODUCT", 164, 188], ["cell", "CELL", 256, 260], ["P1 site", "DNA", 32, 39], ["viral Mpro", "PROTEIN", 114, 124], ["proteases", "PROTEIN", 145, 154], ["cathepsin", "PROTEIN", 164, 173], ["Cathepsin L", "PROTEIN", 177, 188], ["protease", "PROTEIN", 228, 236], ["dual inhibitors", "TREATMENT", 79, 94], ["the viral Mpro", "TREATMENT", 110, 124], ["cathepsin L. Cathepsin L", "TREATMENT", 164, 188], ["the SARS", "TEST", 241, 249]]], ["It plays an essential role in mediating the activation of the viral spike protein, thereby triggering membrane fusion and viral RNA release.20,22 Although the antiviral potency of cathepsin L inhibitors has been demonstrated against coronaviruses including SARS-CoV-2 in several studies, the in vivo antiviral efficacy of cathepsin L is not known.", [["membrane", "ANATOMY", 102, 110], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 180, 191], ["SARS-CoV-2", "ORGANISM", 257, 267], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 322, 333], ["viral spike protein", "PROTEIN", 62, 81], ["viral RNA", "RNA", 122, 131], ["cathepsin L", "PROTEIN", 180, 191], ["cathepsin L", "PROTEIN", 322, 333], ["SARS-CoV", "SPECIES", 257, 265], ["the viral spike protein", "PROBLEM", 58, 81], ["membrane fusion", "TREATMENT", 102, 117], ["viral RNA release", "TREATMENT", 122, 139], ["cathepsin L inhibitors", "TREATMENT", 180, 202], ["coronaviruses", "PROBLEM", 233, 246], ["SARS", "PROBLEM", 257, 261], ["CoV", "TEST", 262, 265], ["several studies", "TEST", 271, 286], ["cathepsin L", "TREATMENT", 322, 333], ["viral spike", "OBSERVATION", 62, 73], ["membrane fusion", "OBSERVATION", 102, 117]]], ["One potential concern is that the coronavirus spike protein can also be activated by other host proteases including trypsin, calpain, and TMPRSS2.", [["coronavirus", "ORGANISM", 34, 45], ["trypsin", "GENE_OR_GENE_PRODUCT", 116, 123], ["calpain", "GENE_OR_GENE_PRODUCT", 125, 132], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 138, 145], ["coronavirus spike protein", "PROTEIN", 34, 59], ["host proteases", "PROTEIN", 91, 105], ["trypsin", "PROTEIN", 116, 123], ["calpain", "PROTEIN", 125, 132], ["TMPRSS2", "PROTEIN", 138, 145], ["the coronavirus spike protein", "PROBLEM", 30, 59], ["trypsin, calpain", "TREATMENT", 116, 132], ["TMPRSS2", "TREATMENT", 138, 145], ["coronavirus spike", "OBSERVATION", 34, 51]]], ["Therefore, it is not clear whether inhibition of cathepsin L alone will be sufficient to completely stop viral replication in vivo.", [["cathepsin L", "GENE_OR_GENE_PRODUCT", 49, 60], ["cathepsin L", "PROTEIN", 49, 60], ["cathepsin L alone", "TREATMENT", 49, 66], ["viral replication", "TREATMENT", 105, 122]]], ["In this regard, a dual inhibitor design strategy that targets both the viral Mpro and host cathepsin L has certain advantages.", [["Mpro", "GENE_OR_GENE_PRODUCT", 77, 81], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 91, 102], ["viral Mpro and host cathepsin L", "PROTEIN", 71, 102], ["a dual inhibitor design strategy", "TREATMENT", 16, 48], ["the viral Mpro", "TREATMENT", 67, 81], ["host cathepsin L", "TREATMENT", 86, 102]]], ["First, compared to mono-specific Mpro inhibitors, dual inhibitors might have a higher genetic barrier to drug resistance as they also target the host cathepsin L. Second, compared to mono-specific cathepsin L inhibitors, dual inhibitors can lead to complete inhibition of viral replication as it targets the essential viral protein Mpro.CONCLUSIONComparing X-ray crystal structures of SARS-CoV-2 Mpro in complex with UAWJ246, UAWJ247, and UAWJ248 with the complex structure of GC-376, we can conclude that 1) the P1\u2019 substitution does not contribute significantly to the potency of drug binding; 2) the P2 position prefers hydrophobic substitutions such as the leucine and phenylalanine side chains.", [["GC-376", "CHEMICAL", 477, 483], ["leucine", "CHEMICAL", 661, 668], ["phenylalanine", "CHEMICAL", 673, 686], ["UAWJ246", "CHEMICAL", 417, 424], ["UAWJ247", "CHEMICAL", 426, 433], ["UAWJ248", "CHEMICAL", 439, 446], ["leucine", "CHEMICAL", 661, 668], ["phenylalanine", "CHEMICAL", 673, 686], ["Mpro", "GENE_OR_GENE_PRODUCT", 33, 37], ["cathepsin L.", "GENE_OR_GENE_PRODUCT", 150, 162], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 197, 208], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 385, 400], ["UAWJ246", "GENE_OR_GENE_PRODUCT", 417, 424], ["UAWJ247", "GENE_OR_GENE_PRODUCT", 426, 433], ["UAWJ248", "SIMPLE_CHEMICAL", 439, 446], ["GC-376", "SIMPLE_CHEMICAL", 477, 483], ["leucine", "AMINO_ACID", 661, 668], ["phenylalanine side chains", "SIMPLE_CHEMICAL", 673, 698], ["essential viral protein", "PROTEIN", 308, 331], ["SARS-CoV-2 Mpro", "PROTEIN", 385, 400], ["UAWJ246", "PROTEIN", 417, 424], ["P2 position", "PROTEIN", 603, 614], ["leucine and phenylalanine side chains", "PROTEIN", 661, 698], ["mono-specific Mpro inhibitors", "TREATMENT", 19, 48], ["dual inhibitors", "TREATMENT", 50, 65], ["mono-specific cathepsin L inhibitors", "TREATMENT", 183, 219], ["dual inhibitors", "TREATMENT", 221, 236], ["viral replication", "TREATMENT", 272, 289], ["the essential viral protein", "TEST", 304, 331], ["SARS", "TEST", 385, 389], ["CoV", "TEST", 390, 393], ["UAWJ247", "TEST", 426, 433], ["GC", "TEST", 477, 479], ["the P1\u2019 substitution", "TREATMENT", 509, 529], ["drug binding", "PROBLEM", 582, 594], ["hydrophobic substitutions", "PROBLEM", 623, 648], ["the leucine and phenylalanine side chains", "TREATMENT", 657, 698], ["viral replication", "OBSERVATION", 272, 289], ["hydrophobic substitutions", "OBSERVATION", 623, 648]]], ["Previous studies also demonstrate the cyclopropyl and cyclohexyl groups can be similarly accommodated.17,18 3) the P3 and P4 positions prefer to be hydrophobic substitutions.", [["cyclopropyl", "CHEMICAL", 38, 49], ["cyclohexyl", "CHEMICAL", 54, 64], ["cyclopropyl", "CHEMICAL", 38, 49], ["cyclohexyl", "CHEMICAL", 54, 64], ["cyclopropyl", "SIMPLE_CHEMICAL", 38, 49], ["cyclohexyl", "SIMPLE_CHEMICAL", 54, 64], ["P3 and P4 positions", "DNA", 115, 134], ["Previous studies", "TEST", 0, 16], ["the cyclopropyl and cyclohexyl groups", "TREATMENT", 34, 71], ["the P3 and P4 positions", "TREATMENT", 111, 134], ["hydrophobic substitutions", "PROBLEM", 148, 173], ["hydrophobic substitutions", "OBSERVATION", 148, 173]]], ["However, these two positions, especially P3, may not be as important as the P1 and P2 substitutions, but favorable interactions with S3 and S4 subpockets can still contribute to the potency of inhibitor binding; 4) while the unique conformation of calpain inhibitor XII demonstrates the versatility of the \u03b1-ketoamide adduct formation, the antiviral activities of the GC-376 analogues indicate that aldehyde-based compounds may be better suited for cell-based activity.CONCLUSIONIn summary, the structure-activity relationship of Mpro inhibitors revealed by the X-ray crystal structures and enzymatic assays described herein can be used to guide lead optimization.", [["cell", "ANATOMY", 449, 453], ["\u03b1-ketoamide", "CHEMICAL", 306, 317], ["GC-376", "CHEMICAL", 368, 374], ["aldehyde", "CHEMICAL", 399, 407], ["\u03b1-ketoamide", "CHEMICAL", 306, 317], ["GC-376", "CHEMICAL", 368, 374], ["aldehyde", "CHEMICAL", 399, 407], ["S3", "GENE_OR_GENE_PRODUCT", 133, 135], ["S4", "GENE_OR_GENE_PRODUCT", 140, 142], ["calpain", "GENE_OR_GENE_PRODUCT", 248, 255], ["XII", "GENE_OR_GENE_PRODUCT", 266, 269], ["\u03b1-ketoamide adduct", "SIMPLE_CHEMICAL", 306, 324], ["GC-376 analogues", "SIMPLE_CHEMICAL", 368, 384], ["aldehyde", "SIMPLE_CHEMICAL", 399, 407], ["cell", "CELL", 449, 453], ["Mpro", "GENE_OR_GENE_PRODUCT", 530, 534], ["S3", "PROTEIN", 133, 135], ["calpain inhibitor XII", "PROTEIN", 248, 269], ["the P1 and P2 substitutions", "PROBLEM", 72, 99], ["S3 and S4 subpockets", "PROBLEM", 133, 153], ["inhibitor binding", "PROBLEM", 193, 210], ["calpain inhibitor XII", "TREATMENT", 248, 269], ["the \u03b1-ketoamide adduct formation", "PROBLEM", 302, 334], ["the GC", "TEST", 364, 370], ["aldehyde-based compounds", "TREATMENT", 399, 423], ["Mpro inhibitors", "TREATMENT", 530, 545], ["the X-ray crystal structures", "TEST", 558, 586], ["enzymatic assays", "TEST", 591, 607], ["lead optimization", "TREATMENT", 646, 663], ["may not be", "UNCERTAINTY", 45, 55], ["adduct formation", "OBSERVATION", 318, 334]]], ["P1 substitution and the reactive warhead contribute significantly to the drug binding potency, followed by P2 substitution.", [["P1 substitution", "TREATMENT", 0, 15], ["the reactive warhead", "PROBLEM", 20, 40], ["P2 substitution", "TREATMENT", 107, 122], ["reactive warhead", "OBSERVATION", 24, 40]]], ["While P1\u2019, P3 and P4 substitutions are less essential, they can be optimized for inhibition against other proteases important for SARS-CoV-2 entry/replication and to improve their pharmacokinetic properties.Cell lines and viruses. ::: MATERIALS AND METHODSHuman rhabdomyosarcoma (RD), MDCK, Vero, Huh-7, and HCT-8 cell lines were maintained in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) medium; Caco-2 and MRC-5 cell lines were maintained in Eagle\u2019s Minimum Essential Medium (EMEM) medium.", [["Cell lines", "ANATOMY", 207, 217], ["rhabdomyosarcoma", "ANATOMY", 262, 278], ["RD", "ANATOMY", 280, 282], ["MDCK", "ANATOMY", 285, 289], ["Vero", "ANATOMY", 291, 295], ["Huh-7", "ANATOMY", 297, 302], ["HCT-8 cell lines", "ANATOMY", 308, 324], ["Caco-2", "ANATOMY", 394, 400], ["MRC-5 cell lines", "ANATOMY", 405, 421], ["rhabdomyosarcoma", "DISEASE", 262, 278], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["Cell lines", "CELL", 207, 217], ["METHODSHuman rhabdomyosarcoma", "CANCER", 249, 278], ["RD", "CELL", 280, 282], ["MDCK", "CELL", 285, 289], ["Vero", "CELL", 291, 295], ["Huh-7", "CELL", 297, 302], ["HCT-8 cell lines", "CELL", 308, 324], ["Caco-2", "CELL", 394, 400], ["MRC-5 cell lines", "CELL", 405, 421], ["P1\u2019, P3 and P4 substitutions", "DNA", 6, 34], ["proteases", "PROTEIN", 106, 115], ["METHODSHuman rhabdomyosarcoma (RD), MDCK, Vero, Huh-7", "CELL_LINE", 249, 302], ["HCT-8 cell lines", "CELL_LINE", 308, 324], ["MRC-5 cell lines", "CELL_LINE", 405, 421], ["P3 and P4 substitutions", "PROBLEM", 11, 34], ["other proteases", "PROBLEM", 100, 115], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["replication", "TREATMENT", 147, 158], ["Cell lines", "TREATMENT", 207, 217], ["viruses", "PROBLEM", 222, 229], ["METHODSHuman rhabdomyosarcoma", "PROBLEM", 249, 278], ["MDCK", "TEST", 285, 289], ["Vero", "TEST", 291, 295], ["Huh", "TEST", 297, 300], ["HCT", "TEST", 308, 311], ["cell lines", "TREATMENT", 314, 324], ["Caco", "TEST", 394, 398], ["MRC", "TEST", 405, 408], ["cell lines", "TREATMENT", 411, 421], ["Cell lines", "OBSERVATION", 207, 217], ["viruses", "OBSERVATION", 222, 229], ["METHODSHuman rhabdomyosarcoma", "OBSERVATION", 249, 278], ["cell lines", "OBSERVATION", 314, 324], ["cell lines", "OBSERVATION", 411, 421], ["Medium", "OBSERVATION_MODIFIER", 467, 473]]], ["Both media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotics.", [["fetal bovine serum", "ANATOMY", 38, 56], ["FBS", "ANATOMY", 58, 61], ["penicillin", "CHEMICAL", 70, 80], ["streptomycin", "CHEMICAL", 81, 93], ["penicillin", "CHEMICAL", 70, 80], ["streptomycin", "CHEMICAL", 81, 93], ["bovine", "ORGANISM", 44, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["penicillin-streptomycin antibiotics", "SIMPLE_CHEMICAL", 70, 105], ["bovine", "SPECIES", 44, 50], ["bovine", "SPECIES", 44, 50], ["10% fetal bovine serum (FBS", "TREATMENT", 34, 61], ["1% penicillin", "TREATMENT", 67, 80], ["streptomycin antibiotics", "TREATMENT", 81, 105]]], ["Cells were kept at 37\u00b0C in a 5% CO2 atmosphere.", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 32, 35], ["CO2", "CHEMICAL", 32, 35], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 32, 35], ["Cells", "TEST", 0, 5], ["a 5% CO2 atmosphere", "TREATMENT", 27, 46]]], ["VERO E6 cells (ATCC, CRL-1586) were cultured in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM), supplemented with 5% heat inactivated FBS in a 37\u00b0C incubator with 5% CO2.", [["VERO E6 cells", "ANATOMY", 0, 13], ["ATCC", "ANATOMY", 15, 19], ["CRL-1586", "ANATOMY", 21, 29], ["FBS", "ANATOMY", 129, 132], ["CRL-1586", "CHEMICAL", 21, 29], ["CO2", "CHEMICAL", 161, 164], ["CO2", "CHEMICAL", 161, 164], ["VERO E6 cells", "CELL", 0, 13], ["ATCC", "CELL", 15, 19], ["CRL-1586", "CELL", 21, 29], ["FBS", "ORGANISM_SUBSTANCE", 129, 132], ["CO2", "SIMPLE_CHEMICAL", 161, 164], ["VERO E6 cells", "CELL_LINE", 0, 13], ["VERO E6 cells", "TEST", 0, 13], ["ATCC", "TEST", 15, 19], ["CRL", "TEST", 21, 24], ["5% heat inactivated FBS", "TREATMENT", 109, 132], ["a 37\u00b0C incubator", "TREATMENT", 136, 152], ["5% CO2", "TREATMENT", 158, 164], ["E6 cells", "OBSERVATION", 5, 13]]], ["SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), was obtained through BEI Resources and propagated once on VERO E6 cells before it was used for this study.", [["VERO E6 cells", "ANATOMY", 103, 116], ["SARS", "DISEASE", 0, 4], ["NR-52281", "CHEMICAL", 34, 42], ["SARS-CoV-2", "ORGANISM", 0, 10], ["USA-WA1", "ORGANISM", 20, 27], ["NR-52281", "CELL", 34, 42], ["VERO E6 cells", "CELL", 103, 116], ["VERO E6 cells", "CELL_LINE", 103, 116], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["isolate USA", "TEST", 12, 23], ["VERO E6 cells", "TREATMENT", 103, 116], ["this study", "TEST", 140, 150]]], ["Studies involving the SARS-CoV-2 were performed at the UTHSCSA biosafety level-3 laboratory by personnel wearing powered air purifying respirators.Protein expression and purification. ::: MATERIALS AND METHODSSARS CoV-2 main protease (Mpro or 3CL) gene from strain BetaCoV/Wuhan/WIV04/2019 was ordered from GenScript (Piscataway, NJ) in the pET29a(+) vector with E. coli codon optimization.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 214, 219], ["Mpro", "GENE_OR_GENE_PRODUCT", 235, 239], ["3CL", "GENE_OR_GENE_PRODUCT", 243, 246], ["pET29a", "GENE_OR_GENE_PRODUCT", 341, 347], ["E. coli", "ORGANISM", 363, 370], ["METHODSSARS CoV-2 main protease (Mpro or 3CL) gene", "DNA", 202, 252], ["pET29a(+) vector", "DNA", 341, 357], ["E. coli", "SPECIES", 363, 370], ["SARS-CoV", "SPECIES", 22, 30], ["BetaCoV/Wuhan/WIV04/2019", "SPECIES", 265, 289], ["E. coli", "SPECIES", 363, 370], ["Studies", "TEST", 0, 7], ["the SARS", "TEST", 18, 26], ["CoV", "TEST", 27, 30], ["powered air purifying respirators", "TREATMENT", 113, 146], ["Protein expression", "TEST", 147, 165], ["CoV", "TEST", 214, 217], ["protease (Mpro", "TREATMENT", 225, 239], ["E. coli codon optimization", "TREATMENT", 363, 389], ["coli codon", "OBSERVATION", 366, 376]]], ["The expression and purification of His-tagged SARS CoV-2 Mpro (Mpro-His) was described as previously.15Protein expression and purification. ::: MATERIALS AND METHODSFor HM-Mpro expression and purification, the SARS-CoV-2 Mpro gene from strain BetaCoV/Wuhan/WIV04/2019 GenScript (Piscataway, NJ, USA) was inserted into pETGSTSUMO vecror.The plasmid was transformed into Rosetta\u2122(DE3) pLysS Competent Cells (Novagen).", [["plasmid", "ANATOMY", 340, 347], ["Cells", "ANATOMY", 399, 404], ["His", "CHEMICAL", 35, 38], ["His", "CHEMICAL", 68, 71], ["Mpro-His", "GENE_OR_GENE_PRODUCT", 63, 71], ["HM-Mpro", "GENE_OR_GENE_PRODUCT", 169, 176], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 210, 220], ["Mpro", "GENE_OR_GENE_PRODUCT", 221, 225], ["Cells", "CELL", 399, 404], ["Novagen", "GENE_OR_GENE_PRODUCT", 406, 413], ["His", "PROTEIN", 35, 38], ["SARS CoV", "PROTEIN", 46, 54], ["Mpro", "PROTEIN", 57, 61], ["Mpro", "PROTEIN", 63, 67], ["Mpro", "PROTEIN", 172, 176], ["SARS-CoV-2 Mpro gene", "DNA", 210, 230], ["pETGSTSUMO vecror", "DNA", 318, 335], ["plasmid", "DNA", 340, 347], ["Rosetta\u2122(DE3) pLysS Competent Cells", "CELL_LINE", 369, 404], ["BetaCoV/Wuhan/WIV04/2019 GenScript", "SPECIES", 243, 277], ["tagged SARS CoV", "TEST", 39, 54], ["purification", "TEST", 192, 204], ["the SARS", "TEST", 206, 214], ["CoV", "TEST", 215, 218], ["The plasmid", "TREATMENT", 336, 347], ["Competent Cells (Novagen)", "TREATMENT", 389, 414]]], ["A single colony was picked for overnight growth to inoculate 50 mL of LB broth with 50 \u03bcg/mL kanamycin and 35 \u03bcg/ mL chloramphenicol.", [["colony", "ANATOMY", 9, 15], ["kanamycin", "CHEMICAL", 93, 102], ["chloramphenicol", "CHEMICAL", 117, 132], ["kanamycin", "CHEMICAL", 93, 102], ["chloramphenicol", "CHEMICAL", 117, 132], ["kanamycin", "SIMPLE_CHEMICAL", 93, 102], ["chloramphenicol", "SIMPLE_CHEMICAL", 117, 132], ["A single colony", "PROBLEM", 0, 15], ["LB broth", "TREATMENT", 70, 78], ["kanamycin", "TREATMENT", 93, 102], ["chloramphenicol", "TREATMENT", 117, 132], ["colony", "OBSERVATION", 9, 15]]], ["10 mL of the overnight culture was used to inoculate 1 L of LB broth with 50 \u03bcg/mL kanamycin and 35 \u03bcg/ mL chloramphenicol.", [["kanamycin", "CHEMICAL", 83, 92], ["chloramphenicol", "CHEMICAL", 107, 122], ["kanamycin", "CHEMICAL", 83, 92], ["chloramphenicol", "CHEMICAL", 107, 122], ["kanamycin", "SIMPLE_CHEMICAL", 83, 92], ["chloramphenicol", "SIMPLE_CHEMICAL", 107, 122], ["the overnight culture", "TEST", 9, 30], ["LB broth", "TREATMENT", 60, 68], ["kanamycin", "TREATMENT", 83, 92], ["chloramphenicol", "TREATMENT", 107, 122]]], ["The 1L culture was grown at 250 RPM, 37 \u00b0C until OD 0.6~0.8.", [["1L culture", "CELL_LINE", 4, 14], ["The 1L culture", "TEST", 0, 14], ["OD", "TEST", 49, 51]]], ["Expression was then induced with 0.5 mM IPTG at 250 RPM, 20 \u00b0C overnight.", [["IPTG", "CHEMICAL", 40, 44], ["IPTG", "CHEMICAL", 40, 44], ["0.5 mM IPTG", "TREATMENT", 33, 44]]], ["The culture was centrifuged at 5,000 g for 20 minutes and the resulting pellet was resuspended in 30 mL of the lysis buffer (20 mM Tris-HCl pH 8.4, 300 mM NaCl, 10% glycerol v/v, and 20 mM imidazole).", [["Tris-HCl", "CHEMICAL", 131, 139], ["NaCl", "CHEMICAL", 155, 159], ["glycerol", "CHEMICAL", 165, 173], ["imidazole", "CHEMICAL", 189, 198], ["Tris-HCl", "CHEMICAL", 131, 139], ["NaCl", "CHEMICAL", 155, 159], ["glycerol", "CHEMICAL", 165, 173], ["imidazole", "CHEMICAL", 189, 198], ["imidazole", "SIMPLE_CHEMICAL", 189, 198], ["The culture", "TEST", 0, 11], ["the lysis buffer", "TREATMENT", 107, 123], ["Tris", "TEST", 131, 135], ["HCl pH", "TEST", 136, 142], ["NaCl", "TEST", 155, 159], ["glycerol v/v", "TREATMENT", 165, 177], ["20 mM imidazole", "TREATMENT", 183, 198]]], ["These cells were lysed by sonication on a 10 second sonication/15 second rest cycle for a total of 15 minutes at an amplitude of 6.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["a 10 second sonication", "TREATMENT", 40, 62]]], ["The lysate was centrifuged at 40,000 \u00d7 g for 45 minutes at 4 \u00b0C and the supernatant was filtered, then loaded onto a HiTrap His column.", [["lysate", "ANATOMY", 4, 10], ["supernatant", "ANATOMY", 72, 83], ["lysate", "ORGANISM_SUBSTANCE", 4, 10], ["The lysate", "TREATMENT", 0, 10], ["a HiTrap His column", "TREATMENT", 115, 134], ["column", "ANATOMY", 128, 134]]], ["The column was washed with lysate buffer and the protein was then eluted by linear gradient of imidazole.", [["imidazole", "CHEMICAL", 95, 104], ["imidazole", "CHEMICAL", 95, 104], ["imidazole", "SIMPLE_CHEMICAL", 95, 104], ["The column", "TREATMENT", 0, 10], ["lysate buffer", "TREATMENT", 27, 40], ["the protein", "TREATMENT", 45, 56], ["imidazole", "TREATMENT", 95, 104], ["column", "ANATOMY", 4, 10]]], ["The peak of the protein was pulled and concentrated.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["The protein was then diluted in ULP1 cleavage buffer (20 mM Tris pH 8.0, 100 mM NaCl and 10 % Glycerol).", [["NaCl", "CHEMICAL", 80, 84], ["Glycerol", "CHEMICAL", 94, 102], ["NaCl", "CHEMICAL", 80, 84], ["Glycerol", "CHEMICAL", 94, 102], ["ULP1", "SIMPLE_CHEMICAL", 32, 36], ["Glycerol", "SIMPLE_CHEMICAL", 94, 102], ["The protein", "TEST", 0, 11], ["ULP1 cleavage buffer", "TREATMENT", 32, 52], ["Tris pH", "TEST", 60, 67], ["100 mM NaCl", "TREATMENT", 73, 84], ["10 % Glycerol", "TREATMENT", 89, 102]]], ["The protease ULP1 was added at 1:20 ratio with incubation at 20C for overnight.", [["ULP1", "CHEMICAL", 13, 17], ["ULP1", "GENE_OR_GENE_PRODUCT", 13, 17], ["protease ULP1", "PROTEIN", 4, 17], ["The protease ULP1", "TREATMENT", 0, 17]]], ["The sample was loaded to His column and the flow through containing the untagged Mpro was collected.", [["sample", "ANATOMY", 4, 10], ["His", "CHEMICAL", 25, 28], ["Mpro", "GENE_OR_GENE_PRODUCT", 81, 85], ["untagged Mpro", "PROTEIN", 72, 85]]], ["The untagged Mpro was concentrated and loaded to Superdex 200/16 equilibrated with 20 mM Tris pH 8.0, 250 mM NaCl.", [["NaCl", "CHEMICAL", 109, 113], ["NaCl", "CHEMICAL", 109, 113], ["Mpro", "GENE_OR_GENE_PRODUCT", 13, 17], ["untagged Mpro", "PROTEIN", 4, 17], ["Superdex", "TEST", 49, 57], ["mM Tris pH", "TEST", 86, 96]]], ["The peak of the protein was pooled and concentrated.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["The purity of the protein was evaluated by SDS-PAGE.Protein expression and purification. ::: MATERIALS AND METHODSThe expression and purification of SARS CoV-2 Mpro with unmodified N- and C-termini (Mpro).", [["N", "CHEMICAL", 181, 182], ["unmodified N- and C-termini", "DNA", 170, 197], ["Mpro", "PROTEIN", 199, 203], ["SARS CoV", "SPECIES", 149, 157], ["Protein expression", "TEST", 52, 70], ["SARS CoV", "TEST", 149, 157], ["unmodified N- and C-termini (Mpro)", "TREATMENT", 170, 204]]], ["SARS CoV-2 Mpro gene was subcloned from pET29a(+) to pE-SUMO vector according to manufacturer\u2019s protocol (LifeSensors Inc, Malvern PA). pE-SUMO plasmid with SARS CoV-2 Main protease gene (Mpro) was transformed into BL21(DE3) cells with kanamycin selection.", [["cells", "ANATOMY", 225, 230], ["kanamycin", "CHEMICAL", 236, 245], ["kanamycin", "CHEMICAL", 236, 245], ["CoV-2", "GENE_OR_GENE_PRODUCT", 5, 10], ["Mpro", "GENE_OR_GENE_PRODUCT", 11, 15], ["pET29a", "GENE_OR_GENE_PRODUCT", 40, 46], ["pE-SUMO", "GENE_OR_GENE_PRODUCT", 53, 60], ["pE-SUMO", "GENE_OR_GENE_PRODUCT", 136, 143], ["CoV-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["Mpro", "GENE_OR_GENE_PRODUCT", 188, 192], ["DE3) cells", "CELL", 220, 230], ["kanamycin", "SIMPLE_CHEMICAL", 236, 245], ["SARS CoV-2 Mpro gene", "DNA", 0, 20], ["pET29a(+) to pE-SUMO vector", "DNA", 40, 67], ["pE-SUMO plasmid", "DNA", 136, 151], ["SARS CoV-2 Main protease gene", "DNA", 157, 186], ["Mpro", "DNA", 188, 192], ["BL21(DE3) cells", "CELL_LINE", 215, 230], ["BL21", "SPECIES", 215, 219], ["SARS CoV", "TEST", 0, 8], ["pE", "PROBLEM", 53, 55], ["SUMO vector", "TREATMENT", 56, 67], ["manufacturer\u2019s protocol", "TREATMENT", 81, 104], ["pE", "PROBLEM", 136, 138], ["SUMO plasmid", "PROBLEM", 139, 151], ["SARS CoV", "TEST", 157, 165], ["Main protease gene (Mpro)", "TREATMENT", 168, 193], ["kanamycin selection", "TREATMENT", 236, 255], ["pE", "OBSERVATION", 53, 55], ["SUMO plasmid", "OBSERVATION", 139, 151]]], ["A single colony was picked to inoculate 10 ml LB media and was cultured 37 \u00b0C overnight.", [["colony", "ANATOMY", 9, 15], ["A single colony", "PROBLEM", 0, 15], ["single", "OBSERVATION_MODIFIER", 2, 8], ["colony", "OBSERVATION", 9, 15]]], ["This 10 ml culture was added to 1 liter LB media and grown to around OD 600 of 0.8.", [["This 10 ml culture", "TEST", 0, 18]]], ["This culture was cooled on ice for 15 min, then induced with 0.5 mM IPTG.", [["IPTG", "CHEMICAL", 68, 72], ["IPTG", "CHEMICAL", 68, 72], ["This culture", "TEST", 0, 12], ["0.5 mM IPTG", "TREATMENT", 61, 72]]], ["Induced cultures were incubated at 18\u00b0C for an additional 24 h and then harvested, lysed same way as His-tagged Mpro protein.15 The supernatant was incubated with Ni-NTA resin for overnight at 4 \u00b0C on a rotator.", [["cultures", "ANATOMY", 8, 16], ["supernatant", "ANATOMY", 132, 143], ["Ni-NTA", "CHEMICAL", 163, 169], ["Ni-NTA", "CHEMICAL", 163, 169], ["C", "GENE_OR_GENE_PRODUCT", 38, 39], ["Mpro", "GENE_OR_GENE_PRODUCT", 112, 116], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 163, 175], ["His-tagged Mpro protein", "PROTEIN", 101, 124], ["Induced cultures", "TEST", 0, 16], ["Ni-NTA resin", "TREATMENT", 163, 175], ["a rotator", "TREATMENT", 201, 210], ["rotator", "ANATOMY", 203, 210]]], ["The Ni-NTA resin was thoroughly washed with 30 mM imidazole in wash buffer (50 mM Tris [pH 7.0], 150 mM NaCl, 2 mM DTT), SUMO-tagged Mpro was eluted from Ni-NTA with 300 mM imidazole.", [["Ni-NTA", "CHEMICAL", 4, 10], ["imidazole", "CHEMICAL", 50, 59], ["NaCl", "CHEMICAL", 104, 108], ["Ni-NTA", "CHEMICAL", 154, 160], ["imidazole", "CHEMICAL", 173, 182], ["Ni-NTA", "CHEMICAL", 4, 10], ["imidazole", "CHEMICAL", 50, 59], ["NaCl", "CHEMICAL", 104, 108], ["DTT", "CHEMICAL", 115, 118], ["Ni-NTA", "CHEMICAL", 154, 160], ["imidazole", "CHEMICAL", 173, 182], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 4, 16], ["imidazole", "SIMPLE_CHEMICAL", 50, 59], ["DTT", "SIMPLE_CHEMICAL", 115, 118], ["SUMO-tagged Mpro", "SIMPLE_CHEMICAL", 121, 137], ["Ni-NTA", "SIMPLE_CHEMICAL", 154, 160], ["imidazole", "SIMPLE_CHEMICAL", 173, 182], ["SUMO", "PROTEIN", 121, 125], ["The Ni-NTA resin", "TREATMENT", 0, 16], ["30 mM imidazole in wash buffer", "TREATMENT", 44, 74], ["pH", "TEST", 88, 90], ["NaCl", "TEST", 104, 108], ["SUMO", "TEST", 121, 125], ["300 mM imidazole", "TREATMENT", 166, 182]]], ["Eluted SUMO-tagged Mpro was dialyzed against 100-fold volume dialysis buffer (50 mM Tris [pH 7.0], 150 mM NaCl, 2 mM DTT) in a 10,000-molecular-weight-cutoff dialysis tubing.", [["NaCl", "CHEMICAL", 106, 110], ["NaCl", "CHEMICAL", 106, 110], ["DTT", "CHEMICAL", 117, 120], ["SUMO", "GENE_OR_GENE_PRODUCT", 7, 11], ["Mpro", "SIMPLE_CHEMICAL", 19, 23], ["SUMO", "PROTEIN", 7, 11], ["Mpro", "PROTEIN", 19, 23], ["fold volume dialysis buffer", "TREATMENT", 49, 76], ["Tris", "TEST", 84, 88], ["pH", "TEST", 90, 92], ["NaCl", "TEST", 106, 110], ["DTT", "TEST", 117, 120], ["dialysis tubing", "TREATMENT", 158, 173], ["dialysis tubing", "OBSERVATION", 158, 173]]], ["After dialysis, SUMO-tagged Mpro was incubated with SUMO protease 1 at 4 \u00b0C for overnight, and SUMO tag was removed by application of another round of Ni-NTA resin.", [["Ni-NTA", "CHEMICAL", 151, 157], ["Ni-NTA", "CHEMICAL", 151, 157], ["SUMO", "GENE_OR_GENE_PRODUCT", 16, 20], ["Mpro", "GENE_OR_GENE_PRODUCT", 28, 32], ["SUMO protease 1", "GENE_OR_GENE_PRODUCT", 52, 67], ["SUMO", "GENE_OR_GENE_PRODUCT", 95, 99], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 151, 163], ["SUMO", "PROTEIN", 16, 20], ["Mpro", "PROTEIN", 28, 32], ["SUMO protease 1", "PROTEIN", 52, 67], ["SUMO", "PROTEIN", 95, 99], ["dialysis", "TREATMENT", 6, 14], ["SUMO protease", "TREATMENT", 52, 65], ["SUMO tag", "TREATMENT", 95, 103], ["Ni-NTA resin", "TREATMENT", 151, 163]]], ["The purity of the protein was confirmed with SDS-page gel.Protein expression and purification. ::: MATERIALS AND METHODSThe expression and purification of SARS CoV-2 papain-like protease (PLpro).", [["CoV-2", "GENE_OR_GENE_PRODUCT", 160, 165], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 166, 186], ["PLpro", "GENE_OR_GENE_PRODUCT", 188, 193], ["SARS CoV-2 papain-like protease", "PROTEIN", 155, 186], ["PLpro", "PROTEIN", 188, 193], ["SARS CoV", "SPECIES", 155, 163], ["Protein expression", "TEST", 58, 76], ["METHODSThe expression", "TREATMENT", 113, 134], ["SARS CoV", "TEST", 155, 163], ["papain", "TREATMENT", 166, 172], ["protease (PLpro)", "TREATMENT", 178, 194]]], ["SARS CoV-2 papain-like protease (PLpro) gene (ORF 1ab 1564 to 1876) from strain BetaCoV/Wuhan/WIV04/2019 was ordered from GenScript (Piscataway, NJ) in the pET28b(+) vector with E. coli codon optimization.", [["CoV-2 papain-like protease", "GENE_OR_GENE_PRODUCT", 5, 31], ["PLpro", "GENE_OR_GENE_PRODUCT", 33, 38], ["pET28b", "GENE_OR_GENE_PRODUCT", 156, 162], ["E. coli", "ORGANISM", 178, 185], ["SARS CoV-2 papain-like protease (PLpro) gene", "DNA", 0, 44], ["ORF 1", "DNA", 46, 51], ["GenScript", "DNA", 122, 131], ["pET28b(+) vector", "DNA", 156, 172], ["E. coli", "SPECIES", 178, 185], ["BetaCoV/Wuhan/WIV04/2019", "SPECIES", 80, 104], ["E. coli", "SPECIES", 178, 185], ["SARS CoV", "TEST", 0, 8], ["papain", "TREATMENT", 11, 17], ["protease (PLpro) gene", "TREATMENT", 23, 44], ["E. coli codon optimization", "TREATMENT", 178, 204], ["coli codon", "OBSERVATION", 181, 191]]], ["The expression and purification procedure is very similar as we express SUMO-Mpro protein as we described in above section except that lysis buffer and Ni-NTA wash and elution buffer in pH7.5 (50 mM Tris [pH 7.5], 150 mM NaCl, 2 mM DTT).Protein expression and purification. ::: MATERIALS AND METHODSHuman liver Cathepsin L was purchased from EMD Millipore (Cat # 219402).Peptide synthesis. ::: MATERIALS AND METHODSThe SARS-CoV-2 Mpro FRET substrate Dabcyl-KTSAVLQ/SGFRKME(Edans) was synthesized as described before.15 The SARS-CoV-2 PLpro FRET substrate Dabcyl-FTLRGG/APTKV(Edans) was synthesized by solid-phase synthesis through iterative cycles of coupling and deprotection using the previously optimized procedure.42 Specifically, chemmatrix rink-amide resin was used.", [["liver", "ANATOMY", 305, 310], ["Ni-NTA", "CHEMICAL", 152, 158], ["NaCl", "CHEMICAL", 221, 225], ["Dabcyl", "CHEMICAL", 450, 456], ["SGFRKME", "CHEMICAL", 465, 472], ["Dabcyl-FTLRGG", "CHEMICAL", 555, 568], ["APTKV", "CHEMICAL", 569, 574], ["chemmatrix rink-amide", "CHEMICAL", 735, 756], ["Ni-NTA", "CHEMICAL", 152, 158], ["NaCl", "CHEMICAL", 221, 225], ["DTT", "CHEMICAL", 232, 235], ["Dabcyl-FTLRGG", "CHEMICAL", 555, 568], ["amide", "CHEMICAL", 751, 756], ["SUMO", "GENE_OR_GENE_PRODUCT", 72, 76], ["Mpro", "GENE_OR_GENE_PRODUCT", 77, 81], ["Ni-NTA", "SIMPLE_CHEMICAL", 152, 158], ["liver", "ORGAN", 305, 310], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 311, 322], ["Edans", "SIMPLE_CHEMICAL", 473, 478], ["Dabcyl-FTLRGG", "SIMPLE_CHEMICAL", 555, 568], ["APTKV", "SIMPLE_CHEMICAL", 569, 574], ["Edans", "SIMPLE_CHEMICAL", 575, 580], ["chemmatrix rink-amide resin", "SIMPLE_CHEMICAL", 735, 762], ["SUMO", "PROTEIN", 72, 76], ["Mpro protein", "PROTEIN", 77, 89], ["KTSAVLQ", "PROTEIN", 457, 464], ["SGFRKME", "PROTEIN", 465, 472], ["Edans", "PROTEIN", 473, 478], ["FTLRGG", "PROTEIN", 562, 568], ["APTKV", "PROTEIN", 569, 574], ["Edans", "PROTEIN", 575, 580], ["purification procedure", "TREATMENT", 19, 41], ["above section", "TREATMENT", 109, 122], ["lysis buffer", "TREATMENT", 135, 147], ["Ni-NTA wash", "TREATMENT", 152, 163], ["elution buffer", "TREATMENT", 168, 182], ["Tris", "TEST", 199, 203], ["pH", "TEST", 205, 207], ["NaCl", "TEST", 221, 225], ["Protein expression", "TEST", 237, 255], ["METHODSHuman liver Cathepsin L", "TREATMENT", 292, 322], ["Peptide synthesis", "PROBLEM", 371, 388], ["METHODSThe SARS", "TEST", 408, 423], ["CoV", "TEST", 424, 427], ["FRET substrate Dabcyl", "TEST", 435, 456], ["The SARS", "TEST", 519, 527], ["CoV", "TEST", 528, 531], ["PLpro FRET substrate Dabcyl", "TREATMENT", 534, 561], ["FTLRGG/APTKV(Edans)", "TREATMENT", 562, 581], ["solid-phase synthesis", "TREATMENT", 601, 622], ["iterative cycles of coupling", "TREATMENT", 631, 659], ["deprotection", "TREATMENT", 664, 676], ["the previously optimized procedure", "TREATMENT", 683, 717], ["chemmatrix rink-amide resin", "TREATMENT", 735, 762], ["liver", "ANATOMY", 305, 310]]], ["Typical coupling condition was 5 equiv of amino acid, 5 equiv of HATU, and 10 equiv of DIEA in DMF for 5 minutes at 80 \u00b0C. For deprotection, 5% piperazine plus 0.1 M HOBt were used and the mixture was heated at 80\u00b0C for 5 minutes.", [["amino acid", "CHEMICAL", 42, 52], ["HATU", "CHEMICAL", 65, 69], ["DIEA", "CHEMICAL", 87, 91], ["DMF", "CHEMICAL", 95, 98], ["piperazine", "CHEMICAL", 144, 154], ["HOBt", "CHEMICAL", 166, 170], ["amino acid", "CHEMICAL", 42, 52], ["HATU", "CHEMICAL", 65, 69], ["DIEA", "CHEMICAL", 87, 91], ["DMF", "CHEMICAL", 95, 98], ["piperazine", "CHEMICAL", 144, 154], ["HOBt", "CHEMICAL", 166, 170], ["amino acid", "AMINO_ACID", 42, 52], ["HATU", "SIMPLE_CHEMICAL", 65, 69], ["DIEA", "SIMPLE_CHEMICAL", 87, 91], ["DMF", "SIMPLE_CHEMICAL", 95, 98], ["piperazine", "SIMPLE_CHEMICAL", 144, 154], ["HOBt", "SIMPLE_CHEMICAL", 166, 170], ["Typical coupling condition", "PROBLEM", 0, 26], ["amino acid", "TREATMENT", 42, 52], ["deprotection", "TREATMENT", 127, 139], ["5% piperazine", "TREATMENT", 141, 154], ["0.1 M HOBt", "TREATMENT", 160, 170]]], ["The peptide was cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O and the crude peptide was precipitated from ether after removal of TFA.", [["TFA", "CHEMICAL", 49, 52], ["H2O", "CHEMICAL", 70, 73], ["TFA", "CHEMICAL", 141, 144], ["TFA", "CHEMICAL", 49, 52], ["Tris", "CHEMICAL", 59, 63], ["H2O", "CHEMICAL", 70, 73], ["ether", "CHEMICAL", 118, 123], ["TFA", "CHEMICAL", 141, 144], ["TFA", "SIMPLE_CHEMICAL", 49, 52], ["H2O", "SIMPLE_CHEMICAL", 70, 73], ["ether", "SIMPLE_CHEMICAL", 118, 123], ["TFA", "SIMPLE_CHEMICAL", 141, 144], ["the resin", "TREATMENT", 29, 38], ["95% TFA", "TREATMENT", 45, 52], ["2.5% Tris", "TREATMENT", 54, 63], ["the crude peptide", "TREATMENT", 78, 95], ["removal of TFA", "TREATMENT", 130, 144]]], ["The purify and identify of the peptide were confirmed by analytical HPLC (> 98% purity) and mass spectrometry.", [["the peptide", "TEST", 27, 38], ["analytical HPLC", "TEST", 57, 72], ["mass spectrometry", "PROBLEM", 92, 109], ["mass spectrometry", "OBSERVATION", 92, 109]]], ["[M+2]2+ calculated 888.04, detected 888.80.Compound synthesis and characterization. ::: MATERIALS AND METHODSDetails for the synthesis procedure (Supplementary Scheme 1) and characterization for compounds UAWJ257, UAWJ246, UAWJ247, and UAWJ248 can be found in the supplementary information.Native Mass Spectrometry. ::: MATERIALS AND METHODSPrior to analysis, the protein was buffer exchanged into 0.2 M ammonium acetate (pH 6.8) and diluted to 10 \u03bcM.", [["UAWJ257", "CHEMICAL", 205, 212], ["UAWJ246", "CHEMICAL", 214, 221], ["UAWJ247", "CHEMICAL", 223, 230], ["UAWJ248", "CHEMICAL", 236, 243], ["ammonium acetate", "CHEMICAL", 404, 420], ["UAWJ257", "CHEMICAL", 205, 212], ["UAWJ246", "CHEMICAL", 214, 221], ["UAWJ247", "CHEMICAL", 223, 230], ["UAWJ248", "CHEMICAL", 236, 243], ["ammonium acetate", "CHEMICAL", 404, 420], ["UAWJ257", "SIMPLE_CHEMICAL", 205, 212], ["UAWJ246", "SIMPLE_CHEMICAL", 214, 221], ["UAWJ247", "SIMPLE_CHEMICAL", 223, 230], ["UAWJ248", "SIMPLE_CHEMICAL", 236, 243], ["ammonium acetate", "SIMPLE_CHEMICAL", 404, 420], ["the synthesis procedure", "TREATMENT", 121, 144], ["UAWJ246", "TEST", 214, 221], ["analysis", "TEST", 350, 358], ["the protein", "TREATMENT", 360, 371], ["0.2 M ammonium acetate", "TREATMENT", 398, 420], ["pH", "TEST", 422, 424], ["Mass Spectrometry", "OBSERVATION", 297, 314]]], ["DTT was dissolved in water and prepared at a 400 mM stock.", [["DTT", "CHEMICAL", 0, 3], ["DTT", "CHEMICAL", 0, 3], ["DTT", "SIMPLE_CHEMICAL", 0, 3], ["DTT", "TREATMENT", 0, 3]]], ["Each ligand was dissolved in ethanol and diluted to 10X stock concentrations.", [["ethanol", "CHEMICAL", 29, 36], ["ethanol", "CHEMICAL", 29, 36], ["ethanol", "SIMPLE_CHEMICAL", 29, 36], ["ethanol", "TREATMENT", 29, 36]]], ["The final mixture was prepared by adding 4 \u03bcL protein, 0.5 \u03bcL DTT stock, and 0.5 \u03bcL ligand stock for final concentration of 4 mM DTT and 8 \u03bcM protein.", [["DTT", "CHEMICAL", 62, 65], ["DTT", "CHEMICAL", 129, 132], ["DTT", "SIMPLE_CHEMICAL", 129, 132], ["4 \u03bcL protein", "TREATMENT", 41, 53], ["4 mM DTT", "TREATMENT", 124, 132]]], ["The mixtures were then incubated for 10 minutes at room temperature prior to analysis.", [["analysis", "TEST", 77, 85]]], ["Each sample was mixed and analyzed in triplicate.Native Mass Spectrometry. ::: MATERIALS AND METHODSNative mass spectrometry (MS) was performed using a Q-Exactive HF quadrupole-Orbitrap mass spectrometer with the Ultra-High Mass Range research modifications (Thermo Fisher Scientific).", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11], ["METHODSNative mass spectrometry", "PROBLEM", 93, 124], ["a Q-Exactive HF quadrupole", "TREATMENT", 150, 176], ["Orbitrap mass spectrometer", "TREATMENT", 177, 203], ["the Ultra", "TEST", 209, 218], ["High Mass", "PROBLEM", 219, 228], ["Mass Spectrometry", "OBSERVATION", 56, 73], ["Mass", "OBSERVATION", 224, 228]]], ["Samples were ionized using nano-electrospray ionization in positive ion mode using 1.0 kV capillary voltage at a 150 \u00b0C capillary temperature.", [["Samples", "ANATOMY", 0, 7], ["capillary", "ANATOMY", 90, 99], ["capillary", "ANATOMY", 120, 129], ["capillary", "TISSUE", 120, 129], ["Samples", "TEST", 0, 7], ["nano-electrospray ionization", "TEST", 27, 55]]], ["The samples were all analyzed with a 1,000\u201325,000 m/z range, the resolution set to 30,000, and a trapping gas pressure set to 3.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["a trapping gas pressure", "TEST", 95, 118], ["gas pressure", "OBSERVATION", 106, 118]]], ["Between 10 and 50 V of source fragmentation was applied to all samples to aid in desolvation.", [["source fragmentation", "PROBLEM", 23, 43], ["fragmentation", "OBSERVATION", 30, 43]]], ["Data were deconvolved and analyzed with UniDec.43Enzymatic assays. ::: MATERIALS AND METHODSThe main protease (Mpro) enzymatic assays were carried out exact as previously described in pH 6.5 reaction buffer containing 20 mM HEPES pH6.5, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol and 4 mM DTT.15Enzymatic assays. ::: MATERIALS AND METHODSThe SARS-CoV-2 papain-like protease (PLpro) enzymatic assays were carried out as follows: the assay was assembled in 96-well plates with 100 \u03bcl of 200 nM PLPro protein in PLPro reaction buffer (50 mM HEPES, pH7.5, 0.01% triton-100 and 5 mM DTT).", [["NaCl", "CHEMICAL", 244, 248], ["glycerol", "CHEMICAL", 267, 275], ["NaCl", "CHEMICAL", 244, 248], ["EDTA", "CHEMICAL", 257, 261], ["glycerol", "CHEMICAL", 267, 275], ["DTT", "CHEMICAL", 285, 288], ["HEPES", "CHEMICAL", 534, 539], ["DTT", "CHEMICAL", 574, 577], ["Mpro", "SIMPLE_CHEMICAL", 111, 115], ["EDTA", "SIMPLE_CHEMICAL", 257, 261], ["glycerol", "SIMPLE_CHEMICAL", 267, 275], ["DTT", "SIMPLE_CHEMICAL", 285, 288], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 349, 369], ["PLpro", "SIMPLE_CHEMICAL", 371, 376], ["PLPro", "SIMPLE_CHEMICAL", 505, 510], ["triton-100", "SIMPLE_CHEMICAL", 554, 564], ["protease", "PROTEIN", 101, 109], ["Mpro", "PROTEIN", 111, 115], ["papain", "PROTEIN", 349, 355], ["protease", "PROTEIN", 361, 369], ["PLpro", "PROTEIN", 371, 376], ["PLPro protein", "PROTEIN", 488, 501], ["METHODSThe main protease (Mpro", "TREATMENT", 85, 115], ["enzymatic assays", "TEST", 117, 133], ["pH", "TEST", 184, 186], ["120 mM NaCl", "TREATMENT", 237, 248], ["0.4 mM EDTA", "TREATMENT", 250, 261], ["20% glycerol", "TREATMENT", 263, 275], ["Enzymatic assays", "TEST", 291, 307], ["METHODSThe SARS", "TEST", 327, 342], ["CoV", "TEST", 343, 346], ["papain", "TREATMENT", 349, 355], ["protease (PLpro)", "TREATMENT", 361, 377], ["enzymatic assays", "TEST", 378, 394], ["the assay", "TEST", 424, 433], ["PLPro reaction buffer", "TREATMENT", 505, 526], ["HEPES", "TEST", 534, 539], ["0.01% triton", "TREATMENT", 548, 560]]], ["The enzymatic reaction was initiated by adding 1 \u03bcl of 1 mM FRET substrate (the final substrate concentration is 10 \u03bcM).", [["FRET", "SIMPLE_CHEMICAL", 60, 64], ["The enzymatic reaction", "PROBLEM", 0, 22], ["1 mM FRET substrate", "TREATMENT", 55, 74], ["the final substrate concentration", "TREATMENT", 76, 109], ["enzymatic reaction", "OBSERVATION", 4, 22]]], ["The reaction was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30 \u00b0C for 1 hr.", [["The reaction", "PROBLEM", 0, 12]]], ["The initial velocity of the enzymatic reaction with and without testing compounds was calculated by linear regression for the first 15 min of the kinetic progress curve.", [["the enzymatic reaction", "PROBLEM", 24, 46], ["testing compounds", "TEST", 64, 81], ["velocity", "OBSERVATION_MODIFIER", 12, 20], ["enzymatic reaction", "OBSERVATION", 28, 46]]], ["The IC50 values were calculated by plotting the initial velocity against various concentrations of testing compounds with a dose response function in Prism 8 software.Enzymatic assays. ::: MATERIALS AND METHODSThe cathepsin L enzymatic assay was carried out as follows: human liver cathepsin L (EMD Millipore 219402) was activated by incubating at reaction buffer (20 mM sodium acetate, 1 mM EDTA and 5 mM DTT pH5.5) for 30 min at 30 \u00b0C. Upon activation, the assay was assembled in 96-well plates with 100 \u03bcl of 300 pm cathepsin L protein in cathepsin L reaction buffer.", [["liver", "ANATOMY", 276, 281], ["sodium acetate", "CHEMICAL", 371, 385], ["sodium acetate", "CHEMICAL", 371, 385], ["EDTA", "CHEMICAL", 392, 396], ["DTT", "CHEMICAL", 406, 409], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 214, 225], ["human", "ORGANISM", 270, 275], ["liver", "ORGAN", 276, 281], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 282, 293], ["sodium acetate", "SIMPLE_CHEMICAL", 371, 385], ["EDTA", "SIMPLE_CHEMICAL", 392, 396], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 519, 530], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 542, 553], ["cathepsin L", "PROTEIN", 214, 225], ["cathepsin L protein", "PROTEIN", 519, 538], ["cathepsin L", "PROTEIN", 542, 553], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 270, 275], ["The IC50 values", "TEST", 0, 15], ["testing compounds", "TEST", 99, 116], ["Enzymatic assays", "TEST", 167, 183], ["METHODSThe cathepsin L enzymatic assay", "TEST", 203, 241], ["human liver cathepsin L (EMD Millipore", "TREATMENT", 270, 308], ["20 mM sodium acetate", "TREATMENT", 365, 385], ["1 mM EDTA", "TREATMENT", 387, 396], ["5 mM DTT pH5", "TREATMENT", 401, 413], ["the assay", "TEST", 455, 464], ["cathepsin L protein", "TREATMENT", 519, 538], ["cathepsin L reaction buffer", "TREATMENT", 542, 569], ["liver", "ANATOMY", 276, 281]]], ["The enzymatic reaction was initiated by adding 1 \u03bcl of 100 \u03bcM FRET substrate Z-Phe-Arg-AMC (the final substrate concentration is about 1 \u03bcM).", [["Z-Phe-Arg-AMC", "CHEMICAL", 77, 90], ["Z-Phe-Arg-AMC", "CHEMICAL", 77, 90], ["Z-Phe-Arg-AMC", "SIMPLE_CHEMICAL", 77, 90], ["The enzymatic reaction", "PROBLEM", 0, 22]]], ["The reaction was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30 \u00b0C for 1 hr.", [["The reaction", "PROBLEM", 0, 12]]], ["The IC50 values were calculated as described in above section.Differential scanning fluorimetry (DSF). ::: MATERIALS AND METHODSThe thermal shift binding assay (TSA) was carried out using a Thermal Fisher QuantStudio\u2122 5 Real-Time PCR System as described previously.15 Briefly, 3 \u03bcM SARS-CoV-2 Mpro protein in Mpro reaction buffer (20 mM HEPES, pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT and 20% glycerol) was incubated with testing compounds at 30 \u00b0C for 30 min.", [["SARS", "DISEASE", 282, 286], ["NaCl", "CHEMICAL", 359, 363], ["glycerol", "CHEMICAL", 395, 403], ["HEPES", "CHEMICAL", 337, 342], ["NaCl", "CHEMICAL", 359, 363], ["EDTA", "CHEMICAL", 372, 376], ["DTT", "CHEMICAL", 383, 386], ["glycerol", "CHEMICAL", 395, 403], ["Mpro", "SIMPLE_CHEMICAL", 309, 313], ["EDTA", "SIMPLE_CHEMICAL", 372, 376], ["DTT", "SIMPLE_CHEMICAL", 383, 386], ["glycerol", "SIMPLE_CHEMICAL", 395, 403], ["CoV-2 Mpro protein", "PROTEIN", 287, 305], ["The IC50 values", "TEST", 0, 15], ["Differential scanning fluorimetry", "TEST", 62, 95], ["a Thermal Fisher QuantStudio\u2122", "TREATMENT", 188, 217], ["CoV", "TEST", 287, 290], ["HEPES", "TEST", 337, 342], ["pH", "TEST", 344, 346], ["NaCl", "TEST", 359, 363], ["EDTA", "TEST", 372, 376], ["DTT", "TEST", 383, 386], ["20% glycerol", "TREATMENT", 391, 403], ["testing compounds", "TEST", 424, 441], ["IC50 values", "OBSERVATION", 4, 15]]], ["1X SYPRO orange dye was added and fluorescence of the well was monitored under a temperature gradient range from 20 \u00b0C to 90 \u00b0C with 0.05 \u00b0C/s incremental step.Cytotoxicity measurement. ::: MATERIALS AND METHODSEvaluation of the cytotoxicity of compounds were carried out using the neutral red uptake assay.44 Briefly, 80,000 cells/mL of the tested cell lines were dispensed into 96-well cell culture plates at 100 \u03bcL/well.", [["cells", "ANATOMY", 326, 331], ["cell lines", "ANATOMY", 349, 359], ["cell", "ANATOMY", 388, 392], ["SYPRO orange dye", "CHEMICAL", 3, 19], ["1X SYPRO orange dye", "SIMPLE_CHEMICAL", 0, 19], ["cells", "CELL", 326, 331], ["cell lines", "CELL", 349, 359], ["cell", "CELL", 388, 392], ["cell lines", "CELL_LINE", 349, 359], ["1X SYPRO orange dye", "TREATMENT", 0, 19], ["a temperature gradient", "TEST", 79, 101], ["Cytotoxicity measurement", "TEST", 160, 184], ["the cytotoxicity of compounds", "PROBLEM", 225, 254], ["the neutral red uptake assay", "TEST", 278, 306], ["the tested cell lines", "TREATMENT", 338, 359], ["cell culture plates", "TEST", 388, 407], ["cell lines", "OBSERVATION", 349, 359]]], ["200 \u03bcL fresh serum-free medium containing serial diluted compounds was added to each well.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["fresh serum", "TEST", 7, 18], ["serial diluted compounds", "TREATMENT", 42, 66]]], ["After incubating for 5 days at 37 \u00b0C, the medium was removed and replaced with 100 \u03bcL DMEM medium containing 40 \u03bcg/mL neutral red and incubated for 2\u20134 h at 37 \u00b0C. The amount of neutral red taken up was determined by measuring the absorbance at 540 nm using a Multiskan FC Microplate Photometer (Fisher Scientific).", [["a Multiskan FC Microplate Photometer", "TREATMENT", 258, 294], ["amount", "OBSERVATION_MODIFIER", 168, 174], ["neutral red", "OBSERVATION", 178, 189]]], ["The CC50 values were calculated from best-fit dose response curves with variable slope in Prism 8.Molecular dynamics simulations. ::: MATERIALS AND METHODSMD simulations were carried out to the covalently bound calpain inhibitor II, calpain inhibitor XII, UAWJ246, UAWJ247, UAWJ248 with SARS-CoV-2 Mpro corresponding to PDB ID 6XA4 (monomer), PDB ID 6XFN (monomer), PDB ID 6XBG (dimer), PDB ID 6XBH (monomer), PDB ID 6XBI (dimer) prepared as described previously.45 The most favored protonation states of ionizable residues (D, E, R, K and H) at pH 7 were assigned using Maestro.46 The protonation states of the histidines in the binding region were set to \u03b4 position in order to contribute to the stabilization of complexes.", [["UAWJ247", "CHEMICAL", 265, 272], ["UAWJ248", "CHEMICAL", 274, 281], ["UAWJ247", "CHEMICAL", 265, 272], ["K", "CHEMICAL", 534, 535], ["H", "CHEMICAL", 540, 541], ["histidines", "CHEMICAL", 612, 622], ["calpain inhibitor II", "GENE_OR_GENE_PRODUCT", 211, 231], ["calpain", "GENE_OR_GENE_PRODUCT", 233, 240], ["XII", "GENE_OR_GENE_PRODUCT", 251, 254], ["UAWJ246", "SIMPLE_CHEMICAL", 256, 263], ["UAWJ247", "SIMPLE_CHEMICAL", 265, 272], ["UAWJ248", "SIMPLE_CHEMICAL", 274, 281], ["PDB ID 6XFN", "SIMPLE_CHEMICAL", 343, 354], ["PDB ID 6XBI", "SIMPLE_CHEMICAL", 410, 421], ["D", "SIMPLE_CHEMICAL", 525, 526], ["CC50", "DNA", 4, 8], ["calpain inhibitor II", "PROTEIN", 211, 231], ["calpain", "PROTEIN", 233, 240], ["6XBG", "PROTEIN", 373, 377], ["dimer", "PROTEIN", 379, 384], ["6XBH", "PROTEIN", 394, 398], ["6XBI", "PROTEIN", 417, 421], ["dimer", "PROTEIN", 423, 428], ["\u03b4 position", "PROTEIN", 657, 667], ["The CC50 values", "TEST", 0, 15], ["fit dose response curves", "TEST", 42, 66], ["variable slope in Prism", "PROBLEM", 72, 95], ["METHODSMD simulations", "TEST", 148, 169], ["UAWJ247", "TEST", 265, 272], ["SARS", "TEST", 287, 291], ["CoV", "TEST", 292, 295], ["ionizable residues", "PROBLEM", 505, 523], ["Maestro", "TREATMENT", 571, 578], ["the histidines", "TREATMENT", 608, 622], ["PDB", "ANATOMY", 410, 413], ["most favored", "OBSERVATION_MODIFIER", 470, 482], ["protonation states", "OBSERVATION", 483, 501], ["ionizable residues", "OBSERVATION", 505, 523], ["protonation states", "OBSERVATION", 586, 604], ["stabilization", "OBSERVATION", 698, 711]]], ["Crystal waters were kept.", [["Crystal waters", "TREATMENT", 0, 14], ["waters", "OBSERVATION", 8, 14]]], ["All hydrogens atoms of the protein complex complex were minimized with the OPLS2005 force field47 by means of Maestro/Macromodel (Schrodinger 2017\u20131) using a distance-dependent dielectric constant of 4.0.", [["hydrogens", "CHEMICAL", 4, 13], ["protein complex complex", "PROTEIN", 27, 50], ["Maestro/Macromodel (Schrodinger", "TREATMENT", 110, 141], ["a distance-dependent dielectric constant", "TREATMENT", 156, 196], ["hydrogens atoms", "OBSERVATION", 4, 19], ["protein complex", "OBSERVATION", 27, 42]]], ["The molecular mechanics minimization was performed with a conjugate gradient (CG) method and a root mean square of the energy gradient (threshold) value of 0.005 kJ \u00c5\u22121 mol\u22121 was used as the convergence criterion.Molecular dynamics simulations. ::: MATERIALS AND METHODSEach complex was solvated using the TIP3P48 water model.", [["root", "ANATOMY", 95, 99], ["TIP3P48", "CHEMICAL", 306, 313], ["a conjugate gradient", "TEST", 56, 76], ["the energy gradient", "TEST", 115, 134], ["METHODSEach complex", "TREATMENT", 263, 282], ["the TIP3P48 water model", "TREATMENT", 302, 325]]], ["Using the \u201cSystem Builder\u201d utility of Schrodinger Desmond v.11.1 each complex was embedded in an orthorhombic water box extending beyond the solute 15 \u00c5 in x,y-plane and z-direction.", [["orthorhombic water box", "PROTEIN", 97, 119], ["Schrodinger Desmond", "TREATMENT", 38, 57], ["an orthorhombic water box", "TREATMENT", 94, 119]]], ["Na+ and Cl\u2212 ions were placed in the water phase to neutralize the systems and to reach the experimental salt concentration of 0.150 M NaCl.", [["Na", "CHEMICAL", 0, 2], ["Cl\u2212", "CHEMICAL", 8, 11], ["NaCl", "CHEMICAL", 134, 138], ["Na+", "CHEMICAL", 0, 3], ["Cl\u2212", "CHEMICAL", 8, 11], ["NaCl", "CHEMICAL", 134, 138], ["Na+", "SIMPLE_CHEMICAL", 0, 3], ["Cl\u2212 ions", "SIMPLE_CHEMICAL", 8, 16], ["salt", "SIMPLE_CHEMICAL", 104, 108], ["Na", "TEST", 0, 2], ["Cl\u2212 ions", "TEST", 8, 16], ["the experimental salt concentration", "TREATMENT", 87, 122], ["NaCl", "TREATMENT", 134, 138]]], ["305 amino acid residues and 4,653 atoms and ~18,600 water residues (55,700 water atoms) or c.a. ~60,350 atoms for the monomer proteins and ~29,700 water residues (89,200 water atoms) for the dimer proteins, i.e., 98,000 atoms.Molecular dynamics simulations. ::: MATERIALS AND METHODSThe OPLS2005 force field49,50 was used to model all protein and ligand interactions and lipids.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["lipids", "SIMPLE_CHEMICAL", 371, 377], ["monomer proteins", "PROTEIN", 118, 134], ["dimer proteins", "PROTEIN", 191, 205], ["amino acid residues", "TEST", 4, 23], ["the monomer proteins", "TEST", 114, 134], ["the dimer proteins", "TEST", 187, 205], ["lipids", "TEST", 371, 377], ["acid residues", "OBSERVATION", 10, 23]]], ["The particle mesh Ewald method (PME)51,52 was employed to calculate long-range electrostatic interactions with a grid spacing of 0.8 \u00c5.", [["a grid spacing", "TEST", 111, 125], ["particle mesh", "OBSERVATION", 4, 17]]], ["Van der Waals and short range electrostatic interactions were smoothly truncated at 9.0 \u00c5.", [["short range electrostatic interactions", "PROBLEM", 18, 56]]], ["The Nose-Hoover thermostat was utilized to maintain a constant temperature in all simulations, and the Martyna-Tobias-Klein barostat was used to control the pressure.", [["Hoover thermostat", "TREATMENT", 9, 26], ["the Martyna", "TREATMENT", 99, 110], ["Klein barostat", "TREATMENT", 118, 132], ["the pressure", "TEST", 153, 165], ["Nose", "ANATOMY", 4, 8], ["pressure", "OBSERVATION_MODIFIER", 157, 165]]], ["Periodic boundary conditions were applied (68\u00d795\u00d797) \u00c53 for the monomers and (105\u00d7106\u00d796) \u00c53 for the dimers.", [["Periodic boundary conditions", "PROBLEM", 0, 28], ["boundary conditions", "OBSERVATION", 9, 28]]], ["The equations of motion were integrated using the multistep RESPA integrator53 with an inner time step of 2 fs for bonded interactions and non-bonded interactions within a cutoff 9 \u00c5.", [["RESPA integrator53", "PROTEIN", 60, 78], ["the multistep RESPA integrator53", "TREATMENT", 46, 78]]], ["An outer time step of 6.0 fs was used for non-bonded interactions beyond the cut-off.Molecular dynamics simulations. ::: MATERIALS AND METHODSEach system was equilibrated in MD simulations with a default protocol for water-soluble proteins provided in Desmond, which consists of a series of restrained MD simulations designed to relax the system, while not deviating substantially from the initial coordinates.Molecular dynamics simulations. ::: MATERIALS AND METHODSThe first simulation was a Brownian dynamics run for 100 ps at a temperature of 10 K in the NVT (constant number of particles, volume, and temperature) ensemble with solute heavy atoms restrained with a force constant of 50 kcal mol \u00c5\u22122.", [["water-soluble proteins", "PROTEIN", 217, 239], ["non-bonded interactions", "PROBLEM", 42, 65], ["a default protocol", "TREATMENT", 194, 212], ["water-soluble proteins", "TREATMENT", 217, 239], ["restrained MD simulations", "TREATMENT", 291, 316], ["a temperature", "TEST", 530, 543], ["volume", "TEST", 594, 600], ["solute heavy atoms restrained", "TREATMENT", 633, 662]]], ["The Langevin thermostat54 was applied in the NVT ensemble and a MD simulation for 12 ps with solute heavy atoms restrained with a force constant of 50 kcal mol \u00c5\u22122.", [["Langevin thermostat54", "DNA", 4, 25], ["The Langevin thermostat54", "TREATMENT", 0, 25], ["solute heavy atoms restrained", "TREATMENT", 93, 122]]], ["The velocities were randomized and MD simulation for 12 ps was performed in the NPT ensemble and a Berendsen barostat55 with solute heavy atoms equally restrained at 10 K and another one at 300 K. The velocities were again randomized and unrestrained MD simulation for 24 ps was performed in the NPT ensemble.", [["barostat55", "CHEMICAL", 109, 119], ["Berendsen barostat55", "PROTEIN", 99, 119], ["The velocities", "TEST", 0, 14], ["MD simulation", "TEST", 35, 48], ["a Berendsen barostat55 with solute heavy atoms", "TREATMENT", 97, 143], ["The velocities", "TEST", 197, 211], ["velocities", "OBSERVATION_MODIFIER", 4, 14]]], ["The above-mentioned equilibration was followed by 100ns simulation without restrains.", [["restrains", "TREATMENT", 75, 84]]], ["Two MD simulations for each system were performed, one in in workstation with GTX 970, and using the GPU implementation of the MD simulations code, and one in ARIS-supercomputer system with cpu-cores.", [["GTX", "CHEMICAL", 78, 81], ["ARIS", "PROTEIN", 159, 163], ["GTX", "TREATMENT", 78, 81]]], ["The visualization of produced trajectories and structures was performed using the programs Chimera56 and VMD.57Immunofluorescence assay. ::: MATERIALS AND METHODSVero E6 cells in 96-well plates (Corning) were infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI of 0.05 in DMEM supplemented with 1% FBS.", [["METHODSVero E6 cells", "ANATOMY", 155, 175], ["FBS", "ANATOMY", 301, 304], ["Chimera56", "GENE_OR_GENE_PRODUCT", 91, 100], ["METHODSVero E6 cells", "CELL", 155, 175], ["SARS-CoV-2", "ORGANISM", 223, 233], ["USA", "ORGANISM", 235, 238], ["FBS", "ORGANISM_SUBSTANCE", 301, 304], ["Chimera56", "PROTEIN", 91, 100], ["METHODSVero E6 cells", "CELL_LINE", 155, 175], ["SARS-CoV-2", "SPECIES", 223, 233], ["METHODSVero E6 cells", "TEST", 155, 175], ["SARS", "TEST", 223, 227], ["CoV", "TEST", 228, 231], ["USA", "TEST", 235, 238], ["1% FBS", "TREATMENT", 298, 304]]], ["Immediately before the viral inoculation, the tested compounds in a three-fold dilution concentration series were also added to the wells in triplicate.", [["the viral inoculation", "TREATMENT", 19, 40], ["a three-fold dilution concentration series", "TREATMENT", 66, 108], ["viral inoculation", "OBSERVATION", 23, 40]]], ["The infection proceeded for 48 h without the removal of the viruses or the compounds.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["the removal", "TREATMENT", 41, 52], ["the viruses", "PROBLEM", 56, 67], ["infection", "OBSERVATION", 4, 13], ["viruses", "OBSERVATION", 60, 67]]], ["The cells were then fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-100, blocked with DMEM containing 10% FBS, and stained with a rabbit monoclonal antibody against SARS-CoV-2 NP (GeneTex, GTX635679) and an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (ThermoFisher Scientific).", [["cells", "ANATOMY", 4, 9], ["FBS", "ANATOMY", 121, 124], ["Triton-100", "CHEMICAL", 76, 86], ["paraformaldehyde", "CHEMICAL", 34, 50], ["Alexa Fluor 488", "CHEMICAL", 222, 237], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 34, 50], ["Triton-100", "SIMPLE_CHEMICAL", 76, 86], ["FBS", "ORGANISM_SUBSTANCE", 121, 124], ["rabbit", "ORGANISM", 145, 151], ["GeneTex", "SIMPLE_CHEMICAL", 195, 202], ["GTX635679", "SIMPLE_CHEMICAL", 204, 213], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 222, 237], ["rabbit monoclonal antibody", "PROTEIN", 145, 171], ["Alexa Fluor 488-conjugated goat anti-mouse secondary antibody", "PROTEIN", 222, 283], ["rabbit", "SPECIES", 145, 151], ["goat", "SPECIES", 249, 253], ["anti-mouse", "SPECIES", 254, 264], ["rabbit", "SPECIES", 145, 151], ["goat", "SPECIES", 249, 253], ["4% paraformaldehyde", "TREATMENT", 31, 50], ["0.1% Triton", "TREATMENT", 71, 82], ["DMEM", "TREATMENT", 101, 105], ["10% FBS", "TEST", 117, 124], ["a rabbit monoclonal antibody", "TEST", 143, 171], ["SARS", "TEST", 180, 184], ["CoV", "TEST", 185, 188], ["an Alexa Fluor", "TEST", 219, 233]]], ["Hoechst 33342 was added in the final step to counterstain the nuclei.", [["nuclei", "ANATOMY", 62, 68], ["Hoechst 33342", "CHEMICAL", 0, 13], ["Hoechst 33342", "CHEMICAL", 0, 13], ["Hoechst 33342", "SIMPLE_CHEMICAL", 0, 13], ["nuclei", "CELLULAR_COMPONENT", 62, 68], ["nuclei", "ANATOMY", 62, 68]]], ["Fluorescence images of approximately ten thousand cells were acquired per well with a 10x objective in a Cytation 5 (BioTek).", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["Fluorescence images", "TEST", 0, 19], ["a Cytation", "TREATMENT", 103, 113]]], ["The total number of cells, as indicated by the nuclei staining, and the fraction of the infected cells, as indicated by the NP staining, were quantified with the cellular analysis module of the Gen5 software (BioTek).Plaque assay. ::: MATERIALS AND METHODSVero E6 cells in 6-well plates (Corning) were infected with SARS-CoV-2 (USA-WA1/2020 isolate) at approximately 40 PFU per well.", [["cells", "ANATOMY", 20, 25], ["nuclei", "ANATOMY", 47, 53], ["cells", "ANATOMY", 97, 102], ["cellular", "ANATOMY", 162, 170], ["METHODSVero E6 cells", "ANATOMY", 249, 269], ["cells", "CELL", 20, 25], ["nuclei", "CELLULAR_COMPONENT", 47, 53], ["cells", "CELL", 97, 102], ["cellular", "CELL", 162, 170], ["METHODSVero E6 cells", "CELL", 249, 269], ["SARS-CoV-2", "ORGANISM", 316, 326], ["USA", "ORGANISM", 328, 331], ["WA1", "ORGANISM", 332, 335], ["infected cells", "CELL_TYPE", 88, 102], ["METHODSVero E6 cells", "CELL_LINE", 249, 269], ["SARS-CoV-2", "SPECIES", 316, 326], ["the nuclei staining", "TEST", 43, 62], ["the infected cells", "PROBLEM", 84, 102], ["the NP staining", "TEST", 120, 135], ["Plaque assay", "TEST", 217, 229], ["METHODSVero E6 cells", "TREATMENT", 249, 269], ["SARS", "TEST", 316, 320], ["CoV", "TEST", 321, 324], ["total", "OBSERVATION_MODIFIER", 4, 9], ["infected cells", "OBSERVATION", 88, 102], ["E6 cells", "OBSERVATION", 261, 269]]], ["After 1 hour of incubation at 37\u00b0C, the inoculum was removed and replaced with DMEM containing 1% FBS, 1.2% Avicel RC-591 (Dupont) and the tested compounds at different concentrations, in duplicate.", [["Avicel RC-591", "CHEMICAL", 108, 121], ["FBS", "ORGANISM_SUBSTANCE", 98, 101], ["Avicel RC-591", "SIMPLE_CHEMICAL", 108, 121], ["incubation", "TREATMENT", 16, 26], ["the inoculum", "TREATMENT", 36, 48], ["DMEM", "TREATMENT", 79, 83], ["1% FBS", "TREATMENT", 95, 101]]], ["After 3 days of infection, the overlay was removed, and the cells were fixed with 4% paraformaldehyde and stained with 0.2% crystal violet.Mpro crystallization and structure determination. ::: MATERIALS AND METHODSSARS-CoV-2 Mpro was diluted to 5 mg/mL and incubated with 1.5 mM of inhibitor at 4 \u00b0C overnight.", [["cells", "ANATOMY", 60, 65], ["infection", "DISEASE", 16, 25], ["paraformaldehyde", "CHEMICAL", 85, 101], ["cells", "CELL", 60, 65], ["paraformaldehyde", "SIMPLE_CHEMICAL", 85, 101], ["Mpro", "SIMPLE_CHEMICAL", 139, 143], ["CoV-2 Mpro", "ORGANISM", 219, 229], ["infection", "PROBLEM", 16, 25], ["4% paraformaldehyde", "TREATMENT", 82, 101], ["0.2% crystal violet", "TREATMENT", 119, 138], ["Mpro crystallization", "TREATMENT", 139, 159], ["structure determination", "TEST", 164, 187], ["METHODSSARS", "TEST", 207, 218], ["CoV", "TEST", 219, 222], ["Mpro", "TREATMENT", 225, 229], ["inhibitor", "TREATMENT", 282, 291], ["infection", "OBSERVATION", 16, 25], ["structure determination", "OBSERVATION", 164, 187]]], ["Samples were centrifuged at 13,000 G for 1 minute to remove precipitate.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Crystals were grown by mixing the protein-inhibitor sample with an equal volume of crystallization buffer (20 % PEG 3000, 0.2 M Na Citrate pH 5.6) in a vapor diffusion, hanging drop apparatus.", [["Crystals", "ANATOMY", 0, 8], ["PEG", "CHEMICAL", 112, 115], ["Na", "CHEMICAL", 128, 130], ["PEG", "CHEMICAL", 112, 115], ["Na Citrate", "CHEMICAL", 128, 138], ["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["Crystals", "TEST", 0, 8], ["the protein", "TEST", 30, 41], ["crystallization buffer", "TREATMENT", 83, 105], ["PEG", "TREATMENT", 112, 115], ["Na Citrate pH", "TEST", 128, 141], ["a vapor diffusion", "TEST", 150, 167], ["hanging drop apparatus", "PROBLEM", 169, 191]]], ["A cryoprotectant solution of 35 % PEG 3000 and 30 % glycerol was added directly to the drop and soaked for 15 minutes.", [["PEG 3000", "CHEMICAL", 34, 42], ["glycerol", "CHEMICAL", 52, 60], ["PEG", "CHEMICAL", 34, 37], ["glycerol", "CHEMICAL", 52, 60], ["glycerol", "SIMPLE_CHEMICAL", 52, 60], ["A cryoprotectant solution", "TREATMENT", 0, 25], ["35 % PEG", "TREATMENT", 29, 37], ["30 % glycerol", "TREATMENT", 47, 60]]], ["Crystals were then flash frozen in liquid nitrogen for X-ray diffraction.Mpro crystallization and structure determination. ::: MATERIALS AND METHODSX-ray diffraction data for the SARS-CoV-2 Mpro structures were collected on the SBC 19-ID beamline at the Advanced Photon Source (APS) in Argonne, IL, and processed with the HKL3000 software suite.", [["SARS", "DISEASE", 179, 183], ["nitrogen", "CHEMICAL", 42, 50], ["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["Mpro", "SIMPLE_CHEMICAL", 73, 77], ["SARS-CoV-2 Mpro structures", "DNA", 179, 205], ["SARS-CoV", "SPECIES", 179, 187], ["Crystals", "TEST", 0, 8], ["liquid nitrogen", "TREATMENT", 35, 50], ["X-ray diffraction", "TEST", 55, 72], ["Mpro crystallization", "TREATMENT", 73, 93], ["METHODSX", "TEST", 141, 149], ["ray diffraction data", "TEST", 150, 170], ["the SARS", "TEST", 175, 183], ["CoV", "TEST", 184, 187], ["the SBC", "TEST", 224, 231]]], ["The CCP4 versions of MOLREP was used for molecular replacement using a previously solved SARS-CoV-2 Mpro structure, PDB ID: 7BRR as a reference model for the dimeric P21 Mpro with UAWJ246.", [["UAWJ246", "CHEMICAL", 180, 187], ["UAWJ246", "CHEMICAL", 180, 187], ["UAWJ246", "SIMPLE_CHEMICAL", 180, 187], ["CCP4", "PROTEIN", 4, 8], ["MOLREP", "PROTEIN", 21, 27], ["SARS-CoV-2 Mpro structure", "PROTEIN", 89, 114], ["dimeric P21 Mpro", "PROTEIN", 158, 174], ["UAWJ246", "PROTEIN", 180, 187], ["MOLREP", "TREATMENT", 21, 27], ["molecular replacement", "TREATMENT", 41, 62]]], ["PDB ID 6YB7 was used as the reference model for the C2 monomeric Mpro with calpain inhibitors II/XII and UAWJ247, and the P1 dimeric structure with UAWJ248.", [["UAWJ248", "CHEMICAL", 148, 155], ["UAWJ248", "CHEMICAL", 148, 155], ["calpain", "GENE_OR_GENE_PRODUCT", 75, 82], ["XII", "GENE_OR_GENE_PRODUCT", 97, 100], ["UAWJ247", "GENE_OR_GENE_PRODUCT", 105, 112], ["UAWJ248", "SIMPLE_CHEMICAL", 148, 155], ["6YB7", "PROTEIN", 7, 11], ["C2 monomeric Mpro", "PROTEIN", 52, 69], ["calpain inhibitors II", "PROTEIN", 75, 96], ["XII", "PROTEIN", 97, 100], ["UAWJ247", "PROTEIN", 105, 112], ["P1 dimeric structure", "PROTEIN", 122, 142], ["the C2 monomeric Mpro", "TEST", 48, 69], ["calpain inhibitors", "TREATMENT", 75, 93], ["UAWJ247", "TEST", 105, 112]]], ["PDB ID 6WTT was used as the reference model for the P3221 trimer with UAWJ246.", [["UAWJ246", "CHEMICAL", 70, 77], ["UAWJ246", "CHEMICAL", 70, 77], ["UAWJ246", "SIMPLE_CHEMICAL", 70, 77], ["P3221 trimer", "PROTEIN", 52, 64], ["UAWJ246", "PROTEIN", 70, 77]]], ["Rigid and restrained refinements were performed using REFMAC and model building was performed with COOT.", [["COOT", "PROTEIN", 99, 103], ["Rigid and restrained refinements", "TREATMENT", 0, 32], ["REFMAC and model building", "TREATMENT", 54, 79]]], ["Protein structure figures were made using PyMOL (Schr\u00f6dinger, LLC).", [["Protein structure figures", "PROBLEM", 0, 25], ["PyMOL (Schr\u00f6dinger, LLC", "TREATMENT", 42, 65], ["LLC", "ANATOMY", 62, 65]]]], "a8f49afaa529a206939904227c57f207838ccacd": [["IntroductionThe coronavirus disease pandemic has placed unprecedented strain on the US health care system, and the possibility that it could become endemic-meaning it will be a common dweller that regularly infects humans-suggests that this strain will persist for some time.", [["coronavirus disease pandemic", "DISEASE", 16, 44], ["coronavirus", "ORGANISM", 16, 27], ["humans", "ORGANISM", 215, 221], ["humans", "SPECIES", 215, 221], ["humans", "SPECIES", 215, 221], ["The coronavirus disease pandemic", "PROBLEM", 12, 44], ["endemic", "PROBLEM", 148, 155], ["this strain", "PROBLEM", 236, 247], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["As COVID-19 cases accelerate, health care workers are becoming more vital than ever, and they are rightly being hailed as heroes for their generous, brave dedication to caring for patients at the risk of their own health.", [["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188]]], ["Providing these heroes with resources to safely deliver high-quality care to their patients and themselves is imperative not only in acute care settings such as emergency rooms and intensive care units (ICUs), but also in nursing homes, where staff provide care for vulnerable older adults in settings that are at risk for infectious disease outbreaks.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["high-quality care", "TREATMENT", 56, 73], ["infectious disease outbreaks", "PROBLEM", 323, 351], ["infectious", "OBSERVATION", 323, 333]]], ["Nursing home staff face unique challenges during the COVID-19 pandemic because they care for older adults with a high level of vulnerability to COVID-19 and experience constraints that far exceed those imposed in acute care settings.", [["acute care settings", "TREATMENT", 213, 232]]], ["Telehealth strategies, automatic clinical decision-making reports, and other uses of technology commonly found in other care settings hold great promise to improve nursing home care and outcomes.IntroductionBy 2030, almost 1 in 5 Americans will be 65 years or older [1] , and today, >1.3 million people live in 15,600 nursing homes [2] ; in society, these people are some of the most frail and vulnerable to viral infections such as COVID-19 because they are older, have other medical conditions such as heart and respiratory disease, and live in group settings.", [["heart", "ANATOMY", 504, 509], ["respiratory", "ANATOMY", 514, 525], ["viral infections", "DISEASE", 408, 424], ["heart and respiratory disease", "DISEASE", 504, 533], ["people", "ORGANISM", 296, 302], ["people", "ORGANISM", 356, 362], ["heart", "ORGAN", 504, 509], ["people", "SPECIES", 296, 302], ["people", "SPECIES", 356, 362], ["nursing home care", "TREATMENT", 164, 181], ["viral infections", "PROBLEM", 408, 424], ["heart and respiratory disease", "PROBLEM", 504, 533], ["heart", "ANATOMY", 504, 509], ["respiratory disease", "OBSERVATION", 514, 533]]], ["US nursing homes are familiar with disease outbreaks, including seasonal influenza and norovirus; although COVID-19 shares similarities with these outbreaks, it will be more devastating because there are no approved therapeutics to slow the course of its toll on the human body and because there is currently no vaccine available to combat it.IntroductionBecause of these vulnerabilities, nursing homes were early reporters of positive COVID-19 cases.", [["body", "ANATOMY", 273, 277], ["influenza", "DISEASE", 73, 82], ["norovirus", "DISEASE", 87, 96], ["human", "ORGANISM", 267, 272], ["body", "ORGANISM_SUBDIVISION", 273, 277], ["human", "SPECIES", 267, 272], ["human", "SPECIES", 267, 272], ["disease outbreaks", "PROBLEM", 35, 52], ["seasonal influenza", "PROBLEM", 64, 82], ["norovirus", "PROBLEM", 87, 96], ["vaccine", "TREATMENT", 312, 319]]], ["The first reported COVID-19 death in the United States was a nursing home resident in Kirkland, Washington, reported on February 28, 2020.", [["death", "DISEASE", 28, 33]]], ["Nursing homes across the country and the Centers for Medicare and Medicaid Services (CMS) acted quickly; by March 13, 2020, they enacted guidelines to protect nursing home residents, including barring visitors and adding infection control measures that restrict communal activities, essentially isolating residents in their rooms.", [["infection", "DISEASE", 221, 230], ["infection control measures", "TREATMENT", 221, 247]]], ["Despite these measures, COVID-19 infections spread quickly between nursing home residents and staff.", [["infections", "DISEASE", 33, 43], ["these measures", "TREATMENT", 8, 22], ["COVID", "TEST", 24, 29], ["infections", "PROBLEM", 33, 43]]], ["As of April 29, 2020, more than 2700 Medicare-certified nursing homes across the country (1 in 6 facilities) acknowledged infections in residents or staff, and in some states, a majority of nursing homes have reported COVID-19 cases [3] .", [["infections", "DISEASE", 122, 132], ["infections", "OBSERVATION", 122, 132]]], ["Nationally, COVID-19 death rates are higher for nursing home residents, who account for over half of deaths in some states [4] .IntroductionCurrently, nursing homes continue to battle COVID-19 infections among residents and staff, which is challenging how nursing homes provide care to our most vulnerable older adults.", [["death", "DISEASE", 21, 26], ["deaths", "DISEASE", 101, 107], ["infections", "DISEASE", 193, 203], ["COVID", "TEST", 12, 17]]], ["In addition to preventing the spread of COVID-19 within nursing homes, it is now necessary to plan for the admission of patients who were hospitalized with COVID-19 and are too debilitated to return to their homes.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["The recovery trajectories and continued health care needs of these patients are uncharted; however, increasing evidence points to long-term post-COVID-19 complications that may increase the complexity and length of rehabilitation [5] .IntroductionDuring the COVID-19 pandemic, there has been much focus on personal protective equipment (PPE), the lack of testing and supplies, and the need for infection control training; however, this pandemic has also highlighted problems that nursing homes were already facing, such as frequent staff shortages and high turnover.", [["infection", "DISEASE", 394, 403], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["personal protective equipment", "TREATMENT", 306, 335], ["testing", "TEST", 355, 362], ["infection control training", "TREATMENT", 394, 420]]], ["It is important to take this opportunity to increase awareness of other aspects of care delivery within nursing homes that have been affected by the pandemic.", [["care delivery", "TREATMENT", 83, 96]]], ["These aspects of care delivery can be enhanced by leveraging strategies such as technology used in other areas of the healthcare system to improve nursing home care both now and in the future.What challenges and issues do nursing homes face?COVID-19 has presented unique challenges and highlighted ongoing issues faced by nursing homes in providing effective, compassionate, and safe care for vulnerable older adults in an institutional home setting.", [["care delivery", "TREATMENT", 17, 30], ["nursing home care", "TREATMENT", 147, 164]]], ["While the strict regulatory controls currently in place for nursing homes have likely prevented further spread of COVID-19 and subsequent deaths, nursing home staff are being challenged with new work patterns, longer hours, and the need to find new ways to communicate with families.", [["deaths", "DISEASE", 138, 144]]], ["These measures pose additional risks for nursing home residents, such as isolation, which limits their mobility and social interactions.", [["nursing home residents", "TREATMENT", 41, 63], ["isolation", "TREATMENT", 73, 82]]], ["Furthermore, family members are not able to visit their loved ones, which can be particularly devastating when residents have dementia or are at end-of-life.", [["dementia", "DISEASE", 126, 134], ["dementia", "PROBLEM", 126, 134]]], ["Together, residents, families, and nursing home staff are facing unprecedented stress as they navigate these challenges and their own fears about the virus.Impact of CMS Regulations on Care DeliveryPrior to COVID-19, the nursing home industry was highly regulated by CMS, which partners with state survey agencies to monitor every Medicare-certified and Medicaid-certified nursing home for safety and quality.", [["the virus", "PROBLEM", 146, 155], ["COVID", "TEST", 207, 212], ["CMS Regulations", "OBSERVATION", 166, 181]]], ["Many of these challenges are related to CMS regulations on how nursing home care is delivered.Regulation WaiversDuring the COVID-19 pandemic, CMS has provided nursing homes with flexibility to decrease COVID-19 infection risk, emphasizing resident care over paperwork [6] .", [["infection", "DISEASE", 211, 220], ["the COVID", "TEST", 119, 128], ["flexibility", "TREATMENT", 178, 189], ["COVID", "TEST", 202, 207]]], ["These waivers impact physical building requirements and relax minimum data set and staffing data submissions.", [["staffing data submissions", "TEST", 83, 108]]], ["Quality assurance and performance improvement (QAPI) requirements are now focused on adverse events and infection control.", [["infection", "DISEASE", 104, 113], ["adverse events", "PROBLEM", 85, 99], ["infection control", "TREATMENT", 104, 121], ["infection", "OBSERVATION", 104, 113]]], ["Staying abreast of evolving CMS, Centers for Disease Control and Prevention (CDC), and state regulations and guidelines is challenging for an already stressed workforce.", [["Disease Control", "TREATMENT", 45, 60]]], ["In particular, implementing new and difficult infection control guidelines, such as stopping congregant activities and preventing families from visiting their loved ones, is particularly stressful for staff, who recognize the impact on residents' general health and quality of life.Staffing and Workforce IssuesNursing home staff, including nurses, physical and occupational therapists, social workers, and direct care workers, often work at several different facilities; this increases the risk of acquiring and spreading COVID-19 between facilities, especially since many people who are positive for COVID-19 do not show outward symptoms.", [["infection", "DISEASE", 46, 55], ["people", "ORGANISM", 574, 580], ["people", "SPECIES", 574, 580], ["new and difficult infection control guidelines", "PROBLEM", 28, 74], ["COVID", "TEST", 602, 607], ["outward symptoms", "PROBLEM", 623, 639], ["new", "OBSERVATION_MODIFIER", 28, 31], ["infection", "OBSERVATION", 46, 55]]], ["As the virus spreads among staff and residents, large numbers of nursing home personnel are remaining at home, contributing further to often pre-existing staff shortages.", [["large", "OBSERVATION_MODIFIER", 48, 53], ["numbers", "OBSERVATION_MODIFIER", 54, 61]]], ["Some nursing homes must rely on agency staff at the risk of inconsistent care delivery and documentation.", [["inconsistent care delivery", "TREATMENT", 60, 86]]], ["The relaxed CMS regulations support the hiring of new CNAs to fill vacancies; however, due to the lack of training requirements, more staff are unprepared to work with nursing home residents during the pandemic.", [["The relaxed CMS regulations", "TREATMENT", 0, 27], ["training requirements", "TREATMENT", 106, 127], ["relaxed CMS", "OBSERVATION", 4, 15]]], ["Further, staff must adjust to workflow changes resulting from residents being confined to their rooms and the added time required for implementing infection control practices.", [["infection", "DISEASE", 147, 156], ["infection control practices", "TREATMENT", 147, 174], ["infection", "OBSERVATION", 147, 156]]], ["The negative impact of social isolation on the physical and mental health of residents further contributes to staff stress, particularly in the face of the probable endemic nature of COVID-19.Infection Control ConstraintsNursing homes must ensure that they are adhering to infection control guidelines issued by a number of CDC, CMS, state, and local regulatory bodies [7] .", [["infection", "DISEASE", 273, 282], ["COVID-19", "CHEMICAL", 183, 191], ["social isolation", "TREATMENT", 23, 39], ["staff stress", "PROBLEM", 110, 122], ["COVID", "TEST", 183, 188], ["Infection Control Constraints", "PROBLEM", 192, 221], ["infection control guidelines", "TREATMENT", 273, 301], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["impact", "OBSERVATION_MODIFIER", 13, 19], ["social isolation", "OBSERVATION", 23, 39], ["probable", "UNCERTAINTY", 156, 164], ["endemic", "OBSERVATION_MODIFIER", 165, 172], ["infection", "OBSERVATION", 273, 282]]], ["Every individual entering a nursing home must be screened for COVID-19 symptoms, and every resident must have their temperature checked daily [8] .", [["symptoms", "PROBLEM", 71, 79]]], ["These measures increase the time and difficulty of working with residents, increasing the difficulty of person-centered care and increasing the stress on staff and residents alike.Impact on ResidentsUnder COVID-19 restrictions, nursing homes are closed to everyone but essential health care providers and staff.", [["person", "SPECIES", 104, 110]]], ["The consequences of isolation on the physical and mental health of nursing home residents will not be known for some time.", [["isolation", "OBSERVATION_MODIFIER", 20, 29]]], ["However, anecdotal reports from staff and families suggest that residents' health is declining rapidly as a result of COVID-19 isolation.", [["COVID-19 isolation", "TREATMENT", 118, 136]]], ["Social isolation itself is associated with increased loneliness, which has been associated with a plethora of behavioral and physical health issues, including increased depression and anxiety, increased risk of falls and hospitalization, and even death [9] .", [["loneliness", "DISEASE", 53, 63], ["depression", "DISEASE", 169, 179], ["anxiety", "DISEASE", 184, 191], ["falls", "DISEASE", 211, 216], ["death", "DISEASE", 247, 252], ["increased loneliness", "PROBLEM", 43, 63], ["behavioral and physical health issues", "PROBLEM", 110, 147], ["increased depression", "PROBLEM", 159, 179], ["anxiety", "PROBLEM", 184, 191], ["falls", "PROBLEM", 211, 216], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["loneliness", "OBSERVATION", 53, 63], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["depression", "OBSERVATION", 169, 179]]], ["Residents living with dementia face particular challenges, as they often cannot understand why their routines are being disrupted and their activities curtailed.", [["dementia", "DISEASE", 22, 30]]], ["These disruptions, in addition to the lack of visitors who are often able to calm cognitively impaired residents, can result in a host of behavioral symptoms that staff have less time to address.", [["These disruptions", "PROBLEM", 0, 17], ["behavioral symptoms", "PROBLEM", 138, 157]]], ["Short-term consequences of social isolation are being reported anecdotally from health care providers, nursing home staff, and family members; these consequences include rapid decline in function and health (eg, dehydration, renal problems, and malnutrition), hopelessness and severe depression, and increases in suicidal ideation [10] .Increased Pressure Injury RiskNursing home residents are at increased risk for pressure injuries because they already have limited mobility and are now being confined to their rooms.", [["renal", "ANATOMY", 225, 230], ["dehydration", "DISEASE", 212, 223], ["renal problems", "DISEASE", 225, 239], ["malnutrition", "DISEASE", 245, 257], ["hopelessness", "DISEASE", 260, 272], ["depression", "DISEASE", 284, 294], ["suicidal ideation", "DISEASE", 313, 330], ["pressure injuries", "DISEASE", 416, 433], ["renal", "ORGAN", 225, 230], ["social isolation", "TREATMENT", 27, 43], ["rapid decline in function and health (eg", "PROBLEM", 170, 210], ["dehydration", "PROBLEM", 212, 223], ["renal problems", "PROBLEM", 225, 239], ["malnutrition)", "PROBLEM", 245, 258], ["hopelessness", "PROBLEM", 260, 272], ["severe depression", "PROBLEM", 277, 294], ["increases in suicidal ideation", "PROBLEM", 300, 330], ["Increased Pressure Injury", "PROBLEM", 337, 362], ["pressure injuries", "PROBLEM", 416, 433], ["renal", "ANATOMY", 225, 230], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["depression", "OBSERVATION", 284, 294], ["Pressure", "OBSERVATION_MODIFIER", 347, 355], ["Injury", "OBSERVATION", 356, 362]]], ["Residents will spend more time sitting or lying down; this increases the intensity and duration of pressure exposure, which are two factors that lead to pressure injury development [11] .", [["pressure exposure", "PROBLEM", 99, 116], ["pressure injury development", "PROBLEM", 153, 180]]], ["The use of prone positioning in COVID-19 treatment further increases risk of pressure injuries, particularly on the face [12] .Increased Hospitalization RiskAs residents spend more time in their rooms, they are at risk for physical deconditioning, malnutrition (due to a lack of shared meals or assistance with eating), and depressive symptoms, all of which increase risk of hospitalization [13, 14] .", [["COVID-19", "CHEMICAL", 32, 40], ["pressure injuries", "DISEASE", 77, 94], ["physical deconditioning", "DISEASE", 223, 246], ["malnutrition", "DISEASE", 248, 260], ["depressive symptoms", "DISEASE", 324, 343], ["COVID-19", "CHEMICAL", 32, 40], ["prone positioning in COVID", "TREATMENT", 11, 37], ["pressure injuries", "PROBLEM", 77, 94], ["physical deconditioning", "PROBLEM", 223, 246], ["malnutrition", "PROBLEM", 248, 260], ["depressive symptoms", "PROBLEM", 324, 343], ["pressure injuries", "OBSERVATION", 77, 94], ["malnutrition", "OBSERVATION", 248, 260]]], ["Dehydration and its associated risk of urinary tract infection and renal problems is also a concern due to the lack of shared meals and, potentially, to decreases in the amount of time staff have available for offering and encouraging oral hydration [15] .Electronic Health RecordsElectronic health record systems have been used in other health care settings to improve workflow and quality of care; however, full integration has been slower in nursing home settings.", [["urinary tract", "ANATOMY", 39, 52], ["renal", "ANATOMY", 67, 72], ["oral", "ANATOMY", 235, 239], ["Dehydration", "DISEASE", 0, 11], ["urinary tract infection", "DISEASE", 39, 62], ["renal problems", "DISEASE", 67, 81], ["urinary tract", "ORGANISM_SUBDIVISION", 39, 52], ["renal", "ORGAN", 67, 72], ["oral", "ORGANISM_SUBDIVISION", 235, 239], ["Dehydration", "PROBLEM", 0, 11], ["urinary tract infection", "PROBLEM", 39, 62], ["renal problems", "PROBLEM", 67, 81], ["oral hydration", "TREATMENT", 235, 249], ["urinary tract", "ANATOMY", 39, 52], ["infection", "OBSERVATION", 53, 62], ["renal", "ANATOMY", 67, 72], ["problems", "OBSERVATION", 73, 81]]], ["For electronic charting to be efficient, adaptation of mobile charting platforms is needed, such as the use of tablets or point-of-care mobile workstations.", [["mobile charting platforms", "TREATMENT", 55, 80], ["tablets", "TREATMENT", 111, 118]]], ["Several potential technology solutions are proposed below.Standardized Documentation and Real-Time (On-Time) Reports to Improve Quality of CareOne example of successful implementation of health information technology is the On-Time Quality Improvement for Long Term Care (On-Time) program to decrease high pressure ulcer incidence rates in nursing homes [16] [17] [18] [19] .", [["ulcer", "ANATOMY", 315, 320], ["ulcer", "DISEASE", 315, 320], ["ulcer", "PATHOLOGICAL_FORMATION", 315, 320], ["Several potential technology solutions", "TREATMENT", 0, 38], ["Long Term Care (On-Time) program", "TREATMENT", 256, 288], ["high pressure ulcer incidence rates", "PROBLEM", 301, 336], ["pressure", "OBSERVATION_MODIFIER", 306, 314], ["ulcer", "OBSERVATION", 315, 320]]], ["The goal was to facilitate consistently good preventive care using the daily information nurses need to target resources to residents at risk of developing pressure ulcers.", [["pressure ulcers", "DISEASE", 156, 171], ["ulcers", "PATHOLOGICAL_FORMATION", 165, 171], ["developing pressure ulcers", "PROBLEM", 145, 171], ["pressure", "OBSERVATION_MODIFIER", 156, 164], ["ulcers", "OBSERVATION", 165, 171]]], ["The developed tools included a documentation form, a documentation completeness report, and four additional ) found a large and statistically significant reduction in pressure ulcer incidence associated with the joint implementation of the four core On-Time reports [20] [21] [22] .TelehealthTelehealth encompasses a broad range of electronic information and telecommunication technologies to support long-distance clinical health care and related activities through videoconferencing, internet-based applications, store-and-forward imaging, streaming media, and telephone-based services [23] .", [["ulcer", "ANATOMY", 176, 181], ["ulcer", "DISEASE", 176, 181], ["ulcer", "PATHOLOGICAL_FORMATION", 176, 181], ["a large and statistically significant reduction", "PROBLEM", 116, 163], ["pressure ulcer incidence", "PROBLEM", 167, 191], ["telecommunication technologies", "TREATMENT", 359, 389], ["long-distance clinical health care", "TREATMENT", 401, 435], ["imaging", "TEST", 533, 540], ["large", "OBSERVATION_MODIFIER", 118, 123], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["reduction", "OBSERVATION_MODIFIER", 154, 163], ["pressure", "OBSERVATION_MODIFIER", 167, 175], ["ulcer", "OBSERVATION", 176, 181], ["joint", "ANATOMY", 212, 217]]], ["Telehealth approaches to improve care access and outcomes among older adults have been extensively studied and are associated with high degrees of patient and caregiver satisfaction [24] .", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["Telehealth approaches", "TREATMENT", 0, 21]]], ["For example, in acute care settings, use of tablets or telepresence robots has allowed staff to interact more with patients while reducing the duration of contact and use of PPE [26] ; these devices have also been found to be acceptable to older adults [27] .", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["tablets", "TREATMENT", 44, 51], ["telepresence robots", "TREATMENT", 55, 74], ["these devices", "TREATMENT", 185, 198], ["acute", "OBSERVATION_MODIFIER", 16, 21]]], ["Likewise, telehealth interventions connecting cardiologists to skilled nursing facility residents permit more frequent monitoring without direct visits and have been shown to reduce rehospitalization following heart failure [28] .TelehealthNursing homes should consider adopting telehealth approaches that have been successfully used in other health care settings to help keep nursing home residents safe and facilitate social connection while observing physical distancing.", [["heart", "ANATOMY", 210, 215], ["heart failure", "DISEASE", 210, 223], ["heart", "ORGAN", 210, 215], ["heart failure", "PROBLEM", 210, 223], ["adopting telehealth approaches", "TREATMENT", 270, 300], ["heart", "ANATOMY", 210, 215], ["failure", "OBSERVATION", 216, 223]]], ["The Electronic Intensive Care Unit (eICU) uses two-way cameras and video monitors connected to a central hub for remote monitoring and care delivery [29] .", [["video monitors", "TEST", 67, 81], ["a central hub", "TREATMENT", 95, 108], ["remote monitoring", "TEST", 113, 130], ["care delivery", "TREATMENT", 135, 148]]], ["Although this technology is primarily used for monitoring physiological processes, eICU staff also provide social support and \"rounds\" for patients to identify any unmet needs, which they communicate to ICU nurses.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147]]], ["A similar process could be implemented in the nursing home setting, where video-enabled rounds, especially for residents who have tested positive for COVID-19, would allow staff to avoid donning and doffing PPE and enhance nursing home residents' ability to express their needs and to experience regular human contact, albeit virtually.", [["human", "ORGANISM", 304, 309], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 304, 309], ["COVID", "TEST", 150, 155]]], ["Video contact is particularly beneficial for residents with hearing impairment who rely on visual cues and mouth movements that are obstructed by PPE such as masks.", [["mouth", "ANATOMY", 107, 112], ["hearing impairment", "DISEASE", 60, 78], ["mouth", "ORGANISM_SUBDIVISION", 107, 112], ["hearing impairment", "PROBLEM", 60, 78], ["obstructed", "OBSERVATION", 132, 142]]], ["First, older adults may be less familiar with tablets or mobile phones and may require initial face-to-face orientation to a new platform [30] .", [["adults", "ORGANISM", 13, 19]]], ["Use of tablets with \"one-touch\" connection features that permit adjustments of font size or volume and accommodate the use of device holders to compensate for arthritis or upper extremity weakness are recommended [31] .Using Technology in End-of-Life Care PlanningNow more than ever, information sharing between nursing home providers and staff, residents, and family members is particularly important at end-of-life to ensure resident preferences are respected.", [["extremity", "ANATOMY", 178, 187], ["arthritis", "DISEASE", 159, 168], ["upper extremity weakness", "DISEASE", 172, 196], ["upper extremity", "ORGANISM_SUBDIVISION", 172, 187], ["tablets", "TREATMENT", 7, 14], ["device holders", "TREATMENT", 126, 140], ["arthritis", "PROBLEM", 159, 168], ["upper extremity weakness", "PROBLEM", 172, 196], ["size", "OBSERVATION_MODIFIER", 84, 88], ["arthritis", "OBSERVATION", 159, 168], ["upper", "ANATOMY_MODIFIER", 172, 177], ["extremity", "ANATOMY", 178, 187], ["weakness", "OBSERVATION", 188, 196]]], ["While filming and editing videos of nursing home residents discussing end-of-life preferences is likely not feasible during the COVID-19 pandemic, real-time discussions between residents, family members, and providers using tablet or smartphone technology are possible and would help ensure that care preferences are met. iPads are facilitating end-of-life conversations between hospitalized COVID-19 patients and family members [34] and could be used similarly in nursing homes both for decision-making and to allow families to say goodbye to loved ones.Access to Technology to Promote Social InteractionIn addition to telehealth technologies, videoconferencing and tablet-based applications have been used to enhance social interaction among nursing home residents and family [35] .", [["patients", "ORGANISM", 401, 409], ["patients", "SPECIES", 401, 409], ["smartphone technology", "TREATMENT", 234, 255]]], ["However, wide adoption has been impeded by limited wireless access within facilities as well as by financial limitations on access to devices [36] .", [["access to devices", "TREATMENT", 124, 141]]], ["These diaries are routinely used in hospitals to assimilate care information and to allow families and friends to maintain a connection, resulting in decreased anxiety and depression among ICU survivors and less posttraumatic stress in survivors' families [37] .", [["anxiety", "DISEASE", 160, 167], ["depression", "DISEASE", 172, 182], ["posttraumatic stress", "DISEASE", 212, 232], ["decreased anxiety", "PROBLEM", 150, 167], ["depression", "PROBLEM", 172, 182]]], ["In addition to clinical information, ICU diaries include details about events occurring at home and in the community, enabling patients and their families to stay abreast of each other's lives during periods of social distancing [38] .", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135]]], ["To make the above technologies available to residents who have mobility and sensory impairments, simple \"hacks\" to telemedicine equipment, such as placing monitors on flexible stands so that they can be moved in front of residents regardless of whether they are sitting, reclining, or lying in bed, could keep this technology in reach of residents.", [["sensory impairments", "DISEASE", 76, 95], ["sensory impairments", "PROBLEM", 76, 95], ["telemedicine equipment", "TREATMENT", 115, 137], ["flexible stands", "TREATMENT", 167, 182]]], ["Devices such as Apple TV can enlarge smartphone or tablet screens for easier viewing.", [["Devices", "TREATMENT", 0, 7]]], ["Ensuring that hearing aids and eyeglasses are available should enhance older adults' ability to communicate with a wider array of friends and family.Technology to Support Staff Education and TrainingRelaxed guidelines for CNA training, the need to train new or agency staff quickly, and the increased workloads faced by nursing home staff increase the need for staff education and training.", [["eyeglasses", "TREATMENT", 31, 41], ["CNA training", "TREATMENT", 222, 234], ["staff education", "TREATMENT", 361, 376]]], ["Some nursing homes are already using learning management systems for staff training.", [["learning management systems", "TREATMENT", 37, 64], ["staff training", "TREATMENT", 69, 83]]], ["Other online educational modules and training videos from reputable sources such as the CDC, health systems, and professional organizations can also be used.Technology to Support Staff Education and TrainingFor example, training on donning and doffing PPE is needed, and demonstration videos that provide this training are available from a number of sources.", [["this training", "TREATMENT", 305, 318]]], ["Almost all of these online training programs can be accessed on a smartphone or tablet, which can help staff complete required training.ConclusionThe unprecedented challenges of the COVID-19 pandemic place particularly great burdens on nursing home staff who are unfairly stigmatized and had the fewest resources in prepandemic times.", [["great", "OBSERVATION_MODIFIER", 219, 224], ["burdens", "OBSERVATION", 225, 232]]], ["We owe increased support to vulnerable older people and those who care for them, and we call for an investment in technology and other resources to support older people and their caregivers during the pandemic.", [["people", "ORGANISM", 45, 51], ["people", "ORGANISM", 162, 168], ["people", "SPECIES", 45, 51], ["people", "SPECIES", 162, 168]]]], "c5deaa8e0c0b475133a12c0a7b9554ab0eb3cfb4": [["IntroductionThe current COVID-19 pandemic has once again reminded us that international travel plays a central 2 role in the rapid spread of epidemics around the world [1] [2] [3] [4] .", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 168, 183]]], ["It is therefore of utmost importance that, 3 before international air travel gradually returns to normal, measures are taken to mitigate the risks of 4 spreading infections associated with such travel, especially since COVID-19 is unlikely to be globally 5 eradicated before travel increases.", [["infections", "DISEASE", 162, 172], ["international air travel", "PROBLEM", 52, 76], ["4 spreading infections", "PROBLEM", 150, 172], ["COVID", "TEST", 219, 224], ["spreading", "OBSERVATION_MODIFIER", 152, 161], ["infections", "OBSERVATION", 162, 172]]], ["Furthermore, border control measures such as screening for 6 symptoms in travellers are unlikely to be effective for infections like COVID- 19 [5] , where there is a 7 high likelihood of asymptomatic transmission [6, 7] .", [["infections", "DISEASE", 117, 127], ["border control measures", "TREATMENT", 13, 36], ["screening", "TEST", 45, 54], ["6 symptoms", "PROBLEM", 59, 69], ["infections", "PROBLEM", 117, 127], ["COVID", "TEST", 133, 138], ["asymptomatic transmission", "PROBLEM", 187, 212]]], ["Hence, there is an important role in ensuring that 8 travellers take adequate precautions during their travel, to reduce the risk that they will be infected 9 during their travel, and also potentially facilitate the spread of the virus.", [["adequate precautions", "TREATMENT", 69, 89], ["the virus", "PROBLEM", 226, 235]]], ["10IntroductionAdequate pre-travel preparations and suitable precautionary behaviour during travel can reduce the 11 risk of acquiring infectious diseases during travel [8] .", [["infectious diseases", "DISEASE", 134, 153], ["Adequate pre-travel preparations", "TREATMENT", 14, 46], ["acquiring infectious diseases", "PROBLEM", 124, 153]]], ["A study found that only a 13 minority of Australian GPs were aware that VFR travellers are a high risk group [9] .", [["A study", "TEST", 0, 7]]], ["It is known that 14 VFR travellers in general often do not undertake adequate pre-travel preparations [10] [11] [12] [13] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 102, 121]]], ["All these 19Introductionfactors place them at increased risk of acquiring infectious diseases during travel [18, 20, 21] which 20 can in turn facilitate the global spread of infections [22, 23] .", [["infectious diseases", "DISEASE", 74, 93], ["infections", "DISEASE", 174, 184], ["acquiring infectious diseases", "PROBLEM", 64, 93], ["infections", "PROBLEM", 174, 184], ["infectious", "OBSERVATION_MODIFIER", 74, 84], ["global", "OBSERVATION_MODIFIER", 157, 163], ["spread", "OBSERVATION_MODIFIER", 164, 170], ["infections", "OBSERVATION", 174, 184]]], ["21IntroductionWhile some aspects of VFR traveller behaviour have been found to be generalisable to VFR travellers 22 of multiple ethnicities, each ethnic group also has culture-specific health behaviours, for example, the 23 use of Chinese medicine among ethnic Chinese.", [["culture", "TEST", 169, 176], ["Chinese medicine", "TREATMENT", 232, 248]]], ["Ethnic Chinese are one of the largest cultural groups 24 in many Western countries, including Australia, and account for a substantial proportion of VFR 25 travel in these countries [24] .", [["largest", "OBSERVATION_MODIFIER", 30, 37]]], ["Participants had undertaken an average of 3 5.5 trips to China since migrating to Australia.", [["Participants", "SPECIES", 0, 12]]], ["The demographic characteristics of the focus group 4 participants are presented in Table 1 .", [["participants", "SPECIES", 53, 65]]], ["5 Reported' means the participant did not answer that question.Risk perception and awareness of travel-associated infectious diseases4 Participants generally believed that China was a low-risk destination for travel-associated infectious 5 diseases and a number of reasons were given for this perception.", [["infectious diseases4", "DISEASE", 114, 134], ["infectious 5 diseases", "DISEASE", 227, 248], ["participant", "SPECIES", 22, 33], ["Participants", "SPECIES", 135, 147], ["infectious 5 diseases", "PROBLEM", 227, 248], ["infectious", "OBSERVATION", 114, 124], ["infectious", "OBSERVATION_MODIFIER", 227, 237]]], ["Familiarity with the destination, 6 including spending their childhood in China, was commonly perceived by participants.", [["participants", "SPECIES", 107, 119]]], ["However, even among participants who see travel to China as low risk for themselves, concern for the 11 potential travel risks for children who did not grow up in China was raised by participants.", [["children", "ORGANISM", 131, 139], ["participants", "SPECIES", 20, 32], ["children", "SPECIES", 131, 139], ["participants", "SPECIES", 183, 195]]], ["One 12 participant mentioned that they were worried about their son, and had previously consulted their GP 13 to vaccinate him against hepatitis A and B before travelling to China.", [["hepatitis A", "DISEASE", 135, 146], ["participant", "SPECIES", 7, 18], ["hepatitis A", "PROBLEM", 135, 146]]], ["14 Accompanying a low perception of risk was a low awareness of potential infectious disease risks 1 during travel to China, including during travel to rural and regional areas.", [["infectious disease", "DISEASE", 74, 92], ["potential infectious disease risks", "PROBLEM", 64, 98], ["infectious", "OBSERVATION", 74, 84], ["regional areas", "ANATOMY", 162, 176]]], ["For example, although 2 regions in southern China are endemic for dengue, and parts of China are endemic for vector-3 transmitted Japanese encephalitis [26] , participants' general awareness and concern about vector-4 borne diseases was poor.", [["dengue", "DISEASE", 66, 72], ["Japanese encephalitis", "DISEASE", 130, 151], ["participants", "SPECIES", 159, 171], ["dengue", "SPECIES", 66, 72], ["dengue", "PROBLEM", 66, 72], ["transmitted Japanese encephalitis", "PROBLEM", 118, 151], ["4 borne diseases", "PROBLEM", 216, 232]]], ["Proffered responses to potential infectious risks in China did not include 5 diseases endemic in many parts of China or with a higher incidence than in Australia, such as hand, 6 foot and mouth disease, chikungunya, typhoid, or malaria [26] .", [["hand", "ANATOMY", 171, 175], ["mouth", "ANATOMY", 188, 193], ["mouth disease", "DISEASE", 188, 201], ["chikungunya", "DISEASE", 203, 214], ["typhoid", "DISEASE", 216, 223], ["malaria", "DISEASE", 228, 235], ["hand", "ORGANISM_SUBDIVISION", 171, 175], ["foot", "ORGANISM_SUBDIVISION", 179, 183], ["mouth", "ORGAN", 188, 193], ["5 diseases endemic", "PROBLEM", 75, 93], ["mouth disease", "PROBLEM", 188, 201], ["chikungunya", "PROBLEM", 203, 214], ["typhoid", "PROBLEM", 216, 223], ["malaria", "PROBLEM", 228, 235], ["hand", "ANATOMY", 171, 175], ["foot", "ANATOMY", 179, 183], ["mouth", "ANATOMY", 188, 193]]], ["However, some participants identified 7 rural travel as posing a higher risk than travel to cities in China, including the perceived need to carry 8 \"a little bit more medicine\" as preparation for rural travel.", [["participants", "SPECIES", 14, 26]]], ["Few participants were concerned about 9 sanitary conditions in rural areas.", [["participants", "SPECIES", 4, 16]]], ["10 1112Participants were generally concerned about outbreaks in China, whether they were planning to travel 1312to China or not.", [["Participants", "SPECIES", 7, 19]]], ["Some participants said they worry about their relatives in China when outbreaks 14 happen, and, in general, participants appeared more concerned about outbreaks than about other 15 infectious risks during travel.", [["participants", "SPECIES", 5, 17], ["participants", "SPECIES", 108, 120]]], ["Few participants would consult 17 their GP for advice before travel when there is an outbreak.", [["participants", "SPECIES", 4, 16], ["outbreak", "OBSERVATION", 85, 93]]], ["1812Some participants did not perceive themselves to be at risk because of their behavioural patterns, or 19 their beliefs in adequately reducing their risks through certain behavioural changes.", [["participants", "SPECIES", 9, 21]]], ["2012If we were to go out I'd wear masks, but it really isn't that big an issue.", [["masks", "TREATMENT", 34, 39]]], ["(Participant 106, regarding 23 a potential respiratory outbreak) 2412Another participant, when specifically asked, said they would not see a GP before VFR travel even if 1 there was an avian influenza outbreak.", [["influenza", "DISEASE", 191, 200], ["participant", "SPECIES", 77, 88], ["an avian influenza outbreak", "PROBLEM", 182, 209], ["influenza", "OBSERVATION", 191, 200]]], ["2 Several other participants also mentioned similar ideas.", [["participants", "SPECIES", 16, 28]]], ["312Opinions differed in the discussion of cancelling or changing travel plans in the event of an outbreak.", [["outbreak", "OBSERVATION", 97, 105]]], ["412Many participants stated that they would not cancel travel to China.", [["participants", "ORGANISM", 8, 20], ["participants", "SPECIES", 8, 20]]], ["Circumstances around the need to 5 travel, such as visiting sick relatives, were considered by many participants in their decision not to 6 cancel travel during an outbreak.", [["participants", "SPECIES", 100, 112]]], ["Some participants would only cancel non-8 essential travel when they perceived the outbreak to be severe.", [["participants", "SPECIES", 5, 17]]], ["However, the risks of both actual and 9 potential travel during outbreaks were often underestimated by participants.", [["participants", "SPECIES", 103, 115]]], ["One participant described 10 their travel to China during the Severe Acute Respiratory Syndrome (SARS) pandemic.", [["Acute Respiratory Syndrome", "DISEASE", 69, 95], ["SARS", "DISEASE", 97, 101], ["participant", "SPECIES", 4, 15], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 58, 95], ["pandemic", "PROBLEM", 103, 111], ["Severe", "OBSERVATION_MODIFIER", 62, 68], ["Acute", "OBSERVATION_MODIFIER", 69, 74], ["Respiratory Syndrome", "OBSERVATION", 75, 95]]], ["Information 11 from Chinese relatives prior to travel described life as normal in China and a perception that the risk 1212was not serious.", [["normal", "OBSERVATION", 72, 78]]], ["The seriousness of the outbreak was only discovered after returning to Australia.", [["the outbreak", "PROBLEM", 19, 31]]], ["Familiarity with the travel destination and perceptions that VFR travel to China carried negligible 8 health risks were important factors in participants' perception that pre-travel health preparation and 9 seeking advice from a travel health provider on minimising infectious disease risks were not 10 necessary.", [["infectious disease", "DISEASE", 266, 284], ["participants", "SPECIES", 141, 153], ["minimising infectious disease risks", "PROBLEM", 255, 290]]], ["In contrast, many participants said they would seek pre-travel health advice if they were to 11 travel to other developing countries.", [["participants", "SPECIES", 18, 30]]], ["1212Participants expressed a range of views on the need for pre-travel advice from a medical professional.", [["Participants", "SPECIES", 4, 16], ["pre-travel advice", "TREATMENT", 60, 77]]], ["1312There was a perception among many participants that if you are not sick, you do not need to see a 14 doctor, or that there is no point in seeing a doctor for travel.", [["participants", "SPECIES", 38, 50]]], ["On the other hand, a minority of 15 participants had consulted a GP for one or more of their previous trips to China, including several 16 participants who did so before every trip.", [["participants", "SPECIES", 36, 48], ["participants", "SPECIES", 139, 151]]], ["Participants who consulted a GP before trips to China, either 17 for some or all trips, tended to be female, had tertiary education and had migrated to Australia 10 or 18 more years ago.", [["Participants", "SPECIES", 0, 12]]], ["Reasons provided for consulting their GP before travel included vaccination, the need 1912for prescription medications and a perception of a change in their immunity after an extended 20 residence in Australia.", [["vaccination", "TREATMENT", 64, 75], ["prescription medications", "TREATMENT", 94, 118]]], ["Some also reported obtaining a prescription from their GP in case they needed 21 to use it in China. for long, normally aware because our immune system is different, we've been in 2 this country for so long, we're not used to those environment, that kind of 3 environment, so the chance of getting any sickness is higher than here.", [["sickness", "DISEASE", 302, 310], ["any sickness", "PROBLEM", 298, 310]]], ["4 (Participant 711, lived in Australia for more than 10 years) 5 I guess being healthy is very important, and before I going to China it's necessary 6 to avoid disease or illness in China, so I guess I will seek some advice from the 7 professional doctor.", [["illness", "DISEASE", 171, 178], ["disease", "PROBLEM", 160, 167]]], ["(Participant 703) 812Only one participant was aware of the availability of specialist travel health clinics.", [["participant", "SPECIES", 30, 41]]], ["After receiving 912information on the activities of travel clinics, many participants were interested.", [["participants", "SPECIES", 73, 85]]], ["However, the cost 10 associated with clinic visits remained a major concern for many participants and many were reluctant 11 to use them for future trips to China.", [["participants", "SPECIES", 85, 97]]], ["12 1314Participants generally felt that vaccination was not specifically needed for travel to China and many 15 had never received a vaccine for the purpose of protecting against travel-associated diseases.", [["Participants", "SPECIES", 7, 19], ["a vaccine", "TREATMENT", 131, 140], ["associated diseases", "PROBLEM", 186, 205], ["diseases", "OBSERVATION", 197, 205]]], ["1614However, many participants were willing to receive a vaccine during an outbreak to protect them 17 against the disease involved.", [["participants", "ORGANISM", 18, 30], ["participants", "SPECIES", 18, 30], ["1614", "SPECIES", 0, 4], ["a vaccine", "TREATMENT", 55, 64]]], ["One participant said they had a hepatitis B vaccine before going to China 18 3 years ago because there was a hepatitis B outbreak, and another had an influenza vaccine before 19 their trip because there was an influenza outbreak.", [["hepatitis B", "DISEASE", 32, 43], ["hepatitis B", "DISEASE", 109, 120], ["influenza", "DISEASE", 150, 159], ["influenza", "DISEASE", 210, 219], ["participant", "SPECIES", 4, 15], ["a hepatitis B vaccine", "TREATMENT", 30, 51], ["a hepatitis B outbreak", "PROBLEM", 107, 129], ["an influenza vaccine", "TREATMENT", 147, 167], ["an influenza outbreak", "PROBLEM", 207, 228], ["influenza", "OBSERVATION", 210, 219]]], ["Some participants would be willing to receive a 20 vaccine during serious outbreaks, even if they otherwise would not consider vaccinations for travel.", [["participants", "SPECIES", 5, 17], ["a 20 vaccine", "TREATMENT", 46, 58], ["vaccinations", "TREATMENT", 127, 139]]], ["2114For example, one participant said they would in general refuse vaccines recommended by their GP for 22 travel because they were worried about vaccine safety, but when asked specifically about whether 23 they would have had a SARS vaccine during the pandemic if there had been one, they said they 24would.", [["SARS", "DISEASE", 229, 233], ["participant", "SPECIES", 21, 32], ["vaccines", "TREATMENT", 67, 75], ["a SARS vaccine", "TREATMENT", 227, 241]]], ["25Apart from vaccines specifically for an outbreak illness, when asked if they would be willing to 1 receive a vaccine for travel if recommended by their doctor, many participants said it would depend 2 on other factors, including the seriousness of the condition, vaccine side effects and safety; others 3would.", [["participants", "SPECIES", 167, 179], ["vaccines", "TREATMENT", 13, 21], ["an outbreak illness", "PROBLEM", 39, 58], ["a vaccine", "TREATMENT", 109, 118], ["vaccine", "TREATMENT", 265, 272]]], ["25were not willing to receive travel vaccines at all.", [["travel vaccines", "TREATMENT", 30, 45]]], ["Other barriers to low uptake of pre-travel vaccination included the lack of recommendations from 7 their GP, not having enough time to obtain such vaccinations for those travelling on short notice, and 8 fear of allergies to vaccines affecting their ability to travel.", [["allergies", "DISEASE", 212, 221], ["pre-travel vaccination", "TREATMENT", 32, 54], ["such vaccinations", "TREATMENT", 142, 159], ["allergies", "PROBLEM", 212, 221], ["vaccines", "TREATMENT", 225, 233]]], ["25A few participants did assess their vaccination status prior to travel.", [["participants", "ORGANISM", 8, 20], ["participants", "SPECIES", 8, 20]]], ["As a consequence of the focus 10 group discussion, several other participants have also indicated that they may ask their GP about 11 vaccinations before their next trip.", [["participants", "SPECIES", 65, 77]]], ["Several participants also reported a habit of getting their yearly 12 influenza vaccines before travel.", [["participants", "SPECIES", 8, 20], ["influenza vaccines", "TREATMENT", 70, 88]]], ["Such participants tended to be older.", [["participants", "SPECIES", 5, 17]]], ["25Many participants demonstrated significant misconceptions about vaccination in general.", [["participants", "SPECIES", 7, 19], ["significant", "OBSERVATION_MODIFIER", 33, 44]]], ["Several 14 participants thought that if they were healthy or had a strong immune system they did not need to get 15 vaccinated, or that getting vaccinated too often would adversely affect the immune system.", [["immune system", "ANATOMY", 192, 205], ["participants", "ORGANISM", 11, 23], ["immune system", "ANATOMICAL_SYSTEM", 192, 205], ["participants", "SPECIES", 11, 23]]], ["Some 16 participants also had misunderstandings about particular vaccines.", [["participants", "SPECIES", 8, 20], ["particular vaccines", "TREATMENT", 54, 73]]], ["For example, one participant 17 thought the influenza vaccine offers protection for SARS as well.", [["influenza", "DISEASE", 44, 53], ["SARS", "DISEASE", 84, 88], ["participant", "SPECIES", 17, 28], ["the influenza vaccine", "TREATMENT", 40, 61], ["SARS", "PROBLEM", 84, 88]]], ["Some participants felt that they 18would.", [["participants", "SPECIES", 5, 17]]], ["25were not well-informed about vaccines in general.", [["vaccines", "TREATMENT", 31, 39]]], ["19 2021Respiratory illness was a major health concern during travel to China.", [["Respiratory illness", "DISEASE", 7, 26], ["Respiratory illness", "PROBLEM", 7, 26], ["illness", "OBSERVATION", 19, 26]]], ["For the participants, the issue One participant from Hong Kong thought that there was a higher risk of getting influenza in mainland 721China than in Hong Kong.", [["influenza", "DISEASE", 111, 120], ["participants", "SPECIES", 8, 20], ["participant", "SPECIES", 36, 47], ["influenza", "PROBLEM", 111, 120]]], ["Some participants believed that 'keeping healthy' (i.e. maintaining good 8 general health by sleeping well, eating well and exercising) can prevent regular respiratory infections.", [["respiratory", "ANATOMY", 156, 167], ["respiratory infections", "DISEASE", 156, 178], ["participants", "SPECIES", 5, 17], ["regular respiratory infections", "PROBLEM", 148, 178], ["respiratory", "ANATOMY", 156, 167], ["infections", "OBSERVATION", 168, 178]]], ["921Participants frequently associated respiratory infections with crowded areas.", [["respiratory", "ANATOMY", 38, 49], ["921Participants", "CHEMICAL", 0, 15], ["respiratory infections", "DISEASE", 38, 60], ["respiratory infections", "PROBLEM", 38, 60], ["crowded areas", "PROBLEM", 66, 79], ["respiratory", "ANATOMY", 38, 49], ["infections", "OBSERVATION", 50, 60], ["crowded", "OBSERVATION_MODIFIER", 66, 73]]], ["China is a very populous 10 country, and many participants reported visiting crowded areas during their trips, including shopping 11 centres.", [["participants", "SPECIES", 46, 58]]], ["Although some participants mentioned avoiding crowded areas as a possible way to reduce 12 the risk of respiratory infections, it was mentioned that in Hong Kong this was difficult because 13 'everywhere is crowded'.", [["respiratory", "ANATOMY", 103, 114], ["respiratory infections", "DISEASE", 103, 125], ["participants", "SPECIES", 14, 26], ["crowded areas", "PROBLEM", 46, 59], ["respiratory infections", "PROBLEM", 103, 125], ["respiratory", "ANATOMY", 103, 114], ["infections", "OBSERVATION", 115, 125]]], ["14 Participants had mixed attitudes to face masks as a method of reducing the risk of acquiring 15 respiratory infections.", [["respiratory", "ANATOMY", 99, 110], ["respiratory infections", "DISEASE", 99, 121], ["Participants", "SPECIES", 3, 15], ["face masks", "TREATMENT", 39, 49], ["15 respiratory infections", "PROBLEM", 96, 121], ["infections", "OBSERVATION", 111, 121]]], ["Several reasons were given for the use of face masks, including poor air 16 quality, cold weather and outbreaks of respiratory infections.", [["respiratory", "ANATOMY", 115, 126], ["respiratory infections", "DISEASE", 115, 137], ["face masks", "TREATMENT", 42, 52], ["poor air 16 quality", "PROBLEM", 64, 83], ["respiratory infections", "PROBLEM", 115, 137], ["respiratory", "ANATOMY", 115, 126], ["infections", "OBSERVATION", 127, 137]]], ["Others preferred not to use masks 17 because they look \"weird\" or were uncomfortable but noted that wearing masks in public was more 18 socially acceptable in China than in Australia.", [["masks", "TREATMENT", 28, 33], ["uncomfortable", "PROBLEM", 71, 84]]], ["1921Most participants were willing to wear masks during outbreaks of infectious diseases, including many 20 of those who would not wear masks outside the context of an outbreak.", [["infectious diseases", "DISEASE", 69, 88], ["participants", "SPECIES", 9, 21], ["infectious diseases", "PROBLEM", 69, 88], ["outbreak", "OBSERVATION", 168, 176]]], ["One participant said they 21 carry masks in their luggage when they travel to China in case of an outbreak.", [["participant", "SPECIES", 4, 15], ["outbreak", "OBSERVATION", 98, 106]]], ["Another participant 2221said they took masks with them wherever they went when they were in China during the SARS 23pandemic.", [["SARS", "DISEASE", 109, 113], ["participant", "SPECIES", 8, 19]]], ["24We did it when SARS was going on, when we travelled.", [["SARS", "DISEASE", 17, 21], ["SARS", "PROBLEM", 17, 21]]], ["(Participant 101, when 25 asked whether they had ever worn a mask when in China) 26pandemic.", [["a mask", "TREATMENT", 59, 65]]], ["24Several other participants, however, were not convinced about the effectiveness of masks.", [["participants", "SPECIES", 16, 28]]], ["(Participant 107) 2Some participants noted that they would not wear masks if nobody around them was wearing masks.", [["participants", "SPECIES", 24, 36]]], ["Some participants said they would go to China for elective dental work because it is cheaper there, 18 even if they were aware that hygienic standards of dentists in China may not be up to Australian 19 standards.", [["participants", "SPECIES", 5, 17]]], ["20I have a Chinese friend with a tooth problem, who flew back to China just to get 21 his teeth done, and it was still cheaper than doing it here.", [["tooth", "ANATOMY", 33, 38], ["teeth", "ANATOMY", 90, 95], ["tooth problem", "DISEASE", 33, 46], ["tooth", "ORGAN", 33, 38], ["teeth", "ORGAN", 90, 95]]], ["(Participant 701) 22Most participants reported no animal contact during their previous trips to China, apart from the 1 animals being sold in the wet markets.", [["participants", "ORGANISM", 25, 37], ["participants", "SPECIES", 25, 37]]], ["3 4 3.8 Behavioural changes during outbreaks 5 Some, but not all, participants reported they would change their behaviour during trips where there 6 was an outbreak.", [["participants", "SPECIES", 66, 78], ["Behavioural changes", "PROBLEM", 8, 27]]], ["Participants said they would avoid crowded areas, be particularly vigilant about 7 personal hygiene and washing hands, refrain from eating certain foods, or wear masks during an 8 outbreak.", [["Participants", "SPECIES", 0, 12], ["masks", "TREATMENT", 162, 167]]], ["Some participants also said they would consider not going out.", [["participants", "SPECIES", 5, 17]]], ["9I have a Chinese friend with a tooth problem, who flew back to China just to get 21 his teeth done, and it was still cheaper than doing it here.", [["tooth", "ANATOMY", 32, 37], ["teeth", "ANATOMY", 89, 94], ["tooth problem", "DISEASE", 32, 45], ["tooth", "ORGAN", 32, 37], ["teeth", "ORGAN", 89, 94]]], ["(Participant 701) 22Actually, this time when we go to Shanghai, there's the period of chicken flu.", [["chicken", "ORGANISM", 86, 93], ["chicken", "SPECIES", 86, 93], ["chicken", "SPECIES", 86, 93], ["chicken flu", "PROBLEM", 86, 97], ["flu", "OBSERVATION", 94, 97]]], ["(Participant 103) 12There was a common idea expressed by many participants that, during outbreaks, one should 'keep20Many participants reported self-medicating, using both Chinese and Western medicine, for what they 21 perceived to be minor illnesses.", [["participants", "SPECIES", 62, 74], ["participants", "SPECIES", 122, 134], ["minor illnesses", "PROBLEM", 235, 250]]], ["Some said they would take medications to China for use as part of 22 their travel preparations.", [["medications", "TREATMENT", 26, 37]]], ["One participant said they took antibiotics, given to them by their son, before 23 going to China.", [["participant", "SPECIES", 4, 15], ["antibiotics", "TREATMENT", 31, 42]]], ["Another participant said they took some Chinese medicine before meals \"to avoid 24 food poisoning\".", [["poisoning", "DISEASE", 88, 97], ["participant", "SPECIES", 8, 19]]], ["Some participants also said they would purchase medicines in China and bring them 1 to Australia to use.", [["participants", "SPECIES", 5, 17]]], ["Mostly, this involved Chinese medicine but some participants bought antibiotics in 220China and brought them to Australia.", [["participants", "SPECIES", 48, 60], ["antibiotics", "TREATMENT", 68, 79]]], ["320Food safety was a particular concern for many participants.", [["participants", "SPECIES", 49, 61]]], ["Since participants spent a lot of time with 4 family and friends, their eating habits and food choices were influenced by their family and friends.", [["participants", "SPECIES", 6, 18]]], ["Participants were divided over whether it is safe to eat street food 7 in China.", [["Participants", "SPECIES", 0, 12]]], ["Attitudes and practices related to street food appeared to be influenced by family and 8 friends. travellers in general [10, 12, 17, 18, 27] , most participants in the focus groups rarely undertook travel 5 health preparations for VFR travel, due to both multiple barriers to health care access and a generally 6 low risk perception of VFR travel.", [["participants", "SPECIES", 148, 160]]], ["Among focus group participants, there was a general perception of 7 VFR travel as low risk which was due to multiple factors, including a perception of familiarity, 8 knowledge deficits and misconceptions.", [["participants", "SPECIES", 18, 30], ["8 knowledge deficits", "PROBLEM", 165, 185]]], ["In the context of the COVID-19 11 pandemic, it is also essential to highlight the importance of seeking medical attention immediately if 12 one experiences respiratory symptoms [28, 29] , and not just assume that it is due to the air quality.", [["respiratory", "ANATOMY", 156, 167], ["respiratory symptoms", "DISEASE", 156, 176], ["the COVID", "TEST", 18, 27], ["respiratory symptoms", "PROBLEM", 156, 176], ["air", "OBSERVATION", 230, 233]]], ["Participants' sources of information about outbreaks include Chinese newspapers and websites, their 20 general practitioner, and family and friends who live in China.", [["Participants", "SPECIES", 0, 12]]], ["This finding is consistent with a 21 previous study conducted in the Netherlands and the UK which found that Chinese immigrants often 22 sought information regarding emerging infectious diseases from family and friends and Chinese 23 language media [33] .", [["infectious diseases", "DISEASE", 175, 194], ["a 21 previous study", "TEST", 32, 51], ["consistent with", "UNCERTAINTY", 16, 31]]], ["This becomes a particularly important concern for 25 the many participants who rely solely on such information, and as a result undertake inadequate 26 precautionary behaviours.", [["participants", "SPECIES", 62, 74]]], ["Also of concern was the common belief that the risk for acquiring the 1 infectious agent during an outbreak was low if they 'keep healthy' or used certain Chinese medicines.", [["certain Chinese medicines", "TREATMENT", 147, 172]]], ["220Underestimating the risks or severity of an outbreak sometimes meant that participants undertook 3 VFR travel for non-essential reasons, for example during the SARS outbreak, when according to 4 WHO advice, they should have cancelled the trip.", [["SARS", "DISEASE", 163, 167], ["participants", "SPECIES", 77, 89]]], ["These findings correlate with the Australian Bureau 5 of Statistics international departures data, which show that the decline in travel episodes during the 6 SARS pandemic was lower for VFR travellers compared with business and holiday travellers [34].", [["SARS", "DISEASE", 159, 163], ["Statistics international departures data", "TEST", 57, 97], ["the decline", "PROBLEM", 115, 126], ["travel episodes", "PROBLEM", 130, 145], ["decline", "OBSERVATION_MODIFIER", 119, 126]]], ["Educational 920interventions should be provided ongoingly to potential VFR travellers to impress upon them the 10 importance of cancelling all non-essential travel during the COVID-19 pandemic.", [["the COVID", "TEST", 171, 180], ["pandemic", "PROBLEM", 184, 192]]], ["Such education 1120should raise awareness regarding the serious risks of travelling during an outbreak and the need to be 12 careful about any outbreak even if it seems contained and/or not severe, and to dispel misconceptions 13 like 'keeping healthy' or taking Chinese medicine being adequate measures to prevent one from 14 getting sick.", [["Chinese medicine", "TREATMENT", 263, 279], ["adequate measures", "TREATMENT", 286, 303]]], ["1520Many participants were willing to receive vaccination specifically for an outbreak or pandemic, which 16 may be relevant for a future COVID-19 vaccine.", [["participants", "ORGANISM", 9, 21], ["participants", "SPECIES", 9, 21], ["vaccination", "TREATMENT", 46, 57], ["pandemic", "PROBLEM", 90, 98], ["a future COVID-19 vaccine", "TREATMENT", 129, 154]]], ["Given that this study found some confusion about 17 whether the influenza vaccine also prevents SARS, there is a real risk that some Chinese VFR 18 travellers may mistake the influenza vaccine to be also effective for COVID-19, which could lead to a 19 misguided sense of complacency.", [["confusion", "DISEASE", 33, 42], ["influenza", "DISEASE", 64, 73], ["SARS", "DISEASE", 96, 100], ["influenza", "DISEASE", 175, 184], ["travellers", "ORGANISM", 148, 158], ["this study", "TEST", 11, 21], ["some confusion", "PROBLEM", 28, 42], ["the influenza vaccine", "TREATMENT", 60, 81], ["SARS", "PROBLEM", 96, 100], ["the influenza vaccine", "TREATMENT", 171, 192], ["COVID", "TEST", 218, 223]]], ["2020On the other hand, where Chinese VFR travellers are aware that the influenza vaccine is not effective 21 for preventing COVID-19, they may refuse to receive it, as among study participants, there was 22 widespread reluctance to be vaccinated for VFR travel other than for outbreaks, due to a lack of 23 perceived need, even among those in the high risk category due to their age.", [["influenza", "DISEASE", 71, 80], ["participants", "SPECIES", 180, 192], ["the influenza vaccine", "TREATMENT", 67, 88]]], ["This is consistent with 24 published quantitative studies which show that VFR travellers have low rates of accepting vaccination 25 and complying with other prophylactic measures for travel, and compare unfavourably to other 26 travellers in this regard [13, [35] [36] [37] .", [["accepting vaccination", "TREATMENT", 107, 128], ["other prophylactic measures", "TREATMENT", 151, 178], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Importantly and encouragingly, the vast majority of participants 2720were not strongly anti-vaccination.", [["participants", "ORGANISM", 52, 64], ["participants", "SPECIES", 52, 64]]], ["Specific education on the benefits of vaccination prior to VFR 1 travel, supported by evidence of vaccine efficacy and safety, are needed to address the problem of 2 under-vaccination.", [["vaccination", "TREATMENT", 38, 49], ["vaccine efficacy", "TREATMENT", 98, 114]]], ["Highlighting the benefits of influenza vaccination could still encourage its uptake, 3 despite not being specifically protective for the current pandemic.", [["influenza", "DISEASE", 29, 38], ["influenza vaccination", "TREATMENT", 29, 50]]], ["420The study revealed the impact of social norms on willingness to wear masks, with participants not 5 comfortable wearing a mask in settings where no-one else was wearing one.", [["participants", "SPECIES", 84, 96], ["The study", "TEST", 3, 12], ["a mask", "TREATMENT", 123, 129]]], ["Community-wide education on the importance of ensuring 9 adequate self-protection during outbreaks, and the protection of others if infectious, despite societal 10 concerns, appears to be needed.", [["infectious", "PROBLEM", 132, 142], ["infectious", "OBSERVATION", 132, 142]]], ["Among focus group participants, there were mixed attitudes towards 11 face masks.", [["participants", "SPECIES", 18, 30], ["11 face masks", "TREATMENT", 67, 80]]], ["In contrast, a survey conducted during the SARS pandemic in Hong Kong found that 12 75.8% of respondents were willing to wear a mask [40] .", [["SARS", "DISEASE", 43, 47], ["a mask", "TREATMENT", 126, 132]]], ["The focus groups were conducted shortly 13 after the 2013 H7N9 outbreak, which, unlike COVID-19, usually required contact with birds or 14 poultry for infection [41] .", [["infection", "DISEASE", 151, 160], ["infection", "PROBLEM", 151, 160]]], ["The participants' mixed responses may be a reflection of their views 1520regarding the then-current outbreak, and general attitudes towards masks during a pandemic like 16 COVID-19 may differ.", [["participants", "SPECIES", 4, 16]]], ["However, the selective uptake of preventative measures by VFR travellers is a 17 concern.", [["selective", "OBSERVATION_MODIFIER", 13, 22], ["uptake", "OBSERVATION", 23, 29]]], ["Because of their low risk perception, VFR travellers may be particularly prone to 18 underestimating the risks posed by outbreaks.", [["their low risk perception", "PROBLEM", 11, 36], ["VFR travellers", "PROBLEM", 38, 52]]], ["1920This study found that cultural factors are important barriers that can prevent optimal travel health 20 practices.", [["1920", "SPECIES", 0, 4], ["This study", "TEST", 4, 14], ["cultural factors", "PROBLEM", 26, 42]]], ["A major factor in the failure of study participants to attend for pre-travel health 2120consultations was a strong belief that there is no need to see a doctor if one is not sick.", [["participants", "SPECIES", 39, 51], ["A major factor", "PROBLEM", 0, 14]]], ["This may 22 reflect a lack of understanding among parts of the Chinese community in Australia about the role of 23 healthcare providers in disease prevention in the Australian healthcare system.", [["disease prevention", "TREATMENT", 139, 157]]], ["This is consistent with published 25 literature regarding VFR travellers in general, which reports very low rates of using travel health 26 services [11, 14] .", [["consistent with", "UNCERTAINTY", 8, 23]]], ["This study also 2 found that those who have lived for longer in Australia were more willing to seek professional pre-3 travel health advice.", [["This study", "TEST", 0, 10]]], ["This is consistent with other studies showing that access to health services and 4 preventive health care increases with increasing acculturation [45, 46] , and highlights the special 5 importance of reaching out to newer migrants.", [["other studies", "TEST", 24, 37], ["consistent with", "UNCERTAINTY", 8, 23]]], ["620The use of complementary or alternative medicines for health issues was commonly raised by 7 participants, including in the context of outbreaks.", [["participants", "SPECIES", 96, 108], ["alternative medicines", "TREATMENT", 31, 52], ["health issues", "PROBLEM", 57, 70]]], ["In particular, despite many participants having 8 resided in Australia for more than 10 years, they commonly used Chinese medicine for both curative 920and preventive or health maintenance purposes.", [["participants", "SPECIES", 28, 40], ["Chinese medicine", "TREATMENT", 114, 130]]], ["This shows their continued ties to Chinese culture 10 despite acculturation, and highlights the need for culturally relevant educational interventions even for 11 long-term migrants.", [["Chinese culture", "TEST", 35, 50], ["educational interventions", "TREATMENT", 125, 150]]], ["1220This study also found that Australian Chinese VFR travellers share many important characteristics 1320with what is previously known about other VFR travellers, regarding their activities during travel.", [["This study", "TEST", 4, 14]]], ["In this study, the context in which these factors arise was also 17 explored.", [["this study", "TEST", 3, 13]]], ["VFR travellers living with local families by definition have prolonged close contact with 19 the local population, which is a known risk factor for acquiring many infections, including respiratory 20 viruses like COVID-19.", [["infections", "DISEASE", 163, 173], ["respiratory 20 viruses", "DISEASE", 185, 207], ["a known risk factor", "PROBLEM", 124, 143], ["many infections", "PROBLEM", 158, 173], ["respiratory 20 viruses", "PROBLEM", 185, 207], ["COVID", "TEST", 213, 218], ["infections", "OBSERVATION", 163, 173]]], ["They are therefore 24 particularly exposed to diseases that may be circulating in the local population.", [["diseases", "PROBLEM", 46, 54], ["diseases", "OBSERVATION", 46, 54], ["may be", "UNCERTAINTY", 60, 66], ["circulating", "OBSERVATION_MODIFIER", 67, 78]]], ["2520This was the first study of Chinese VFR travellers living in a Western country.", [["2520", "CHEMICAL", 0, 4]]], ["The study found that 2620Chinese VFR travellers share many issues with other VFR travellers, while it was also able to explore 27 beliefs and behaviour that are specifically related to Chinese culture.", [["The study", "TEST", 0, 9], ["Chinese culture", "TEST", 185, 200]]], ["Misconceptions and knowledge deficits were also more thoroughly 4 explored.", [["knowledge deficits", "PROBLEM", 19, 37]]], ["This rich and in-depth information can inform the development of education interventions, 520and compliments the quantitative data on VFR traveller enablers and barriers.", [["education interventions", "TREATMENT", 65, 88]]], ["The focus groups were 6 conducted in English, but participants could also converse in Cantonese or Mandarin if they wished 7 to, which reduced the language barrier.", [["participants", "SPECIES", 50, 62]]], ["During transcription, conversation was translated verbatim 8 into English, and random sections of the transcripts were checked by a third transcriber, which 9 ensured accuracy.", [["sections", "ANATOMY", 86, 94]]], ["Demographic information was collected from participants, who were found to have 10 a reasonable diversity in age, educational background, and length of residence in Australia.", [["participants", "SPECIES", 43, 55]]], ["Some 11 participants did not provide all the demographic details requested, however the amount of missing 12 data in each category was less than 10%.", [["participants", "SPECIES", 8, 20]]], ["There were more female than male participants, which could 13 have influenced the observation that participants who consulted a GP before travel tended to be 14 female.", [["participants", "ORGANISM", 99, 111], ["participants", "SPECIES", 33, 45], ["participants", "SPECIES", 99, 111]]], ["However, most findings in this study were not observed to be associated with gender.", [["this study", "TEST", 26, 36]]], ["The in-depth focus on outbreak-related attitudes and behaviour in this study thus 17 represents a novel contribution to the understanding of VFR travel health. informed of the latest outbreaks, but some appear to underestimate the risks posed by an outbreak 25 especially in the early stages, and may thus undertake non-essential travel during outbreaks.", [["this study", "TEST", 66, 76], ["-depth", "OBSERVATION_MODIFIER", 6, 12]]], ["Low risk perception, 1 misconceptions and other issues need to be addressed to encourage proper preventive behaviour, 2 including pandemic awareness and application of public health messages during pandemics [47, 48] .", [["Low risk perception", "PROBLEM", 0, 19]]], ["320While this research was not conducted specifically in relation to a pandemic situation like COVID-19, 4 its findings are useful in informing educational interventions for Chinese VFR travellers as part of the 5 ongoing pandemic response.", [["a pandemic situation", "PROBLEM", 69, 89], ["COVID", "TEST", 95, 100], ["educational interventions", "TREATMENT", 144, 169], ["Chinese VFR travellers", "TREATMENT", 174, 196]]]], "PMC5146304": [["IntroductionNeonatal calf septicemia causes high morbidity and mortality and is one of the leading and most significant difficulties in raising cattle.", [["septicemia", "DISEASE", 26, 36], ["calf", "ORGANISM", 21, 25], ["cattle", "ORGANISM", 144, 150], ["calf", "SPECIES", 21, 25], ["cattle", "SPECIES", 144, 150], ["cattle", "SPECIES", 144, 150], ["Neonatal calf septicemia", "PROBLEM", 12, 36], ["high morbidity", "PROBLEM", 44, 58], ["calf", "ANATOMY", 21, 25], ["septicemia", "OBSERVATION", 26, 36], ["high", "OBSERVATION_MODIFIER", 44, 48], ["morbidity", "OBSERVATION", 49, 58], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["difficulties", "OBSERVATION", 120, 132]]], ["Calf septicemia is the main cause of death in the neonatal period [1].", [["septicemia", "DISEASE", 5, 15], ["death", "DISEASE", 37, 42], ["Calf", "ORGANISM", 0, 4], ["Calf", "SPECIES", 0, 4], ["Calf", "SPECIES", 0, 4], ["Calf septicemia", "PROBLEM", 0, 15], ["death", "PROBLEM", 37, 42], ["septicemia", "OBSERVATION", 5, 15], ["main", "OBSERVATION_MODIFIER", 23, 27]]], ["Its etiology involves bacteria (commonly Escherichia coli), viruses (rota and coronavirus), parasites, and other factors.", [["rota and coronavirus), parasites", "DISEASE", 69, 101], ["Escherichia coli", "ORGANISM", 41, 57], ["Escherichia coli", "SPECIES", 41, 57], ["Escherichia coli", "SPECIES", 41, 57], ["bacteria", "PROBLEM", 22, 30], ["commonly Escherichia coli", "PROBLEM", 32, 57], ["viruses", "PROBLEM", 60, 67], ["coronavirus", "PROBLEM", 78, 89], ["parasites", "PROBLEM", 92, 101], ["bacteria", "OBSERVATION_MODIFIER", 22, 30], ["Escherichia coli", "OBSERVATION", 41, 57]]], ["As the disease progresses quickly and is lethal, diagnosis and treatment should be initiated as quickly as possible [2].IntroductionHepcidin is a low molecular weight, antimicrobial peptide hormone and was first discovered in human urine [3].", [["urine", "ANATOMY", 232, 237], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 132, 140], ["human", "ORGANISM", 226, 231], ["urine", "ORGANISM_SUBSTANCE", 232, 237], ["Hepcidin", "PROTEIN", 132, 140], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["the disease", "PROBLEM", 3, 14], ["treatment", "TREATMENT", 63, 72], ["Hepcidin", "TREATMENT", 132, 140], ["a low molecular weight", "TREATMENT", 144, 166], ["antimicrobial peptide hormone", "TREATMENT", 168, 197], ["disease", "OBSERVATION", 7, 14]]], ["It is produced by the liver as a first-line response to inflammatory reactions and high Fe concentrations [4,5].", [["liver", "ANATOMY", 22, 27], ["Fe", "CHEMICAL", 88, 90], ["Fe", "CHEMICAL", 88, 90], ["liver", "ORGAN", 22, 27], ["Fe", "SIMPLE_CHEMICAL", 88, 90], ["inflammatory reactions", "PROBLEM", 56, 78], ["high Fe concentrations", "PROBLEM", 83, 105], ["liver", "ANATOMY", 22, 27], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68]]], ["Hepcidin plays a fundamental role in the regulation of Fe metabolism [6], which is a part of foundational cellular functions and thus of vital importance.", [["cellular", "ANATOMY", 106, 114], ["Fe", "CHEMICAL", 55, 57], ["Fe", "CHEMICAL", 55, 57], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Fe", "SIMPLE_CHEMICAL", 55, 57], ["cellular", "CELL", 106, 114], ["Hepcidin", "PROTEIN", 0, 8], ["Hepcidin", "TREATMENT", 0, 8]]], ["On the other hand, by participating in redox reactions leading to the production of reactive oxygen species (ROSs), Fe also causes oxidative stress.", [["oxygen", "CHEMICAL", 93, 99], ["Fe", "CHEMICAL", 116, 118], ["oxygen", "CHEMICAL", 93, 99], ["Fe", "CHEMICAL", 116, 118], ["reactive oxygen species", "SIMPLE_CHEMICAL", 84, 107], ["ROSs", "SIMPLE_CHEMICAL", 109, 113], ["Fe", "SIMPLE_CHEMICAL", 116, 118], ["redox reactions", "PROBLEM", 39, 54], ["reactive oxygen species", "PROBLEM", 84, 107], ["oxidative stress", "PROBLEM", 131, 147], ["reactive", "OBSERVATION_MODIFIER", 84, 92], ["oxygen species", "OBSERVATION", 93, 107], ["oxidative stress", "OBSERVATION", 131, 147]]], ["Therefore, Fe has been regarded as a potentially toxic element to cells [7].", [["cells", "ANATOMY", 66, 71], ["Fe", "CHEMICAL", 11, 13], ["Fe", "CHEMICAL", 11, 13], ["Fe", "SIMPLE_CHEMICAL", 11, 13], ["cells", "CELL", 66, 71], ["Fe", "PROTEIN", 11, 13], ["Fe", "TREATMENT", 11, 13]]], ["Fe also plays an important role in pathogenesis of bacterial infections as bacteria utilize Fe for survival, growth and proliferation; therefore, it is of paramount importance to control the Fe metabolism [6].", [["Fe", "CHEMICAL", 0, 2], ["bacterial infections", "DISEASE", 51, 71], ["Fe", "CHEMICAL", 92, 94], ["Fe", "CHEMICAL", 191, 193], ["Fe", "CHEMICAL", 0, 2], ["Fe", "CHEMICAL", 92, 94], ["Fe", "CHEMICAL", 191, 193], ["Fe", "SIMPLE_CHEMICAL", 0, 2], ["Fe", "SIMPLE_CHEMICAL", 92, 94], ["Fe", "SIMPLE_CHEMICAL", 191, 193], ["bacterial infections", "PROBLEM", 51, 71], ["bacteria", "PROBLEM", 75, 83], ["survival", "TREATMENT", 99, 107], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["infections", "OBSERVATION", 61, 71], ["proliferation", "OBSERVATION_MODIFIER", 120, 133]]], ["It is well known that the abundance of Fe suppresses defense system leading host vulnerable to infections.", [["Fe", "CHEMICAL", 39, 41], ["infections", "DISEASE", 95, 105], ["Fe", "CHEMICAL", 39, 41], ["Fe", "SIMPLE_CHEMICAL", 39, 41], ["Fe", "PROTEIN", 39, 41], ["Fe suppresses defense system", "TREATMENT", 39, 67], ["infections", "PROBLEM", 95, 105], ["infections", "OBSERVATION", 95, 105]]], ["There is a significant relationship between Hepcidin, Fe metabolism, inflammation, and the immune system.", [["immune system", "ANATOMY", 91, 104], ["Fe", "CHEMICAL", 54, 56], ["inflammation", "DISEASE", 69, 81], ["Fe", "CHEMICAL", 54, 56], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 44, 52], ["Fe", "SIMPLE_CHEMICAL", 54, 56], ["Hepcidin", "TREATMENT", 44, 52], ["Fe metabolism", "PROBLEM", 54, 67], ["inflammation", "PROBLEM", 69, 81], ["the immune system", "PROBLEM", 87, 104], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["Fe metabolism", "OBSERVATION", 54, 67], ["inflammation", "OBSERVATION", 69, 81], ["immune system", "OBSERVATION", 91, 104]]], ["The fact that hepcidin plays an active role in the regulation of Fe release from macrophages and in the control of excessive Fe absorption from the duodenum is well documented [6].", [["macrophages", "ANATOMY", 81, 92], ["duodenum", "ANATOMY", 148, 156], ["Fe", "CHEMICAL", 65, 67], ["Fe", "CHEMICAL", 125, 127], ["Fe", "CHEMICAL", 65, 67], ["Fe", "CHEMICAL", 125, 127], ["hepcidin", "GENE_OR_GENE_PRODUCT", 14, 22], ["Fe", "SIMPLE_CHEMICAL", 65, 67], ["macrophages", "CELL", 81, 92], ["Fe", "SIMPLE_CHEMICAL", 125, 127], ["duodenum", "ORGAN", 148, 156], ["hepcidin", "PROTEIN", 14, 22], ["macrophages", "CELL_TYPE", 81, 92], ["hepcidin", "TREATMENT", 14, 22], ["Fe release", "TREATMENT", 65, 75], ["macrophages", "TREATMENT", 81, 92], ["excessive Fe absorption", "TREATMENT", 115, 138], ["hepcidin", "OBSERVATION", 14, 22], ["active", "OBSERVATION_MODIFIER", 32, 38], ["duodenum", "ANATOMY", 148, 156]]], ["Hepcidin is a part of the natural defense mechanism, thus it limits the amount of Fe that can be utilized by pathogens [8].", [["Fe", "CHEMICAL", 82, 84], ["Fe", "CHEMICAL", 82, 84], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Fe", "SIMPLE_CHEMICAL", 82, 84], ["Hepcidin", "PROTEIN", 0, 8], ["Hepcidin", "TREATMENT", 0, 8]]], ["In inflammatory conditions, hypoferremia is an important first-line protective mechanism in response to infections [9].", [["hypoferremia", "DISEASE", 28, 40], ["infections", "DISEASE", 104, 114], ["inflammatory conditions", "PROBLEM", 3, 26], ["hypoferremia", "PROBLEM", 28, 40], ["infections", "PROBLEM", 104, 114], ["inflammatory", "OBSERVATION_MODIFIER", 3, 15]]], ["Fe also participates in redox reactions, causing the production of ROS, and thus leading to oxidative stress [7].", [["Fe", "CHEMICAL", 0, 2], ["ROS", "CHEMICAL", 67, 70], ["Fe", "CHEMICAL", 0, 2], ["Fe", "SIMPLE_CHEMICAL", 0, 2], ["ROS", "SIMPLE_CHEMICAL", 67, 70], ["redox reactions", "PROBLEM", 24, 39], ["oxidative stress", "PROBLEM", 92, 108]]], ["Free radicals play a significant role in the pathogenesis of many diseases [10].", [["Free radicals", "SIMPLE_CHEMICAL", 0, 13], ["many diseases", "PROBLEM", 61, 74], ["radicals", "OBSERVATION", 5, 13], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["Newborns are subject to oxidative stress during birth.", [["Newborns", "ORGANISM", 0, 8], ["Newborns", "SPECIES", 0, 8], ["oxidative stress", "PROBLEM", 24, 40]]], ["It is also reported that in livestock diseases, especially enteritis and pneumonia, antioxidant capacity is efficacious [11].IntroductionThis study was designed to determine the clinical significance of hepcidin in calves with suspected neonatal septicemia by evaluating serum hepcidin, total antioxidant status (TAS), total oxidant status (TOS), and Fe levels in calves suspected of neonatal septicemia before and after treatment.Ethical approval ::: Materials and MethodsThis study was conducted after obtaining approval from the Mehmet Akif Ersoy University Animal Experiments Local Ethics Committee (MAKU-HADYEK-Submission: 2014/77).Animals ::: Materials and MethodsThe study consisted of 15 calves with suspected neonatal septicemia aged between 1 and 10 days old admitted to the Teaching Hospital of Veterinary Medicine.", [["serum", "ANATOMY", 271, 276], ["livestock diseases", "DISEASE", 28, 46], ["enteritis", "DISEASE", 59, 68], ["pneumonia", "DISEASE", 73, 82], ["septicemia", "DISEASE", 246, 256], ["Fe", "CHEMICAL", 351, 353], ["septicemia", "DISEASE", 393, 403], ["septicemia", "DISEASE", 727, 737], ["Fe", "CHEMICAL", 351, 353], ["hepcidin", "GENE_OR_GENE_PRODUCT", 203, 211], ["calves", "ORGANISM", 215, 221], ["serum", "ORGANISM_SUBSTANCE", 271, 276], ["hepcidin", "GENE_OR_GENE_PRODUCT", 277, 285], ["TAS", "SIMPLE_CHEMICAL", 313, 316], ["TOS", "SIMPLE_CHEMICAL", 341, 344], ["Fe", "SIMPLE_CHEMICAL", 351, 353], ["calves", "ORGANISM", 364, 370], ["calves", "ORGANISM", 696, 702], ["hepcidin", "PROTEIN", 203, 211], ["serum hepcidin", "PROTEIN", 271, 285], ["calves", "SPECIES", 215, 221], ["calves", "SPECIES", 364, 370], ["calves", "SPECIES", 696, 702], ["livestock diseases", "PROBLEM", 28, 46], ["enteritis", "PROBLEM", 59, 68], ["pneumonia", "PROBLEM", 73, 82], ["antioxidant capacity", "PROBLEM", 84, 104], ["This study", "TEST", 137, 147], ["hepcidin in calves", "TREATMENT", 203, 221], ["neonatal septicemia", "PROBLEM", 237, 256], ["serum hepcidin", "TEST", 271, 285], ["total oxidant status (TOS)", "TEST", 319, 345], ["Fe levels", "TEST", 351, 360], ["neonatal septicemia", "PROBLEM", 384, 403], ["treatment", "TREATMENT", 421, 430], ["This study", "TEST", 473, 483], ["The study", "TEST", 670, 679], ["neonatal septicemia", "PROBLEM", 718, 737], ["livestock diseases", "OBSERVATION", 28, 46], ["enteritis", "OBSERVATION", 59, 68], ["pneumonia", "OBSERVATION", 73, 82], ["septicemia", "OBSERVATION", 246, 256], ["neonatal", "OBSERVATION_MODIFIER", 384, 392], ["septicemia", "OBSERVATION", 393, 403], ["septicemia", "OBSERVATION", 727, 737]]], ["Suspected septicemia was diagnosed based on clinical (diarrhea, weakness in or absence of sucking reflex, the calf being in a supine position on the ground or being unable to stand, severe dehydration, abnormal rectal temperature [hypo- or hyperthermia], mucosal hyperemia, and full sclera) and hematological (increase in white blood cell [WBC] count) examinations; the animals were suspected to have septicemia [12,13].", [["rectal", "ANATOMY", 211, 217], ["mucosal", "ANATOMY", 255, 262], ["sclera", "ANATOMY", 283, 289], ["white blood cell", "ANATOMY", 322, 338], ["WBC", "ANATOMY", 340, 343], ["septicemia", "DISEASE", 10, 20], ["diarrhea", "DISEASE", 54, 62], ["weakness", "DISEASE", 64, 72], ["dehydration", "DISEASE", 189, 200], ["hyperthermia", "DISEASE", 240, 252], ["hyperemia", "DISEASE", 263, 272], ["septicemia", "DISEASE", 401, 411], ["calf", "ORGANISM_SUBDIVISION", 110, 114], ["rectal", "ORGANISM_SUBDIVISION", 211, 217], ["mucosal", "ORGANISM_SUBDIVISION", 255, 262], ["white blood cell", "CELL", 322, 338], ["WBC", "CELL", 340, 343], ["animals", "ORGANISM", 370, 377], ["calf", "SPECIES", 110, 114], ["septicemia", "PROBLEM", 10, 20], ["clinical (diarrhea", "PROBLEM", 44, 62], ["weakness", "PROBLEM", 64, 72], ["sucking reflex", "PROBLEM", 90, 104], ["severe dehydration", "PROBLEM", 182, 200], ["abnormal rectal temperature", "PROBLEM", 202, 229], ["hypo", "PROBLEM", 231, 235], ["hyperthermia", "PROBLEM", 240, 252], ["mucosal hyperemia", "PROBLEM", 255, 272], ["hematological (increase", "PROBLEM", 295, 318], ["white blood cell", "TEST", 322, 338], ["WBC] count", "TEST", 340, 350], ["examinations", "TEST", 352, 364], ["septicemia", "PROBLEM", 401, 411], ["septicemia", "OBSERVATION", 10, 20], ["calf", "ANATOMY", 110, 114], ["rectal", "ANATOMY", 211, 217], ["mucosal", "ANATOMY", 255, 262], ["hyperemia", "OBSERVATION", 263, 272], ["sclera", "ANATOMY", 283, 289], ["increase", "OBSERVATION_MODIFIER", 310, 318], ["septicemia", "OBSERVATION", 401, 411]]], ["The animals were given standard treatment (antibiotic, nonsteroidal anti-inflammatory drugs, vitamin C, fluid therapy, and intestinal astringent).", [["nonsteroidal", "ANATOMY", 55, 67], ["intestinal", "ANATOMY", 123, 133], ["vitamin C", "CHEMICAL", 93, 102], ["vitamin C", "CHEMICAL", 93, 102], ["animals", "ORGANISM", 4, 11], ["vitamin C", "SIMPLE_CHEMICAL", 93, 102], ["intestinal", "ORGAN", 123, 133], ["standard treatment", "TREATMENT", 23, 41], ["antibiotic", "TREATMENT", 43, 53], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 55, 91], ["vitamin C", "TREATMENT", 93, 102], ["fluid therapy", "TREATMENT", 104, 117], ["intestinal astringent", "TREATMENT", 123, 144], ["intestinal", "ANATOMY", 123, 133]]], ["For determination of serum hepcidin, TAS, TOS, Fe levels, and hematological parameters; blood samples were taken before and after treatment in all cases.", [["serum", "ANATOMY", 21, 26], ["blood samples", "ANATOMY", 88, 101], ["Fe", "CHEMICAL", 47, 49], ["Fe", "CHEMICAL", 47, 49], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["hepcidin", "GENE_OR_GENE_PRODUCT", 27, 35], ["TAS", "SIMPLE_CHEMICAL", 37, 40], ["TOS", "SIMPLE_CHEMICAL", 42, 45], ["Fe", "SIMPLE_CHEMICAL", 47, 49], ["blood samples", "ORGANISM_SUBSTANCE", 88, 101], ["serum hepcidin", "PROTEIN", 21, 35], ["serum hepcidin", "TEST", 21, 35], ["TAS", "TEST", 37, 40], ["TOS", "TEST", 42, 45], ["Fe levels", "TEST", 47, 56], ["hematological parameters", "TEST", 62, 86], ["blood samples", "TEST", 88, 101], ["treatment", "TREATMENT", 130, 139]]], ["8.5 mL of blood was taken from the jugular vein of each animal into coagulant tubes for biochemical analysis, and 3 mL blood was taken into ETDA tubes for hematological analysis.", [["blood", "ANATOMY", 10, 15], ["jugular vein", "ANATOMY", 35, 47], ["blood", "ANATOMY", 119, 124], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 35, 47], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["coagulant tubes", "TREATMENT", 68, 83], ["biochemical analysis", "TEST", 88, 108], ["ETDA tubes", "TREATMENT", 140, 150], ["hematological analysis", "TEST", 155, 177], ["jugular vein", "ANATOMY", 35, 47], ["coagulant tubes", "OBSERVATION", 68, 83]]], ["Samples were centrifuged at 3000 rpm for 10 min, and the serum was harvested and kept at \u221220\u00b0C until the analysis.", [["Samples", "ANATOMY", 0, 7], ["serum", "ANATOMY", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["Samples", "TEST", 0, 7], ["the serum", "TEST", 53, 62], ["the analysis", "TEST", 101, 113]]], ["Serum hepcidin (Mybiosource\u00ae), TAS (Rel Assay Diagnostics\u00ae), and TOS (Rel Assay Diagnostics\u00ae) were determined using commercial ELISA kits, and Fe value was measured spectrophotometrically.", [["Serum", "ANATOMY", 0, 5], ["Fe", "CHEMICAL", 143, 145], ["Fe", "CHEMICAL", 143, 145], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["hepcidin", "GENE_OR_GENE_PRODUCT", 6, 14], ["Mybiosource\u00ae", "SIMPLE_CHEMICAL", 16, 28], ["TAS", "SIMPLE_CHEMICAL", 31, 34], ["Fe", "SIMPLE_CHEMICAL", 143, 145], ["Serum hepcidin", "PROTEIN", 0, 14], ["TAS", "PROTEIN", 31, 34], ["Rel", "PROTEIN", 36, 39], ["Rel", "PROTEIN", 70, 73], ["Serum hepcidin", "TEST", 0, 14], ["TOS", "TEST", 65, 68], ["commercial ELISA kits", "TEST", 116, 137], ["Fe value", "TEST", 143, 151]]], ["Hematological (WBC, lymphocyte [LYM], red blood cells [RBC], mean corpuscular volume (MCV), and hematocrit [HCT]) analysis was performed on blood counter (VG-MS4e\u00ae, Melet Schloes\u0131ng, France).Statistical analysis ::: Materials and MethodsThe results were evaluated using the t-test in the SPSS\u00ae (SPSS 20, USA) statistical package program to determine the differences between values before and after treatment.Clinical examination findings ::: ResultsCalves with suspected septicemia exhibited clinical signs of loss of appetite, fatigue, indifference to surroundings, reduced/absence of sucking reflex, cool extremities, inability to stand, diarrhea, eye sinking into their sockets, and hyperemia in the conjunctiva.", [["WBC", "ANATOMY", 15, 18], ["lymphocyte", "ANATOMY", 20, 30], ["LYM", "ANATOMY", 32, 35], ["red blood cells", "ANATOMY", 38, 53], ["RBC", "ANATOMY", 55, 58], ["corpuscular", "ANATOMY", 66, 77], ["blood", "ANATOMY", 140, 145], ["extremities", "ANATOMY", 607, 618], ["eye", "ANATOMY", 650, 653], ["sockets", "ANATOMY", 673, 680], ["conjunctiva", "ANATOMY", 703, 714], ["septicemia", "DISEASE", 471, 481], ["loss of appetite", "DISEASE", 510, 526], ["fatigue", "DISEASE", 528, 535], ["diarrhea", "DISEASE", 640, 648], ["hyperemia", "DISEASE", 686, 695], ["WBC", "CELL", 15, 18], ["lymphocyte", "CELL", 20, 30], ["LYM", "CELL", 32, 35], ["red blood cells", "CELL", 38, 53], ["RBC", "CELL", 55, 58], ["corpuscular", "ORGANISM_SUBSTANCE", 66, 77], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["extremities", "ORGANISM_SUBDIVISION", 607, 618], ["eye", "ORGAN", 650, 653], ["sockets", "TISSUE", 673, 680], ["conjunctiva", "ORGAN", 703, 714], ["lymphocyte", "CELL_TYPE", 20, 30], ["red blood cells", "CELL_TYPE", 38, 53], ["RBC", "CELL_TYPE", 55, 58], ["Hematological (WBC", "TEST", 0, 18], ["lymphocyte", "TEST", 20, 30], ["LYM", "TEST", 32, 35], ["red blood cells", "TEST", 38, 53], ["RBC", "TEST", 55, 58], ["mean corpuscular volume", "TEST", 61, 84], ["MCV", "TEST", 86, 89], ["hematocrit", "TEST", 96, 106], ["HCT", "TEST", 108, 111], ["analysis", "TEST", 114, 122], ["blood counter", "TEST", 140, 153], ["VG", "TEST", 155, 157], ["the t-test", "TEST", 270, 280], ["treatment", "TREATMENT", 398, 407], ["Clinical examination", "TEST", 408, 428], ["septicemia", "PROBLEM", 471, 481], ["loss of appetite", "PROBLEM", 510, 526], ["fatigue", "PROBLEM", 528, 535], ["sucking reflex", "PROBLEM", 586, 600], ["cool extremities", "PROBLEM", 602, 618], ["inability to stand", "PROBLEM", 620, 638], ["diarrhea", "PROBLEM", 640, 648], ["eye sinking into their sockets", "PROBLEM", 650, 680], ["hyperemia in the conjunctiva", "PROBLEM", 686, 714], ["septicemia", "OBSERVATION", 471, 481], ["loss", "OBSERVATION_MODIFIER", 510, 514], ["extremities", "ANATOMY", 607, 618], ["eye", "ANATOMY", 650, 653], ["hyperemia", "OBSERVATION", 686, 695], ["conjunctiva", "ANATOMY", 703, 714]]], ["The average body temperature, heart rate, and respiratory rates of the animals were 37.18\u00b10.13\u00b0C, 104\u00b14.33/min, and 28.86\u00b10.75/min pre-treatment; and 38.54\u00b10.1\u00b0C, 107.53\u00b12.20/min and 26.40\u00b10.36/min post-treatment, respectively.Biochemical findings ::: ResultsThe changes in hepcidin, TAS, TOS and Fe levels in the calves with suspected septicemia before and after treatment are given in Table-1.", [["body", "ANATOMY", 12, 16], ["heart", "ANATOMY", 30, 35], ["Fe", "CHEMICAL", 297, 299], ["septicemia", "DISEASE", 336, 346], ["Fe", "CHEMICAL", 297, 299], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["heart", "ORGAN", 30, 35], ["hepcidin", "GENE_OR_GENE_PRODUCT", 274, 282], ["TAS", "SIMPLE_CHEMICAL", 284, 287], ["TOS", "SIMPLE_CHEMICAL", 289, 292], ["Fe", "SIMPLE_CHEMICAL", 297, 299], ["calves", "ORGANISM", 314, 320], ["hepcidin", "PROTEIN", 274, 282], ["TAS", "PROTEIN", 284, 287], ["calves", "SPECIES", 314, 320], ["The average body temperature", "TEST", 0, 28], ["heart rate", "TEST", 30, 40], ["respiratory rates", "TEST", 46, 63], ["\u00b0C", "TEST", 94, 96], ["\u00b0C", "TEST", 159, 161], ["The changes in hepcidin", "PROBLEM", 259, 282], ["TAS, TOS and Fe levels", "TEST", 284, 306], ["septicemia", "PROBLEM", 336, 346], ["treatment", "TREATMENT", 364, 373], ["average", "OBSERVATION_MODIFIER", 4, 11], ["heart", "ANATOMY", 30, 35], ["respiratory rates", "OBSERVATION", 46, 63], ["hepcidin", "ANATOMY", 274, 282], ["calves", "ANATOMY", 314, 320], ["septicemia", "OBSERVATION", 336, 346]]], ["After treatment, serum hepcidin and TOS levels were significantly lower than before treatment in calves.", [["serum", "ANATOMY", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["hepcidin", "GENE_OR_GENE_PRODUCT", 23, 31], ["TOS", "SIMPLE_CHEMICAL", 36, 39], ["calves", "ORGANISM", 97, 103], ["serum hepcidin", "PROTEIN", 17, 31], ["calves", "SPECIES", 97, 103], ["treatment", "TREATMENT", 6, 15], ["serum hepcidin", "TEST", 17, 31], ["TOS levels", "TEST", 36, 46], ["treatment in calves", "TREATMENT", 84, 103]]], ["On contrary, serum TAS and Fe levels were significantly higher than before treatment (Table-1).Hematological findings ::: ResultsThe treatment of calves resulted in significant changes in the hematological parameters that were examined except for RBC.", [["serum", "ANATOMY", 13, 18], ["RBC", "ANATOMY", 247, 250], ["Fe", "CHEMICAL", 27, 29], ["Fe", "CHEMICAL", 27, 29], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["TAS", "SIMPLE_CHEMICAL", 19, 22], ["Fe", "SIMPLE_CHEMICAL", 27, 29], ["calves", "ORGANISM", 146, 152], ["RBC", "CELL", 247, 250], ["RBC", "CELL_TYPE", 247, 250], ["calves", "SPECIES", 146, 152], ["serum TAS", "TEST", 13, 22], ["Fe levels", "TEST", 27, 36], ["The treatment of calves", "TREATMENT", 129, 152], ["significant changes in the hematological parameters", "PROBLEM", 165, 216], ["RBC", "TEST", 247, 250], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["changes", "OBSERVATION", 177, 184]]], ["The WBC count, LYM count, MCV and HCT significantly changed after treatment when compared to values obtained before treatment (Table-2).DiscussionThis study aimed to determine the clinical importance or use of hepcidin by comparing the values of serum hepcidin, TAS, TOS and Fe levels in calves with suspected neonatal septicemia before and after treatment.DiscussionClinicians rely on clinical and laboratory examinations of patients to form a working diagnosis, so hematological and serum biochemical parameters are usually used for this purpose [14].", [["WBC", "ANATOMY", 4, 7], ["serum", "ANATOMY", 246, 251], ["hematological", "ANATOMY", 467, 480], ["serum", "ANATOMY", 485, 490], ["Fe", "CHEMICAL", 275, 277], ["neonatal septicemia", "DISEASE", 310, 329], ["Fe", "CHEMICAL", 275, 277], ["WBC", "CELL", 4, 7], ["hepcidin", "GENE_OR_GENE_PRODUCT", 210, 218], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["hepcidin", "GENE_OR_GENE_PRODUCT", 252, 260], ["TAS", "SIMPLE_CHEMICAL", 262, 265], ["TOS", "SIMPLE_CHEMICAL", 267, 270], ["Fe", "SIMPLE_CHEMICAL", 275, 277], ["calves", "ORGANISM", 288, 294], ["patients", "ORGANISM", 426, 434], ["serum", "ORGANISM_SUBSTANCE", 485, 490], ["LYM", "PROTEIN", 15, 18], ["hepcidin", "PROTEIN", 210, 218], ["serum hepcidin", "PROTEIN", 246, 260], ["calves", "SPECIES", 288, 294], ["patients", "SPECIES", 426, 434], ["The WBC count", "TEST", 0, 13], ["LYM count", "TEST", 15, 24], ["MCV", "TEST", 26, 29], ["HCT", "TEST", 34, 37], ["treatment", "TREATMENT", 66, 75], ["This study", "TEST", 146, 156], ["hepcidin", "TREATMENT", 210, 218], ["serum hepcidin", "TEST", 246, 260], ["TAS", "TEST", 262, 265], ["TOS and Fe levels", "TEST", 267, 284], ["neonatal septicemia", "PROBLEM", 310, 329], ["treatment", "TREATMENT", 347, 356], ["laboratory examinations", "TEST", 399, 422], ["serum biochemical parameters", "TEST", 485, 513], ["calves", "ANATOMY", 288, 294], ["neonatal", "OBSERVATION_MODIFIER", 310, 318], ["septicemia", "OBSERVATION", 319, 329]]], ["The hematological parameters (WBC, HCT, LYM, and MCV) evaluated in this study were comparable with those reported by others in neonatal calves with diarrhea and suspected septicemia [15-17].", [["diarrhea", "DISEASE", 148, 156], ["septicemia", "DISEASE", 171, 181], ["calves", "ORGANISM", 136, 142], ["calves", "SPECIES", 136, 142], ["The hematological parameters", "TEST", 0, 28], ["WBC", "TEST", 30, 33], ["HCT", "TEST", 35, 38], ["LYM", "TEST", 40, 43], ["MCV", "TEST", 49, 52], ["this study", "TEST", 67, 77], ["diarrhea", "PROBLEM", 148, 156], ["septicemia", "PROBLEM", 171, 181], ["septicemia", "OBSERVATION", 171, 181]]], ["Treatment significantly corrected to normal values the hematological parameters that were examined with the exception of RBC.", [["RBC", "ANATOMY", 121, 124], ["RBC", "CELL", 121, 124], ["RBC", "CELL_TYPE", 121, 124], ["the hematological parameters", "TEST", 51, 79], ["RBC", "TEST", 121, 124]]], ["Pre-treatment leukocyte count was high because of the inflammation that occurred in the organism, and that the HCT levels were high due to the dehydration that occurred due to diarrhea.DiscussionHepcidin is controlled by the presence of inflammation in the body, Fe storage, and erythropoietic activity in the bone marrow and plays a primary role in the homeostasis of Fe [4].", [["leukocyte", "ANATOMY", 14, 23], ["HCT", "ANATOMY", 111, 114], ["body", "ANATOMY", 257, 261], ["bone marrow", "ANATOMY", 310, 321], ["inflammation", "DISEASE", 54, 66], ["dehydration", "DISEASE", 143, 154], ["diarrhea", "DISEASE", 176, 184], ["inflammation", "DISEASE", 237, 249], ["Fe", "CHEMICAL", 263, 265], ["Fe", "CHEMICAL", 369, 371], ["Fe", "CHEMICAL", 263, 265], ["Fe [4]", "CHEMICAL", 369, 375], ["leukocyte", "CELL", 14, 23], ["HCT", "CANCER", 111, 114], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 195, 203], ["body", "ORGANISM_SUBDIVISION", 257, 261], ["Fe", "SIMPLE_CHEMICAL", 263, 265], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 310, 321], ["Fe [4]", "SIMPLE_CHEMICAL", 369, 375], ["Hepcidin", "PROTEIN", 195, 203], ["Pre-treatment leukocyte count", "TEST", 0, 29], ["the inflammation", "PROBLEM", 50, 66], ["the HCT levels", "TEST", 107, 121], ["the dehydration", "PROBLEM", 139, 154], ["diarrhea", "PROBLEM", 176, 184], ["Hepcidin", "TREATMENT", 195, 203], ["inflammation in the body", "PROBLEM", 237, 261], ["Fe storage", "PROBLEM", 263, 273], ["erythropoietic activity in the bone marrow", "PROBLEM", 279, 321], ["inflammation", "OBSERVATION", 54, 66], ["dehydration", "OBSERVATION", 143, 154], ["inflammation", "OBSERVATION", 237, 249], ["body", "ANATOMY", 257, 261], ["Fe storage", "OBSERVATION", 263, 273], ["erythropoietic activity", "OBSERVATION", 279, 302], ["bone marrow", "ANATOMY", 310, 321]]], ["The increase in tissue and plasma Fe levels stimulates the synthesis of hepcidin and reduces Fe release and enteric Fe absorption from macrophages and hepatocytes [18].", [["tissue", "ANATOMY", 16, 22], ["plasma", "ANATOMY", 27, 33], ["macrophages", "ANATOMY", 135, 146], ["hepatocytes", "ANATOMY", 151, 162], ["Fe", "CHEMICAL", 34, 36], ["Fe", "CHEMICAL", 93, 95], ["Fe", "CHEMICAL", 116, 118], ["Fe", "CHEMICAL", 34, 36], ["Fe", "CHEMICAL", 93, 95], ["Fe", "CHEMICAL", 116, 118], ["tissue", "TISSUE", 16, 22], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["Fe", "SIMPLE_CHEMICAL", 34, 36], ["hepcidin", "GENE_OR_GENE_PRODUCT", 72, 80], ["Fe", "SIMPLE_CHEMICAL", 93, 95], ["Fe", "SIMPLE_CHEMICAL", 116, 118], ["macrophages", "CELL", 135, 146], ["hepatocytes", "CELL", 151, 162], ["hepcidin", "PROTEIN", 72, 80], ["macrophages", "CELL_TYPE", 135, 146], ["hepatocytes", "CELL_TYPE", 151, 162], ["The increase in tissue and plasma", "PROBLEM", 0, 33], ["Fe levels", "TEST", 34, 43], ["the synthesis of hepcidin", "TREATMENT", 55, 80], ["Fe release", "TREATMENT", 93, 103], ["enteric Fe absorption", "TREATMENT", 108, 129], ["hepatocytes", "TEST", 151, 162], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["tissue", "ANATOMY", 16, 22], ["hepatocytes", "ANATOMY", 151, 162]]], ["Increased hepcidin concentrations during inflammation and infection reduce serum Fe levels by decreasing Fe release from macrophages and hepatocytes, and thus Fe required for microorganisms and tumor cells is restricted [19].DiscussionSerum hepcidin levels in calves with suspected septicemia were significantly high before treatment when compared to after treatment; also Fe levels were lower before treatment when compared to after treatment in this study.", [["serum", "ANATOMY", 75, 80], ["macrophages", "ANATOMY", 121, 132], ["hepatocytes", "ANATOMY", 137, 148], ["tumor cells", "ANATOMY", 194, 205], ["inflammation", "DISEASE", 41, 53], ["infection", "DISEASE", 58, 67], ["Fe", "CHEMICAL", 81, 83], ["Fe", "CHEMICAL", 105, 107], ["Fe", "CHEMICAL", 159, 161], ["tumor", "DISEASE", 194, 199], ["septicemia", "DISEASE", 282, 292], ["Fe", "CHEMICAL", 373, 375], ["Fe", "CHEMICAL", 81, 83], ["Fe", "CHEMICAL", 105, 107], ["Fe", "CHEMICAL", 159, 161], ["Fe", "CHEMICAL", 373, 375], ["hepcidin", "GENE_OR_GENE_PRODUCT", 10, 18], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["Fe", "SIMPLE_CHEMICAL", 81, 83], ["Fe", "SIMPLE_CHEMICAL", 105, 107], ["macrophages", "CELL", 121, 132], ["hepatocytes", "CELL", 137, 148], ["Fe", "SIMPLE_CHEMICAL", 159, 161], ["tumor cells", "CELL", 194, 205], ["hepcidin", "GENE_OR_GENE_PRODUCT", 241, 249], ["calves", "ORGANISM", 260, 266], ["Fe", "SIMPLE_CHEMICAL", 373, 375], ["hepcidin", "PROTEIN", 10, 18], ["macrophages", "CELL_TYPE", 121, 132], ["hepatocytes", "CELL_TYPE", 137, 148], ["Fe", "PROTEIN", 159, 161], ["tumor cells", "CELL_TYPE", 194, 205], ["hepcidin", "PROTEIN", 241, 249], ["calves", "SPECIES", 260, 266], ["Increased hepcidin concentrations", "PROBLEM", 0, 33], ["inflammation", "PROBLEM", 41, 53], ["infection", "PROBLEM", 58, 67], ["serum", "TEST", 75, 80], ["Fe levels", "TEST", 81, 90], ["Fe release from macrophages", "TEST", 105, 132], ["hepatocytes", "TEST", 137, 148], ["Fe", "TEST", 159, 161], ["microorganisms", "PROBLEM", 175, 189], ["tumor cells", "PROBLEM", 194, 205], ["DiscussionSerum hepcidin levels", "TEST", 225, 256], ["suspected septicemia", "PROBLEM", 272, 292], ["treatment", "TREATMENT", 324, 333], ["treatment", "TREATMENT", 357, 366], ["Fe levels", "TEST", 373, 382], ["treatment", "TREATMENT", 401, 410], ["treatment", "TREATMENT", 434, 443], ["this study", "TEST", 447, 457], ["hepcidin concentrations", "OBSERVATION", 10, 33], ["inflammation", "OBSERVATION", 41, 53], ["infection", "OBSERVATION", 58, 67], ["decreasing", "OBSERVATION_MODIFIER", 94, 104], ["macrophages", "OBSERVATION", 121, 132], ["hepatocytes", "ANATOMY", 137, 148], ["tumor cells", "OBSERVATION", 194, 205], ["septicemia", "OBSERVATION", 282, 292]]], ["This situation could be related to the interaction between hepcidin and Fe and also gives credence to the role of hepcidin in the hemostasis of Fe during inflammation and infection.", [["Fe", "CHEMICAL", 72, 74], ["Fe", "CHEMICAL", 144, 146], ["inflammation", "DISEASE", 154, 166], ["infection", "DISEASE", 171, 180], ["Fe", "CHEMICAL", 72, 74], ["Fe", "CHEMICAL", 144, 146], ["hepcidin", "GENE_OR_GENE_PRODUCT", 59, 67], ["Fe", "SIMPLE_CHEMICAL", 72, 74], ["hepcidin", "GENE_OR_GENE_PRODUCT", 114, 122], ["Fe", "SIMPLE_CHEMICAL", 144, 146], ["hepcidin", "PROTEIN", 59, 67], ["Fe", "PROTEIN", 72, 74], ["hepcidin", "PROTEIN", 114, 122], ["hepcidin and Fe", "TREATMENT", 59, 74], ["hepcidin", "TREATMENT", 114, 122], ["inflammation", "PROBLEM", 154, 166], ["infection", "PROBLEM", 171, 180], ["inflammation", "OBSERVATION", 154, 166], ["infection", "OBSERVATION", 171, 180]]], ["As in our study, Fe levels are well known to decrease in diarrheic calves when compared to healthy calves [20,21].", [["Fe", "CHEMICAL", 17, 19], ["Fe", "CHEMICAL", 17, 19], ["Fe", "SIMPLE_CHEMICAL", 17, 19], ["calves", "ORGANISM", 67, 73], ["calves", "ORGANISM", 99, 105], ["Fe", "PROTEIN", 17, 19], ["calves", "SPECIES", 67, 73], ["calves", "SPECIES", 99, 105], ["our study", "TEST", 6, 15], ["Fe levels", "TEST", 17, 26], ["diarrheic calves", "PROBLEM", 57, 73], ["decrease", "OBSERVATION_MODIFIER", 45, 53], ["diarrheic calves", "OBSERVATION", 57, 73]]], ["Although no study exists reporting hepcidin concentration in diseased calves, studies in human subjects show that cord blood hepcidin levels might be an important indicator in diagnosing early-onset of neonatal sepsis.", [["cord blood", "ANATOMY", 114, 124], ["sepsis", "DISEASE", 211, 217], ["hepcidin", "GENE_OR_GENE_PRODUCT", 35, 43], ["calves", "ORGANISM", 70, 76], ["human", "ORGANISM", 89, 94], ["cord blood", "ORGANISM_SUBSTANCE", 114, 124], ["hepcidin", "GENE_OR_GENE_PRODUCT", 125, 133], ["hepcidin", "PROTEIN", 35, 43], ["hepcidin", "PROTEIN", 125, 133], ["calves", "SPECIES", 70, 76], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["study", "TEST", 12, 17], ["hepcidin concentration in diseased calves", "PROBLEM", 35, 76], ["studies in human subjects", "TEST", 78, 103], ["cord blood hepcidin levels", "TEST", 114, 140], ["neonatal sepsis", "PROBLEM", 202, 217], ["diseased calves", "OBSERVATION", 61, 76], ["neonatal", "OBSERVATION_MODIFIER", 202, 210], ["sepsis", "OBSERVATION", 211, 217]]], ["The cord blood hepcidin levels of neonatal infants with sepsis varied between 118.1 and 8400 ng/mL and were significantly higher than the healthy infants [22].", [["cord blood", "ANATOMY", 4, 14], ["sepsis", "DISEASE", 56, 62], ["cord blood", "ORGANISM_SUBSTANCE", 4, 14], ["hepcidin", "GENE_OR_GENE_PRODUCT", 15, 23], ["infants", "ORGANISM", 43, 50], ["hepcidin", "PROTEIN", 15, 23], ["infants", "SPECIES", 43, 50], ["infants", "SPECIES", 146, 153], ["The cord blood hepcidin levels", "TEST", 0, 30], ["sepsis", "PROBLEM", 56, 62], ["cord", "ANATOMY", 4, 8], ["sepsis", "OBSERVATION", 56, 62]]], ["A similar result was reported that hepcidin concentrations in neonatal infants with sepsis were significantly higher than in healthy infants [23].", [["sepsis", "DISEASE", 84, 90], ["hepcidin", "GENE_OR_GENE_PRODUCT", 35, 43], ["infants", "ORGANISM", 71, 78], ["hepcidin", "PROTEIN", 35, 43], ["infants", "SPECIES", 71, 78], ["infants", "SPECIES", 133, 140], ["hepcidin concentrations", "TREATMENT", 35, 58], ["sepsis", "PROBLEM", 84, 90], ["sepsis", "OBSERVATION", 84, 90]]], ["These findings along with our results add credence to the idea that hepcidin-Fe interaction may play a role in the pathogenesis of septicemia.DiscussionThe production of free oxygen species causes alterations in protein, lipid, and DNA during oxidative stress and leads to the development of lesions in the organs [24].", [["lesions", "ANATOMY", 292, 299], ["organs", "ANATOMY", 307, 313], ["Fe", "CHEMICAL", 77, 79], ["septicemia", "DISEASE", 131, 141], ["oxygen", "CHEMICAL", 175, 181], ["Fe", "CHEMICAL", 77, 79], ["oxygen", "CHEMICAL", 175, 181], ["hepcidin", "GENE_OR_GENE_PRODUCT", 68, 76], ["Fe", "SIMPLE_CHEMICAL", 77, 79], ["free oxygen species", "SIMPLE_CHEMICAL", 170, 189], ["lipid", "SIMPLE_CHEMICAL", 221, 226], ["DNA", "CELLULAR_COMPONENT", 232, 235], ["lesions", "PATHOLOGICAL_FORMATION", 292, 299], ["organs", "ORGAN", 307, 313], ["hepcidin", "PROTEIN", 68, 76], ["septicemia", "PROBLEM", 131, 141], ["free oxygen species", "PROBLEM", 170, 189], ["alterations in protein, lipid", "PROBLEM", 197, 226], ["DNA during oxidative stress", "PROBLEM", 232, 259], ["lesions in the organs", "PROBLEM", 292, 313], ["septicemia", "OBSERVATION", 131, 141], ["free", "OBSERVATION", 170, 174], ["oxygen species", "OBSERVATION", 175, 189], ["lesions", "OBSERVATION", 292, 299], ["organs", "ANATOMY", 307, 313]]], ["Free iron has toxic characteristics as it catalyses the production of ROSs [25] and thus causes oxidative stress [26].", [["iron", "CHEMICAL", 5, 9], ["ROSs [25]", "CHEMICAL", 70, 79], ["iron", "CHEMICAL", 5, 9], ["iron", "SIMPLE_CHEMICAL", 5, 9], ["toxic characteristics", "PROBLEM", 14, 35], ["oxidative stress", "PROBLEM", 96, 112], ["toxic characteristics", "OBSERVATION_MODIFIER", 14, 35]]], ["The role of Fe in the development of oxidative stress may once more show the importance of hepcidin, as an important Fe regulator, with regard to enhancing antioxidant capacity through inhibiting utilization of Fe by the organism as well as the host cells.DiscussionThe antioxidant and oxidative system are in a constant state of balance in the organism.", [["cells", "ANATOMY", 250, 255], ["Fe", "CHEMICAL", 12, 14], ["Fe", "CHEMICAL", 117, 119], ["Fe", "CHEMICAL", 211, 213], ["Fe", "CHEMICAL", 12, 14], ["Fe", "CHEMICAL", 117, 119], ["Fe", "CHEMICAL", 211, 213], ["Fe", "SIMPLE_CHEMICAL", 12, 14], ["hepcidin", "GENE_OR_GENE_PRODUCT", 91, 99], ["Fe", "SIMPLE_CHEMICAL", 117, 119], ["Fe", "SIMPLE_CHEMICAL", 211, 213], ["host cells", "CELL", 245, 255], ["Fe", "PROTEIN", 12, 14], ["hepcidin", "PROTEIN", 91, 99], ["Fe regulator", "PROTEIN", 117, 129], ["Fe", "PROTEIN", 211, 213], ["host cells", "CELL_TYPE", 245, 255], ["oxidative stress", "PROBLEM", 37, 53], ["hepcidin", "TREATMENT", 91, 99], ["Fe regulator", "TREATMENT", 117, 129], ["enhancing antioxidant capacity", "PROBLEM", 146, 176], ["The antioxidant and oxidative system", "TREATMENT", 266, 302], ["host cells", "OBSERVATION", 245, 255]]], ["Any event breaking up this balance in favor of the oxidative stress molecules will cause cell damage [27,28].", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["Any event", "PROBLEM", 0, 9], ["the oxidative stress molecules", "PROBLEM", 47, 77], ["cell damage", "PROBLEM", 89, 100]]], ["The host cells initiate the antioxidant system in case of exposure to oxidative stress [27].", [["cells", "ANATOMY", 9, 14], ["host cells", "CELL", 4, 14], ["host cells", "CELL_TYPE", 4, 14], ["The host cells", "TREATMENT", 0, 14], ["the antioxidant system", "TREATMENT", 24, 46], ["oxidative stress", "PROBLEM", 70, 86], ["host cells", "OBSERVATION", 4, 14]]], ["Kabu et al. [16] reported TOS and TAS values in neonatal calves with diarrhea as 13.47\u00b10.81 \u00b5mol H2O2/L and 0.51\u00b10.02 mmol Trolox-equivalent/L, respectively, and treatment of these calves caused changes in these values of 11.21\u00b10.26 \u00b5mol H2O2/L and 0.55\u00b10.02 mmol Trolox-equivalent/L, respectively.", [["diarrhea", "DISEASE", 69, 77], ["H2O2", "CHEMICAL", 97, 101], ["Trolox", "CHEMICAL", 123, 129], ["H2O2", "CHEMICAL", 238, 242], ["Trolox", "CHEMICAL", 264, 270], ["H2O2", "CHEMICAL", 97, 101], ["Trolox", "CHEMICAL", 123, 129], ["H2O2", "CHEMICAL", 238, 242], ["Trolox", "CHEMICAL", 264, 270], ["TOS", "PATHOLOGICAL_FORMATION", 26, 29], ["TAS", "SIMPLE_CHEMICAL", 34, 37], ["calves", "ORGANISM", 57, 63], ["Trolox", "SIMPLE_CHEMICAL", 123, 129], ["calves", "ORGANISM", 181, 187], ["Trolox", "SIMPLE_CHEMICAL", 264, 270], ["calves", "SPECIES", 57, 63], ["calves", "SPECIES", 181, 187], ["TOS", "TEST", 26, 29], ["TAS values", "TEST", 34, 44], ["diarrhea", "PROBLEM", 69, 77], ["H2O2", "TEST", 97, 101], ["Trolox", "TEST", 123, 129], ["these calves", "PROBLEM", 175, 187], ["these values", "TEST", 206, 218], ["Trolox", "TEST", 264, 270], ["neonatal calves", "ANATOMY", 48, 63], ["calves", "OBSERVATION", 181, 187]]], ["Studies also reported that parameters used for oxidative stress (malondialdehyde) were higher [29] and antioxidant parameters (superoxide dismutase [21], TAS) were lower in diarrheic calves [29].", [["malondialdehyde", "CHEMICAL", 65, 80], ["superoxide", "CHEMICAL", 127, 137], ["malondialdehyde", "CHEMICAL", 65, 80], ["superoxide", "CHEMICAL", 127, 137], ["malondialdehyde", "SIMPLE_CHEMICAL", 65, 80], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 127, 147], ["TAS", "SIMPLE_CHEMICAL", 154, 157], ["superoxide dismutase", "PROTEIN", 127, 147], ["calves", "SPECIES", 183, 189], ["oxidative stress (malondialdehyde)", "TEST", 47, 81], ["antioxidant parameters", "TEST", 103, 125], ["superoxide dismutase", "TEST", 127, 147], ["TAS", "TEST", 154, 157]]], ["Similarly, in our study, TAS level was significantly lower and TOS level was significantly higher in diarrheic calves before treatment, and treatment caused corrections in these parameters.", [["TAS", "SIMPLE_CHEMICAL", 25, 28], ["calves", "ORGANISM", 111, 117], ["TAS", "PROTEIN", 25, 28], ["calves", "SPECIES", 111, 117], ["our study", "TEST", 14, 23], ["TAS level", "TEST", 25, 34], ["TOS level", "TEST", 63, 72], ["treatment", "TREATMENT", 125, 134], ["treatment", "TREATMENT", 140, 149], ["higher", "OBSERVATION_MODIFIER", 91, 97], ["diarrheic calves", "OBSERVATION", 101, 117]]], ["Decrease in TAS and increase in TOS levels demonstrated that oxidative stress was evident in the diseased calves in our study.", [["TAS", "SIMPLE_CHEMICAL", 12, 15], ["TOS", "SIMPLE_CHEMICAL", 32, 35], ["calves", "ORGANISM", 106, 112], ["calves", "SPECIES", 106, 112], ["Decrease in TAS", "PROBLEM", 0, 15], ["TOS levels", "TEST", 32, 42], ["oxidative stress", "PROBLEM", 61, 77], ["our study", "TEST", 116, 125], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["oxidative stress", "OBSERVATION", 61, 77], ["diseased", "OBSERVATION_MODIFIER", 97, 105], ["calves", "OBSERVATION", 106, 112]]], ["Increased TOS and hepcidin levels before treatment are thought that associated with inflammation.", [["inflammation", "DISEASE", 84, 96], ["hepcidin", "GENE_OR_GENE_PRODUCT", 18, 26], ["TOS", "PROTEIN", 10, 13], ["hepcidin", "PROTEIN", 18, 26], ["Increased TOS", "PROBLEM", 0, 13], ["hepcidin levels", "TEST", 18, 33], ["treatment", "TREATMENT", 41, 50], ["inflammation", "PROBLEM", 84, 96], ["thought that associated with", "UNCERTAINTY", 55, 83], ["inflammation", "OBSERVATION", 84, 96]]], ["After treatment increased TAS and decreased hepcidin levels support this opinion.ConclusionHepcidin may play an important part in non-specific immunity and is a key molecule that plays a role in the pathogenesis of diseases by enhancing the development of antioxidant system.", [["TAS", "SIMPLE_CHEMICAL", 26, 29], ["hepcidin", "GENE_OR_GENE_PRODUCT", 44, 52], ["Hepcidin", "GENE_OR_GENE_PRODUCT", 91, 99], ["hepcidin", "PROTEIN", 44, 52], ["Hepcidin", "PROTEIN", 91, 99], ["treatment increased TAS", "TREATMENT", 6, 29], ["decreased hepcidin levels support", "TREATMENT", 34, 67], ["Hepcidin", "TREATMENT", 91, 99], ["diseases", "PROBLEM", 215, 223], ["antioxidant system", "TREATMENT", 256, 274], ["diseases", "OBSERVATION", 215, 223]]], ["However, more detailed studies are needed on the role of hepcidin in the pathogenesis of septicemia.Authors\u2019 ContributionsThis work was carried out in collaboration between all authors.", [["septicemia", "DISEASE", 89, 99], ["hepcidin", "GENE_OR_GENE_PRODUCT", 57, 65], ["hepcidin", "PROTEIN", 57, 65], ["detailed studies", "TEST", 14, 30], ["hepcidin", "TREATMENT", 57, 65], ["septicemia", "PROBLEM", 89, 99], ["septicemia", "OBSERVATION", 89, 99]]], ["EEE, HME and AHK: Designed the experimental procedures.", [["the experimental procedures", "TREATMENT", 27, 54]]], ["EEE, AHK, MO and AK: Helped in laboratory analysis.", [["MO", "GENE_OR_GENE_PRODUCT", 10, 12], ["laboratory analysis", "TEST", 31, 50]]]], "a43c646b7e235bfd28cb68bf8ee44d3218328e1b": [["Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies INTRODUCTIONPatients undergoing hematopoietic cell transplantation (HCT) or treatment of hematologic malignancy (HM) have profound impairment of cell-mediated and humoral immunity.", [["Hematopoietic Cell", "ANATOMY", 33, 51], ["hematopoietic cell", "ANATOMY", 129, 147], ["HCT", "ANATOMY", 165, 168], ["hematologic malignancy", "ANATOMY", 186, 208], ["cell", "ANATOMY", 242, 246], ["Viral Pneumonia", "DISEASE", 0, 15], ["Hematologic Malignancies", "DISEASE", 72, 96], ["hematologic malignancy", "DISEASE", 186, 208], ["HM", "DISEASE", 210, 212], ["Patients", "ORGANISM", 19, 27], ["Hematopoietic Cell", "CELL", 33, 51], ["hematopoietic cell", "CELL", 129, 147], ["hematologic malignancy", "CANCER", 186, 208], ["cell", "CELL", 242, 246], ["Patients", "SPECIES", 19, 27], ["Viral Pneumonia", "PROBLEM", 0, 15], ["Hematopoietic Cell Transplantation", "TREATMENT", 33, 67], ["Hematologic Malignancies", "PROBLEM", 72, 96], ["hematopoietic cell transplantation", "TREATMENT", 129, 163], ["HCT", "TEST", 165, 168], ["treatment", "TREATMENT", 173, 182], ["hematologic malignancy", "PROBLEM", 186, 208], ["profound impairment of cell", "PROBLEM", 219, 246], ["Pneumonia", "OBSERVATION", 6, 15], ["Hematopoietic Cell Transplantation", "OBSERVATION", 33, 67], ["Hematologic Malignancies", "OBSERVATION", 72, 96], ["hematopoietic cell transplantation", "OBSERVATION", 129, 163], ["hematologic", "ANATOMY", 186, 197], ["malignancy", "OBSERVATION", 198, 208], ["profound", "OBSERVATION_MODIFIER", 219, 227], ["impairment", "OBSERVATION", 228, 238], ["cell", "OBSERVATION", 242, 246]]], ["As such they are at risk of lower respiratory tract infection from reactivation of latent infections, such as cytomegalovirus (CMV), and progression of community-acquired upper respiratory tract infections, such as respiratory syncytial virus (RSV) influenza A and B. The clinical presentation of these infections is varied, and diagnosis is often complicated by high rates of coinfection with bacterial, fungal, and other viral pathogens ( Table 1) .", [["lower respiratory tract", "ANATOMY", 28, 51], ["upper respiratory tract", "ANATOMY", 171, 194], ["respiratory tract infection", "DISEASE", 34, 61], ["infections", "DISEASE", 90, 100], ["cytomegalovirus (CMV)", "DISEASE", 110, 131], ["upper respiratory tract infections", "DISEASE", 171, 205], ["respiratory syncytial virus (RSV) influenza A", "DISEASE", 215, 260], ["infections", "DISEASE", 303, 313], ["coinfection", "DISEASE", 377, 388], ["bacterial, fungal, and other viral pathogens", "DISEASE", 394, 438], ["lower", "ORGANISM_SUBDIVISION", 28, 33], ["respiratory tract", "ORGANISM_SUBDIVISION", 34, 51], ["cytomegalovirus", "ORGANISM", 110, 125], ["CMV", "ORGANISM", 127, 130], ["upper", "ORGANISM_SUBDIVISION", 171, 176], ["respiratory tract", "ORGANISM_SUBDIVISION", 177, 194], ["respiratory syncytial virus", "ORGANISM", 215, 242], ["RSV", "ORGANISM", 244, 247], ["respiratory syncytial virus", "SPECIES", 215, 242], ["CMV", "SPECIES", 127, 130], ["respiratory syncytial virus", "SPECIES", 215, 242], ["RSV", "SPECIES", 244, 247], ["lower respiratory tract infection", "PROBLEM", 28, 61], ["latent infections", "PROBLEM", 83, 100], ["cytomegalovirus (CMV)", "PROBLEM", 110, 131], ["community-acquired upper respiratory tract infections", "PROBLEM", 152, 205], ["respiratory syncytial virus (RSV) influenza A", "PROBLEM", 215, 260], ["these infections", "PROBLEM", 297, 313], ["coinfection", "PROBLEM", 377, 388], ["bacterial, fungal", "PROBLEM", 394, 411], ["other viral pathogens", "PROBLEM", 417, 438], ["lower", "ANATOMY_MODIFIER", 28, 33], ["respiratory tract", "ANATOMY", 34, 51], ["infection", "OBSERVATION", 52, 61], ["latent", "OBSERVATION_MODIFIER", 83, 89], ["infections", "OBSERVATION", 90, 100], ["cytomegalovirus", "OBSERVATION", 110, 125], ["upper", "ANATOMY_MODIFIER", 171, 176], ["respiratory tract", "ANATOMY", 177, 194], ["infections", "OBSERVATION", 195, 205], ["respiratory", "ANATOMY", 215, 226], ["syncytial virus", "OBSERVATION", 227, 242], ["infections", "OBSERVATION", 303, 313], ["coinfection", "OBSERVATION", 377, 388]]], ["[1] [2] [3] [4] This article reviews the epidemiology of the major viral pathogens for pneumonia in patients with HCT/HM with discussion of evidence-based prevention strategies and treatments.ImagingComputed tomography (CT) is helpful in distinguishing between infectious and noninfectious causes of lung disease in this patient population and also between viral and fungal or bacterial infections.", [["lung", "ANATOMY", 300, 304], ["pneumonia", "DISEASE", 87, 96], ["lung disease", "DISEASE", 300, 312], ["viral and fungal or bacterial infections", "DISEASE", 357, 397], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 0, 15], ["patients", "ORGANISM", 100, 108], ["lung", "ORGAN", 300, 304], ["patient", "ORGANISM", 321, 328], ["patients", "SPECIES", 100, 108], ["patient", "SPECIES", 321, 328], ["the major viral pathogens", "PROBLEM", 57, 82], ["pneumonia", "PROBLEM", 87, 96], ["HCT/HM", "TREATMENT", 114, 120], ["based prevention strategies", "TREATMENT", 149, 176], ["treatments", "TREATMENT", 181, 191], ["ImagingComputed tomography", "TEST", 192, 218], ["CT", "TEST", 220, 222], ["lung disease", "PROBLEM", 300, 312], ["viral and fungal or bacterial infections", "PROBLEM", 357, 397], ["pneumonia", "OBSERVATION", 87, 96], ["infectious", "OBSERVATION", 261, 271], ["noninfectious", "OBSERVATION", 276, 289], ["lung", "ANATOMY", 300, 304], ["disease", "OBSERVATION", 305, 312], ["fungal", "OBSERVATION_MODIFIER", 367, 373], ["bacterial", "OBSERVATION_MODIFIER", 377, 386], ["infections", "OBSERVATION", 387, 397]]], ["5,6 Viral pneumonias are similar in appearance on CT often demonstrating small centrilobular nodules, patchy bilateral areas of ground glass opacities and consolidation, bronchial wall thickening, and tree-in-bud opacities (Fig. 1) .", [["centrilobular nodules", "ANATOMY", 79, 100], ["bronchial wall", "ANATOMY", 170, 184], ["bud", "ANATOMY", 209, 212], ["pneumonias", "DISEASE", 10, 20], ["Viral", "ORGANISM", 4, 9], ["centrilobular nodules", "PATHOLOGICAL_FORMATION", 79, 100], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 170, 184], ["Viral pneumonias", "PROBLEM", 4, 20], ["CT", "TEST", 50, 52], ["small centrilobular nodules", "PROBLEM", 73, 100], ["ground glass opacities", "PROBLEM", 128, 150], ["consolidation", "PROBLEM", 155, 168], ["bronchial wall thickening", "PROBLEM", 170, 195], ["tree", "TEST", 201, 205], ["bud opacities", "PROBLEM", 209, 222], ["Viral", "OBSERVATION_MODIFIER", 4, 9], ["pneumonias", "OBSERVATION", 10, 20], ["similar", "OBSERVATION_MODIFIER", 25, 32], ["small", "OBSERVATION_MODIFIER", 73, 78], ["centrilobular", "OBSERVATION_MODIFIER", 79, 92], ["nodules", "OBSERVATION", 93, 100], ["patchy", "OBSERVATION_MODIFIER", 102, 108], ["bilateral", "OBSERVATION_MODIFIER", 109, 118], ["areas", "OBSERVATION_MODIFIER", 119, 124], ["ground glass opacities", "OBSERVATION", 128, 150], ["consolidation", "OBSERVATION", 155, 168], ["bronchial", "ANATOMY", 170, 179], ["wall", "ANATOMY_MODIFIER", 180, 184], ["thickening", "OBSERVATION", 185, 195], ["tree", "OBSERVATION_MODIFIER", 201, 205], ["bud", "ANATOMY_MODIFIER", 209, 212], ["opacities", "OBSERVATION", 213, 222], ["Fig", "OBSERVATION_MODIFIER", 224, 227]]], ["If there is significant bronchiolitis, air trapping can also be evident.", [["bronchiolitis", "DISEASE", 24, 37], ["significant bronchiolitis", "PROBLEM", 12, 37], ["air trapping", "PROBLEM", 39, 51], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["bronchiolitis", "OBSERVATION", 24, 37], ["air trapping", "OBSERVATION", 39, 51], ["can also be evident", "UNCERTAINTY", 52, 71]]], ["[5] [6] [7] [8] [9] [10] Diagnostic SamplingImagingFiberoptic bronchoscopy with bronchoalveolar lavage is the predominant sampling method to confirm a diagnosis of viral pneumonia in the HCT/HM population.", [["bronchoalveolar lavage", "ANATOMY", 80, 102], ["viral pneumonia", "DISEASE", 164, 179], ["[5] [6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 18], ["HCT", "CANCER", 187, 190], ["Diagnostic SamplingImaging", "TEST", 25, 51], ["Fiberoptic bronchoscopy", "TEST", 51, 74], ["bronchoalveolar lavage", "TEST", 80, 102], ["viral pneumonia", "PROBLEM", 164, 179], ["the HCT/HM population", "TREATMENT", 183, 204], ["bronchoalveolar lavage", "OBSERVATION", 80, 102], ["viral", "OBSERVATION_MODIFIER", 164, 169], ["pneumonia", "OBSERVATION", 170, 179]]], ["Although sampling of the upper respiratory tract with nasopharyngeal aspirate/wash may provide an early identification of the involved virus or viruses, sampling of the lower tract is usually recommended to confirm the diagnosis and to exclude other copathogens.", [["upper respiratory tract", "ANATOMY", 25, 48], ["nasopharyngeal aspirate", "ANATOMY", 54, 77], ["lower tract", "ANATOMY", 169, 180], ["upper respiratory", "ORGANISM_SUBDIVISION", 25, 42], ["tract", "ORGANISM_SUBDIVISION", 43, 48], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 54, 77], ["lower tract", "ORGANISM_SUBDIVISION", 169, 180], ["sampling of the upper respiratory tract", "PROBLEM", 9, 48], ["nasopharyngeal aspirate/wash", "TREATMENT", 54, 82], ["the involved virus", "PROBLEM", 122, 140], ["viruses", "PROBLEM", 144, 151], ["sampling of the lower tract", "TEST", 153, 180], ["other copathogens", "PROBLEM", 244, 261], ["upper", "ANATOMY_MODIFIER", 25, 30], ["respiratory tract", "ANATOMY", 31, 48], ["nasopharyngeal", "ANATOMY", 54, 68], ["aspirate", "OBSERVATION", 69, 77], ["lower tract", "ANATOMY", 169, 180]]], ["Because of the risk of hemorrhage in these patients who often have thrombocytopenia, endobronchial biopsy is usually avoided.", [["endobronchial", "ANATOMY", 85, 98], ["hemorrhage", "DISEASE", 23, 33], ["thrombocytopenia", "DISEASE", 67, 83], ["patients", "ORGANISM", 43, 51], ["endobronchial biopsy", "MULTI-TISSUE_STRUCTURE", 85, 105], ["patients", "SPECIES", 43, 51], ["hemorrhage", "PROBLEM", 23, 33], ["thrombocytopenia", "PROBLEM", 67, 83], ["endobronchial biopsy", "TEST", 85, 105], ["hemorrhage", "OBSERVATION", 23, 33], ["thrombocytopenia", "OBSERVATION", 67, 83], ["endobronchial", "ANATOMY", 85, 98]]], ["Surgical lung biopsy, which was once the principle method by which lung abnormalities were evaluated after HCT, is now rarely performed.", [["lung", "ANATOMY", 9, 13], ["lung", "ANATOMY", 67, 71], ["lung abnormalities", "DISEASE", 67, 85], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 9, 20], ["lung", "ORGAN", 67, 71], ["Surgical lung biopsy", "TEST", 0, 20], ["lung abnormalities", "PROBLEM", 67, 85], ["HCT", "TEST", 107, 110], ["lung", "ANATOMY", 9, 13], ["biopsy", "OBSERVATION", 14, 20], ["lung", "ANATOMY", 67, 71], ["abnormalities", "OBSERVATION", 72, 85]]], ["11Virologic DiagnosisStandard viral cultures are of waning utility in the diagnosis of viral pneumonias because it can take up to 2 weeks to become positive and several more recently identified respiratory viruses, such as human metapneumovirus, coronaviruses, and bocavirus, are notoriously difficult to isolate in culture.", [["viral pneumonias", "DISEASE", 87, 103], ["respiratory viruses", "DISEASE", 194, 213], ["human metapneumovirus, coronaviruses", "DISEASE", 223, 259], ["human metapneumovirus", "ORGANISM", 223, 244], ["coronaviruses", "ORGANISM", 246, 259], ["human", "SPECIES", 223, 228], ["metapneumovirus", "SPECIES", 229, 244], ["human metapneumovirus", "SPECIES", 223, 244], ["Standard viral cultures", "TEST", 21, 44], ["viral pneumonias", "PROBLEM", 87, 103], ["positive", "PROBLEM", 148, 156], ["respiratory viruses", "PROBLEM", 194, 213], ["human metapneumovirus", "PROBLEM", 223, 244], ["coronaviruses", "PROBLEM", 246, 259], ["bocavirus", "PROBLEM", 265, 274], ["culture", "TEST", 316, 323], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["pneumonias", "OBSERVATION", 93, 103], ["respiratory viruses", "OBSERVATION", 194, 213], ["metapneumovirus", "OBSERVATION", 229, 244]]], ["For most viral pathogens, molecular methods of viral detection, such as direct or indirect fluorescent antibody tests or nucleic acid tests, can be used to give reliable results with a rapid turnaround time.", [["nucleic acid", "CHEMICAL", 121, 133], ["most viral pathogens", "PROBLEM", 4, 24], ["viral detection", "TEST", 47, 62], ["indirect fluorescent antibody tests", "TEST", 82, 117], ["nucleic acid tests", "TEST", 121, 139]]], ["Multiplex polymerase chain reaction (PCR) panels have the advantage of being able to test for multiple viruses at the same time and are more sensitive than fluorescent antibody tests.", [["Multiplex polymerase chain reaction", "PROBLEM", 0, 35], ["PCR) panels", "TEST", 37, 48], ["multiple viruses", "PROBLEM", 94, 110], ["fluorescent antibody tests", "TEST", 156, 182], ["chain", "OBSERVATION_MODIFIER", 21, 26]]], ["[12] [13] [14] [15] [16] [17] The diagnosis of CMV pneumonia, however, continues to rely on the use of standard viral or shell vial culture, histopathology, or immunohistochemical testing.", [["CMV pneumonia", "DISEASE", 47, 60], ["[12] [13] [14] [15] [16] [17", "SIMPLE_CHEMICAL", 0, 28], ["CMV", "ORGANISM", 47, 50], ["CMV", "SPECIES", 47, 50], ["CMV pneumonia", "PROBLEM", 47, 60], ["shell vial culture", "TEST", 121, 139], ["histopathology", "TEST", 141, 155], ["immunohistochemical testing", "TEST", 160, 187], ["CMV", "OBSERVATION", 47, 50], ["pneumonia", "OBSERVATION", 51, 60]]], ["18 The assumption has been that the CMV PCR tests would be too sensitive and have a low positive predictive value for CMV pneumonitis.", [["pneumonitis", "DISEASE", 122, 133], ["CMV", "ORGANISM", 36, 39], ["CMV", "ORGANISM", 118, 121], ["CMV", "SPECIES", 36, 39], ["CMV", "SPECIES", 118, 121], ["the CMV PCR tests", "TEST", 32, 49], ["a low positive predictive value", "PROBLEM", 82, 113], ["CMV pneumonitis", "PROBLEM", 118, 133], ["pneumonitis", "OBSERVATION", 122, 133]]], ["[19] [20] [21] [22] However, because of the operational advantages of PCR testing with much faster turnaround time, efforts are underway to estimate a quantitative CMV viral load threshold that would be more predictive of CMV pneumonitis rather than asymptomatic shedding.CYTOMEGALOVIRUS EpidemiologyCMV is the most common cause of viral pneumonia after allogeneic HCT.", [["pneumonitis", "DISEASE", 226, 237], ["pneumonia", "DISEASE", 338, 347], ["[19] [20] [21", "SIMPLE_CHEMICAL", 0, 13], ["CMV", "ORGANISM", 164, 167], ["CMV", "ORGANISM", 222, 225], ["HCT", "CANCER", 365, 368], ["CMV", "SPECIES", 164, 167], ["CMV", "SPECIES", 222, 225], ["PCR testing", "TEST", 70, 81], ["a quantitative CMV viral load threshold", "PROBLEM", 149, 188], ["CMV pneumonitis", "PROBLEM", 222, 237], ["asymptomatic shedding", "PROBLEM", 250, 271], ["CYTOMEGALOVIRUS EpidemiologyCMV", "PROBLEM", 272, 303], ["viral pneumonia", "PROBLEM", 332, 347], ["allogeneic HCT", "TEST", 354, 368], ["CMV pneumonitis", "OBSERVATION", 222, 237], ["most common", "OBSERVATION_MODIFIER", 311, 322], ["viral", "OBSERVATION_MODIFIER", 332, 337], ["pneumonia", "OBSERVATION", 338, 347]]], ["23-25 The development of ganciclovir resulted in significant improvements in the mortality associated with CMV pneumonia but with mortality rates still 60% to 80% focus shifted to prevention of disease.", [["ganciclovir", "CHEMICAL", 25, 36], ["pneumonia", "DISEASE", 111, 120], ["ganciclovir", "CHEMICAL", 25, 36], ["ganciclovir", "SIMPLE_CHEMICAL", 25, 36], ["CMV", "ORGANISM", 107, 110], ["CMV", "SPECIES", 107, 110], ["ganciclovir", "TREATMENT", 25, 36], ["CMV pneumonia", "PROBLEM", 107, 120], ["mortality rates", "TEST", 130, 145], ["disease", "PROBLEM", 194, 201], ["ganciclovir", "OBSERVATION", 25, 36], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["improvements", "OBSERVATION_MODIFIER", 61, 73], ["CMV pneumonia", "OBSERVATION", 107, 120], ["disease", "OBSERVATION", 194, 201]]], ["[26] [27] [28] [29] The use of ganciclovir for prophylaxis decreased the incidence of pneumonitis and other CMV end-organ disease, but was associated with increased rates of neutropenia and late-occurring disease (ie, after Day 100 posttransplant).", [["organ", "ANATOMY", 116, 121], ["ganciclovir", "CHEMICAL", 31, 42], ["pneumonitis", "DISEASE", 86, 97], ["CMV end-organ disease", "DISEASE", 108, 129], ["neutropenia", "DISEASE", 174, 185], ["ganciclovir", "CHEMICAL", 31, 42], ["[26] [27] [28] [29]", "SIMPLE_CHEMICAL", 0, 19], ["ganciclovir", "SIMPLE_CHEMICAL", 31, 42], ["CMV", "ORGANISM", 108, 111], ["organ", "ORGAN", 116, 121], ["CMV", "SPECIES", 108, 111], ["ganciclovir", "TREATMENT", 31, 42], ["prophylaxis", "TREATMENT", 47, 58], ["pneumonitis", "PROBLEM", 86, 97], ["other CMV end-organ disease", "PROBLEM", 102, 129], ["increased rates of neutropenia", "PROBLEM", 155, 185], ["late-occurring disease", "PROBLEM", 190, 212], ["pneumonitis", "OBSERVATION", 86, 97], ["CMV", "OBSERVATION", 108, 111], ["organ", "ANATOMY", 116, 121], ["disease", "OBSERVATION", 122, 129], ["neutropenia", "OBSERVATION", 174, 185]]], ["25, [30] [31] [32] [33] In the current era of preemptive therapy, where patients are monitored for CMV replication with either pp65 antigen or CMV DNA PCR in the blood or plasma and antiviral treatment is initiated before the development of CMV pneumonia, the incidence of CMV pneumonia is now only 1% to 3% in the early posttransplant period (100 days posttransplant).", [["blood", "ANATOMY", 162, 167], ["plasma", "ANATOMY", 171, 177], ["CMV pneumonia", "DISEASE", 241, 254], ["pneumonia", "DISEASE", 277, 286], ["[30] [31] [32", "SIMPLE_CHEMICAL", 4, 17], ["patients", "ORGANISM", 72, 80], ["CMV", "ORGANISM", 99, 102], ["pp65 antigen", "GENE_OR_GENE_PRODUCT", 127, 139], ["CMV", "ORGANISM", 143, 146], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["plasma", "ORGANISM_SUBSTANCE", 171, 177], ["CMV", "ORGANISM", 241, 244], ["CMV", "ORGANISM", 273, 276], ["pp65 antigen", "PROTEIN", 127, 139], ["patients", "SPECIES", 72, 80], ["CMV", "SPECIES", 99, 102], ["CMV", "SPECIES", 143, 146], ["CMV", "SPECIES", 241, 244], ["CMV", "SPECIES", 273, 276], ["preemptive therapy", "TREATMENT", 46, 64], ["CMV replication", "TREATMENT", 99, 114], ["pp65 antigen", "TEST", 127, 139], ["CMV DNA PCR", "TEST", 143, 154], ["the blood", "TEST", 158, 167], ["plasma", "TREATMENT", 171, 177], ["antiviral treatment", "TREATMENT", 182, 201], ["CMV pneumonia", "PROBLEM", 241, 254], ["CMV pneumonia", "PROBLEM", 273, 286], ["CMV pneumonia", "OBSERVATION", 241, 254], ["CMV pneumonia", "OBSERVATION", 273, 286]]], ["34-36 An additional 1% to 8% of patients develop CMV pneumonia within the first year after transplant.", [["pneumonia", "DISEASE", 53, 62], ["patients", "ORGANISM", 32, 40], ["CMV", "ORGANISM", 49, 52], ["patients", "SPECIES", 32, 40], ["CMV", "SPECIES", 49, 52], ["CMV pneumonia", "PROBLEM", 49, 62], ["transplant", "TREATMENT", 91, 101], ["CMV", "OBSERVATION", 49, 52], ["pneumonia", "OBSERVATION", 53, 62], ["transplant", "OBSERVATION", 91, 101]]], ["[36] [37] [38] Risk factors for development of CMV pneumonia after allogeneic HCT are CMV seropositivity, recipient of a cord blood graft, HLA-mismatched donors, myeloablative conditioning regimens, acute and chronic graft-versushost disease (GVHD), and use of T-cell-depleted stem cells.", [["cord blood", "ANATOMY", 121, 131], ["graft", "ANATOMY", 217, 222], ["T-cell", "ANATOMY", 261, 267], ["stem cells", "ANATOMY", 277, 287], ["pneumonia", "DISEASE", 51, 60], ["chronic graft-versushost disease", "DISEASE", 209, 241], ["GVHD", "DISEASE", 243, 247], ["CMV", "ORGANISM", 47, 50], ["HCT", "CANCER", 78, 81], ["CMV", "ORGANISM", 86, 89], ["cord blood", "MULTI-TISSUE_STRUCTURE", 121, 131], ["graft", "TISSUE", 132, 137], ["donors", "ORGANISM", 154, 160], ["graft", "TISSUE", 217, 222], ["T-cell", "CELL", 261, 267], ["stem cells", "CELL", 277, 287], ["T-cell-depleted stem cells", "CELL_TYPE", 261, 287], ["CMV", "SPECIES", 47, 50], ["CMV", "SPECIES", 86, 89], ["CMV pneumonia", "PROBLEM", 47, 60], ["allogeneic HCT", "TREATMENT", 67, 81], ["CMV seropositivity", "PROBLEM", 86, 104], ["a cord blood graft", "TREATMENT", 119, 137], ["mismatched donors", "TREATMENT", 143, 160], ["myeloablative conditioning regimens", "TREATMENT", 162, 197], ["acute and chronic graft-versushost disease", "PROBLEM", 199, 241], ["GVHD", "PROBLEM", 243, 247], ["depleted stem cells", "PROBLEM", 268, 287], ["CMV pneumonia", "OBSERVATION", 47, 60], ["cord blood", "ANATOMY", 121, 131], ["graft", "OBSERVATION", 132, 137], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["chronic", "OBSERVATION_MODIFIER", 209, 216], ["graft", "OBSERVATION", 217, 222], ["depleted stem cells", "OBSERVATION", 268, 287]]], ["34, 36, [39] [40] [41] [42] [43] CMV pneumonia is much less common in patients who have received an autologous transplant, or in patients receiving treatment of HM with incidence of 1% to 5% reported in the absence of surveillance and preemptive therapy.", [["34, 36, [39] [40] [41] [42]", "CHEMICAL", 0, 27], ["pneumonia", "DISEASE", 37, 46], ["HM", "DISEASE", 161, 163], ["[39] [40] [41] [42] [43]", "SIMPLE_CHEMICAL", 8, 32], ["CMV", "ORGANISM", 33, 36], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 129, 137], ["CMV pneumonia", "PROBLEM", 33, 46], ["an autologous transplant", "TREATMENT", 97, 121], ["treatment of HM", "TREATMENT", 148, 163], ["surveillance", "TEST", 218, 230], ["preemptive therapy", "TREATMENT", 235, 253], ["pneumonia", "OBSERVATION", 37, 46], ["less common", "OBSERVATION_MODIFIER", 55, 66], ["transplant", "OBSERVATION", 111, 121]]], ["[44] [45] [46] [47] [48] Treatment Ganciclovir (5 mg/kg intravenous [IV] every 12 hours) remains the first-line treatment for CMV pneumonitis.", [["[44] [45] [46] [47]", "CHEMICAL", 0, 19], ["Ganciclovir", "CHEMICAL", 35, 46], ["CMV pneumonitis", "DISEASE", 126, 141], ["Ganciclovir", "CHEMICAL", 35, 46], ["[44] [45] [46] [47] [48]", "SIMPLE_CHEMICAL", 0, 24], ["Ganciclovir", "SIMPLE_CHEMICAL", 35, 46], ["CMV", "ORGANISM", 126, 129], ["CMV", "SPECIES", 126, 129], ["Treatment Ganciclovir", "TREATMENT", 25, 46], ["the first-line treatment", "TREATMENT", 97, 121], ["CMV pneumonitis", "PROBLEM", 126, 141], ["CMV pneumonitis", "OBSERVATION", 126, 141]]], ["49 Based on the results of three nonrandomized studies, 50-52 CMV immunoglobulin was often recommended as adjunctive treatment.", [["CMV", "ORGANISM", 62, 65], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 66, 80], ["CMV immunoglobulin", "PROTEIN", 62, 80], ["CMV", "SPECIES", 62, 65], ["three nonrandomized studies", "TEST", 27, 54], ["CMV immunoglobulin", "TEST", 62, 80], ["adjunctive treatment", "TREATMENT", 106, 126]]], ["However, more recent analyses have called into question the additional benefit of this therapy.", [["this therapy", "TREATMENT", 82, 94]]], ["29,47,53,54 Duration of treatment is generally induction therapy for 21 to 28 days, followed by 21 to 28 days of maintenance therapy (ganciclovir, 5 mg/kg IV every 24 hours).", [["ganciclovir", "CHEMICAL", 134, 145], ["ganciclovir", "CHEMICAL", 134, 145], ["ganciclovir", "SIMPLE_CHEMICAL", 134, 145], ["treatment", "TREATMENT", 24, 33], ["generally induction therapy", "TREATMENT", 37, 64], ["maintenance therapy (ganciclovir", "TREATMENT", 113, 145]]], ["Foscarnet (90 mg/kg IV every 12 hours) may be used in the setting of neutropenia because it is associated with less bone marrow suppression than ganciclovir, but commonly causes significant nephrotoxicity.", [["bone marrow", "ANATOMY", 116, 127], ["Foscarnet", "CHEMICAL", 0, 9], ["neutropenia", "DISEASE", 69, 80], ["bone marrow suppression", "DISEASE", 116, 139], ["ganciclovir", "CHEMICAL", 145, 156], ["nephrotoxicity", "DISEASE", 190, 204], ["Foscarnet", "CHEMICAL", 0, 9], ["ganciclovir", "CHEMICAL", 145, 156], ["Foscarnet", "SIMPLE_CHEMICAL", 0, 9], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 116, 127], ["ganciclovir", "SIMPLE_CHEMICAL", 145, 156], ["Foscarnet", "TREATMENT", 0, 9], ["neutropenia", "PROBLEM", 69, 80], ["less bone marrow suppression", "PROBLEM", 111, 139], ["ganciclovir", "TREATMENT", 145, 156], ["significant nephrotoxicity", "PROBLEM", 178, 204], ["neutropenia", "OBSERVATION", 69, 80], ["significant", "OBSERVATION_MODIFIER", 178, 189], ["nephrotoxicity", "OBSERVATION", 190, 204]]], ["Antiviral resistance mutations have been identified in the viral encoded UL97 kinase, required only by ganciclovir, and the viral DNA polymerase, the target of ganciclovir, foscarnet, and cidofovir.", [["ganciclovir", "CHEMICAL", 103, 114], ["ganciclovir", "CHEMICAL", 160, 171], ["foscarnet", "CHEMICAL", 173, 182], ["cidofovir", "CHEMICAL", 188, 197], ["ganciclovir", "CHEMICAL", 103, 114], ["ganciclovir", "CHEMICAL", 160, 171], ["foscarnet", "CHEMICAL", 173, 182], ["cidofovir", "CHEMICAL", 188, 197], ["UL97", "GENE_OR_GENE_PRODUCT", 73, 77], ["ganciclovir", "SIMPLE_CHEMICAL", 103, 114], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["ganciclovir", "SIMPLE_CHEMICAL", 160, 171], ["foscarnet", "SIMPLE_CHEMICAL", 173, 182], ["cidofovir", "SIMPLE_CHEMICAL", 188, 197], ["viral encoded UL97 kinase", "PROTEIN", 59, 84], ["viral DNA polymerase", "PROTEIN", 124, 144], ["Antiviral resistance mutations", "PROBLEM", 0, 30], ["the viral encoded UL97 kinase", "TEST", 55, 84], ["ganciclovir", "TREATMENT", 103, 114], ["the viral DNA polymerase", "TEST", 120, 144], ["ganciclovir", "TREATMENT", 160, 171], ["foscarnet", "TREATMENT", 173, 182], ["cidofovir", "TREATMENT", 188, 197]]], ["55 Fortunately, antiviral resistance is a rare occurrence in patients with HCT/HM occurring in 0% to 4% of patients with CMV reactivation.", [["HCT/HM", "DISEASE", 75, 81], ["patients", "ORGANISM", 61, 69], ["HCT", "CANCER", 75, 78], ["patients", "ORGANISM", 107, 115], ["CMV", "ORGANISM", 121, 124], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 107, 115], ["CMV", "SPECIES", 121, 124], ["HCT/HM", "PROBLEM", 75, 81], ["CMV reactivation", "PROBLEM", 121, 137], ["antiviral resistance", "OBSERVATION", 16, 36], ["CMV reactivation", "OBSERVATION", 121, 137]]], ["56-58 Foscarnet, cidofovir, and brincidofovir (an oral nucleotide analogue and prodrug of cidofovir) could be used for treatment of resistant CMV caused by UL97 mutations.", [["oral", "ANATOMY", 50, 54], ["56-58 Foscarnet", "CHEMICAL", 0, 15], ["cidofovir", "CHEMICAL", 17, 26], ["brincidofovir", "CHEMICAL", 32, 45], ["nucleotide", "CHEMICAL", 55, 65], ["cidofovir", "CHEMICAL", 90, 99], ["cidofovir", "CHEMICAL", 17, 26], ["brincidofovir", "CHEMICAL", 32, 45], ["nucleotide", "CHEMICAL", 55, 65], ["cidofovir", "CHEMICAL", 90, 99], ["Foscarnet", "SIMPLE_CHEMICAL", 6, 15], ["cidofovir", "SIMPLE_CHEMICAL", 17, 26], ["brincidofovir", "SIMPLE_CHEMICAL", 32, 45], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["prodrug", "SIMPLE_CHEMICAL", 79, 86], ["cidofovir", "SIMPLE_CHEMICAL", 90, 99], ["CMV", "ORGANISM", 142, 145], ["UL97", "GENE_OR_GENE_PRODUCT", 156, 160], ["CMV", "SPECIES", 142, 145], ["Foscarnet", "TREATMENT", 6, 15], ["cidofovir", "TREATMENT", 17, 26], ["brincidofovir", "TREATMENT", 32, 45], ["an oral nucleotide analogue", "TREATMENT", 47, 74], ["prodrug of cidofovir)", "TREATMENT", 79, 100], ["resistant CMV", "PROBLEM", 132, 145], ["UL97 mutations", "PROBLEM", 156, 170], ["UL97 mutations", "OBSERVATION", 156, 170]]], ["Maribavir and letermovir, two agents currently undergoing clinical trials, have distinct mechanisms of action that may make them useful for treatment of resistant CMV disease; however, little is known of their genetic barrier to resistance.", [["Maribavir", "CHEMICAL", 0, 9], ["letermovir", "CHEMICAL", 14, 24], ["CMV disease", "DISEASE", 163, 174], ["Maribavir", "CHEMICAL", 0, 9], ["letermovir", "CHEMICAL", 14, 24], ["Maribavir", "SIMPLE_CHEMICAL", 0, 9], ["letermovir", "SIMPLE_CHEMICAL", 14, 24], ["CMV", "ORGANISM", 163, 166], ["CMV", "SPECIES", 163, 166], ["Maribavir", "TREATMENT", 0, 9], ["letermovir", "TREATMENT", 14, 24], ["clinical trials", "TREATMENT", 58, 73], ["resistant CMV disease", "PROBLEM", 153, 174], ["CMV disease", "OBSERVATION", 163, 174]]], ["59-62Other HerpesvirusesReactivation of latent varicella zoster virus and herpes simplex virus in immunocompromised patients can result in disseminated disease with pneumonia and was a significant clinical problem for patients with HCT/HM.", [["varicella zoster", "DISEASE", 47, 63], ["herpes simplex virus", "DISEASE", 74, 94], ["pneumonia", "DISEASE", 165, 174], ["HCT/HM", "DISEASE", 232, 238], ["latent", "ORGANISM", 40, 46], ["varicella zoster virus", "ORGANISM", 47, 69], ["herpes simplex virus", "ORGANISM", 74, 94], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 218, 226], ["varicella zoster virus", "SPECIES", 47, 69], ["herpes simplex virus", "SPECIES", 74, 94], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 218, 226], ["varicella zoster virus", "SPECIES", 47, 69], ["herpes simplex virus", "SPECIES", 74, 94], ["latent varicella zoster virus", "PROBLEM", 40, 69], ["herpes simplex virus", "PROBLEM", 74, 94], ["disseminated disease", "PROBLEM", 139, 159], ["pneumonia", "PROBLEM", 165, 174], ["a significant clinical problem", "PROBLEM", 183, 213], ["HCT/HM", "PROBLEM", 232, 238], ["latent", "OBSERVATION_MODIFIER", 40, 46], ["varicella zoster virus", "OBSERVATION", 47, 69], ["herpes simplex virus", "OBSERVATION", 74, 94], ["disseminated", "OBSERVATION_MODIFIER", 139, 151], ["disease", "OBSERVATION", 152, 159], ["pneumonia", "OBSERVATION", 165, 174]]], ["63,64 Long-term prophylaxis with acyclovir or valacyclovir has been the standard of care for more than a decade.", [["acyclovir", "CHEMICAL", 33, 42], ["valacyclovir", "CHEMICAL", 46, 58], ["acyclovir", "CHEMICAL", 33, 42], ["valacyclovir", "CHEMICAL", 46, 58], ["acyclovir", "SIMPLE_CHEMICAL", 33, 42], ["valacyclovir", "SIMPLE_CHEMICAL", 46, 58], ["Long-term prophylaxis", "TREATMENT", 6, 27], ["acyclovir", "TREATMENT", 33, 42], ["valacyclovir", "TREATMENT", 46, 58]]], ["65-68 Cases still rarely occur in patients who have discontinued acyclovir prophylaxis, but generally respond well to high-dose parenteral acyclovir.", [["acyclovir", "CHEMICAL", 65, 74], ["acyclovir", "CHEMICAL", 139, 148], ["acyclovir", "CHEMICAL", 65, 74], ["acyclovir", "CHEMICAL", 139, 148], ["patients", "ORGANISM", 34, 42], ["acyclovir", "SIMPLE_CHEMICAL", 65, 74], ["acyclovir", "SIMPLE_CHEMICAL", 139, 148], ["patients", "SPECIES", 34, 42], ["acyclovir prophylaxis", "TREATMENT", 65, 86], ["high-dose parenteral acyclovir", "TREATMENT", 118, 148]]], ["69-71COMMUNITY RESPIRATORY VIRUSESCRVs are a common cause of infection in patients with HCT/HM; however, the risk of pneumonia varies by virus type and patient risk factors.", [["infection", "DISEASE", 61, 70], ["HCT/HM", "DISEASE", 88, 94], ["pneumonia", "DISEASE", 117, 126], ["patients", "ORGANISM", 74, 82], ["patient", "ORGANISM", 152, 159], ["patients", "SPECIES", 74, 82], ["patient", "SPECIES", 152, 159], ["infection", "PROBLEM", 61, 70], ["HCT/HM", "PROBLEM", 88, 94], ["pneumonia varies", "PROBLEM", 117, 133], ["virus type and patient risk factors", "PROBLEM", 137, 172], ["RESPIRATORY VIRUSESCRVs", "OBSERVATION", 15, 38], ["infection", "OBSERVATION", 61, 70], ["pneumonia", "OBSERVATION", 117, 126]]], ["Several of the viruses, such as influenza and RSV, have significant seasonal variation of incidence, whereas others, such as parainfluenza virus (PIV) and adenovirus, tend to cause disease year round.", [["influenza and RSV", "DISEASE", 32, 49], ["parainfluenza virus", "DISEASE", 125, 144], ["RSV", "ORGANISM", 46, 49], ["parainfluenza virus", "ORGANISM", 125, 144], ["adenovirus", "ORGANISM", 155, 165], ["RSV", "SPECIES", 46, 49], ["parainfluenza virus", "SPECIES", 125, 144], ["RSV", "SPECIES", 46, 49], ["parainfluenza virus", "SPECIES", 125, 144], ["PIV", "SPECIES", 146, 149], ["adenovirus", "SPECIES", 155, 165], ["the viruses", "PROBLEM", 11, 22], ["influenza", "PROBLEM", 32, 41], ["RSV", "PROBLEM", 46, 49], ["parainfluenza virus (PIV)", "TREATMENT", 125, 150], ["adenovirus", "PROBLEM", 155, 165], ["viruses", "OBSERVATION", 15, 22]]], ["Outbreaks on oncology and HCT hospital wards and ambulatory clinics have been described for many of these viruses, 72-76 emphasizing the importance of infection-prevention policies and procedures that can prevent the transmission of viruses among highly susceptible patients.", [["infection", "DISEASE", 151, 160], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["these viruses", "PROBLEM", 100, 113], ["infection-prevention policies", "TREATMENT", 151, 180], ["procedures", "TREATMENT", 185, 195], ["viruses", "PROBLEM", 233, 240], ["infection", "OBSERVATION", 151, 160]]], ["This is particularly challenging with this patient population because of prolonged viral shedding, which often lasts weeks or months.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["prolonged viral shedding", "PROBLEM", 73, 97], ["prolonged", "OBSERVATION_MODIFIER", 73, 82], ["viral", "OBSERVATION", 83, 88]]], ["[77] [78] [79] Influenza Influenza is diagnosed in approximately 1% of patients with HCT/HM during treatment, and in 33% of patients presenting with respiratory virus symptoms.", [["Influenza", "DISEASE", 25, 34], ["HCT/HM", "DISEASE", 85, 91], ["respiratory virus symptoms", "DISEASE", 149, 175], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 124, 132], ["Influenza Influenza", "PROBLEM", 15, 34], ["HCT", "TEST", 85, 88], ["treatment", "TREATMENT", 99, 108], ["respiratory virus symptoms", "PROBLEM", 149, 175], ["respiratory", "ANATOMY", 149, 160], ["virus", "OBSERVATION", 161, 166]]], ["80-82 Progression to pneumonia occurs in 14% to 30% of patients and is associated with mortality rates of 15% to 28%.", [["pneumonia", "DISEASE", 21, 30], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["pneumonia", "PROBLEM", 21, 30], ["mortality rates", "TEST", 87, 102], ["pneumonia", "OBSERVATION", 21, 30]]], ["80-83 During the 2009 H1N1 influenza pandemic, rates of pneumonia were much higher (>50%), but mortality was similar.", [["influenza pandemic", "DISEASE", 27, 45], ["pneumonia", "DISEASE", 56, 65], ["H1N1 influenza pandemic", "SPECIES", 22, 45], ["H1N1 influenza pandemic", "PROBLEM", 22, 45], ["pneumonia", "PROBLEM", 56, 65], ["pneumonia", "OBSERVATION", 56, 65]]], ["84 Risk factors for development of pneumonia include lymphopenia (<100 cells/mL), neutropenia (<500 cells/mL), steroid use at time of diagnosis, and absence of antiviral treatment.", [["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 100, 105], ["pneumonia", "DISEASE", 35, 44], ["lymphopenia", "DISEASE", 53, 64], ["neutropenia", "DISEASE", 82, 93], ["steroid", "CHEMICAL", 111, 118], ["steroid", "CHEMICAL", 111, 118], ["steroid", "SIMPLE_CHEMICAL", 111, 118], ["pneumonia", "PROBLEM", 35, 44], ["lymphopenia", "PROBLEM", 53, 64], ["neutropenia", "PROBLEM", 82, 93], ["steroid use", "TREATMENT", 111, 122], ["antiviral treatment", "TREATMENT", 160, 179], ["pneumonia", "OBSERVATION", 35, 44], ["lymphopenia", "OBSERVATION", 53, 64], ["antiviral treatment", "OBSERVATION", 160, 179]]], ["80,81, 83, 84 Neuraminidase inhibitors, primarily oseltamivir, are currently the standard of care for influenza treatment and postexposure prophylaxis.", [["oseltamivir", "CHEMICAL", 50, 61], ["influenza", "DISEASE", 102, 111], ["oseltamivir", "CHEMICAL", 50, 61], ["Neuraminidase inhibitors", "SIMPLE_CHEMICAL", 14, 38], ["oseltamivir", "SIMPLE_CHEMICAL", 50, 61], ["Neuraminidase inhibitors", "TREATMENT", 14, 38], ["oseltamivir", "TREATMENT", 50, 61], ["influenza treatment", "TREATMENT", 102, 121], ["postexposure prophylaxis", "TREATMENT", 126, 150]]], ["Oseltamivir resistance has been described but remains uncommon.", [["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "CHEMICAL", 0, 11], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["Oseltamivir resistance", "TREATMENT", 0, 22]]], ["[85] [86] [87] [88] In the setting of documented or suspected oseltamivir resistance, or in patients who have impaired enteric absorption, inhaled zanamivir or the newly licensed parenteral peramivir have been used.", [["oseltamivir", "CHEMICAL", 62, 73], ["impaired enteric absorption", "DISEASE", 110, 137], ["zanamivir", "CHEMICAL", 147, 156], ["peramivir", "CHEMICAL", 190, 199], ["oseltamivir", "CHEMICAL", 62, 73], ["zanamivir", "CHEMICAL", 147, 156], ["peramivir", "CHEMICAL", 190, 199], ["[85] [86] [87", "SIMPLE_CHEMICAL", 0, 13], ["patients", "ORGANISM", 92, 100], ["zanamivir", "SIMPLE_CHEMICAL", 147, 156], ["peramivir", "SIMPLE_CHEMICAL", 190, 199], ["patients", "SPECIES", 92, 100], ["suspected oseltamivir resistance", "PROBLEM", 52, 84], ["impaired enteric absorption", "PROBLEM", 110, 137], ["inhaled zanamivir", "TREATMENT", 139, 156], ["the newly licensed parenteral peramivir", "TREATMENT", 160, 199], ["oseltamivir resistance", "OBSERVATION", 62, 84], ["enteric absorption", "OBSERVATION", 119, 137]]], ["[89] [90] [91] Seasonal vaccination with the trivalent inactivated vaccine is recommended for all health care workers caring for patients with HCT/HM, family members, and household contacts.", [["trivalent", "CHEMICAL", 45, 54], ["HCT/HM", "DISEASE", 143, 149], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["Seasonal vaccination", "TREATMENT", 15, 35], ["the trivalent inactivated vaccine", "TREATMENT", 41, 74]]], ["Additionally, it is recommended that patients undergoing treatment of leukemia and lymphoma are vaccinated because it may reduce the risk of hospitalization for respiratory illness.", [["leukemia", "ANATOMY", 70, 78], ["lymphoma", "ANATOMY", 83, 91], ["respiratory", "ANATOMY", 161, 172], ["leukemia", "DISEASE", 70, 78], ["lymphoma", "DISEASE", 83, 91], ["respiratory illness", "DISEASE", 161, 180], ["patients", "ORGANISM", 37, 45], ["leukemia", "CANCER", 70, 78], ["lymphoma", "CANCER", 83, 91], ["patients", "SPECIES", 37, 45], ["treatment", "TREATMENT", 57, 66], ["leukemia", "PROBLEM", 70, 78], ["lymphoma", "PROBLEM", 83, 91], ["respiratory illness", "PROBLEM", 161, 180], ["leukemia", "OBSERVATION", 70, 78], ["lymphoma", "OBSERVATION", 83, 91]]], ["[92] [93] [94] [95] Ideally, vaccine should be administered at least 2 weeks before any cytotoxic therapy.", [["[92] [93] [94] [95]", "SIMPLE_CHEMICAL", 0, 19], ["vaccine", "TREATMENT", 29, 36], ["any cytotoxic therapy", "TREATMENT", 84, 105]]], ["For HCT recipients, vaccination of patients less than 6 months after transplant is ineffective and is generally not recommended.", [["HCT", "ANATOMY", 4, 7], ["HCT", "CANCER", 4, 7], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["HCT recipients", "TREATMENT", 4, 18], ["vaccination", "TREATMENT", 20, 31], ["transplant", "TREATMENT", 69, 79]]], ["66,95,96 Chemoprophylaxis after exposure is recommended for patients with HCT within 1 year of transplant or for patients with HM during chemotherapy.", [["HCT", "DISEASE", 74, 77], ["HM", "DISEASE", 127, 129], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 113, 121], ["Chemoprophylaxis", "TREATMENT", 9, 25], ["HCT", "TEST", 74, 77], ["transplant", "TREATMENT", 95, 105], ["HM", "PROBLEM", 127, 129], ["chemotherapy", "TREATMENT", 137, 149]]], ["66,97Respiratory Syncytial VirusInfection with RSV is more common than influenza, occurring in 7% to 10% of patients undergoing allogeneic HCT.", [["Respiratory Syncytial VirusInfection", "DISEASE", 5, 41], ["RSV", "DISEASE", 47, 50], ["influenza", "DISEASE", 71, 80], ["RSV", "ORGANISM", 47, 50], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["RSV", "SPECIES", 47, 50], ["Respiratory Syncytial VirusInfection", "PROBLEM", 5, 41], ["RSV", "PROBLEM", 47, 50], ["influenza", "PROBLEM", 71, 80], ["allogeneic HCT", "TEST", 128, 142], ["Syncytial VirusInfection", "OBSERVATION", 17, 41], ["RSV", "OBSERVATION", 47, 50], ["more common", "OBSERVATION_MODIFIER", 54, 65]]], ["98, 99 Among patients with HCT/HM presenting with viral respiratory symptoms, RSV is diagnosed in 14% to 30%.", [["respiratory", "ANATOMY", 56, 67], ["HCT/HM", "DISEASE", 27, 33], ["viral respiratory symptoms", "DISEASE", 50, 76], ["RSV", "DISEASE", 78, 81], ["patients", "ORGANISM", 13, 21], ["RSV", "ORGANISM", 78, 81], ["patients", "SPECIES", 13, 21], ["RSV", "SPECIES", 78, 81], ["HCT/HM", "PROBLEM", 27, 33], ["viral respiratory symptoms", "PROBLEM", 50, 76], ["RSV", "PROBLEM", 78, 81]]], ["81, 99 Involvement of the lower respiratory tract occurs in 40% to 75% of infected patients.", [["lower respiratory tract", "ANATOMY", 26, 49], ["lower respiratory", "ORGANISM_SUBDIVISION", 26, 43], ["tract", "ORGANISM_SUBDIVISION", 44, 49], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["the lower respiratory tract", "PROBLEM", 22, 49], ["lower", "ANATOMY_MODIFIER", 26, 31], ["respiratory tract", "ANATOMY", 32, 49], ["infected", "OBSERVATION", 74, 82]]], ["81,98,99 Risk factors for progression to pneumonia include patient age, allogeneic HCT, mismatched or unrelated donor, GVHD, myeloablative conditioning regimens, infection less than 30 days posttransplant, prolonged lymphopenia, and lack of ribavirin-based therapy.", [["pneumonia", "DISEASE", 41, 50], ["GVHD", "DISEASE", 119, 123], ["infection", "DISEASE", 162, 171], ["lymphopenia", "DISEASE", 216, 227], ["ribavirin", "CHEMICAL", 241, 250], ["ribavirin", "CHEMICAL", 241, 250], ["patient", "ORGANISM", 59, 66], ["ribavirin", "SIMPLE_CHEMICAL", 241, 250], ["patient", "SPECIES", 59, 66], ["Risk factors", "PROBLEM", 9, 21], ["progression", "PROBLEM", 26, 37], ["pneumonia", "PROBLEM", 41, 50], ["allogeneic HCT", "PROBLEM", 72, 86], ["unrelated donor", "TREATMENT", 102, 117], ["GVHD", "TREATMENT", 119, 123], ["myeloablative conditioning regimens", "TREATMENT", 125, 160], ["infection", "PROBLEM", 162, 171], ["prolonged lymphopenia", "PROBLEM", 206, 227], ["ribavirin", "TREATMENT", 241, 250], ["based therapy", "TREATMENT", 251, 264], ["pneumonia", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 162, 171], ["prolonged", "OBSERVATION_MODIFIER", 206, 215], ["lymphopenia", "OBSERVATION", 216, 227]]], ["81,98-101 RSV pneumonia is associated with mortality rates of 28% to 55%.", [["pneumonia", "DISEASE", 14, 23], ["RSV", "ORGANISM", 10, 13], ["RSV", "SPECIES", 10, 13], ["RSV pneumonia", "PROBLEM", 10, 23], ["mortality rates", "TEST", 43, 58], ["RSV", "OBSERVATION_MODIFIER", 10, 13], ["pneumonia", "OBSERVATION", 14, 23]]], ["100, 102, 103 Treatment with inhaled ribavirin has been shown in several retrospective studies to be associated with decreased rates of progression and a 67% to 83% reduction in the risk of mortality after RSV infection.", [["ribavirin", "CHEMICAL", 37, 46], ["RSV infection", "DISEASE", 206, 219], ["ribavirin", "CHEMICAL", 37, 46], ["ribavirin", "SIMPLE_CHEMICAL", 37, 46], ["RSV", "ORGANISM", 206, 209], ["RSV", "SPECIES", 206, 209], ["Treatment", "TREATMENT", 14, 23], ["inhaled ribavirin", "TREATMENT", 29, 46], ["decreased rates of progression", "PROBLEM", 117, 147], ["RSV infection", "PROBLEM", 206, 219], ["progression", "OBSERVATION_MODIFIER", 136, 147], ["infection", "OBSERVATION", 210, 219]]], ["100, 102 Based on these data, many centers use inhaled ribavirin (2 g for 2 hours every 8 hours for 10 days) in select, high-risk patient populations.", [["ribavirin", "CHEMICAL", 55, 64], ["ribavirin", "CHEMICAL", 55, 64], ["ribavirin", "SIMPLE_CHEMICAL", 55, 64], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["these data", "TEST", 18, 28], ["inhaled ribavirin", "TREATMENT", 47, 64]]], ["66,104 However, because of recent increases in the cost of this formulation, the use of systemic (oral or parenteral) ribavirin is increasing despite a paucity of evidence to support this practice.", [["oral", "ANATOMY", 98, 102], ["ribavirin", "CHEMICAL", 118, 127], ["ribavirin", "CHEMICAL", 118, 127], ["oral", "ORGANISM_SUBDIVISION", 98, 102], ["this formulation", "TREATMENT", 59, 75], ["systemic (oral or parenteral) ribavirin", "TREATMENT", 88, 127], ["this practice", "TREATMENT", 183, 196], ["increases", "OBSERVATION_MODIFIER", 34, 43]]], ["102, 105, 106 There are a few noteworthy agents with novel mechanisms of action that are currently in trial: GS5806, an oral RSV entry inhibitor; and ALS8176, a nucleoside RSV polymerase inhibitor.", [["oral", "ANATOMY", 120, 124], ["GS5806", "CHEMICAL", 109, 115], ["ALS8176", "CHEMICAL", 150, 157], ["nucleoside", "CHEMICAL", 161, 171], ["ALS8176", "CHEMICAL", 150, 157], ["nucleoside", "CHEMICAL", 161, 171], ["GS5806", "SIMPLE_CHEMICAL", 109, 115], ["oral", "ORGANISM_SUBDIVISION", 120, 124], ["RSV", "ORGANISM", 125, 128], ["ALS8176", "SIMPLE_CHEMICAL", 150, 157], ["RSV", "SPECIES", 125, 128], ["RSV", "SPECIES", 172, 175], ["GS", "TEST", 109, 111], ["a nucleoside RSV polymerase inhibitor", "TREATMENT", 159, 196], ["few", "OBSERVATION_MODIFIER", 26, 29]]], ["107, 108 Finally, pneumonia caused by RSV has been associated with a significant airflow decline by 1 year posttransplant, an important long-term sequela of this common infection.", [["pneumonia", "DISEASE", 18, 27], ["RSV", "DISEASE", 38, 41], ["infection", "DISEASE", 169, 178], ["RSV", "ORGANISM", 38, 41], ["RSV", "SPECIES", 38, 41], ["pneumonia", "PROBLEM", 18, 27], ["RSV", "PROBLEM", 38, 41], ["a significant airflow decline", "PROBLEM", 67, 96], ["this common infection", "PROBLEM", 157, 178], ["pneumonia", "OBSERVATION", 18, 27], ["RSV", "OBSERVATION", 38, 41], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["airflow", "OBSERVATION", 81, 88], ["long-term sequela", "OBSERVATION_MODIFIER", 136, 153], ["common", "OBSERVATION_MODIFIER", 162, 168], ["infection", "OBSERVATION", 169, 178]]], ["109Parainfluenza VirusUnlike influenza and RSV, PIV infections occur without much seasonal variation.", [["influenza", "DISEASE", 29, 38], ["PIV infections", "DISEASE", 48, 62], ["Parainfluenza VirusUnlike influenza", "ORGANISM", 3, 38], ["RSV", "ORGANISM", 43, 46], ["influenza", "SPECIES", 29, 38], ["RSV", "SPECIES", 43, 46], ["RSV", "SPECIES", 43, 46], ["PIV", "SPECIES", 48, 51], ["Parainfluenza VirusUnlike influenza", "PROBLEM", 3, 38], ["RSV", "PROBLEM", 43, 46], ["PIV infections", "PROBLEM", 48, 62], ["infections", "OBSERVATION", 52, 62]]], ["The incidence of PIV infection in patients with HCT/HM is 1% to 10%, and 30% of infected patients develop pneumonia; most cases are caused by PIV type 3.", [["PIV infection", "DISEASE", 17, 30], ["HCT/HM", "DISEASE", 48, 54], ["infected", "DISEASE", 80, 88], ["pneumonia", "DISEASE", 106, 115], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 89, 97], ["PIV", "SPECIES", 17, 20], ["PIV infection", "PROBLEM", 17, 30], ["HCT/HM", "TEST", 48, 54], ["pneumonia", "PROBLEM", 106, 115], ["PIV", "ANATOMY", 17, 20], ["infection", "OBSERVATION", 21, 30], ["pneumonia", "OBSERVATION", 106, 115], ["PIV type", "OBSERVATION", 142, 150]]], ["[110] [111] [112] [113] Death occurs in 17% to 46% of patients who develop pneumonia.", [["Death", "DISEASE", 24, 29], ["pneumonia", "DISEASE", 75, 84], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["pneumonia", "PROBLEM", 75, 84], ["pneumonia", "OBSERVATION", 75, 84]]], ["110, 112, 113 Risk factors for development of pneumonia include high-dose corticosteroid use, lymphopenia, neutropenia, infection occurring early posttransplantation, the presence of copathogens, and a higher Acute Physiology and Chronic Health Evaluation II score.", [["pneumonia", "DISEASE", 46, 55], ["lymphopenia", "DISEASE", 94, 105], ["neutropenia", "DISEASE", 107, 118], ["infection", "DISEASE", 120, 129], ["Acute Physiology and Chronic Health Evaluation II", "DISEASE", 209, 258], ["pneumonia", "PROBLEM", 46, 55], ["high-dose corticosteroid use", "TREATMENT", 64, 92], ["lymphopenia", "PROBLEM", 94, 105], ["neutropenia", "PROBLEM", 107, 118], ["infection", "PROBLEM", 120, 129], ["copathogens", "PROBLEM", 183, 194], ["a higher Acute Physiology", "PROBLEM", 200, 225], ["pneumonia", "OBSERVATION", 46, 55], ["lymphopenia", "OBSERVATION", 94, 105], ["neutropenia", "OBSERVATION", 107, 118], ["infection", "OBSERVATION", 120, 129], ["higher", "OBSERVATION_MODIFIER", 202, 208], ["Acute", "OBSERVATION_MODIFIER", 209, 214], ["Chronic", "OBSERVATION_MODIFIER", 230, 237]]], ["110, 113, 114 There are currently no licensed treatments for PIV pneumonia.", [["pneumonia", "DISEASE", 65, 74], ["licensed treatments", "TREATMENT", 37, 56], ["PIV pneumonia", "PROBLEM", 61, 74], ["no", "UNCERTAINTY", 34, 36], ["pneumonia", "OBSERVATION", 65, 74]]], ["Ribavirin has been used with little noted improvement in mortality or clinical response.", [["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["Ribavirin", "TREATMENT", 0, 9]]], ["110,114 DAS181, an investigational sialidase fusion protein that works by removing sialic acid-containing receptors from respiratory epithelial cells, preventing PIV from binding, has been successfully used in several cases of adult and pediatric PIV pneumonia in HCT/HM and is currently in phase III clinical trials.", [["respiratory epithelial cells", "ANATOMY", 121, 149], ["DAS181", "CHEMICAL", 8, 14], ["PIV pneumonia", "DISEASE", 247, 260], ["HCT/HM", "DISEASE", 264, 270], ["sialidase", "GENE_OR_GENE_PRODUCT", 35, 44], ["respiratory epithelial cells", "CELL", 121, 149], ["110,114 DAS181", "PROTEIN", 0, 14], ["sialidase fusion protein", "PROTEIN", 35, 59], ["sialic acid-containing receptors", "PROTEIN", 83, 115], ["respiratory epithelial cells", "CELL_TYPE", 121, 149], ["an investigational sialidase fusion protein", "TREATMENT", 16, 59], ["sialic acid-containing receptors", "TREATMENT", 83, 115], ["respiratory epithelial cells", "PROBLEM", 121, 149], ["PIV", "TREATMENT", 162, 165], ["pediatric PIV pneumonia", "PROBLEM", 237, 260], ["HCT/HM", "TREATMENT", 264, 270], ["respiratory epithelial cells", "OBSERVATION", 121, 149], ["PIV", "ANATOMY", 247, 250], ["pneumonia", "OBSERVATION", 251, 260]]], ["115, 116 Adenovirus Human adenovirus (HAdV) infections can cause significant disseminated disease in patients with HCT/HM, including severe pneumonia.", [["Human adenovirus (HAdV) infections", "DISEASE", 20, 54], ["disseminated disease", "DISEASE", 77, 97], ["HCT/HM", "DISEASE", 115, 121], ["pneumonia", "DISEASE", 140, 149], ["Adenovirus", "ORGANISM", 9, 19], ["Human adenovirus", "ORGANISM", 20, 36], ["HAdV", "ORGANISM", 38, 42], ["patients", "ORGANISM", 101, 109], ["Human", "SPECIES", 20, 25], ["patients", "SPECIES", 101, 109], ["Human adenovirus", "SPECIES", 20, 36], ["HAdV", "SPECIES", 38, 42], ["Adenovirus Human adenovirus (HAdV) infections", "PROBLEM", 9, 54], ["significant disseminated disease", "PROBLEM", 65, 97], ["HCT/HM", "PROBLEM", 115, 121], ["severe pneumonia", "PROBLEM", 133, 149], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["disseminated", "OBSERVATION_MODIFIER", 77, 89], ["disease", "OBSERVATION", 90, 97], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["pneumonia", "OBSERVATION", 140, 149]]], ["The most severe disease occurs after HCT, especially in children, and in patients with HM treated with alemtuzumab.", [["HM", "DISEASE", 87, 89], ["alemtuzumab", "CHEMICAL", 103, 114], ["HCT", "CANCER", 37, 40], ["children", "ORGANISM", 56, 64], ["patients", "ORGANISM", 73, 81], ["alemtuzumab", "SIMPLE_CHEMICAL", 103, 114], ["children", "SPECIES", 56, 64], ["patients", "SPECIES", 73, 81], ["The most severe disease", "PROBLEM", 0, 23], ["HCT", "TEST", 37, 40], ["alemtuzumab", "TREATMENT", 103, 114], ["most", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["disease", "OBSERVATION", 16, 23]]], ["[117] [118] [119] Adenovirus infection occurs in 8% to 17% of patients undergoing allogeneic HCT, with most cases occurring in children.", [["Adenovirus infection", "DISEASE", 18, 38], ["Adenovirus", "ORGANISM", 18, 28], ["patients", "ORGANISM", 62, 70], ["children", "ORGANISM", 127, 135], ["patients", "SPECIES", 62, 70], ["children", "SPECIES", 127, 135], ["Adenovirus infection", "PROBLEM", 18, 38], ["allogeneic HCT", "TEST", 82, 96]]], ["120, 121 A total of 10% of patients develop HAdV endorgan disease; the lungs are involved in 75% of these cases.", [["lungs", "ANATOMY", 71, 76], ["HAdV endorgan disease", "DISEASE", 44, 65], ["patients", "ORGANISM", 27, 35], ["HAdV", "ORGANISM", 44, 48], ["lungs", "ORGAN", 71, 76], ["patients", "SPECIES", 27, 35], ["HAdV endorgan disease", "PROBLEM", 44, 65], ["endorgan disease", "OBSERVATION", 49, 65], ["lungs", "ANATOMY", 71, 76]]], ["120, 121 Infection is less common after autologous HCT, occurring in only 6% of patients, and end-organ disease including pneumonia is rare.", [["HCT", "ANATOMY", 51, 54], ["organ", "ANATOMY", 98, 103], ["end-organ disease", "DISEASE", 94, 111], ["pneumonia", "DISEASE", 122, 131], ["HCT", "CANCER", 51, 54], ["patients", "ORGANISM", 80, 88], ["organ", "ORGAN", 98, 103], ["patients", "SPECIES", 80, 88], ["Infection", "PROBLEM", 9, 18], ["autologous HCT", "TEST", 40, 54], ["end-organ disease", "PROBLEM", 94, 111], ["pneumonia", "PROBLEM", 122, 131], ["Infection", "OBSERVATION", 9, 18], ["less common", "OBSERVATION_MODIFIER", 22, 33], ["organ", "ANATOMY", 98, 103], ["disease", "OBSERVATION", 104, 111], ["pneumonia", "OBSERVATION", 122, 131]]], ["In addition to T-cell depletion, risk factors for HAdV disease are lymphopenia, receipt of cord blood grafts, GVHD requiring increased or prolonged immunosuppression, and absence of HAdV-specific T-cell responses.", [["T-cell", "ANATOMY", 15, 21], ["cord blood grafts", "ANATOMY", 91, 108], ["T-cell", "ANATOMY", 196, 202], ["HAdV disease", "DISEASE", 50, 62], ["lymphopenia", "DISEASE", 67, 78], ["GVHD", "DISEASE", 110, 114], ["T-cell", "CELL", 15, 21], ["HAdV", "ORGANISM", 50, 54], ["cord blood", "MULTI-TISSUE_STRUCTURE", 91, 101], ["grafts", "TISSUE", 102, 108], ["HAdV", "ORGANISM", 182, 186], ["T-cell", "CELL", 196, 202], ["T-cell depletion", "PROBLEM", 15, 31], ["risk factors", "PROBLEM", 33, 45], ["HAdV disease", "PROBLEM", 50, 62], ["lymphopenia", "PROBLEM", 67, 78], ["cord blood grafts", "TREATMENT", 91, 108], ["GVHD", "PROBLEM", 110, 114], ["prolonged immunosuppression", "TREATMENT", 138, 165], ["HAdV", "PROBLEM", 182, 186], ["cell depletion", "OBSERVATION", 17, 31], ["lymphopenia", "OBSERVATION", 67, 78], ["cord", "ANATOMY", 91, 95], ["GVHD", "OBSERVATION", 110, 114], ["increased", "OBSERVATION_MODIFIER", 125, 134]]], ["122 Patients with adenoviral pneumonia often have involvement at other sites, such as the gut and liver, and mortality rates with disseminated disease are high.", [["sites", "ANATOMY", 71, 76], ["gut", "ANATOMY", 90, 93], ["liver", "ANATOMY", 98, 103], ["adenoviral pneumonia", "DISEASE", 18, 38], ["disseminated disease", "DISEASE", 130, 150], ["Patients", "ORGANISM", 4, 12], ["adenoviral", "ORGANISM", 18, 28], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["liver", "ORGAN", 98, 103], ["Patients", "SPECIES", 4, 12], ["adenoviral", "SPECIES", 18, 28], ["adenoviral pneumonia", "PROBLEM", 18, 38], ["involvement at other sites", "PROBLEM", 50, 76], ["disseminated disease", "PROBLEM", 130, 150], ["adenoviral", "ANATOMY", 18, 28], ["pneumonia", "OBSERVATION", 29, 38], ["gut", "ANATOMY", 90, 93], ["liver", "ANATOMY", 98, 103], ["disseminated", "OBSERVATION_MODIFIER", 130, 142], ["disease", "OBSERVATION", 143, 150], ["high", "OBSERVATION_MODIFIER", 155, 159]]], ["First-line treatment of HAdV disease including pneumonitis is cidofovir (5 mg/kg once weekly, or 1 mg/kg three times weekly) and reduction in immunosuppression whenever possible.", [["HAdV disease", "DISEASE", 24, 36], ["pneumonitis", "DISEASE", 47, 58], ["cidofovir", "CHEMICAL", 62, 71], ["cidofovir", "CHEMICAL", 62, 71], ["HAdV", "ORGANISM", 24, 28], ["cidofovir", "SIMPLE_CHEMICAL", 62, 71], ["First-line treatment", "TREATMENT", 0, 20], ["HAdV disease", "PROBLEM", 24, 36], ["pneumonitis", "PROBLEM", 47, 58], ["cidofovir", "TREATMENT", 62, 71], ["immunosuppression", "TREATMENT", 142, 159], ["HAdV disease", "OBSERVATION", 24, 36], ["pneumonitis", "OBSERVATION", 47, 58], ["immunosuppression", "OBSERVATION", 142, 159]]], ["66,122-124Other Community Respiratory VirusesOther common CRVs, such as human metapneumovirus, novel coronaviruses (eg, SARS-CoV, MERS-CoV), and even human rhinovirus, cause lower respiratory tract infection in patients with HCT/HM.", [["lower respiratory tract", "ANATOMY", 174, 197], ["Respiratory VirusesOther common CRVs", "DISEASE", 26, 62], ["human metapneumovirus", "DISEASE", 72, 93], ["respiratory tract infection", "DISEASE", 180, 207], ["HCT/HM", "DISEASE", 225, 231], ["CRVs", "CANCER", 58, 62], ["human", "ORGANISM", 72, 77], ["metapneumovirus", "ORGANISM", 78, 93], ["coronaviruses", "ORGANISM", 101, 114], ["SARS-CoV", "ORGANISM", 120, 128], ["MERS-CoV", "ORGANISM", 130, 138], ["human", "ORGANISM", 150, 155], ["rhinovirus", "ORGANISM", 156, 166], ["lower", "ORGANISM_SUBDIVISION", 174, 179], ["respiratory tract", "ORGANISM_SUBDIVISION", 180, 197], ["patients", "ORGANISM", 211, 219], ["human", "SPECIES", 72, 77], ["metapneumovirus", "SPECIES", 78, 93], ["human", "SPECIES", 150, 155], ["rhinovirus", "SPECIES", 156, 166], ["patients", "SPECIES", 211, 219], ["human metapneumovirus", "SPECIES", 72, 93], ["SARS-CoV", "SPECIES", 120, 128], ["MERS-CoV", "SPECIES", 130, 138], ["human rhinovirus", "SPECIES", 150, 166], ["Other Community Respiratory VirusesOther common CRVs", "PROBLEM", 10, 62], ["human metapneumovirus", "PROBLEM", 72, 93], ["novel coronaviruses", "PROBLEM", 95, 114], ["SARS", "PROBLEM", 120, 124], ["human rhinovirus", "PROBLEM", 150, 166], ["lower respiratory tract infection", "PROBLEM", 174, 207], ["HCT/HM", "PROBLEM", 225, 231], ["metapneumovirus", "OBSERVATION", 78, 93], ["respiratory tract", "ANATOMY", 180, 197], ["infection", "OBSERVATION", 198, 207]]], ["[125] [126] [127] [128] Although each of these viruses have their own specific biology and epidemiology, the risk factors for pneumonia that have been identified for other CRVs, such as lymphopenia and infection occurring early after HCT, are shared.", [["pneumonia", "DISEASE", 126, 135], ["CRVs", "DISEASE", 172, 176], ["lymphopenia", "DISEASE", 186, 197], ["infection", "DISEASE", 202, 211], ["CRVs", "CANCER", 172, 176], ["these viruses", "PROBLEM", 41, 54], ["the risk factors", "PROBLEM", 105, 121], ["pneumonia", "PROBLEM", 126, 135], ["other CRVs", "PROBLEM", 166, 176], ["lymphopenia", "PROBLEM", 186, 197], ["infection", "PROBLEM", 202, 211], ["HCT", "TEST", 234, 237], ["viruses", "OBSERVATION", 47, 54], ["pneumonia", "OBSERVATION", 126, 135], ["lymphopenia", "OBSERVATION", 186, 197], ["infection", "OBSERVATION", 202, 211]]], ["Because there are yet no direct-acting treatments for these viruses, efforts to prevent infection in these highly immunosuppressed patients remains paramount.", [["infection", "DISEASE", 88, 97], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["direct-acting treatments", "TREATMENT", 25, 49], ["these viruses", "PROBLEM", 54, 67], ["infection", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 88, 97], ["highly", "OBSERVATION_MODIFIER", 107, 113], ["immunosuppressed", "OBSERVATION", 114, 130]]], ["Current guidelines recommend preventing contact from symptomatic health care workers and family members, daily screening of health care workers and visitors to inpatient units for symptoms, active surveillance for CRV disease, and isolation of symptomatic patients with recognition that viral shedding is prolonged in this patient population.", [["CRV disease", "DISEASE", 214, 225], ["patients", "ORGANISM", 256, 264], ["patient", "ORGANISM", 323, 330], ["patients", "SPECIES", 256, 264], ["patient", "SPECIES", 323, 330], ["CRV", "SPECIES", 214, 217], ["symptoms", "PROBLEM", 180, 188], ["CRV disease", "PROBLEM", 214, 225], ["viral shedding", "PROBLEM", 287, 301], ["prolonged", "OBSERVATION_MODIFIER", 305, 314]]], ["129, 130 SUMMARY The profound and prolonged immunosuppression experienced by patients undergoing HCT and intensive chemotherapy for HM results in rates of viral pneumonia that far surpass the incidence in the general population.", [["HM", "DISEASE", 132, 134], ["pneumonia", "DISEASE", 161, 170], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["prolonged immunosuppression", "TREATMENT", 34, 61], ["HCT", "TEST", 97, 100], ["intensive chemotherapy", "TREATMENT", 105, 127], ["HM", "PROBLEM", 132, 134], ["viral pneumonia", "PROBLEM", 155, 170], ["profound", "OBSERVATION_MODIFIER", 21, 29], ["prolonged", "OBSERVATION_MODIFIER", 34, 43], ["immunosuppression", "OBSERVATION", 44, 61], ["viral", "OBSERVATION_MODIFIER", 155, 160], ["pneumonia", "OBSERVATION", 161, 170]]], ["Patients with viral pneumonia generally present with fever; hypoxia; and often bilateral, patchy nodular infiltrates with or without surrounding ground glass opacities on high-resolution CT imaging.", [["nodular infiltrates", "ANATOMY", 97, 116], ["viral pneumonia", "DISEASE", 14, 29], ["fever", "DISEASE", 53, 58], ["hypoxia", "DISEASE", 60, 67], ["Patients", "ORGANISM", 0, 8], ["nodular infiltrates", "PATHOLOGICAL_FORMATION", 97, 116], ["Patients", "SPECIES", 0, 8], ["viral pneumonia", "PROBLEM", 14, 29], ["fever", "PROBLEM", 53, 58], ["hypoxia", "PROBLEM", 60, 67], ["often bilateral, patchy nodular infiltrates", "PROBLEM", 73, 116], ["surrounding ground glass opacities", "PROBLEM", 133, 167], ["high-resolution CT imaging", "TEST", 171, 197], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["pneumonia", "OBSERVATION", 20, 29], ["fever", "OBSERVATION", 53, 58], ["hypoxia", "OBSERVATION", 60, 67], ["bilateral", "ANATOMY_MODIFIER", 79, 88], ["patchy", "OBSERVATION_MODIFIER", 90, 96], ["nodular", "OBSERVATION_MODIFIER", 97, 104], ["infiltrates", "OBSERVATION", 105, 116], ["without", "UNCERTAINTY", 125, 132], ["ground glass opacities", "OBSERVATION", 145, 167]]], ["Because the imaging findings do not help distinguish among different viral etiologies, and these patients commonly have other viral, bacterial, and fungal coinfections, a microbiologic diagnosis typically requires fiberoptic bronchoscopy with bronchoalveolar lavage.Other Community Respiratory VirusesAlthough CMV remains the most common cause of viral pneumonia in this population, efforts to treat CMV replication early in its course and changes in transplant practices have resulted in improvements in the incidence and associated mortality of CMV pneumonia.", [["bronchoalveolar lavage", "ANATOMY", 243, 265], ["fungal coinfections", "DISEASE", 148, 167], ["Respiratory VirusesAlthough CMV", "DISEASE", 282, 313], ["pneumonia", "DISEASE", 353, 362], ["pneumonia", "DISEASE", 551, 560], ["patients", "ORGANISM", 97, 105], ["CMV", "ORGANISM", 310, 313], ["CMV", "ORGANISM", 400, 403], ["CMV", "ORGANISM", 547, 550], ["patients", "SPECIES", 97, 105], ["CMV", "SPECIES", 400, 403], ["CMV", "SPECIES", 547, 550], ["the imaging findings", "TEST", 8, 28], ["different viral etiologies", "PROBLEM", 59, 85], ["other viral, bacterial, and fungal coinfections", "PROBLEM", 120, 167], ["fiberoptic bronchoscopy", "TEST", 214, 237], ["bronchoalveolar lavage", "TEST", 243, 265], ["Other Community Respiratory VirusesAlthough CMV", "PROBLEM", 266, 313], ["viral pneumonia", "PROBLEM", 347, 362], ["CMV replication", "TREATMENT", 400, 415], ["transplant practices", "TREATMENT", 451, 471], ["CMV pneumonia", "PROBLEM", 547, 560], ["viral", "OBSERVATION", 126, 131], ["fungal coinfections", "OBSERVATION", 148, 167], ["bronchoalveolar lavage", "OBSERVATION", 243, 265], ["Respiratory VirusesAlthough CMV", "OBSERVATION", 282, 313], ["viral", "OBSERVATION_MODIFIER", 347, 352], ["pneumonia", "OBSERVATION", 353, 362], ["CMV pneumonia", "OBSERVATION", 547, 560]]], ["Taken together, CRV infections also occur commonly in this patient population.", [["infections", "DISEASE", 20, 30], ["CRV", "GENE_OR_GENE_PRODUCT", 16, 19], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["CRV", "SPECIES", 16, 19], ["CRV infections", "PROBLEM", 16, 30], ["infections", "OBSERVATION", 20, 30]]], ["However, the rates of progression to pneumonia vary depending on the virus with influenza, RSV, and PIV causing lower tract disease more commonly than adenovirus, human metapneumovirus, and rhinovirus, and patient risk factors relating to the degree of immunosuppression (ie, lymphopenia, early posttransplant, steroid use).", [["lower tract", "ANATOMY", 112, 123], ["pneumonia", "DISEASE", 37, 46], ["influenza, RSV", "DISEASE", 80, 94], ["lower tract disease", "DISEASE", 112, 131], ["human metapneumovirus", "DISEASE", 163, 184], ["lymphopenia", "DISEASE", 276, 287], ["steroid", "CHEMICAL", 311, 318], ["steroid", "CHEMICAL", 311, 318], ["RSV", "ORGANISM", 91, 94], ["lower tract", "ORGANISM_SUBDIVISION", 112, 123], ["adenovirus", "ORGANISM", 151, 161], ["human", "ORGANISM", 163, 168], ["metapneumovirus", "ORGANISM", 169, 184], ["rhinovirus", "ORGANISM", 190, 200], ["patient", "ORGANISM", 206, 213], ["human", "SPECIES", 163, 168], ["metapneumovirus", "SPECIES", 169, 184], ["patient", "SPECIES", 206, 213], ["RSV", "SPECIES", 91, 94], ["PIV", "SPECIES", 100, 103], ["adenovirus", "SPECIES", 151, 161], ["human metapneumovirus", "SPECIES", 163, 184], ["pneumonia", "PROBLEM", 37, 46], ["the virus", "PROBLEM", 65, 74], ["influenza", "PROBLEM", 80, 89], ["RSV", "PROBLEM", 91, 94], ["PIV", "TREATMENT", 100, 103], ["lower tract disease", "PROBLEM", 112, 131], ["adenovirus", "PROBLEM", 151, 161], ["human metapneumovirus", "PROBLEM", 163, 184], ["rhinovirus", "PROBLEM", 190, 200], ["patient risk factors", "PROBLEM", 206, 226], ["immunosuppression", "TREATMENT", 253, 270], ["lymphopenia", "PROBLEM", 276, 287], ["steroid use", "TREATMENT", 311, 322], ["pneumonia", "OBSERVATION", 37, 46], ["lower tract", "ANATOMY", 112, 123], ["metapneumovirus", "OBSERVATION", 169, 184], ["rhinovirus", "OBSERVATION", 190, 200], ["immunosuppression", "OBSERVATION", 253, 270], ["lymphopenia", "OBSERVATION", 276, 287]]], ["Once established, however, pneumonia caused by these infections is associated with high mortality rates in part because of the lack of direct-acting antiviral agents for most of these viruses.", [["pneumonia", "DISEASE", 27, 36], ["infections", "DISEASE", 53, 63], ["pneumonia", "PROBLEM", 27, 36], ["these infections", "PROBLEM", 47, 63], ["high mortality rates", "PROBLEM", 83, 103], ["direct-acting antiviral agents", "TREATMENT", 135, 165], ["these viruses", "PROBLEM", 178, 191], ["pneumonia", "OBSERVATION", 27, 36], ["infections", "OBSERVATION", 53, 63]]], ["Infection prevention practices that limit the acquisition of CRVs by patients with HCT/HM and decrease the risk of spread within the clinics and inpatient settings are of particular importance.", [["CRVs", "DISEASE", 61, 65], ["HCT", "DISEASE", 83, 86], ["HM", "DISEASE", 87, 89], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Infection prevention practices", "TREATMENT", 0, 30], ["HCT/HM", "PROBLEM", 83, 89]]]]}